The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@vascular retinopathy and interferon are Adverse-Effect relation .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@anterior ischemic optic neuropathy and interferon alfa are Adverse-Effect relation .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@anterior ischemic optic neuropathy and anterior ischemic optic neuropathy are not related .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@anterior ischemic optic neuropathy and vascular retinopathy are not related .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@anterior ischemic optic neuropathy and interferon are not related .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@interferon alfa and anterior ischemic optic neuropathy are not related .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@interferon alfa and interferon alfa are not related .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@interferon alfa and vascular retinopathy are not related .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@interferon alfa and interferon are not related .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@vascular retinopathy and anterior ischemic optic neuropathy are not related .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@vascular retinopathy and interferon alfa are not related .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@vascular retinopathy and vascular retinopathy are not related .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@interferon and anterior ischemic optic neuropathy are not related .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@interferon and interferon alfa are not related .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@interferon and vascular retinopathy are not related .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@interferon and interferon are not related .
The authors describe a case of neuroleptic malignant syndrome that occurred in a patient on amitriptyline and lithium carbonate .@_@neuroleptic malignant syndrome and amitriptyline are Adverse-Effect relation .
The authors describe a case of neuroleptic malignant syndrome that occurred in a patient on amitriptyline and lithium carbonate .@_@neuroleptic malignant syndrome and lithium carbonate are Adverse-Effect relation .
The authors describe a case of neuroleptic malignant syndrome that occurred in a patient on amitriptyline and lithium carbonate .@_@neuroleptic malignant syndrome and neuroleptic malignant syndrome are not related .
The authors describe a case of neuroleptic malignant syndrome that occurred in a patient on amitriptyline and lithium carbonate .@_@amitriptyline and neuroleptic malignant syndrome are not related .
The authors describe a case of neuroleptic malignant syndrome that occurred in a patient on amitriptyline and lithium carbonate .@_@amitriptyline and amitriptyline are not related .
The authors describe a case of neuroleptic malignant syndrome that occurred in a patient on amitriptyline and lithium carbonate .@_@amitriptyline and lithium carbonate are not related .
The authors describe a case of neuroleptic malignant syndrome that occurred in a patient on amitriptyline and lithium carbonate .@_@lithium carbonate and neuroleptic malignant syndrome are not related .
The authors describe a case of neuroleptic malignant syndrome that occurred in a patient on amitriptyline and lithium carbonate .@_@lithium carbonate and amitriptyline are not related .
The authors describe a case of neuroleptic malignant syndrome that occurred in a patient on amitriptyline and lithium carbonate .@_@lithium carbonate and lithium carbonate are not related .
CASE SUMMARIES : Two patients with stable hypothyroidism experienced symptoms of hypothyroidism with increased serum thyroid - stimulating hormone ( TSH ) concentrations after switching from 1 levothyroxine product to another .@_@increased serum thyroid - stimulating hormone and levothyroxine are Adverse-Effect relation .
CASE SUMMARIES : Two patients with stable hypothyroidism experienced symptoms of hypothyroidism with increased serum thyroid - stimulating hormone ( TSH ) concentrations after switching from 1 levothyroxine product to another .@_@increased serum thyroid - stimulating hormone and increased serum thyroid - stimulating hormone are not related .
CASE SUMMARIES : Two patients with stable hypothyroidism experienced symptoms of hypothyroidism with increased serum thyroid - stimulating hormone ( TSH ) concentrations after switching from 1 levothyroxine product to another .@_@levothyroxine and increased serum thyroid - stimulating hormone are not related .
CASE SUMMARIES : Two patients with stable hypothyroidism experienced symptoms of hypothyroidism with increased serum thyroid - stimulating hormone ( TSH ) concentrations after switching from 1 levothyroxine product to another .@_@levothyroxine and levothyroxine are not related .
Evidence is shown in this report that adenosine was associated with dangerous worsening of arrhythmia in patients with atrial flutter .@_@arrhythmia and adenosine are Adverse-Effect relation .
Evidence is shown in this report that adenosine was associated with dangerous worsening of arrhythmia in patients with atrial flutter .@_@arrhythmia and arrhythmia are not related .
Evidence is shown in this report that adenosine was associated with dangerous worsening of arrhythmia in patients with atrial flutter .@_@adenosine and arrhythmia are not related .
Evidence is shown in this report that adenosine was associated with dangerous worsening of arrhythmia in patients with atrial flutter .@_@adenosine and adenosine are not related .
Life - threatening alterations in heart rate after the use of adenosine in atrial flutter .@_@alterations in heart rate and adenosine are Adverse-Effect relation .
Life - threatening alterations in heart rate after the use of adenosine in atrial flutter .@_@alterations in heart rate and alterations in heart rate are not related .
Life - threatening alterations in heart rate after the use of adenosine in atrial flutter .@_@adenosine and alterations in heart rate are not related .
Life - threatening alterations in heart rate after the use of adenosine in atrial flutter .@_@adenosine and adenosine are not related .
Comparable adverse effects , such as disorientation and temporary amnesia , have been reported in patients in the analogous agent , propranolol .@_@disorientation and propranolol are Adverse-Effect relation .
Comparable adverse effects , such as disorientation and temporary amnesia , have been reported in patients in the analogous agent , propranolol .@_@temporary amnesia and propranolol are Adverse-Effect relation .
Comparable adverse effects , such as disorientation and temporary amnesia , have been reported in patients in the analogous agent , propranolol .@_@disorientation and disorientation are not related .
Comparable adverse effects , such as disorientation and temporary amnesia , have been reported in patients in the analogous agent , propranolol .@_@disorientation and temporary amnesia are not related .
Comparable adverse effects , such as disorientation and temporary amnesia , have been reported in patients in the analogous agent , propranolol .@_@propranolol and disorientation are not related .
Comparable adverse effects , such as disorientation and temporary amnesia , have been reported in patients in the analogous agent , propranolol .@_@propranolol and propranolol are not related .
Comparable adverse effects , such as disorientation and temporary amnesia , have been reported in patients in the analogous agent , propranolol .@_@propranolol and temporary amnesia are not related .
Comparable adverse effects , such as disorientation and temporary amnesia , have been reported in patients in the analogous agent , propranolol .@_@temporary amnesia and disorientation are not related .
Comparable adverse effects , such as disorientation and temporary amnesia , have been reported in patients in the analogous agent , propranolol .@_@temporary amnesia and temporary amnesia are not related .
OBJECTIVE : To describe a probable case of transient global amnesia caused by propafenone .@_@transient global amnesia and propafenone are Adverse-Effect relation .
OBJECTIVE : To describe a probable case of transient global amnesia caused by propafenone .@_@transient global amnesia and transient global amnesia are not related .
OBJECTIVE : To describe a probable case of transient global amnesia caused by propafenone .@_@propafenone and transient global amnesia are not related .
OBJECTIVE : To describe a probable case of transient global amnesia caused by propafenone .@_@propafenone and propafenone are not related .
Probable propafenone - induced transient global amnesia .@_@transient global amnesia and propafenone are Adverse-Effect relation .
Probable propafenone - induced transient global amnesia .@_@transient global amnesia and transient global amnesia are not related .
Probable propafenone - induced transient global amnesia .@_@propafenone and transient global amnesia are not related .
Probable propafenone - induced transient global amnesia .@_@propafenone and propafenone are not related .
A case of acute subdural haematoma originating spontaneously from an angiomatous meningioma in a patient receiving prophylactic aspirin therapy is presented .@_@acute subdural haematoma and aspirin are Adverse-Effect relation .
A case of acute subdural haematoma originating spontaneously from an angiomatous meningioma in a patient receiving prophylactic aspirin therapy is presented .@_@acute subdural haematoma and acute subdural haematoma are not related .
A case of acute subdural haematoma originating spontaneously from an angiomatous meningioma in a patient receiving prophylactic aspirin therapy is presented .@_@aspirin and acute subdural haematoma are not related .
A case of acute subdural haematoma originating spontaneously from an angiomatous meningioma in a patient receiving prophylactic aspirin therapy is presented .@_@aspirin and aspirin are not related .
Intracranial haemorrhage from a meningioma in a patient receiving aspirin prophylaxis : a case report .@_@Intracranial haemorrhage and aspirin are Adverse-Effect relation .
Intracranial haemorrhage from a meningioma in a patient receiving aspirin prophylaxis : a case report .@_@Intracranial haemorrhage and Intracranial haemorrhage are not related .
Intracranial haemorrhage from a meningioma in a patient receiving aspirin prophylaxis : a case report .@_@aspirin and Intracranial haemorrhage are not related .
Intracranial haemorrhage from a meningioma in a patient receiving aspirin prophylaxis : a case report .@_@aspirin and aspirin are not related .
Beneficial effect of low - dose mianserin on fluvoxamine - induced akathisia in an obsessive - compulsive patient .@_@akathisia and fluvoxamine are Adverse-Effect relation .
Beneficial effect of low - dose mianserin on fluvoxamine - induced akathisia in an obsessive - compulsive patient .@_@akathisia and akathisia are not related .
Beneficial effect of low - dose mianserin on fluvoxamine - induced akathisia in an obsessive - compulsive patient .@_@fluvoxamine and akathisia are not related .
Beneficial effect of low - dose mianserin on fluvoxamine - induced akathisia in an obsessive - compulsive patient .@_@fluvoxamine and fluvoxamine are not related .
Extrapyramidal side effects induced by some selective serotonin reuptake inhibitors ( SSRIs ) , i.e. fluoxetine and sertraline , have been previously reported in patients with depression and obsessive - compulsive disorder ( OCD ) .@_@Extrapyramidal side effects and fluoxetine are Adverse-Effect relation .
Extrapyramidal side effects induced by some selective serotonin reuptake inhibitors ( SSRIs ) , i.e. fluoxetine and sertraline , have been previously reported in patients with depression and obsessive - compulsive disorder ( OCD ) .@_@Extrapyramidal side effects and sertraline are Adverse-Effect relation .
Extrapyramidal side effects induced by some selective serotonin reuptake inhibitors ( SSRIs ) , i.e. fluoxetine and sertraline , have been previously reported in patients with depression and obsessive - compulsive disorder ( OCD ) .@_@Extrapyramidal side effects and Extrapyramidal side effects are not related .
Extrapyramidal side effects induced by some selective serotonin reuptake inhibitors ( SSRIs ) , i.e. fluoxetine and sertraline , have been previously reported in patients with depression and obsessive - compulsive disorder ( OCD ) .@_@fluoxetine and Extrapyramidal side effects are not related .
Extrapyramidal side effects induced by some selective serotonin reuptake inhibitors ( SSRIs ) , i.e. fluoxetine and sertraline , have been previously reported in patients with depression and obsessive - compulsive disorder ( OCD ) .@_@fluoxetine and fluoxetine are not related .
Extrapyramidal side effects induced by some selective serotonin reuptake inhibitors ( SSRIs ) , i.e. fluoxetine and sertraline , have been previously reported in patients with depression and obsessive - compulsive disorder ( OCD ) .@_@fluoxetine and sertraline are not related .
Extrapyramidal side effects induced by some selective serotonin reuptake inhibitors ( SSRIs ) , i.e. fluoxetine and sertraline , have been previously reported in patients with depression and obsessive - compulsive disorder ( OCD ) .@_@sertraline and Extrapyramidal side effects are not related .
Extrapyramidal side effects induced by some selective serotonin reuptake inhibitors ( SSRIs ) , i.e. fluoxetine and sertraline , have been previously reported in patients with depression and obsessive - compulsive disorder ( OCD ) .@_@sertraline and fluoxetine are not related .
Extrapyramidal side effects induced by some selective serotonin reuptake inhibitors ( SSRIs ) , i.e. fluoxetine and sertraline , have been previously reported in patients with depression and obsessive - compulsive disorder ( OCD ) .@_@sertraline and sertraline are not related .
However , the occurrence and management of akathisia induced by fluvoxamine have not been described .@_@akathisia and fluvoxamine are Adverse-Effect relation .
However , the occurrence and management of akathisia induced by fluvoxamine have not been described .@_@akathisia and akathisia are not related .
However , the occurrence and management of akathisia induced by fluvoxamine have not been described .@_@fluvoxamine and akathisia are not related .
However , the occurrence and management of akathisia induced by fluvoxamine have not been described .@_@fluvoxamine and fluvoxamine are not related .
In the presented case fluvoxamine - induced akathisia in an OCD patient was partially resistant to the anticholinergic agent biperiden , and was successfully treated with the 5-HT2A/5-HT2C antagonist mianserin .@_@akathisia and fluvoxamine are Adverse-Effect relation .
In the presented case fluvoxamine - induced akathisia in an OCD patient was partially resistant to the anticholinergic agent biperiden , and was successfully treated with the 5-HT2A/5-HT2C antagonist mianserin .@_@akathisia and akathisia are not related .
In the presented case fluvoxamine - induced akathisia in an OCD patient was partially resistant to the anticholinergic agent biperiden , and was successfully treated with the 5-HT2A/5-HT2C antagonist mianserin .@_@fluvoxamine and akathisia are not related .
In the presented case fluvoxamine - induced akathisia in an OCD patient was partially resistant to the anticholinergic agent biperiden , and was successfully treated with the 5-HT2A/5-HT2C antagonist mianserin .@_@fluvoxamine and fluvoxamine are not related .
A 42 year old man , treated for testicular carcinoma with combination chemotherapy that included bleomycin , developed life threatening interstitial pneumonitis .@_@interstitial pneumonitis and bleomycin are Adverse-Effect relation .
A 42 year old man , treated for testicular carcinoma with combination chemotherapy that included bleomycin , developed life threatening interstitial pneumonitis .@_@interstitial pneumonitis and interstitial pneumonitis are not related .
A 42 year old man , treated for testicular carcinoma with combination chemotherapy that included bleomycin , developed life threatening interstitial pneumonitis .@_@bleomycin and interstitial pneumonitis are not related .
A 42 year old man , treated for testicular carcinoma with combination chemotherapy that included bleomycin , developed life threatening interstitial pneumonitis .@_@bleomycin and bleomycin are not related .
Severe bleomycin lung toxicity : reversal with high dose corticosteroids .@_@lung toxicity and bleomycin are Adverse-Effect relation .
Severe bleomycin lung toxicity : reversal with high dose corticosteroids .@_@lung toxicity and lung toxicity are not related .
Severe bleomycin lung toxicity : reversal with high dose corticosteroids .@_@bleomycin and lung toxicity are not related .
Severe bleomycin lung toxicity : reversal with high dose corticosteroids .@_@bleomycin and bleomycin are not related .
This report suggests that bleomycin lung toxicity may be reversible if treated aggressively .@_@lung toxicity and bleomycin are Adverse-Effect relation .
This report suggests that bleomycin lung toxicity may be reversible if treated aggressively .@_@lung toxicity and lung toxicity are not related .
This report suggests that bleomycin lung toxicity may be reversible if treated aggressively .@_@bleomycin and lung toxicity are not related .
This report suggests that bleomycin lung toxicity may be reversible if treated aggressively .@_@bleomycin and bleomycin are not related .
Reversal of gold - induced neutropenia with granulocyte colony - stimulating factor ( G - CSF ) .@_@neutropenia and gold are Adverse-Effect relation .
Reversal of gold - induced neutropenia with granulocyte colony - stimulating factor ( G - CSF ) .@_@neutropenia and neutropenia are not related .
Reversal of gold - induced neutropenia with granulocyte colony - stimulating factor ( G - CSF ) .@_@gold and neutropenia are not related .
Reversal of gold - induced neutropenia with granulocyte colony - stimulating factor ( G - CSF ) .@_@gold and gold are not related .
We have successfully overcome severe neutropenia in an RA patient treated with gold salts , using granulocyte colony - stimulating factor ( G - CSF ) , reducing the duration of neutropenia and risk of infection .@_@severe neutropenia and gold are Adverse-Effect relation .
We have successfully overcome severe neutropenia in an RA patient treated with gold salts , using granulocyte colony - stimulating factor ( G - CSF ) , reducing the duration of neutropenia and risk of infection .@_@severe neutropenia and severe neutropenia are not related .
We have successfully overcome severe neutropenia in an RA patient treated with gold salts , using granulocyte colony - stimulating factor ( G - CSF ) , reducing the duration of neutropenia and risk of infection .@_@gold and severe neutropenia are not related .
We have successfully overcome severe neutropenia in an RA patient treated with gold salts , using granulocyte colony - stimulating factor ( G - CSF ) , reducing the duration of neutropenia and risk of infection .@_@gold and gold are not related .
Arrhythmias and cardiac arrest have been reported during amphotericin B administration but no effective technique has been described to prevent them .@_@Arrhythmias and amphotericin B are Adverse-Effect relation .
Arrhythmias and cardiac arrest have been reported during amphotericin B administration but no effective technique has been described to prevent them .@_@cardiac arrest and amphotericin B are Adverse-Effect relation .
Arrhythmias and cardiac arrest have been reported during amphotericin B administration but no effective technique has been described to prevent them .@_@Arrhythmias and Arrhythmias are not related .
Arrhythmias and cardiac arrest have been reported during amphotericin B administration but no effective technique has been described to prevent them .@_@Arrhythmias and cardiac arrest are not related .
Arrhythmias and cardiac arrest have been reported during amphotericin B administration but no effective technique has been described to prevent them .@_@amphotericin B and Arrhythmias are not related .
Arrhythmias and cardiac arrest have been reported during amphotericin B administration but no effective technique has been described to prevent them .@_@amphotericin B and amphotericin B are not related .
Arrhythmias and cardiac arrest have been reported during amphotericin B administration but no effective technique has been described to prevent them .@_@amphotericin B and cardiac arrest are not related .
Arrhythmias and cardiac arrest have been reported during amphotericin B administration but no effective technique has been described to prevent them .@_@cardiac arrest and Arrhythmias are not related .
Arrhythmias and cardiac arrest have been reported during amphotericin B administration but no effective technique has been described to prevent them .@_@cardiac arrest and cardiac arrest are not related .
Correction of serum electrolyte imbalance prevents cardiac arrhythmia during amphotericin B administration .@_@cardiac arrhythmia and amphotericin B are Adverse-Effect relation .
Correction of serum electrolyte imbalance prevents cardiac arrhythmia during amphotericin B administration .@_@cardiac arrhythmia and cardiac arrhythmia are not related .
Correction of serum electrolyte imbalance prevents cardiac arrhythmia during amphotericin B administration .@_@amphotericin B and cardiac arrhythmia are not related .
Correction of serum electrolyte imbalance prevents cardiac arrhythmia during amphotericin B administration .@_@amphotericin B and amphotericin B are not related .
I saw two patients with kala - azar resistant to sodium stibogluconate who developed cardiac arrest after amphotericin infusion ( in spite of tolerating a test dose ) .@_@cardiac arrest and amphotericin are Adverse-Effect relation .
I saw two patients with kala - azar resistant to sodium stibogluconate who developed cardiac arrest after amphotericin infusion ( in spite of tolerating a test dose ) .@_@cardiac arrest and cardiac arrest are not related .
I saw two patients with kala - azar resistant to sodium stibogluconate who developed cardiac arrest after amphotericin infusion ( in spite of tolerating a test dose ) .@_@amphotericin and cardiac arrest are not related .
I saw two patients with kala - azar resistant to sodium stibogluconate who developed cardiac arrest after amphotericin infusion ( in spite of tolerating a test dose ) .@_@amphotericin and amphotericin are not related .
We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts .@_@angry outbursts and lithium are Adverse-Effect relation .
We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts .@_@irritability and lithium are Adverse-Effect relation .
We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts .@_@angry outbursts and angry outbursts are not related .
We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts .@_@angry outbursts and irritability are not related .
We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts .@_@lithium and angry outbursts are not related .
We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts .@_@lithium and lithium are not related .
We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts .@_@lithium and irritability are not related .
We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts .@_@irritability and angry outbursts are not related .
We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts .@_@irritability and irritability are not related .
Graves ' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C .@_@transient thyrotoxicosis and interferon are Adverse-Effect relation .
Graves ' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C .@_@Graves ' hyperthyroidism and interferon are Adverse-Effect relation .
Graves ' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C .@_@Graves ' hyperthyroidism and Graves ' hyperthyroidism are not related .
Graves ' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C .@_@Graves ' hyperthyroidism and transient thyrotoxicosis are not related .
Graves ' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C .@_@interferon and Graves ' hyperthyroidism are not related .
Graves ' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C .@_@interferon and interferon are not related .
Graves ' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C .@_@interferon and transient thyrotoxicosis are not related .
Graves ' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C .@_@transient thyrotoxicosis and Graves ' hyperthyroidism are not related .
Graves ' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C .@_@transient thyrotoxicosis and transient thyrotoxicosis are not related .
This case showed sequential manifestation from transient thyrotoxicosis to the appearance of TSH - receptor autoantibodies , and then the occurrence of Graves ' hyperthyroidism during IFN therapy .@_@Graves ' hyperthyroidism and IFN are Adverse-Effect relation .
This case showed sequential manifestation from transient thyrotoxicosis to the appearance of TSH - receptor autoantibodies , and then the occurrence of Graves ' hyperthyroidism during IFN therapy .@_@Graves ' hyperthyroidism and Graves ' hyperthyroidism are not related .
This case showed sequential manifestation from transient thyrotoxicosis to the appearance of TSH - receptor autoantibodies , and then the occurrence of Graves ' hyperthyroidism during IFN therapy .@_@IFN and Graves ' hyperthyroidism are not related .
This case showed sequential manifestation from transient thyrotoxicosis to the appearance of TSH - receptor autoantibodies , and then the occurrence of Graves ' hyperthyroidism during IFN therapy .@_@IFN and IFN are not related .
We report a case of Graves ' hyperthyroidism induced by long - term interferon ( IFN ) therapy .@_@Graves ' hyperthyroidism and IFN are Adverse-Effect relation .
We report a case of Graves ' hyperthyroidism induced by long - term interferon ( IFN ) therapy .@_@Graves ' hyperthyroidism and interferon are Adverse-Effect relation .
We report a case of Graves ' hyperthyroidism induced by long - term interferon ( IFN ) therapy .@_@Graves ' hyperthyroidism and Graves ' hyperthyroidism are not related .
We report a case of Graves ' hyperthyroidism induced by long - term interferon ( IFN ) therapy .@_@IFN and Graves ' hyperthyroidism are not related .
We report a case of Graves ' hyperthyroidism induced by long - term interferon ( IFN ) therapy .@_@IFN and IFN are not related .
We report a case of Graves ' hyperthyroidism induced by long - term interferon ( IFN ) therapy .@_@IFN and interferon are not related .
We report a case of Graves ' hyperthyroidism induced by long - term interferon ( IFN ) therapy .@_@interferon and Graves ' hyperthyroidism are not related .
We report a case of Graves ' hyperthyroidism induced by long - term interferon ( IFN ) therapy .@_@interferon and IFN are not related .
We report a case of Graves ' hyperthyroidism induced by long - term interferon ( IFN ) therapy .@_@interferon and interferon are not related .
Acute INH neurotoxicity was not suspected on the first admission ; however , when readmitted 4 weeks later with another seizure , the diagnosis of acute INH neurotoxicity was made .@_@neurotoxicity and INH are Adverse-Effect relation .
Acute INH neurotoxicity was not suspected on the first admission ; however , when readmitted 4 weeks later with another seizure , the diagnosis of acute INH neurotoxicity was made .@_@neurotoxicity and neurotoxicity are not related .
Acute INH neurotoxicity was not suspected on the first admission ; however , when readmitted 4 weeks later with another seizure , the diagnosis of acute INH neurotoxicity was made .@_@INH and neurotoxicity are not related .
Acute INH neurotoxicity was not suspected on the first admission ; however , when readmitted 4 weeks later with another seizure , the diagnosis of acute INH neurotoxicity was made .@_@INH and INH are not related .
Acute isoniazid neurotoxicity in an urban hospital .@_@neurotoxicity and isoniazid are Adverse-Effect relation .
Acute isoniazid neurotoxicity in an urban hospital .@_@neurotoxicity and neurotoxicity are not related .
Acute isoniazid neurotoxicity in an urban hospital .@_@isoniazid and neurotoxicity are not related .
Acute isoniazid neurotoxicity in an urban hospital .@_@isoniazid and isoniazid are not related .
CONCLUSIONS : We have seen an increased incidence of acute INH neurotoxicity because of the resurgence of TB in New York City .@_@neurotoxicity and INH are Adverse-Effect relation .
CONCLUSIONS : We have seen an increased incidence of acute INH neurotoxicity because of the resurgence of TB in New York City .@_@neurotoxicity and neurotoxicity are not related .
CONCLUSIONS : We have seen an increased incidence of acute INH neurotoxicity because of the resurgence of TB in New York City .@_@INH and neurotoxicity are not related .
CONCLUSIONS : We have seen an increased incidence of acute INH neurotoxicity because of the resurgence of TB in New York City .@_@INH and INH are not related .
In patients with a known access to INH , seizures should be considered to be caused by INH toxicity unless proved otherwise .@_@seizures and INH are Adverse-Effect relation .
In patients with a known access to INH , seizures should be considered to be caused by INH toxicity unless proved otherwise .@_@seizures and seizures are not related .
In patients with a known access to INH , seizures should be considered to be caused by INH toxicity unless proved otherwise .@_@INH and seizures are not related .
In patients with a known access to INH , seizures should be considered to be caused by INH toxicity unless proved otherwise .@_@INH and INH are not related .
OBJECTIVES : To describe the presentation and treatment of acute isoniazid ( INH ) neurotoxicity appearing at an inner - city municipal hospital .@_@neurotoxicity and isoniazid are Adverse-Effect relation .
OBJECTIVES : To describe the presentation and treatment of acute isoniazid ( INH ) neurotoxicity appearing at an inner - city municipal hospital .@_@neurotoxicity and INH are Adverse-Effect relation .
OBJECTIVES : To describe the presentation and treatment of acute isoniazid ( INH ) neurotoxicity appearing at an inner - city municipal hospital .@_@neurotoxicity and neurotoxicity are not related .
OBJECTIVES : To describe the presentation and treatment of acute isoniazid ( INH ) neurotoxicity appearing at an inner - city municipal hospital .@_@INH and neurotoxicity are not related .
OBJECTIVES : To describe the presentation and treatment of acute isoniazid ( INH ) neurotoxicity appearing at an inner - city municipal hospital .@_@INH and INH are not related .
OBJECTIVES : To describe the presentation and treatment of acute isoniazid ( INH ) neurotoxicity appearing at an inner - city municipal hospital .@_@INH and isoniazid are not related .
OBJECTIVES : To describe the presentation and treatment of acute isoniazid ( INH ) neurotoxicity appearing at an inner - city municipal hospital .@_@isoniazid and neurotoxicity are not related .
OBJECTIVES : To describe the presentation and treatment of acute isoniazid ( INH ) neurotoxicity appearing at an inner - city municipal hospital .@_@isoniazid and INH are not related .
OBJECTIVES : To describe the presentation and treatment of acute isoniazid ( INH ) neurotoxicity appearing at an inner - city municipal hospital .@_@isoniazid and isoniazid are not related .
Parenteral pyridoxine , the specific antidote for INH - induced refractory seizures , should be readily available in every emergency department in the areas similarly experiencing increasing trends of TB .@_@refractory seizures and INH are Adverse-Effect relation .
Parenteral pyridoxine , the specific antidote for INH - induced refractory seizures , should be readily available in every emergency department in the areas similarly experiencing increasing trends of TB .@_@refractory seizures and refractory seizures are not related .
Parenteral pyridoxine , the specific antidote for INH - induced refractory seizures , should be readily available in every emergency department in the areas similarly experiencing increasing trends of TB .@_@INH and refractory seizures are not related .
Parenteral pyridoxine , the specific antidote for INH - induced refractory seizures , should be readily available in every emergency department in the areas similarly experiencing increasing trends of TB .@_@INH and INH are not related .
RESULTS : At our institution , no children appeared with acute INH neurotoxicity in the period 1985 through 1990 , whereas seven patients were treated from 1991 through 1993 .@_@neurotoxicity and INH are Adverse-Effect relation .
RESULTS : At our institution , no children appeared with acute INH neurotoxicity in the period 1985 through 1990 , whereas seven patients were treated from 1991 through 1993 .@_@neurotoxicity and neurotoxicity are not related .
RESULTS : At our institution , no children appeared with acute INH neurotoxicity in the period 1985 through 1990 , whereas seven patients were treated from 1991 through 1993 .@_@INH and neurotoxicity are not related .
RESULTS : At our institution , no children appeared with acute INH neurotoxicity in the period 1985 through 1990 , whereas seven patients were treated from 1991 through 1993 .@_@INH and INH are not related .
Arterial hypertension associated with topical ocular use of phenylephrine in dogs .@_@Arterial hypertension and phenylephrine are Adverse-Effect relation .
Arterial hypertension associated with topical ocular use of phenylephrine in dogs .@_@Arterial hypertension and Arterial hypertension are not related .
Arterial hypertension associated with topical ocular use of phenylephrine in dogs .@_@phenylephrine and Arterial hypertension are not related .
Arterial hypertension associated with topical ocular use of phenylephrine in dogs .@_@phenylephrine and phenylephrine are not related .
CONCLUSION : Squamous metaplasia in these cases appears to be a consequence of progestin therapy .@_@Squamous metaplasia and progestin are Adverse-Effect relation .
CONCLUSION : Squamous metaplasia in these cases appears to be a consequence of progestin therapy .@_@Squamous metaplasia and Squamous metaplasia are not related .
CONCLUSION : Squamous metaplasia in these cases appears to be a consequence of progestin therapy .@_@progestin and Squamous metaplasia are not related .
CONCLUSION : Squamous metaplasia in these cases appears to be a consequence of progestin therapy .@_@progestin and progestin are not related .
OBJECTIVE : To report the finding of squamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia .@_@squamous metaplasia within endometrial glands and progestin are Adverse-Effect relation .
OBJECTIVE : To report the finding of squamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia .@_@squamous metaplasia within endometrial glands and squamous metaplasia within endometrial glands are not related .
OBJECTIVE : To report the finding of squamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia .@_@progestin and squamous metaplasia within endometrial glands are not related .
OBJECTIVE : To report the finding of squamous metaplasia within endometrial glands occurring as a result of progestin therapy of hyperplasia .@_@progestin and progestin are not related .
RESULTS : Extensive squamous metaplasia was found in endometrial glands following progestin therapy .@_@squamous metaplasia and progestin are Adverse-Effect relation .
RESULTS : Extensive squamous metaplasia was found in endometrial glands following progestin therapy .@_@squamous metaplasia and squamous metaplasia are not related .
RESULTS : Extensive squamous metaplasia was found in endometrial glands following progestin therapy .@_@progestin and squamous metaplasia are not related .
RESULTS : Extensive squamous metaplasia was found in endometrial glands following progestin therapy .@_@progestin and progestin are not related .
Fever caused by the use of furosemide was proved ; the fever resolved after discontinuation of this medication and recurred after its reintroduction .@_@Fever and furosemide are Adverse-Effect relation .
Fever caused by the use of furosemide was proved ; the fever resolved after discontinuation of this medication and recurred after its reintroduction .@_@Fever and Fever are not related .
Fever caused by the use of furosemide was proved ; the fever resolved after discontinuation of this medication and recurred after its reintroduction .@_@furosemide and Fever are not related .
Fever caused by the use of furosemide was proved ; the fever resolved after discontinuation of this medication and recurred after its reintroduction .@_@furosemide and furosemide are not related .
Furosemide - associated fever .@_@fever and Furosemide are Adverse-Effect relation .
Furosemide - associated fever .@_@fever and fever are not related .
Furosemide - associated fever .@_@Furosemide and fever are not related .
Furosemide - associated fever .@_@Furosemide and Furosemide are not related .
The dose - limiting toxicity of KW-2149 is pulmonary toxicity .@_@pulmonary toxicity and KW-2149 are Adverse-Effect relation .
The dose - limiting toxicity of KW-2149 is pulmonary toxicity .@_@pulmonary toxicity and pulmonary toxicity are not related .
The dose - limiting toxicity of KW-2149 is pulmonary toxicity .@_@KW-2149 and pulmonary toxicity are not related .
The dose - limiting toxicity of KW-2149 is pulmonary toxicity .@_@KW-2149 and KW-2149 are not related .
Musculoskeletal complaints were the presenting symptoms in four of 44 children ( 9 % ) treated for relapsed Wilms ' tumors with ifosfamide , a derivative of cyclophosphamide .@_@Musculoskeletal complaints and ifosfamide are Adverse-Effect relation .
Musculoskeletal complaints were the presenting symptoms in four of 44 children ( 9 % ) treated for relapsed Wilms ' tumors with ifosfamide , a derivative of cyclophosphamide .@_@Musculoskeletal complaints and cyclophosphamide are Adverse-Effect relation .
Musculoskeletal complaints were the presenting symptoms in four of 44 children ( 9 % ) treated for relapsed Wilms ' tumors with ifosfamide , a derivative of cyclophosphamide .@_@Musculoskeletal complaints and Musculoskeletal complaints are not related .
Musculoskeletal complaints were the presenting symptoms in four of 44 children ( 9 % ) treated for relapsed Wilms ' tumors with ifosfamide , a derivative of cyclophosphamide .@_@cyclophosphamide and Musculoskeletal complaints are not related .
Musculoskeletal complaints were the presenting symptoms in four of 44 children ( 9 % ) treated for relapsed Wilms ' tumors with ifosfamide , a derivative of cyclophosphamide .@_@cyclophosphamide and cyclophosphamide are not related .
Musculoskeletal complaints were the presenting symptoms in four of 44 children ( 9 % ) treated for relapsed Wilms ' tumors with ifosfamide , a derivative of cyclophosphamide .@_@cyclophosphamide and ifosfamide are not related .
Musculoskeletal complaints were the presenting symptoms in four of 44 children ( 9 % ) treated for relapsed Wilms ' tumors with ifosfamide , a derivative of cyclophosphamide .@_@ifosfamide and Musculoskeletal complaints are not related .
Musculoskeletal complaints were the presenting symptoms in four of 44 children ( 9 % ) treated for relapsed Wilms ' tumors with ifosfamide , a derivative of cyclophosphamide .@_@ifosfamide and cyclophosphamide are not related .
Musculoskeletal complaints were the presenting symptoms in four of 44 children ( 9 % ) treated for relapsed Wilms ' tumors with ifosfamide , a derivative of cyclophosphamide .@_@ifosfamide and ifosfamide are not related .
Recognition of a potential drug - induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide .@_@Fanconi syndrome and ifosfamide are Adverse-Effect relation .
Recognition of a potential drug - induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide .@_@Fanconi syndrome and Fanconi syndrome are not related .
Recognition of a potential drug - induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide .@_@ifosfamide and Fanconi syndrome are not related .
Recognition of a potential drug - induced Fanconi syndrome is important when managing pediatric oncology patients previously treated with ifosfamide .@_@ifosfamide and ifosfamide are not related .
Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far , and comprise the first cases of ( sub)fulminant hepatitis and cirrhosis related to benzarone .@_@cirrhosis and benzarone are Adverse-Effect relation .
Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far , and comprise the first cases of ( sub)fulminant hepatitis and cirrhosis related to benzarone .@_@hepatotoxicity and benzarone are Adverse-Effect relation .
Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far , and comprise the first cases of ( sub)fulminant hepatitis and cirrhosis related to benzarone .@_@( sub)fulminant hepatitis and benzarone are Adverse-Effect relation .
Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far , and comprise the first cases of ( sub)fulminant hepatitis and cirrhosis related to benzarone .@_@cirrhosis and cirrhosis are not related .
Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far , and comprise the first cases of ( sub)fulminant hepatitis and cirrhosis related to benzarone .@_@cirrhosis and hepatotoxicity are not related .
Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far , and comprise the first cases of ( sub)fulminant hepatitis and cirrhosis related to benzarone .@_@cirrhosis and ( sub)fulminant hepatitis are not related .
Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far , and comprise the first cases of ( sub)fulminant hepatitis and cirrhosis related to benzarone .@_@benzarone and cirrhosis are not related .
Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far , and comprise the first cases of ( sub)fulminant hepatitis and cirrhosis related to benzarone .@_@benzarone and benzarone are not related .
Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far , and comprise the first cases of ( sub)fulminant hepatitis and cirrhosis related to benzarone .@_@benzarone and hepatotoxicity are not related .
Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far , and comprise the first cases of ( sub)fulminant hepatitis and cirrhosis related to benzarone .@_@benzarone and ( sub)fulminant hepatitis are not related .
Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far , and comprise the first cases of ( sub)fulminant hepatitis and cirrhosis related to benzarone .@_@hepatotoxicity and cirrhosis are not related .
Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far , and comprise the first cases of ( sub)fulminant hepatitis and cirrhosis related to benzarone .@_@hepatotoxicity and hepatotoxicity are not related .
Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far , and comprise the first cases of ( sub)fulminant hepatitis and cirrhosis related to benzarone .@_@hepatotoxicity and ( sub)fulminant hepatitis are not related .
Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far , and comprise the first cases of ( sub)fulminant hepatitis and cirrhosis related to benzarone .@_@( sub)fulminant hepatitis and cirrhosis are not related .
Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far , and comprise the first cases of ( sub)fulminant hepatitis and cirrhosis related to benzarone .@_@( sub)fulminant hepatitis and hepatotoxicity are not related .
Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far , and comprise the first cases of ( sub)fulminant hepatitis and cirrhosis related to benzarone .@_@( sub)fulminant hepatitis and ( sub)fulminant hepatitis are not related .
Severe hepatotoxicity related to benzarone : a report of three cases with two fatalities .@_@Severe hepatotoxicity and benzarone are Adverse-Effect relation .
Severe hepatotoxicity related to benzarone : a report of three cases with two fatalities .@_@Severe hepatotoxicity and Severe hepatotoxicity are not related .
Severe hepatotoxicity related to benzarone : a report of three cases with two fatalities .@_@benzarone and Severe hepatotoxicity are not related .
Severe hepatotoxicity related to benzarone : a report of three cases with two fatalities .@_@benzarone and benzarone are not related .
We report three cases of severe hepatotoxicity related to benzarone , a benzofuran derivative .@_@severe hepatotoxicity and benzarone are Adverse-Effect relation .
We report three cases of severe hepatotoxicity related to benzarone , a benzofuran derivative .@_@severe hepatotoxicity and severe hepatotoxicity are not related .
We report three cases of severe hepatotoxicity related to benzarone , a benzofuran derivative .@_@benzarone and severe hepatotoxicity are not related .
We report three cases of severe hepatotoxicity related to benzarone , a benzofuran derivative .@_@benzarone and benzarone are not related .
We stress the potential of benzarone to cause hepatotoxicity , which usually resembles severe chronic active hepatitis .@_@hepatotoxicity and benzarone are Adverse-Effect relation .
We stress the potential of benzarone to cause hepatotoxicity , which usually resembles severe chronic active hepatitis .@_@severe chronic active hepatitis and benzarone are Adverse-Effect relation .
We stress the potential of benzarone to cause hepatotoxicity , which usually resembles severe chronic active hepatitis .@_@hepatotoxicity and hepatotoxicity are not related .
We stress the potential of benzarone to cause hepatotoxicity , which usually resembles severe chronic active hepatitis .@_@hepatotoxicity and severe chronic active hepatitis are not related .
We stress the potential of benzarone to cause hepatotoxicity , which usually resembles severe chronic active hepatitis .@_@benzarone and hepatotoxicity are not related .
We stress the potential of benzarone to cause hepatotoxicity , which usually resembles severe chronic active hepatitis .@_@benzarone and benzarone are not related .
We stress the potential of benzarone to cause hepatotoxicity , which usually resembles severe chronic active hepatitis .@_@benzarone and severe chronic active hepatitis are not related .
We stress the potential of benzarone to cause hepatotoxicity , which usually resembles severe chronic active hepatitis .@_@severe chronic active hepatitis and hepatotoxicity are not related .
We stress the potential of benzarone to cause hepatotoxicity , which usually resembles severe chronic active hepatitis .@_@severe chronic active hepatitis and severe chronic active hepatitis are not related .
Case study : a modified topical treatment regimen for sodium warfarin - induced necrotizing fasciitis .@_@necrotizing fasciitis and warfarin are Adverse-Effect relation .
Case study : a modified topical treatment regimen for sodium warfarin - induced necrotizing fasciitis .@_@necrotizing fasciitis and necrotizing fasciitis are not related .
Case study : a modified topical treatment regimen for sodium warfarin - induced necrotizing fasciitis .@_@warfarin and necrotizing fasciitis are not related .
Case study : a modified topical treatment regimen for sodium warfarin - induced necrotizing fasciitis .@_@warfarin and warfarin are not related .
This case study describes an atypical case of refractory , sodium warfarin - induced necrotizing fasciitis and myonecrosis .@_@myonecrosis and sodium warfarin are Adverse-Effect relation .
This case study describes an atypical case of refractory , sodium warfarin - induced necrotizing fasciitis and myonecrosis .@_@necrotizing fasciitis and sodium warfarin are Adverse-Effect relation .
This case study describes an atypical case of refractory , sodium warfarin - induced necrotizing fasciitis and myonecrosis .@_@myonecrosis and myonecrosis are not related .
This case study describes an atypical case of refractory , sodium warfarin - induced necrotizing fasciitis and myonecrosis .@_@myonecrosis and necrotizing fasciitis are not related .
This case study describes an atypical case of refractory , sodium warfarin - induced necrotizing fasciitis and myonecrosis .@_@sodium warfarin and myonecrosis are not related .
This case study describes an atypical case of refractory , sodium warfarin - induced necrotizing fasciitis and myonecrosis .@_@sodium warfarin and sodium warfarin are not related .
This case study describes an atypical case of refractory , sodium warfarin - induced necrotizing fasciitis and myonecrosis .@_@sodium warfarin and necrotizing fasciitis are not related .
This case study describes an atypical case of refractory , sodium warfarin - induced necrotizing fasciitis and myonecrosis .@_@necrotizing fasciitis and myonecrosis are not related .
This case study describes an atypical case of refractory , sodium warfarin - induced necrotizing fasciitis and myonecrosis .@_@necrotizing fasciitis and necrotizing fasciitis are not related .
Clinicians who manage cachectic patients , particularly those with protracted diarrhoea and/or receiving anti - malarial drugs including mefloquine , should be aware of the risk of severe hypoglycaemia .@_@severe hypoglycaemia and mefloquine are Adverse-Effect relation .
Clinicians who manage cachectic patients , particularly those with protracted diarrhoea and/or receiving anti - malarial drugs including mefloquine , should be aware of the risk of severe hypoglycaemia .@_@severe hypoglycaemia and severe hypoglycaemia are not related .
Clinicians who manage cachectic patients , particularly those with protracted diarrhoea and/or receiving anti - malarial drugs including mefloquine , should be aware of the risk of severe hypoglycaemia .@_@mefloquine and severe hypoglycaemia are not related .
Clinicians who manage cachectic patients , particularly those with protracted diarrhoea and/or receiving anti - malarial drugs including mefloquine , should be aware of the risk of severe hypoglycaemia .@_@mefloquine and mefloquine are not related .
Mechanisms and triggering factors of hypoglycaemia induced by mefloquine and some other anti - malarial quinine analogues are discussed .@_@hypoglycaemia and mefloquine are Adverse-Effect relation .
Mechanisms and triggering factors of hypoglycaemia induced by mefloquine and some other anti - malarial quinine analogues are discussed .@_@hypoglycaemia and hypoglycaemia are not related .
Mechanisms and triggering factors of hypoglycaemia induced by mefloquine and some other anti - malarial quinine analogues are discussed .@_@mefloquine and hypoglycaemia are not related .
Mechanisms and triggering factors of hypoglycaemia induced by mefloquine and some other anti - malarial quinine analogues are discussed .@_@mefloquine and mefloquine are not related .
Mefloquine - associated hypoglycaemia in a cachectic AIDS patient .@_@hypoglycaemia and Mefloquine are Adverse-Effect relation .
Mefloquine - associated hypoglycaemia in a cachectic AIDS patient .@_@hypoglycaemia and hypoglycaemia are not related .
Mefloquine - associated hypoglycaemia in a cachectic AIDS patient .@_@Mefloquine and hypoglycaemia are not related .
Mefloquine - associated hypoglycaemia in a cachectic AIDS patient .@_@Mefloquine and Mefloquine are not related .
Quinine and its isomer quinidine are well - known causes of iatrogenic hypoglycaemia , due to excessive insulin secretion .@_@iatrogenic hypoglycaemia and quinidine are Adverse-Effect relation .
Quinine and its isomer quinidine are well - known causes of iatrogenic hypoglycaemia , due to excessive insulin secretion .@_@iatrogenic hypoglycaemia and Quinine are Adverse-Effect relation .
Quinine and its isomer quinidine are well - known causes of iatrogenic hypoglycaemia , due to excessive insulin secretion .@_@iatrogenic hypoglycaemia and iatrogenic hypoglycaemia are not related .
Quinine and its isomer quinidine are well - known causes of iatrogenic hypoglycaemia , due to excessive insulin secretion .@_@quinidine and iatrogenic hypoglycaemia are not related .
Quinine and its isomer quinidine are well - known causes of iatrogenic hypoglycaemia , due to excessive insulin secretion .@_@quinidine and quinidine are not related .
Quinine and its isomer quinidine are well - known causes of iatrogenic hypoglycaemia , due to excessive insulin secretion .@_@quinidine and Quinine are not related .
Quinine and its isomer quinidine are well - known causes of iatrogenic hypoglycaemia , due to excessive insulin secretion .@_@Quinine and iatrogenic hypoglycaemia are not related .
Quinine and its isomer quinidine are well - known causes of iatrogenic hypoglycaemia , due to excessive insulin secretion .@_@Quinine and quinidine are not related .
Quinine and its isomer quinidine are well - known causes of iatrogenic hypoglycaemia , due to excessive insulin secretion .@_@Quinine and Quinine are not related .
We report a case of hypoglycaemia after mefloquine therapy ( 1,500 mg over two days ) for severe gastrointestinal cryptosporidiasis in a cachectic AIDS patient with protracted diarrhoea .@_@hypoglycaemia and mefloquine are Adverse-Effect relation .
We report a case of hypoglycaemia after mefloquine therapy ( 1,500 mg over two days ) for severe gastrointestinal cryptosporidiasis in a cachectic AIDS patient with protracted diarrhoea .@_@hypoglycaemia and hypoglycaemia are not related .
We report a case of hypoglycaemia after mefloquine therapy ( 1,500 mg over two days ) for severe gastrointestinal cryptosporidiasis in a cachectic AIDS patient with protracted diarrhoea .@_@mefloquine and hypoglycaemia are not related .
We report a case of hypoglycaemia after mefloquine therapy ( 1,500 mg over two days ) for severe gastrointestinal cryptosporidiasis in a cachectic AIDS patient with protracted diarrhoea .@_@mefloquine and mefloquine are not related .
Because sumatriptan can cause coronary artery vasospasm , patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan .@_@coronary artery vasospasm and sumatriptan are Adverse-Effect relation .
Because sumatriptan can cause coronary artery vasospasm , patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan .@_@coronary artery vasospasm and coronary artery vasospasm are not related .
Because sumatriptan can cause coronary artery vasospasm , patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan .@_@sumatriptan and coronary artery vasospasm are not related .
Because sumatriptan can cause coronary artery vasospasm , patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan .@_@sumatriptan and sumatriptan are not related .
Cardiac arrest following use of sumatriptan .@_@Cardiac arrest and sumatriptan are Adverse-Effect relation .
Cardiac arrest following use of sumatriptan .@_@Cardiac arrest and Cardiac arrest are not related .
Cardiac arrest following use of sumatriptan .@_@sumatriptan and Cardiac arrest are not related .
Cardiac arrest following use of sumatriptan .@_@sumatriptan and sumatriptan are not related .
I report a 35-year - old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first - time dose of subcutaneous sumatriptan for migraine .@_@cardiac arrest and sumatriptan are Adverse-Effect relation .
I report a 35-year - old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first - time dose of subcutaneous sumatriptan for migraine .@_@cardiac arrest and cardiac arrest are not related .
I report a 35-year - old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first - time dose of subcutaneous sumatriptan for migraine .@_@sumatriptan and cardiac arrest are not related .
I report a 35-year - old woman with occult coronary artery disease who experienced cardiac arrest within minutes after receiving a first - time dose of subcutaneous sumatriptan for migraine .@_@sumatriptan and sumatriptan are not related .
Sotalol - induced bradycardia reversed by glucagon .@_@bradycardia and Sotalol are Adverse-Effect relation .
Sotalol - induced bradycardia reversed by glucagon .@_@bradycardia and bradycardia are not related .
Sotalol - induced bradycardia reversed by glucagon .@_@Sotalol and bradycardia are not related .
Sotalol - induced bradycardia reversed by glucagon .@_@Sotalol and Sotalol are not related .
We present a case of sotalol - induced bradycardia reversed by glucagon .@_@bradycardia and sotalol are Adverse-Effect relation .
We present a case of sotalol - induced bradycardia reversed by glucagon .@_@bradycardia and bradycardia are not related .
We present a case of sotalol - induced bradycardia reversed by glucagon .@_@sotalol and bradycardia are not related .
We present a case of sotalol - induced bradycardia reversed by glucagon .@_@sotalol and sotalol are not related .
Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer : a report of a case .@_@Secretory endometrial adenocarcinoma and tamoxifen are Adverse-Effect relation .
Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer : a report of a case .@_@Secretory endometrial adenocarcinoma and Secretory endometrial adenocarcinoma are not related .
Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer : a report of a case .@_@tamoxifen and Secretory endometrial adenocarcinoma are not related .
Secretory endometrial adenocarcinoma in a patient on tamoxifen for breast cancer : a report of a case .@_@tamoxifen and tamoxifen are not related .
This unusual pattern of low - grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy .@_@uterine neoplasia and tamoxifen are Adverse-Effect relation .
This unusual pattern of low - grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy .@_@low - grade endometrial carcinoma and tamoxifen are Adverse-Effect relation .
This unusual pattern of low - grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy .@_@low - grade endometrial carcinoma and low - grade endometrial carcinoma are not related .
This unusual pattern of low - grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy .@_@low - grade endometrial carcinoma and uterine neoplasia are not related .
This unusual pattern of low - grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy .@_@tamoxifen and low - grade endometrial carcinoma are not related .
This unusual pattern of low - grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy .@_@tamoxifen and tamoxifen are not related .
This unusual pattern of low - grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy .@_@tamoxifen and uterine neoplasia are not related .
This unusual pattern of low - grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy .@_@uterine neoplasia and low - grade endometrial carcinoma are not related .
This unusual pattern of low - grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with tamoxifen therapy .@_@uterine neoplasia and uterine neoplasia are not related .
We believe that this is the first report of secretory carcinoma of the endometrium associated with tamoxifen use .@_@secretory carcinoma of the endometrium and tamoxifen are Adverse-Effect relation .
We believe that this is the first report of secretory carcinoma of the endometrium associated with tamoxifen use .@_@secretory carcinoma of the endometrium and secretory carcinoma of the endometrium are not related .
We believe that this is the first report of secretory carcinoma of the endometrium associated with tamoxifen use .@_@tamoxifen and secretory carcinoma of the endometrium are not related .
We believe that this is the first report of secretory carcinoma of the endometrium associated with tamoxifen use .@_@tamoxifen and tamoxifen are not related .
Well - differentiated endometrial adenocarcinoma of the secretory type ( FIGO Grade 1 ) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma .@_@endometrial adenocarcinoma of the secretory type and tamoxifen are Adverse-Effect relation .
Well - differentiated endometrial adenocarcinoma of the secretory type ( FIGO Grade 1 ) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma .@_@endometrial adenocarcinoma of the secretory type and endometrial adenocarcinoma of the secretory type are not related .
Well - differentiated endometrial adenocarcinoma of the secretory type ( FIGO Grade 1 ) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma .@_@tamoxifen and endometrial adenocarcinoma of the secretory type are not related .
Well - differentiated endometrial adenocarcinoma of the secretory type ( FIGO Grade 1 ) with minimal myometrial invasion occurred in a postmenopausal patient on tamoxifen therapy 5 years after mastectomy for breast carcinoma .@_@tamoxifen and tamoxifen are not related .
Esophageal candidiasis following omeprazole therapy : a report of two cases .@_@Esophageal candidiasis and omeprazole are Adverse-Effect relation .
Esophageal candidiasis following omeprazole therapy : a report of two cases .@_@Esophageal candidiasis and Esophageal candidiasis are not related .
Esophageal candidiasis following omeprazole therapy : a report of two cases .@_@omeprazole and Esophageal candidiasis are not related .
Esophageal candidiasis following omeprazole therapy : a report of two cases .@_@omeprazole and omeprazole are not related .
Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy .@_@Esophageal candidiasis and omeprazole are Adverse-Effect relation .
Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy .@_@Esophageal candidiasis and Esophageal candidiasis are not related .
Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy .@_@omeprazole and Esophageal candidiasis are not related .
Esophageal candidiasis was diagnosed at endoscopy in two patients receiving omeprazole therapy .@_@omeprazole and omeprazole are not related .
High - grade atrioventricular block during dipyridamole stress testing .@_@High - grade atrioventricular block and dipyridamole are Adverse-Effect relation .
High - grade atrioventricular block during dipyridamole stress testing .@_@High - grade atrioventricular block and High - grade atrioventricular block are not related .
High - grade atrioventricular block during dipyridamole stress testing .@_@dipyridamole and High - grade atrioventricular block are not related .
High - grade atrioventricular block during dipyridamole stress testing .@_@dipyridamole and dipyridamole are not related .
We present a case in which dipyridamole induced high - grade atrioventricular ( AV ) block that responded promptly to intravenous aminophylline but not to atropine .@_@high - grade atrioventricular ( AV ) block and dipyridamole are Adverse-Effect relation .
We present a case in which dipyridamole induced high - grade atrioventricular ( AV ) block that responded promptly to intravenous aminophylline but not to atropine .@_@high - grade atrioventricular ( AV ) block and high - grade atrioventricular ( AV ) block are not related .
We present a case in which dipyridamole induced high - grade atrioventricular ( AV ) block that responded promptly to intravenous aminophylline but not to atropine .@_@dipyridamole and high - grade atrioventricular ( AV ) block are not related .
We present a case in which dipyridamole induced high - grade atrioventricular ( AV ) block that responded promptly to intravenous aminophylline but not to atropine .@_@dipyridamole and dipyridamole are not related .
Aggressive management of doxorubicin - induced cardiomyopathy associated with ' low ' doses of doxorubicin .@_@cardiomyopathy and doxorubicin are Adverse-Effect relation .
Aggressive management of doxorubicin - induced cardiomyopathy associated with ' low ' doses of doxorubicin .@_@cardiomyopathy and cardiomyopathy are not related .
Aggressive management of doxorubicin - induced cardiomyopathy associated with ' low ' doses of doxorubicin .@_@doxorubicin and cardiomyopathy are not related .
Aggressive management of doxorubicin - induced cardiomyopathy associated with ' low ' doses of doxorubicin .@_@doxorubicin and doxorubicin are not related .
There is a dose - effect relationship between doxorubicin and the incidence of symptomatic cardiac failure .@_@symptomatic cardiac failure and doxorubicin are Adverse-Effect relation .
There is a dose - effect relationship between doxorubicin and the incidence of symptomatic cardiac failure .@_@symptomatic cardiac failure and symptomatic cardiac failure are not related .
There is a dose - effect relationship between doxorubicin and the incidence of symptomatic cardiac failure .@_@doxorubicin and symptomatic cardiac failure are not related .
There is a dose - effect relationship between doxorubicin and the incidence of symptomatic cardiac failure .@_@doxorubicin and doxorubicin are not related .
Ovarian endometrioid carcinoma and endometriosis developing in a postmenopausal breast cancer patient during tamoxifen therapy : a case report and review of the literature .@_@endometriosis and tamoxifen are Adverse-Effect relation .
Ovarian endometrioid carcinoma and endometriosis developing in a postmenopausal breast cancer patient during tamoxifen therapy : a case report and review of the literature .@_@Ovarian endometrioid carcinoma and tamoxifen are Adverse-Effect relation .
Ovarian endometrioid carcinoma and endometriosis developing in a postmenopausal breast cancer patient during tamoxifen therapy : a case report and review of the literature .@_@endometriosis and endometriosis are not related .
Ovarian endometrioid carcinoma and endometriosis developing in a postmenopausal breast cancer patient during tamoxifen therapy : a case report and review of the literature .@_@endometriosis and Ovarian endometrioid carcinoma are not related .
Ovarian endometrioid carcinoma and endometriosis developing in a postmenopausal breast cancer patient during tamoxifen therapy : a case report and review of the literature .@_@tamoxifen and endometriosis are not related .
Ovarian endometrioid carcinoma and endometriosis developing in a postmenopausal breast cancer patient during tamoxifen therapy : a case report and review of the literature .@_@tamoxifen and tamoxifen are not related .
Ovarian endometrioid carcinoma and endometriosis developing in a postmenopausal breast cancer patient during tamoxifen therapy : a case report and review of the literature .@_@tamoxifen and Ovarian endometrioid carcinoma are not related .
Ovarian endometrioid carcinoma and endometriosis developing in a postmenopausal breast cancer patient during tamoxifen therapy : a case report and review of the literature .@_@Ovarian endometrioid carcinoma and endometriosis are not related .
Ovarian endometrioid carcinoma and endometriosis developing in a postmenopausal breast cancer patient during tamoxifen therapy : a case report and review of the literature .@_@Ovarian endometrioid carcinoma and Ovarian endometrioid carcinoma are not related .
The association with prolonged unopposed estrogen - like stimulation with tamoxifen as a possible factor in the development of ovarian endometrioid carcinoma is discussed .@_@ovarian endometrioid carcinoma and tamoxifen are Adverse-Effect relation .
The association with prolonged unopposed estrogen - like stimulation with tamoxifen as a possible factor in the development of ovarian endometrioid carcinoma is discussed .@_@ovarian endometrioid carcinoma and ovarian endometrioid carcinoma are not related .
The association with prolonged unopposed estrogen - like stimulation with tamoxifen as a possible factor in the development of ovarian endometrioid carcinoma is discussed .@_@tamoxifen and ovarian endometrioid carcinoma are not related .
The association with prolonged unopposed estrogen - like stimulation with tamoxifen as a possible factor in the development of ovarian endometrioid carcinoma is discussed .@_@tamoxifen and tamoxifen are not related .
We present the first case of ovarian endometrioid carcinoma and endometriosis in a postmenopausal patient who was treated with tamoxifen for breast cancer .@_@ovarian endometrioid carcinoma and tamoxifen are Adverse-Effect relation .
We present the first case of ovarian endometrioid carcinoma and endometriosis in a postmenopausal patient who was treated with tamoxifen for breast cancer .@_@endometriosis and tamoxifen are Adverse-Effect relation .
We present the first case of ovarian endometrioid carcinoma and endometriosis in a postmenopausal patient who was treated with tamoxifen for breast cancer .@_@endometriosis and endometriosis are not related .
We present the first case of ovarian endometrioid carcinoma and endometriosis in a postmenopausal patient who was treated with tamoxifen for breast cancer .@_@endometriosis and ovarian endometrioid carcinoma are not related .
We present the first case of ovarian endometrioid carcinoma and endometriosis in a postmenopausal patient who was treated with tamoxifen for breast cancer .@_@tamoxifen and endometriosis are not related .
We present the first case of ovarian endometrioid carcinoma and endometriosis in a postmenopausal patient who was treated with tamoxifen for breast cancer .@_@tamoxifen and tamoxifen are not related .
We present the first case of ovarian endometrioid carcinoma and endometriosis in a postmenopausal patient who was treated with tamoxifen for breast cancer .@_@tamoxifen and ovarian endometrioid carcinoma are not related .
We present the first case of ovarian endometrioid carcinoma and endometriosis in a postmenopausal patient who was treated with tamoxifen for breast cancer .@_@ovarian endometrioid carcinoma and endometriosis are not related .
We present the first case of ovarian endometrioid carcinoma and endometriosis in a postmenopausal patient who was treated with tamoxifen for breast cancer .@_@ovarian endometrioid carcinoma and ovarian endometrioid carcinoma are not related .
Cerebral demyelinating disease developed in a patient during adjuvant therapy with levamisole for malignant melanoma .@_@Cerebral demyelinating disease and levamisole are Adverse-Effect relation .
Cerebral demyelinating disease developed in a patient during adjuvant therapy with levamisole for malignant melanoma .@_@Cerebral demyelinating disease and Cerebral demyelinating disease are not related .
Cerebral demyelinating disease developed in a patient during adjuvant therapy with levamisole for malignant melanoma .@_@levamisole and Cerebral demyelinating disease are not related .
Cerebral demyelinating disease developed in a patient during adjuvant therapy with levamisole for malignant melanoma .@_@levamisole and levamisole are not related .
Multifocal inflammatory leukoencephalopathy associated with levamisole therapy .@_@Multifocal inflammatory leukoencephalopathy and levamisole are Adverse-Effect relation .
Multifocal inflammatory leukoencephalopathy associated with levamisole therapy .@_@Multifocal inflammatory leukoencephalopathy and Multifocal inflammatory leukoencephalopathy are not related .
Multifocal inflammatory leukoencephalopathy associated with levamisole therapy .@_@levamisole and Multifocal inflammatory leukoencephalopathy are not related .
Multifocal inflammatory leukoencephalopathy associated with levamisole therapy .@_@levamisole and levamisole are not related .
Observations in our patient suggest that the leukoencephalopathy that developed in previously reported patients who received 5-fluorouracil and levamisole may have been caused at least partly by levamisole .@_@leukoencephalopathy and 5-fluorouracil are Adverse-Effect relation .
Observations in our patient suggest that the leukoencephalopathy that developed in previously reported patients who received 5-fluorouracil and levamisole may have been caused at least partly by levamisole .@_@leukoencephalopathy and levamisole are Adverse-Effect relation .
Observations in our patient suggest that the leukoencephalopathy that developed in previously reported patients who received 5-fluorouracil and levamisole may have been caused at least partly by levamisole .@_@leukoencephalopathy and leukoencephalopathy are not related .
Observations in our patient suggest that the leukoencephalopathy that developed in previously reported patients who received 5-fluorouracil and levamisole may have been caused at least partly by levamisole .@_@5-fluorouracil and leukoencephalopathy are not related .
Observations in our patient suggest that the leukoencephalopathy that developed in previously reported patients who received 5-fluorouracil and levamisole may have been caused at least partly by levamisole .@_@5-fluorouracil and 5-fluorouracil are not related .
Observations in our patient suggest that the leukoencephalopathy that developed in previously reported patients who received 5-fluorouracil and levamisole may have been caused at least partly by levamisole .@_@5-fluorouracil and levamisole are not related .
Observations in our patient suggest that the leukoencephalopathy that developed in previously reported patients who received 5-fluorouracil and levamisole may have been caused at least partly by levamisole .@_@levamisole and leukoencephalopathy are not related .
Observations in our patient suggest that the leukoencephalopathy that developed in previously reported patients who received 5-fluorouracil and levamisole may have been caused at least partly by levamisole .@_@levamisole and 5-fluorouracil are not related .
Observations in our patient suggest that the leukoencephalopathy that developed in previously reported patients who received 5-fluorouracil and levamisole may have been caused at least partly by levamisole .@_@levamisole and levamisole are not related .
A case of noncardiogenic pulmonary edema by ethanolamine oleate .@_@noncardiogenic pulmonary edema and ethanolamine oleate are Adverse-Effect relation .
A case of noncardiogenic pulmonary edema by ethanolamine oleate .@_@noncardiogenic pulmonary edema and noncardiogenic pulmonary edema are not related .
A case of noncardiogenic pulmonary edema by ethanolamine oleate .@_@ethanolamine oleate and noncardiogenic pulmonary edema are not related .
A case of noncardiogenic pulmonary edema by ethanolamine oleate .@_@ethanolamine oleate and ethanolamine oleate are not related .
However , EO - induced noncardiogenic pulmonary edema has not been reported in human .@_@noncardiogenic pulmonary edema and EO are Adverse-Effect relation .
However , EO - induced noncardiogenic pulmonary edema has not been reported in human .@_@noncardiogenic pulmonary edema and noncardiogenic pulmonary edema are not related .
However , EO - induced noncardiogenic pulmonary edema has not been reported in human .@_@EO and noncardiogenic pulmonary edema are not related .
However , EO - induced noncardiogenic pulmonary edema has not been reported in human .@_@EO and EO are not related .
We report a case of noncardiogenic pulmonary edema developed after therapeutic trial of EO as sclerosing agent for esophageal varix .@_@noncardiogenic pulmonary edema and EO are Adverse-Effect relation .
We report a case of noncardiogenic pulmonary edema developed after therapeutic trial of EO as sclerosing agent for esophageal varix .@_@noncardiogenic pulmonary edema and noncardiogenic pulmonary edema are not related .
We report a case of noncardiogenic pulmonary edema developed after therapeutic trial of EO as sclerosing agent for esophageal varix .@_@EO and noncardiogenic pulmonary edema are not related .
We report a case of noncardiogenic pulmonary edema developed after therapeutic trial of EO as sclerosing agent for esophageal varix .@_@EO and EO are not related .
Five patients are described in whom only gentamicin sulfate appeared responsible for acute renal failure .@_@acute renal failure and gentamicin sulfate are Adverse-Effect relation .
Five patients are described in whom only gentamicin sulfate appeared responsible for acute renal failure .@_@acute renal failure and acute renal failure are not related .
Five patients are described in whom only gentamicin sulfate appeared responsible for acute renal failure .@_@gentamicin sulfate and acute renal failure are not related .
Five patients are described in whom only gentamicin sulfate appeared responsible for acute renal failure .@_@gentamicin sulfate and gentamicin sulfate are not related .
Gentamicin - associated acute renal failure .@_@acute renal failure and Gentamicin are Adverse-Effect relation .
Gentamicin - associated acute renal failure .@_@acute renal failure and acute renal failure are not related .
Gentamicin - associated acute renal failure .@_@Gentamicin and acute renal failure are not related .
Gentamicin - associated acute renal failure .@_@Gentamicin and Gentamicin are not related .
Renal failure appeared 8 to 17 days after beginning gentamicin therapy and was characterized by creatinine clearances 4 to 10 ml / min , urine to plasma creatinine ratios less than 20 , urinary sodium concentrations 16 to 60 mEq / liter , proteinuria , and cylindruria .@_@Renal failure and gentamicin are Adverse-Effect relation .
Renal failure appeared 8 to 17 days after beginning gentamicin therapy and was characterized by creatinine clearances 4 to 10 ml / min , urine to plasma creatinine ratios less than 20 , urinary sodium concentrations 16 to 60 mEq / liter , proteinuria , and cylindruria .@_@Renal failure and Renal failure are not related .
Renal failure appeared 8 to 17 days after beginning gentamicin therapy and was characterized by creatinine clearances 4 to 10 ml / min , urine to plasma creatinine ratios less than 20 , urinary sodium concentrations 16 to 60 mEq / liter , proteinuria , and cylindruria .@_@gentamicin and Renal failure are not related .
Renal failure appeared 8 to 17 days after beginning gentamicin therapy and was characterized by creatinine clearances 4 to 10 ml / min , urine to plasma creatinine ratios less than 20 , urinary sodium concentrations 16 to 60 mEq / liter , proteinuria , and cylindruria .@_@gentamicin and gentamicin are not related .
A 15-year follow - up of phenytoin - induced unilateral gingival hyperplasia : a case report .@_@unilateral gingival hyperplasia and phenytoin are Adverse-Effect relation .
A 15-year follow - up of phenytoin - induced unilateral gingival hyperplasia : a case report .@_@unilateral gingival hyperplasia and unilateral gingival hyperplasia are not related .
A 15-year follow - up of phenytoin - induced unilateral gingival hyperplasia : a case report .@_@phenytoin and unilateral gingival hyperplasia are not related .
A 15-year follow - up of phenytoin - induced unilateral gingival hyperplasia : a case report .@_@phenytoin and phenytoin are not related .
INTRODUCTION - The aim of this case report is to present a 15-year follow - up of a patient with phenytoin ( PHT ) intoxication with unilateral gingival hyperplasia ( GH ) .@_@unilateral gingival hyperplasia and PHT are Adverse-Effect relation .
INTRODUCTION - The aim of this case report is to present a 15-year follow - up of a patient with phenytoin ( PHT ) intoxication with unilateral gingival hyperplasia ( GH ) .@_@unilateral gingival hyperplasia and phenytoin are Adverse-Effect relation .
INTRODUCTION - The aim of this case report is to present a 15-year follow - up of a patient with phenytoin ( PHT ) intoxication with unilateral gingival hyperplasia ( GH ) .@_@unilateral gingival hyperplasia and unilateral gingival hyperplasia are not related .
INTRODUCTION - The aim of this case report is to present a 15-year follow - up of a patient with phenytoin ( PHT ) intoxication with unilateral gingival hyperplasia ( GH ) .@_@phenytoin and unilateral gingival hyperplasia are not related .
INTRODUCTION - The aim of this case report is to present a 15-year follow - up of a patient with phenytoin ( PHT ) intoxication with unilateral gingival hyperplasia ( GH ) .@_@phenytoin and phenytoin are not related .
INTRODUCTION - The aim of this case report is to present a 15-year follow - up of a patient with phenytoin ( PHT ) intoxication with unilateral gingival hyperplasia ( GH ) .@_@phenytoin and PHT are not related .
INTRODUCTION - The aim of this case report is to present a 15-year follow - up of a patient with phenytoin ( PHT ) intoxication with unilateral gingival hyperplasia ( GH ) .@_@PHT and unilateral gingival hyperplasia are not related .
INTRODUCTION - The aim of this case report is to present a 15-year follow - up of a patient with phenytoin ( PHT ) intoxication with unilateral gingival hyperplasia ( GH ) .@_@PHT and phenytoin are not related .
INTRODUCTION - The aim of this case report is to present a 15-year follow - up of a patient with phenytoin ( PHT ) intoxication with unilateral gingival hyperplasia ( GH ) .@_@PHT and PHT are not related .
We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil , diuron and aminotriazole .@_@generalized cutaneous sclerosis and aminotriazole are Adverse-Effect relation .
We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil , diuron and aminotriazole .@_@generalized cutaneous sclerosis and diuron are Adverse-Effect relation .
We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil , diuron and aminotriazole .@_@generalized cutaneous sclerosis and bromocil are Adverse-Effect relation .
We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil , diuron and aminotriazole .@_@generalized cutaneous sclerosis and generalized cutaneous sclerosis are not related .
We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil , diuron and aminotriazole .@_@aminotriazole and generalized cutaneous sclerosis are not related .
We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil , diuron and aminotriazole .@_@aminotriazole and aminotriazole are not related .
We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil , diuron and aminotriazole .@_@aminotriazole and bromocil are not related .
We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil , diuron and aminotriazole .@_@aminotriazole and diuron are not related .
We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil , diuron and aminotriazole .@_@bromocil and generalized cutaneous sclerosis are not related .
We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil , diuron and aminotriazole .@_@bromocil and aminotriazole are not related .
We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil , diuron and aminotriazole .@_@bromocil and bromocil are not related .
We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil , diuron and aminotriazole .@_@bromocil and diuron are not related .
We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil , diuron and aminotriazole .@_@diuron and generalized cutaneous sclerosis are not related .
We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil , diuron and aminotriazole .@_@diuron and aminotriazole are not related .
We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil , diuron and aminotriazole .@_@diuron and bromocil are not related .
We report a case of generalized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil , diuron and aminotriazole .@_@diuron and diuron are not related .
Albuterol - induced hypokalemia and its potential cardiac toxicity are discussed briefly .@_@hypokalemia and Albuterol are Adverse-Effect relation .
Albuterol - induced hypokalemia and its potential cardiac toxicity are discussed briefly .@_@cardiac toxicity and Albuterol are Adverse-Effect relation .
Albuterol - induced hypokalemia and its potential cardiac toxicity are discussed briefly .@_@cardiac toxicity and cardiac toxicity are not related .
Albuterol - induced hypokalemia and its potential cardiac toxicity are discussed briefly .@_@cardiac toxicity and hypokalemia are not related .
Albuterol - induced hypokalemia and its potential cardiac toxicity are discussed briefly .@_@Albuterol and cardiac toxicity are not related .
Albuterol - induced hypokalemia and its potential cardiac toxicity are discussed briefly .@_@Albuterol and Albuterol are not related .
Albuterol - induced hypokalemia and its potential cardiac toxicity are discussed briefly .@_@Albuterol and hypokalemia are not related .
Albuterol - induced hypokalemia and its potential cardiac toxicity are discussed briefly .@_@hypokalemia and cardiac toxicity are not related .
Albuterol - induced hypokalemia and its potential cardiac toxicity are discussed briefly .@_@hypokalemia and hypokalemia are not related .
Hypokalemia after normal doses of neubulized albuterol ( salbutamol ) .@_@Hypokalemia and salbutamol are Adverse-Effect relation .
Hypokalemia after normal doses of neubulized albuterol ( salbutamol ) .@_@Hypokalemia and albuterol are Adverse-Effect relation .
Hypokalemia after normal doses of neubulized albuterol ( salbutamol ) .@_@Hypokalemia and Hypokalemia are not related .
Hypokalemia after normal doses of neubulized albuterol ( salbutamol ) .@_@albuterol and Hypokalemia are not related .
Hypokalemia after normal doses of neubulized albuterol ( salbutamol ) .@_@albuterol and albuterol are not related .
Hypokalemia after normal doses of neubulized albuterol ( salbutamol ) .@_@albuterol and salbutamol are not related .
Hypokalemia after normal doses of neubulized albuterol ( salbutamol ) .@_@salbutamol and Hypokalemia are not related .
Hypokalemia after normal doses of neubulized albuterol ( salbutamol ) .@_@salbutamol and albuterol are not related .
Hypokalemia after normal doses of neubulized albuterol ( salbutamol ) .@_@salbutamol and salbutamol are not related .
The cases of two asthmatic patients who became hypokalemic after inhalation of normal doses of albuterol are presented .@_@hypokalemic and albuterol are Adverse-Effect relation .
The cases of two asthmatic patients who became hypokalemic after inhalation of normal doses of albuterol are presented .@_@hypokalemic and hypokalemic are not related .
The cases of two asthmatic patients who became hypokalemic after inhalation of normal doses of albuterol are presented .@_@albuterol and hypokalemic are not related .
The cases of two asthmatic patients who became hypokalemic after inhalation of normal doses of albuterol are presented .@_@albuterol and albuterol are not related .
Propoxyphene - induced wide complex dysrhythmia responsive to sodium bicarbonate therapy has not been previously reported in the literature .@_@wide complex dysrhythmia and Propoxyphene are Adverse-Effect relation .
Propoxyphene - induced wide complex dysrhythmia responsive to sodium bicarbonate therapy has not been previously reported in the literature .@_@wide complex dysrhythmia and wide complex dysrhythmia are not related .
Propoxyphene - induced wide complex dysrhythmia responsive to sodium bicarbonate therapy has not been previously reported in the literature .@_@Propoxyphene and wide complex dysrhythmia are not related .
Propoxyphene - induced wide complex dysrhythmia responsive to sodium bicarbonate therapy has not been previously reported in the literature .@_@Propoxyphene and Propoxyphene are not related .
Propoxyphene - induced wide QRS complex dysrhythmia responsive to sodium bicarbonate -- a case report .@_@wide QRS complex dysrhythmia and Propoxyphene are Adverse-Effect relation .
Propoxyphene - induced wide QRS complex dysrhythmia responsive to sodium bicarbonate -- a case report .@_@wide QRS complex dysrhythmia and wide QRS complex dysrhythmia are not related .
Propoxyphene - induced wide QRS complex dysrhythmia responsive to sodium bicarbonate -- a case report .@_@Propoxyphene and wide QRS complex dysrhythmia are not related .
Propoxyphene - induced wide QRS complex dysrhythmia responsive to sodium bicarbonate -- a case report .@_@Propoxyphene and Propoxyphene are not related .
Case report : mannitol nephrotoxicity syndrome : role of hemodialysis and postulate of mechanisms .@_@nephrotoxicity syndrome and mannitol are Adverse-Effect relation .
Case report : mannitol nephrotoxicity syndrome : role of hemodialysis and postulate of mechanisms .@_@nephrotoxicity syndrome and nephrotoxicity syndrome are not related .
Case report : mannitol nephrotoxicity syndrome : role of hemodialysis and postulate of mechanisms .@_@mannitol and nephrotoxicity syndrome are not related .
Case report : mannitol nephrotoxicity syndrome : role of hemodialysis and postulate of mechanisms .@_@mannitol and mannitol are not related .
Hemodialysis should be performed for rapid reversal of mannitol - induced ARF .@_@ARF and mannitol are Adverse-Effect relation .
Hemodialysis should be performed for rapid reversal of mannitol - induced ARF .@_@ARF and ARF are not related .
Hemodialysis should be performed for rapid reversal of mannitol - induced ARF .@_@mannitol and ARF are not related .
Hemodialysis should be performed for rapid reversal of mannitol - induced ARF .@_@mannitol and mannitol are not related .
High - dose intravenous mannitol infusion in various clinical settings may result in acute renal failure ( ARF ) .@_@acute renal failure and mannitol are Adverse-Effect relation .
High - dose intravenous mannitol infusion in various clinical settings may result in acute renal failure ( ARF ) .@_@ARF and mannitol are Adverse-Effect relation .
High - dose intravenous mannitol infusion in various clinical settings may result in acute renal failure ( ARF ) .@_@acute renal failure and acute renal failure are not related .
High - dose intravenous mannitol infusion in various clinical settings may result in acute renal failure ( ARF ) .@_@acute renal failure and ARF are not related .
High - dose intravenous mannitol infusion in various clinical settings may result in acute renal failure ( ARF ) .@_@mannitol and acute renal failure are not related .
High - dose intravenous mannitol infusion in various clinical settings may result in acute renal failure ( ARF ) .@_@mannitol and mannitol are not related .
High - dose intravenous mannitol infusion in various clinical settings may result in acute renal failure ( ARF ) .@_@mannitol and ARF are not related .
High - dose intravenous mannitol infusion in various clinical settings may result in acute renal failure ( ARF ) .@_@ARF and acute renal failure are not related .
High - dose intravenous mannitol infusion in various clinical settings may result in acute renal failure ( ARF ) .@_@ARF and ARF are not related .
Mannitol - induced ARF responds promptly to hemodialysis with rapid resolution of anuria and recovery of renal failure .@_@ARF and Mannitol are Adverse-Effect relation .
Mannitol - induced ARF responds promptly to hemodialysis with rapid resolution of anuria and recovery of renal failure .@_@ARF and ARF are not related .
Mannitol - induced ARF responds promptly to hemodialysis with rapid resolution of anuria and recovery of renal failure .@_@Mannitol and ARF are not related .
Mannitol - induced ARF responds promptly to hemodialysis with rapid resolution of anuria and recovery of renal failure .@_@Mannitol and Mannitol are not related .
The literature is also reviewed for ARF associated with mannitol infusion in patients who received dialysis and those who did not receive dialysis ; and the possible mechanism(s ) of mannitol nephrotoxicity are discussed .@_@ARF and mannitol are Adverse-Effect relation .
The literature is also reviewed for ARF associated with mannitol infusion in patients who received dialysis and those who did not receive dialysis ; and the possible mechanism(s ) of mannitol nephrotoxicity are discussed .@_@nephrotoxicity and mannitol are Adverse-Effect relation .
The literature is also reviewed for ARF associated with mannitol infusion in patients who received dialysis and those who did not receive dialysis ; and the possible mechanism(s ) of mannitol nephrotoxicity are discussed .@_@ARF and ARF are not related .
The literature is also reviewed for ARF associated with mannitol infusion in patients who received dialysis and those who did not receive dialysis ; and the possible mechanism(s ) of mannitol nephrotoxicity are discussed .@_@ARF and nephrotoxicity are not related .
The literature is also reviewed for ARF associated with mannitol infusion in patients who received dialysis and those who did not receive dialysis ; and the possible mechanism(s ) of mannitol nephrotoxicity are discussed .@_@mannitol and ARF are not related .
The literature is also reviewed for ARF associated with mannitol infusion in patients who received dialysis and those who did not receive dialysis ; and the possible mechanism(s ) of mannitol nephrotoxicity are discussed .@_@mannitol and mannitol are not related .
The literature is also reviewed for ARF associated with mannitol infusion in patients who received dialysis and those who did not receive dialysis ; and the possible mechanism(s ) of mannitol nephrotoxicity are discussed .@_@mannitol and nephrotoxicity are not related .
The literature is also reviewed for ARF associated with mannitol infusion in patients who received dialysis and those who did not receive dialysis ; and the possible mechanism(s ) of mannitol nephrotoxicity are discussed .@_@nephrotoxicity and ARF are not related .
The literature is also reviewed for ARF associated with mannitol infusion in patients who received dialysis and those who did not receive dialysis ; and the possible mechanism(s ) of mannitol nephrotoxicity are discussed .@_@nephrotoxicity and nephrotoxicity are not related .
This is a report of a case of anuric ARF after high - dose mannitol infusion for treatment of narrow - angle glaucoma that readily responded to acute hemodialysis .@_@anuric ARF and mannitol are Adverse-Effect relation .
This is a report of a case of anuric ARF after high - dose mannitol infusion for treatment of narrow - angle glaucoma that readily responded to acute hemodialysis .@_@anuric ARF and anuric ARF are not related .
This is a report of a case of anuric ARF after high - dose mannitol infusion for treatment of narrow - angle glaucoma that readily responded to acute hemodialysis .@_@mannitol and anuric ARF are not related .
This is a report of a case of anuric ARF after high - dose mannitol infusion for treatment of narrow - angle glaucoma that readily responded to acute hemodialysis .@_@mannitol and mannitol are not related .
Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM - SPECT .@_@extrapyramidal side effects and fluphenazine decanoate are Adverse-Effect relation .
Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM - SPECT .@_@extrapyramidal side effects and extrapyramidal side effects are not related .
Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM - SPECT .@_@fluphenazine decanoate and extrapyramidal side effects are not related .
Two patients with extrapyramidal side effects after the use of fluphenazine decanoate were evaluated by means of IBZM - SPECT .@_@fluphenazine decanoate and fluphenazine decanoate are not related .
Flumazenil reversal of benzodiazepine - induced sedation for a patient with severe pre - ECT anxiety .@_@sedation and benzodiazepine are Adverse-Effect relation .
Flumazenil reversal of benzodiazepine - induced sedation for a patient with severe pre - ECT anxiety .@_@sedation and sedation are not related .
Flumazenil reversal of benzodiazepine - induced sedation for a patient with severe pre - ECT anxiety .@_@benzodiazepine and sedation are not related .
Flumazenil reversal of benzodiazepine - induced sedation for a patient with severe pre - ECT anxiety .@_@benzodiazepine and benzodiazepine are not related .
CASE SUMMARY : A 68-year - old woman developed a dry , irritating cough within one month of starting quinapril therapy for the treatment of essential hypertension .@_@irritating cough and quinapril are Adverse-Effect relation .
CASE SUMMARY : A 68-year - old woman developed a dry , irritating cough within one month of starting quinapril therapy for the treatment of essential hypertension .@_@irritating cough and irritating cough are not related .
CASE SUMMARY : A 68-year - old woman developed a dry , irritating cough within one month of starting quinapril therapy for the treatment of essential hypertension .@_@quinapril and irritating cough are not related .
CASE SUMMARY : A 68-year - old woman developed a dry , irritating cough within one month of starting quinapril therapy for the treatment of essential hypertension .@_@quinapril and quinapril are not related .
Cough induced by quinapril with resolution after changing to fosinopril .@_@Cough and quinapril are Adverse-Effect relation .
Cough induced by quinapril with resolution after changing to fosinopril .@_@Cough and Cough are not related .
Cough induced by quinapril with resolution after changing to fosinopril .@_@quinapril and Cough are not related .
Cough induced by quinapril with resolution after changing to fosinopril .@_@quinapril and quinapril are not related .
OBJECTIVE : To report a case of chronic , nonproductive cough secondary to the angiotensin - converting enzyme ( ACE ) inhibitor quinapril , with complete resolution after switching to another ACE inhibitor , fosinopril .@_@cough and quinapril are Adverse-Effect relation .
OBJECTIVE : To report a case of chronic , nonproductive cough secondary to the angiotensin - converting enzyme ( ACE ) inhibitor quinapril , with complete resolution after switching to another ACE inhibitor , fosinopril .@_@cough and cough are not related .
OBJECTIVE : To report a case of chronic , nonproductive cough secondary to the angiotensin - converting enzyme ( ACE ) inhibitor quinapril , with complete resolution after switching to another ACE inhibitor , fosinopril .@_@quinapril and cough are not related .
OBJECTIVE : To report a case of chronic , nonproductive cough secondary to the angiotensin - converting enzyme ( ACE ) inhibitor quinapril , with complete resolution after switching to another ACE inhibitor , fosinopril .@_@quinapril and quinapril are not related .
The cough continued for the duration of therapy with quinapril .@_@cough and quinapril are Adverse-Effect relation .
The cough continued for the duration of therapy with quinapril .@_@cough and cough are not related .
The cough continued for the duration of therapy with quinapril .@_@quinapril and cough are not related .
The cough continued for the duration of therapy with quinapril .@_@quinapril and quinapril are not related .
We report a case of cough following the administration of quinapril , with complete resolution after changing to the alternative ACE inhibitor fosinopril in a patient with essential hypertension .@_@cough and quinapril are Adverse-Effect relation .
We report a case of cough following the administration of quinapril , with complete resolution after changing to the alternative ACE inhibitor fosinopril in a patient with essential hypertension .@_@cough and cough are not related .
We report a case of cough following the administration of quinapril , with complete resolution after changing to the alternative ACE inhibitor fosinopril in a patient with essential hypertension .@_@quinapril and cough are not related .
We report a case of cough following the administration of quinapril , with complete resolution after changing to the alternative ACE inhibitor fosinopril in a patient with essential hypertension .@_@quinapril and quinapril are not related .
Fracture of the femoral neck occurred in one patient during PSL therapy , although the relationship between the fracture and PSL therapy was uncertain .@_@Fracture of the femoral neck and PSL are Adverse-Effect relation .
Fracture of the femoral neck occurred in one patient during PSL therapy , although the relationship between the fracture and PSL therapy was uncertain .@_@Fracture of the femoral neck and Fracture of the femoral neck are not related .
Fracture of the femoral neck occurred in one patient during PSL therapy , although the relationship between the fracture and PSL therapy was uncertain .@_@PSL and Fracture of the femoral neck are not related .
Fracture of the femoral neck occurred in one patient during PSL therapy , although the relationship between the fracture and PSL therapy was uncertain .@_@PSL and PSL are not related .
Cefuroxime - induced acute renal failure .@_@acute renal failure and Cefuroxime are Adverse-Effect relation .
Cefuroxime - induced acute renal failure .@_@acute renal failure and acute renal failure are not related .
Cefuroxime - induced acute renal failure .@_@Cefuroxime and acute renal failure are not related .
Cefuroxime - induced acute renal failure .@_@Cefuroxime and Cefuroxime are not related .
In our patient , DIAN possibly was related to cefuroxime , but the patient did not experience associated allergic symptoms .@_@DIAN and cefuroxime are Adverse-Effect relation .
In our patient , DIAN possibly was related to cefuroxime , but the patient did not experience associated allergic symptoms .@_@DIAN and DIAN are not related .
In our patient , DIAN possibly was related to cefuroxime , but the patient did not experience associated allergic symptoms .@_@cefuroxime and DIAN are not related .
In our patient , DIAN possibly was related to cefuroxime , but the patient did not experience associated allergic symptoms .@_@cefuroxime and cefuroxime are not related .
The diagnosis was supported by the temporal course of renal deterioration during exposure to cefuroxime and improvement on its discontinuation ; the pattern repeated with rechallenge .@_@renal deterioration and cefuroxime are Adverse-Effect relation .
The diagnosis was supported by the temporal course of renal deterioration during exposure to cefuroxime and improvement on its discontinuation ; the pattern repeated with rechallenge .@_@renal deterioration and renal deterioration are not related .
The diagnosis was supported by the temporal course of renal deterioration during exposure to cefuroxime and improvement on its discontinuation ; the pattern repeated with rechallenge .@_@cefuroxime and renal deterioration are not related .
The diagnosis was supported by the temporal course of renal deterioration during exposure to cefuroxime and improvement on its discontinuation ; the pattern repeated with rechallenge .@_@cefuroxime and cefuroxime are not related .
This is the first reported case of suspected DIAN due to cefuroxime .@_@DIAN and cefuroxime are Adverse-Effect relation .
This is the first reported case of suspected DIAN due to cefuroxime .@_@DIAN and DIAN are not related .
This is the first reported case of suspected DIAN due to cefuroxime .@_@cefuroxime and DIAN are not related .
This is the first reported case of suspected DIAN due to cefuroxime .@_@cefuroxime and cefuroxime are not related .
A case of basilar invagination which is thought to have arisen from the patient 's intrauterine exposure to phenytoin is presented .@_@basilar invagination and phenytoin are Adverse-Effect relation .
A case of basilar invagination which is thought to have arisen from the patient 's intrauterine exposure to phenytoin is presented .@_@basilar invagination and basilar invagination are not related .
A case of basilar invagination which is thought to have arisen from the patient 's intrauterine exposure to phenytoin is presented .@_@phenytoin and basilar invagination are not related .
A case of basilar invagination which is thought to have arisen from the patient 's intrauterine exposure to phenytoin is presented .@_@phenytoin and phenytoin are not related .
Basilar invagination and mid - line skeletal abnormalities due to in utero exposure to phenytoin .@_@mid - line skeletal abnormalities and phenytoin are Adverse-Effect relation .
Basilar invagination and mid - line skeletal abnormalities due to in utero exposure to phenytoin .@_@Basilar invagination and phenytoin are Adverse-Effect relation .
Basilar invagination and mid - line skeletal abnormalities due to in utero exposure to phenytoin .@_@Basilar invagination and Basilar invagination are not related .
Basilar invagination and mid - line skeletal abnormalities due to in utero exposure to phenytoin .@_@Basilar invagination and mid - line skeletal abnormalities are not related .
Basilar invagination and mid - line skeletal abnormalities due to in utero exposure to phenytoin .@_@phenytoin and Basilar invagination are not related .
Basilar invagination and mid - line skeletal abnormalities due to in utero exposure to phenytoin .@_@phenytoin and phenytoin are not related .
Basilar invagination and mid - line skeletal abnormalities due to in utero exposure to phenytoin .@_@phenytoin and mid - line skeletal abnormalities are not related .
Basilar invagination and mid - line skeletal abnormalities due to in utero exposure to phenytoin .@_@mid - line skeletal abnormalities and Basilar invagination are not related .
Basilar invagination and mid - line skeletal abnormalities due to in utero exposure to phenytoin .@_@mid - line skeletal abnormalities and mid - line skeletal abnormalities are not related .
His symptoms of brain stem compression were alleviated and the role of phenytoin in the production of his craniocervical abnormality is discussed .@_@craniocervical abnormality and phenytoin are Adverse-Effect relation .
His symptoms of brain stem compression were alleviated and the role of phenytoin in the production of his craniocervical abnormality is discussed .@_@craniocervical abnormality and craniocervical abnormality are not related .
His symptoms of brain stem compression were alleviated and the role of phenytoin in the production of his craniocervical abnormality is discussed .@_@phenytoin and craniocervical abnormality are not related .
His symptoms of brain stem compression were alleviated and the role of phenytoin in the production of his craniocervical abnormality is discussed .@_@phenytoin and phenytoin are not related .
Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high - dose methotrexate ( HD - MTX ) for osteogenic sarcoma .@_@Temporary neurologic abnormalities and methotrexate are Adverse-Effect relation .
Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high - dose methotrexate ( HD - MTX ) for osteogenic sarcoma .@_@Temporary neurologic abnormalities and Temporary neurologic abnormalities are not related .
Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high - dose methotrexate ( HD - MTX ) for osteogenic sarcoma .@_@methotrexate and Temporary neurologic abnormalities are not related .
Temporary neurologic abnormalities were observed in one out of 23 patients undergoing chemotherapy with high - dose methotrexate ( HD - MTX ) for osteogenic sarcoma .@_@methotrexate and methotrexate are not related .
This patient developed sequential symptoms including alternative hemiparesis , dysarthria and altered consciousness 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue .@_@dysarthria and HD - MTX are Adverse-Effect relation .
This patient developed sequential symptoms including alternative hemiparesis , dysarthria and altered consciousness 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue .@_@hemiparesis and HD - MTX are Adverse-Effect relation .
This patient developed sequential symptoms including alternative hemiparesis , dysarthria and altered consciousness 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue .@_@altered consciousness and HD - MTX are Adverse-Effect relation .
This patient developed sequential symptoms including alternative hemiparesis , dysarthria and altered consciousness 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue .@_@altered consciousness and altered consciousness are not related .
This patient developed sequential symptoms including alternative hemiparesis , dysarthria and altered consciousness 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue .@_@altered consciousness and dysarthria are not related .
This patient developed sequential symptoms including alternative hemiparesis , dysarthria and altered consciousness 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue .@_@altered consciousness and hemiparesis are not related .
This patient developed sequential symptoms including alternative hemiparesis , dysarthria and altered consciousness 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue .@_@HD - MTX and altered consciousness are not related .
This patient developed sequential symptoms including alternative hemiparesis , dysarthria and altered consciousness 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue .@_@HD - MTX and HD - MTX are not related .
This patient developed sequential symptoms including alternative hemiparesis , dysarthria and altered consciousness 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue .@_@HD - MTX and dysarthria are not related .
This patient developed sequential symptoms including alternative hemiparesis , dysarthria and altered consciousness 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue .@_@HD - MTX and hemiparesis are not related .
This patient developed sequential symptoms including alternative hemiparesis , dysarthria and altered consciousness 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue .@_@dysarthria and altered consciousness are not related .
This patient developed sequential symptoms including alternative hemiparesis , dysarthria and altered consciousness 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue .@_@dysarthria and dysarthria are not related .
This patient developed sequential symptoms including alternative hemiparesis , dysarthria and altered consciousness 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue .@_@dysarthria and hemiparesis are not related .
This patient developed sequential symptoms including alternative hemiparesis , dysarthria and altered consciousness 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue .@_@hemiparesis and altered consciousness are not related .
This patient developed sequential symptoms including alternative hemiparesis , dysarthria and altered consciousness 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue .@_@hemiparesis and dysarthria are not related .
This patient developed sequential symptoms including alternative hemiparesis , dysarthria and altered consciousness 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue .@_@hemiparesis and hemiparesis are not related .
Transient neurological disturbances induced by the chemotherapy of high - dose methotrexate for osteogenic sarcoma .@_@Transient neurological disturbances and methotrexate are Adverse-Effect relation .
Transient neurological disturbances induced by the chemotherapy of high - dose methotrexate for osteogenic sarcoma .@_@Transient neurological disturbances and Transient neurological disturbances are not related .
Transient neurological disturbances induced by the chemotherapy of high - dose methotrexate for osteogenic sarcoma .@_@methotrexate and Transient neurological disturbances are not related .
Transient neurological disturbances induced by the chemotherapy of high - dose methotrexate for osteogenic sarcoma .@_@methotrexate and methotrexate are not related .
We report a 5-year - old boy with CF who had a stricture of the hepatic flexure region with associated narrowing due to submucosal fibrosis of the transverse colon , secondary to high - lipase pancreatin therapy .@_@stricture of the hepatic flexure region with associated narrowing and high - lipase pancreatin are Adverse-Effect relation .
We report a 5-year - old boy with CF who had a stricture of the hepatic flexure region with associated narrowing due to submucosal fibrosis of the transverse colon , secondary to high - lipase pancreatin therapy .@_@submucosal fibrosis of the transverse colon and high - lipase pancreatin are Adverse-Effect relation .
We report a 5-year - old boy with CF who had a stricture of the hepatic flexure region with associated narrowing due to submucosal fibrosis of the transverse colon , secondary to high - lipase pancreatin therapy .@_@stricture of the hepatic flexure region with associated narrowing and stricture of the hepatic flexure region with associated narrowing are not related .
We report a 5-year - old boy with CF who had a stricture of the hepatic flexure region with associated narrowing due to submucosal fibrosis of the transverse colon , secondary to high - lipase pancreatin therapy .@_@stricture of the hepatic flexure region with associated narrowing and submucosal fibrosis of the transverse colon are not related .
We report a 5-year - old boy with CF who had a stricture of the hepatic flexure region with associated narrowing due to submucosal fibrosis of the transverse colon , secondary to high - lipase pancreatin therapy .@_@high - lipase pancreatin and stricture of the hepatic flexure region with associated narrowing are not related .
We report a 5-year - old boy with CF who had a stricture of the hepatic flexure region with associated narrowing due to submucosal fibrosis of the transverse colon , secondary to high - lipase pancreatin therapy .@_@high - lipase pancreatin and high - lipase pancreatin are not related .
We report a 5-year - old boy with CF who had a stricture of the hepatic flexure region with associated narrowing due to submucosal fibrosis of the transverse colon , secondary to high - lipase pancreatin therapy .@_@high - lipase pancreatin and submucosal fibrosis of the transverse colon are not related .
We report a 5-year - old boy with CF who had a stricture of the hepatic flexure region with associated narrowing due to submucosal fibrosis of the transverse colon , secondary to high - lipase pancreatin therapy .@_@submucosal fibrosis of the transverse colon and stricture of the hepatic flexure region with associated narrowing are not related .
We report a 5-year - old boy with CF who had a stricture of the hepatic flexure region with associated narrowing due to submucosal fibrosis of the transverse colon , secondary to high - lipase pancreatin therapy .@_@submucosal fibrosis of the transverse colon and submucosal fibrosis of the transverse colon are not related .
Acute pancreatitis associated with danazol treatment for endometriosis .@_@Acute pancreatitis and danazol are Adverse-Effect relation .
Acute pancreatitis associated with danazol treatment for endometriosis .@_@Acute pancreatitis and Acute pancreatitis are not related .
Acute pancreatitis associated with danazol treatment for endometriosis .@_@danazol and Acute pancreatitis are not related .
Acute pancreatitis associated with danazol treatment for endometriosis .@_@danazol and danazol are not related .
Additionally , danazol produces hepatocellular damage in approximately 10 % of women .@_@hepatocellular damage and danazol are Adverse-Effect relation .
Additionally , danazol produces hepatocellular damage in approximately 10 % of women .@_@hepatocellular damage and hepatocellular damage are not related .
Additionally , danazol produces hepatocellular damage in approximately 10 % of women .@_@danazol and hepatocellular damage are not related .
Additionally , danazol produces hepatocellular damage in approximately 10 % of women .@_@danazol and danazol are not related .
Hypo - oestrogenic and anabolic / androgenic side - effects of danazol are well known by the gynaecologist and some of them are present in > 50 % of patients being treated for endometriosis .@_@Hypo - oestrogenic and anabolic / androgenic side - effects and danazol are Adverse-Effect relation .
Hypo - oestrogenic and anabolic / androgenic side - effects of danazol are well known by the gynaecologist and some of them are present in > 50 % of patients being treated for endometriosis .@_@Hypo - oestrogenic and anabolic / androgenic side - effects and Hypo - oestrogenic and anabolic / androgenic side - effects are not related .
Hypo - oestrogenic and anabolic / androgenic side - effects of danazol are well known by the gynaecologist and some of them are present in > 50 % of patients being treated for endometriosis .@_@danazol and Hypo - oestrogenic and anabolic / androgenic side - effects are not related .
Hypo - oestrogenic and anabolic / androgenic side - effects of danazol are well known by the gynaecologist and some of them are present in > 50 % of patients being treated for endometriosis .@_@danazol and danazol are not related .
The present report describes the first case of acute pancreatitis associated with danazol treatment of endometriosis .@_@acute pancreatitis and danazol are Adverse-Effect relation .
The present report describes the first case of acute pancreatitis associated with danazol treatment of endometriosis .@_@acute pancreatitis and acute pancreatitis are not related .
The present report describes the first case of acute pancreatitis associated with danazol treatment of endometriosis .@_@danazol and acute pancreatitis are not related .
The present report describes the first case of acute pancreatitis associated with danazol treatment of endometriosis .@_@danazol and danazol are not related .
Acyclovir neurotoxicity : clinical experience and review of the literature .@_@neurotoxicity and Acyclovir are Adverse-Effect relation .
Acyclovir neurotoxicity : clinical experience and review of the literature .@_@neurotoxicity and neurotoxicity are not related .
Acyclovir neurotoxicity : clinical experience and review of the literature .@_@Acyclovir and neurotoxicity are not related .
Acyclovir neurotoxicity : clinical experience and review of the literature .@_@Acyclovir and Acyclovir are not related .
Acyclovir produces neurologic symptoms that resemble extension of viral infection into the central nervous system .@_@neurologic symptoms and Acyclovir are Adverse-Effect relation .
Acyclovir produces neurologic symptoms that resemble extension of viral infection into the central nervous system .@_@neurologic symptoms and neurologic symptoms are not related .
Acyclovir produces neurologic symptoms that resemble extension of viral infection into the central nervous system .@_@Acyclovir and neurologic symptoms are not related .
Acyclovir produces neurologic symptoms that resemble extension of viral infection into the central nervous system .@_@Acyclovir and Acyclovir are not related .
Systemic disease , most commonly renal dysfunction , preceded all 30 reported cases of acyclovir neurotoxicity .@_@neurotoxicity and acyclovir are Adverse-Effect relation .
Systemic disease , most commonly renal dysfunction , preceded all 30 reported cases of acyclovir neurotoxicity .@_@neurotoxicity and neurotoxicity are not related .
Systemic disease , most commonly renal dysfunction , preceded all 30 reported cases of acyclovir neurotoxicity .@_@acyclovir and neurotoxicity are not related .
Systemic disease , most commonly renal dysfunction , preceded all 30 reported cases of acyclovir neurotoxicity .@_@acyclovir and acyclovir are not related .
We discuss our observations in the cases of two patients with acyclovir neurotoxicity and review the findings of all previous reports in the English language literature .@_@neurotoxicity and acyclovir are Adverse-Effect relation .
We discuss our observations in the cases of two patients with acyclovir neurotoxicity and review the findings of all previous reports in the English language literature .@_@neurotoxicity and neurotoxicity are not related .
We discuss our observations in the cases of two patients with acyclovir neurotoxicity and review the findings of all previous reports in the English language literature .@_@acyclovir and neurotoxicity are not related .
We discuss our observations in the cases of two patients with acyclovir neurotoxicity and review the findings of all previous reports in the English language literature .@_@acyclovir and acyclovir are not related .
Response of a promethazine - induced coma to flumazenil .@_@coma and promethazine are Adverse-Effect relation .
Response of a promethazine - induced coma to flumazenil .@_@coma and coma are not related .
Response of a promethazine - induced coma to flumazenil .@_@promethazine and coma are not related .
Response of a promethazine - induced coma to flumazenil .@_@promethazine and promethazine are not related .
We report the first case of a patient in a promethazine - induced coma responding to treatment with flumazenil .@_@coma and promethazine are Adverse-Effect relation .
We report the first case of a patient in a promethazine - induced coma responding to treatment with flumazenil .@_@coma and coma are not related .
We report the first case of a patient in a promethazine - induced coma responding to treatment with flumazenil .@_@promethazine and coma are not related .
We report the first case of a patient in a promethazine - induced coma responding to treatment with flumazenil .@_@promethazine and promethazine are not related .
Amebic abscess of the spleen complicated by metronidazole - induced neurotoxicity : case report .@_@Amebic abscess of the spleen and metronidazole are Adverse-Effect relation .
Amebic abscess of the spleen complicated by metronidazole - induced neurotoxicity : case report .@_@neurotoxicity and metronidazole are Adverse-Effect relation .
Amebic abscess of the spleen complicated by metronidazole - induced neurotoxicity : case report .@_@Amebic abscess of the spleen and Amebic abscess of the spleen are not related .
Amebic abscess of the spleen complicated by metronidazole - induced neurotoxicity : case report .@_@Amebic abscess of the spleen and neurotoxicity are not related .
Amebic abscess of the spleen complicated by metronidazole - induced neurotoxicity : case report .@_@metronidazole and Amebic abscess of the spleen are not related .
Amebic abscess of the spleen complicated by metronidazole - induced neurotoxicity : case report .@_@metronidazole and metronidazole are not related .
Amebic abscess of the spleen complicated by metronidazole - induced neurotoxicity : case report .@_@metronidazole and neurotoxicity are not related .
Amebic abscess of the spleen complicated by metronidazole - induced neurotoxicity : case report .@_@neurotoxicity and Amebic abscess of the spleen are not related .
Amebic abscess of the spleen complicated by metronidazole - induced neurotoxicity : case report .@_@neurotoxicity and neurotoxicity are not related .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@reversible deafness and metronidazole are Adverse-Effect relation .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@liver abscess and metronidazole are Adverse-Effect relation .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@splenic abscess and metronidazole are Adverse-Effect relation .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@ataxia and metronidazole are Adverse-Effect relation .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@tinnitus and metronidazole are Adverse-Effect relation .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@ataxia and ataxia are not related .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@ataxia and liver abscess are not related .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@ataxia and reversible deafness are not related .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@ataxia and splenic abscess are not related .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@ataxia and tinnitus are not related .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@metronidazole and ataxia are not related .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@metronidazole and metronidazole are not related .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@metronidazole and liver abscess are not related .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@metronidazole and reversible deafness are not related .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@metronidazole and splenic abscess are not related .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@metronidazole and tinnitus are not related .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@liver abscess and ataxia are not related .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@liver abscess and liver abscess are not related .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@liver abscess and reversible deafness are not related .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@liver abscess and splenic abscess are not related .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@liver abscess and tinnitus are not related .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@reversible deafness and ataxia are not related .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@reversible deafness and liver abscess are not related .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@reversible deafness and reversible deafness are not related .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@reversible deafness and splenic abscess are not related .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@reversible deafness and tinnitus are not related .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@splenic abscess and ataxia are not related .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@splenic abscess and liver abscess are not related .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@splenic abscess and reversible deafness are not related .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@splenic abscess and splenic abscess are not related .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@splenic abscess and tinnitus are not related .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@tinnitus and ataxia are not related .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@tinnitus and liver abscess are not related .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@tinnitus and reversible deafness are not related .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@tinnitus and splenic abscess are not related .
We describe a patient with a liver abscess due to Entamoeba histolytica , in whom metronidazole therapy ( total dose , 21 g over 14 days ) was complicated by reversible deafness , tinnitus , and ataxia and who relapsed 5 months later with a splenic abscess .@_@tinnitus and tinnitus are not related .
Actinomycin D associated hepatic veno - occlusive disease -- a report of 2 cases .@_@hepatic veno - occlusive disease and Actinomycin D are Adverse-Effect relation .
Actinomycin D associated hepatic veno - occlusive disease -- a report of 2 cases .@_@hepatic veno - occlusive disease and hepatic veno - occlusive disease are not related .
Actinomycin D associated hepatic veno - occlusive disease -- a report of 2 cases .@_@Actinomycin D and hepatic veno - occlusive disease are not related .
Actinomycin D associated hepatic veno - occlusive disease -- a report of 2 cases .@_@Actinomycin D and Actinomycin D are not related .
There are now reports of liver failure following treatment of childhood cancers with AMD .@_@liver failure and AMD are Adverse-Effect relation .
There are now reports of liver failure following treatment of childhood cancers with AMD .@_@liver failure and liver failure are not related .
There are now reports of liver failure following treatment of childhood cancers with AMD .@_@AMD and liver failure are not related .
There are now reports of liver failure following treatment of childhood cancers with AMD .@_@AMD and AMD are not related .
Phenylpropanolamine - induced psychosis .@_@psychosis and Phenylpropanolamine are Adverse-Effect relation .
Phenylpropanolamine - induced psychosis .@_@psychosis and psychosis are not related .
Phenylpropanolamine - induced psychosis .@_@Phenylpropanolamine and psychosis are not related .
Phenylpropanolamine - induced psychosis .@_@Phenylpropanolamine and Phenylpropanolamine are not related .
We report a cae of paranoid psychosis following use of a decongestant containing PPA and summarize the case report literature of psychiatric adverse effects to PPA in which doses were known and stated to be within recommended guidelines .@_@paranoid psychosis and PPA are Adverse-Effect relation .
We report a cae of paranoid psychosis following use of a decongestant containing PPA and summarize the case report literature of psychiatric adverse effects to PPA in which doses were known and stated to be within recommended guidelines .@_@psychiatric adverse effects and PPA are Adverse-Effect relation .
We report a cae of paranoid psychosis following use of a decongestant containing PPA and summarize the case report literature of psychiatric adverse effects to PPA in which doses were known and stated to be within recommended guidelines .@_@paranoid psychosis and paranoid psychosis are not related .
We report a cae of paranoid psychosis following use of a decongestant containing PPA and summarize the case report literature of psychiatric adverse effects to PPA in which doses were known and stated to be within recommended guidelines .@_@paranoid psychosis and psychiatric adverse effects are not related .
We report a cae of paranoid psychosis following use of a decongestant containing PPA and summarize the case report literature of psychiatric adverse effects to PPA in which doses were known and stated to be within recommended guidelines .@_@PPA and paranoid psychosis are not related .
We report a cae of paranoid psychosis following use of a decongestant containing PPA and summarize the case report literature of psychiatric adverse effects to PPA in which doses were known and stated to be within recommended guidelines .@_@PPA and PPA are not related .
We report a cae of paranoid psychosis following use of a decongestant containing PPA and summarize the case report literature of psychiatric adverse effects to PPA in which doses were known and stated to be within recommended guidelines .@_@PPA and psychiatric adverse effects are not related .
We report a cae of paranoid psychosis following use of a decongestant containing PPA and summarize the case report literature of psychiatric adverse effects to PPA in which doses were known and stated to be within recommended guidelines .@_@psychiatric adverse effects and paranoid psychosis are not related .
We report a cae of paranoid psychosis following use of a decongestant containing PPA and summarize the case report literature of psychiatric adverse effects to PPA in which doses were known and stated to be within recommended guidelines .@_@psychiatric adverse effects and psychiatric adverse effects are not related .
CONCLUSIONS : Although budesonide may be beneficial because of its anti - inflammatory effects , clinicians should be alert to its potential for causing contact dermatitis .@_@contact dermatitis and budesonide are Adverse-Effect relation .
CONCLUSIONS : Although budesonide may be beneficial because of its anti - inflammatory effects , clinicians should be alert to its potential for causing contact dermatitis .@_@contact dermatitis and contact dermatitis are not related .
CONCLUSIONS : Although budesonide may be beneficial because of its anti - inflammatory effects , clinicians should be alert to its potential for causing contact dermatitis .@_@budesonide and contact dermatitis are not related .
CONCLUSIONS : Although budesonide may be beneficial because of its anti - inflammatory effects , clinicians should be alert to its potential for causing contact dermatitis .@_@budesonide and budesonide are not related .
Contact dermatitis due to budesonide : report of five cases and review of the Japanese literature .@_@Contact dermatitis and budesonide are Adverse-Effect relation .
Contact dermatitis due to budesonide : report of five cases and review of the Japanese literature .@_@Contact dermatitis and Contact dermatitis are not related .
Contact dermatitis due to budesonide : report of five cases and review of the Japanese literature .@_@budesonide and Contact dermatitis are not related .
Contact dermatitis due to budesonide : report of five cases and review of the Japanese literature .@_@budesonide and budesonide are not related .
METHODS : Five cases of contact dermatitis due to budesonide , a nonhalogenated steroid , are described .@_@contact dermatitis and budesonide are Adverse-Effect relation .
METHODS : Five cases of contact dermatitis due to budesonide , a nonhalogenated steroid , are described .@_@contact dermatitis and contact dermatitis are not related .
METHODS : Five cases of contact dermatitis due to budesonide , a nonhalogenated steroid , are described .@_@budesonide and contact dermatitis are not related .
METHODS : Five cases of contact dermatitis due to budesonide , a nonhalogenated steroid , are described .@_@budesonide and budesonide are not related .
RESULTS : Budesonide use can cause contact dermatitis .@_@contact dermatitis and Budesonide are Adverse-Effect relation .
RESULTS : Budesonide use can cause contact dermatitis .@_@contact dermatitis and contact dermatitis are not related .
RESULTS : Budesonide use can cause contact dermatitis .@_@Budesonide and contact dermatitis are not related .
RESULTS : Budesonide use can cause contact dermatitis .@_@Budesonide and Budesonide are not related .
Although other nitrites induce methemoglobinemia , exposure to methyl nitrite during phenylpropanolamine production appears to be a new cause of occupational methemoglobinemia .@_@methemoglobinemia and methyl nitrite are Adverse-Effect relation .
Although other nitrites induce methemoglobinemia , exposure to methyl nitrite during phenylpropanolamine production appears to be a new cause of occupational methemoglobinemia .@_@methemoglobinemia and methemoglobinemia are not related .
Although other nitrites induce methemoglobinemia , exposure to methyl nitrite during phenylpropanolamine production appears to be a new cause of occupational methemoglobinemia .@_@methyl nitrite and methemoglobinemia are not related .
Although other nitrites induce methemoglobinemia , exposure to methyl nitrite during phenylpropanolamine production appears to be a new cause of occupational methemoglobinemia .@_@methyl nitrite and methyl nitrite are not related .
Methemoglobinemia : an occupational hazard of phenylpropanolamine production .@_@Methemoglobinemia and phenylpropanolamine are Adverse-Effect relation .
Methemoglobinemia : an occupational hazard of phenylpropanolamine production .@_@Methemoglobinemia and Methemoglobinemia are not related .
Methemoglobinemia : an occupational hazard of phenylpropanolamine production .@_@phenylpropanolamine and Methemoglobinemia are not related .
Methemoglobinemia : an occupational hazard of phenylpropanolamine production .@_@phenylpropanolamine and phenylpropanolamine are not related .
During and after IFN therapy we should consider the possibility of occurrence of IDDM as well as other autoimmune diseases and observe the clinical course carefully .@_@IDDM and IFN are Adverse-Effect relation .
During and after IFN therapy we should consider the possibility of occurrence of IDDM as well as other autoimmune diseases and observe the clinical course carefully .@_@IDDM and IDDM are not related .
During and after IFN therapy we should consider the possibility of occurrence of IDDM as well as other autoimmune diseases and observe the clinical course carefully .@_@IFN and IDDM are not related .
During and after IFN therapy we should consider the possibility of occurrence of IDDM as well as other autoimmune diseases and observe the clinical course carefully .@_@IFN and IFN are not related .
Four years after the beginning of IFN therapy , he acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody , and then 28 units / day of insulin injection was started .@_@moderate hyperglycemia and IFN are Adverse-Effect relation .
Four years after the beginning of IFN therapy , he acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody , and then 28 units / day of insulin injection was started .@_@severe ketonuria and IFN are Adverse-Effect relation .
Four years after the beginning of IFN therapy , he acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody , and then 28 units / day of insulin injection was started .@_@moderate hyperglycemia and moderate hyperglycemia are not related .
Four years after the beginning of IFN therapy , he acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody , and then 28 units / day of insulin injection was started .@_@moderate hyperglycemia and severe ketonuria are not related .
Four years after the beginning of IFN therapy , he acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody , and then 28 units / day of insulin injection was started .@_@IFN and moderate hyperglycemia are not related .
Four years after the beginning of IFN therapy , he acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody , and then 28 units / day of insulin injection was started .@_@IFN and IFN are not related .
Four years after the beginning of IFN therapy , he acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody , and then 28 units / day of insulin injection was started .@_@IFN and severe ketonuria are not related .
Four years after the beginning of IFN therapy , he acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody , and then 28 units / day of insulin injection was started .@_@severe ketonuria and moderate hyperglycemia are not related .
Four years after the beginning of IFN therapy , he acutely developed moderate hyperglycemia and severe ketonuria with positive islet cell antibody , and then 28 units / day of insulin injection was started .@_@severe ketonuria and severe ketonuria are not related .
Occurrence of IDDM during interferon therapy for chronic viral hepatitis .@_@IDDM and interferon are Adverse-Effect relation .
Occurrence of IDDM during interferon therapy for chronic viral hepatitis .@_@IDDM and IDDM are not related .
Occurrence of IDDM during interferon therapy for chronic viral hepatitis .@_@interferon and IDDM are not related .
Occurrence of IDDM during interferon therapy for chronic viral hepatitis .@_@interferon and interferon are not related .
We report a case of IDDM which occurred during interferon therapy for chronic hepatitis .@_@IDDM and interferon are Adverse-Effect relation .
We report a case of IDDM which occurred during interferon therapy for chronic hepatitis .@_@IDDM and IDDM are not related .
We report a case of IDDM which occurred during interferon therapy for chronic hepatitis .@_@interferon and IDDM are not related .
We report a case of IDDM which occurred during interferon therapy for chronic hepatitis .@_@interferon and interferon are not related .
Four patients who manifested symptoms of the antiepileptic drug ( AED ) hypersensitivity syndrome during therapy with carbamazepine are reported .@_@hypersensitivity syndrome and carbamazepine are Adverse-Effect relation .
Four patients who manifested symptoms of the antiepileptic drug ( AED ) hypersensitivity syndrome during therapy with carbamazepine are reported .@_@hypersensitivity syndrome and hypersensitivity syndrome are not related .
Four patients who manifested symptoms of the antiepileptic drug ( AED ) hypersensitivity syndrome during therapy with carbamazepine are reported .@_@carbamazepine and hypersensitivity syndrome are not related .
Four patients who manifested symptoms of the antiepileptic drug ( AED ) hypersensitivity syndrome during therapy with carbamazepine are reported .@_@carbamazepine and carbamazepine are not related .
Recurrent hypotension immediately after seizures in nortriptyline overdose .@_@Recurrent hypotension and nortriptyline are Adverse-Effect relation .
Recurrent hypotension immediately after seizures in nortriptyline overdose .@_@seizures and nortriptyline are Adverse-Effect relation .
Recurrent hypotension immediately after seizures in nortriptyline overdose .@_@Recurrent hypotension and Recurrent hypotension are not related .
Recurrent hypotension immediately after seizures in nortriptyline overdose .@_@Recurrent hypotension and seizures are not related .
Recurrent hypotension immediately after seizures in nortriptyline overdose .@_@nortriptyline and Recurrent hypotension are not related .
Recurrent hypotension immediately after seizures in nortriptyline overdose .@_@nortriptyline and nortriptyline are not related .
Recurrent hypotension immediately after seizures in nortriptyline overdose .@_@nortriptyline and seizures are not related .
Recurrent hypotension immediately after seizures in nortriptyline overdose .@_@seizures and Recurrent hypotension are not related .
Recurrent hypotension immediately after seizures in nortriptyline overdose .@_@seizures and seizures are not related .
The use of methotrexate ( MTX ) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and accelerate HIV disease .@_@accelerate HIV disease and MTX are Adverse-Effect relation .
The use of methotrexate ( MTX ) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and accelerate HIV disease .@_@accelerate HIV disease and methotrexate are Adverse-Effect relation .
The use of methotrexate ( MTX ) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and accelerate HIV disease .@_@accelerate HIV disease and accelerate HIV disease are not related .
The use of methotrexate ( MTX ) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and accelerate HIV disease .@_@methotrexate and accelerate HIV disease are not related .
The use of methotrexate ( MTX ) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and accelerate HIV disease .@_@methotrexate and methotrexate are not related .
The use of methotrexate ( MTX ) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and accelerate HIV disease .@_@methotrexate and MTX are not related .
The use of methotrexate ( MTX ) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and accelerate HIV disease .@_@MTX and accelerate HIV disease are not related .
The use of methotrexate ( MTX ) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and accelerate HIV disease .@_@MTX and methotrexate are not related .
The use of methotrexate ( MTX ) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and accelerate HIV disease .@_@MTX and MTX are not related .
CONCLUSIONS : This case describes the clinically significant increase of INR in an elderly patient after adding a chemotherapy regimen of levamisole and 5-FU to a previous regimen of warfarin alone .@_@increase of INR and levamisole are Adverse-Effect relation .
CONCLUSIONS : This case describes the clinically significant increase of INR in an elderly patient after adding a chemotherapy regimen of levamisole and 5-FU to a previous regimen of warfarin alone .@_@increase of INR and 5-FU are Adverse-Effect relation .
CONCLUSIONS : This case describes the clinically significant increase of INR in an elderly patient after adding a chemotherapy regimen of levamisole and 5-FU to a previous regimen of warfarin alone .@_@increase of INR and warfarin are Adverse-Effect relation .
CONCLUSIONS : This case describes the clinically significant increase of INR in an elderly patient after adding a chemotherapy regimen of levamisole and 5-FU to a previous regimen of warfarin alone .@_@increase of INR and increase of INR are not related .
CONCLUSIONS : This case describes the clinically significant increase of INR in an elderly patient after adding a chemotherapy regimen of levamisole and 5-FU to a previous regimen of warfarin alone .@_@5-FU and increase of INR are not related .
CONCLUSIONS : This case describes the clinically significant increase of INR in an elderly patient after adding a chemotherapy regimen of levamisole and 5-FU to a previous regimen of warfarin alone .@_@5-FU and 5-FU are not related .
CONCLUSIONS : This case describes the clinically significant increase of INR in an elderly patient after adding a chemotherapy regimen of levamisole and 5-FU to a previous regimen of warfarin alone .@_@5-FU and levamisole are not related .
CONCLUSIONS : This case describes the clinically significant increase of INR in an elderly patient after adding a chemotherapy regimen of levamisole and 5-FU to a previous regimen of warfarin alone .@_@5-FU and warfarin are not related .
CONCLUSIONS : This case describes the clinically significant increase of INR in an elderly patient after adding a chemotherapy regimen of levamisole and 5-FU to a previous regimen of warfarin alone .@_@levamisole and increase of INR are not related .
CONCLUSIONS : This case describes the clinically significant increase of INR in an elderly patient after adding a chemotherapy regimen of levamisole and 5-FU to a previous regimen of warfarin alone .@_@levamisole and 5-FU are not related .
CONCLUSIONS : This case describes the clinically significant increase of INR in an elderly patient after adding a chemotherapy regimen of levamisole and 5-FU to a previous regimen of warfarin alone .@_@levamisole and levamisole are not related .
CONCLUSIONS : This case describes the clinically significant increase of INR in an elderly patient after adding a chemotherapy regimen of levamisole and 5-FU to a previous regimen of warfarin alone .@_@levamisole and warfarin are not related .
CONCLUSIONS : This case describes the clinically significant increase of INR in an elderly patient after adding a chemotherapy regimen of levamisole and 5-FU to a previous regimen of warfarin alone .@_@warfarin and increase of INR are not related .
CONCLUSIONS : This case describes the clinically significant increase of INR in an elderly patient after adding a chemotherapy regimen of levamisole and 5-FU to a previous regimen of warfarin alone .@_@warfarin and 5-FU are not related .
CONCLUSIONS : This case describes the clinically significant increase of INR in an elderly patient after adding a chemotherapy regimen of levamisole and 5-FU to a previous regimen of warfarin alone .@_@warfarin and levamisole are not related .
CONCLUSIONS : This case describes the clinically significant increase of INR in an elderly patient after adding a chemotherapy regimen of levamisole and 5-FU to a previous regimen of warfarin alone .@_@warfarin and warfarin are not related .
However , prolongation of 5-FU half - life and an increase in INR have been reported with the concurrent use of 5-FU and warfarin .@_@increase in INR and warfarin are Adverse-Effect relation .
However , prolongation of 5-FU half - life and an increase in INR have been reported with the concurrent use of 5-FU and warfarin .@_@increase in INR and 5-FU are Adverse-Effect relation .
However , prolongation of 5-FU half - life and an increase in INR have been reported with the concurrent use of 5-FU and warfarin .@_@increase in INR and increase in INR are not related .
However , prolongation of 5-FU half - life and an increase in INR have been reported with the concurrent use of 5-FU and warfarin .@_@5-FU and increase in INR are not related .
However , prolongation of 5-FU half - life and an increase in INR have been reported with the concurrent use of 5-FU and warfarin .@_@5-FU and 5-FU are not related .
However , prolongation of 5-FU half - life and an increase in INR have been reported with the concurrent use of 5-FU and warfarin .@_@5-FU and warfarin are not related .
However , prolongation of 5-FU half - life and an increase in INR have been reported with the concurrent use of 5-FU and warfarin .@_@warfarin and increase in INR are not related .
However , prolongation of 5-FU half - life and an increase in INR have been reported with the concurrent use of 5-FU and warfarin .@_@warfarin and 5-FU are not related .
However , prolongation of 5-FU half - life and an increase in INR have been reported with the concurrent use of 5-FU and warfarin .@_@warfarin and warfarin are not related .
Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .@_@Cholestatic liver disease and trimethoprim - sulfamethoxazole are Adverse-Effect relation .
Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .@_@ductopenia and clindamycin are Adverse-Effect relation .
Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .@_@vanishing bile duct syndrome and trimethoprim - sulfamethoxazole are Adverse-Effect relation .
Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .@_@Cholestatic liver disease and clindamycin are Adverse-Effect relation .
Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .@_@ductopenia and trimethoprim - sulfamethoxazole are Adverse-Effect relation .
Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .@_@vanishing bile duct syndrome and clindamycin are Adverse-Effect relation .
Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .@_@Cholestatic liver disease and Cholestatic liver disease are not related .
Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .@_@Cholestatic liver disease and ductopenia are not related .
Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .@_@Cholestatic liver disease and vanishing bile duct syndrome are not related .
Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .@_@clindamycin and Cholestatic liver disease are not related .
Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .@_@clindamycin and clindamycin are not related .
Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .@_@clindamycin and trimethoprim - sulfamethoxazole are not related .
Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .@_@clindamycin and ductopenia are not related .
Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .@_@clindamycin and vanishing bile duct syndrome are not related .
Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .@_@trimethoprim - sulfamethoxazole and Cholestatic liver disease are not related .
Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .@_@trimethoprim - sulfamethoxazole and clindamycin are not related .
Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .@_@trimethoprim - sulfamethoxazole and trimethoprim - sulfamethoxazole are not related .
Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .@_@trimethoprim - sulfamethoxazole and ductopenia are not related .
Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .@_@trimethoprim - sulfamethoxazole and vanishing bile duct syndrome are not related .
Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .@_@ductopenia and Cholestatic liver disease are not related .
Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .@_@ductopenia and ductopenia are not related .
Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .@_@ductopenia and vanishing bile duct syndrome are not related .
Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .@_@vanishing bile duct syndrome and Cholestatic liver disease are not related .
Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .@_@vanishing bile duct syndrome and ductopenia are not related .
Cholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and trimethoprim - sulfamethoxazole .@_@vanishing bile duct syndrome and vanishing bile duct syndrome are not related .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@bile duct injury and clindamycin are Adverse-Effect relation .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@marked cholestasis and clindamycin are Adverse-Effect relation .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@bile duct paucity and clindamycin are Adverse-Effect relation .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@ductopenia and clindamycin are Adverse-Effect relation .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@portal inflammation and clindamycin are Adverse-Effect relation .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@bile duct injury and bile duct injury are not related .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@bile duct injury and bile duct paucity are not related .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@bile duct injury and ductopenia are not related .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@bile duct injury and marked cholestasis are not related .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@bile duct injury and portal inflammation are not related .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@clindamycin and bile duct injury are not related .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@clindamycin and clindamycin are not related .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@clindamycin and bile duct paucity are not related .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@clindamycin and ductopenia are not related .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@clindamycin and marked cholestasis are not related .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@clindamycin and portal inflammation are not related .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@bile duct paucity and bile duct injury are not related .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@bile duct paucity and bile duct paucity are not related .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@bile duct paucity and ductopenia are not related .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@bile duct paucity and marked cholestasis are not related .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@bile duct paucity and portal inflammation are not related .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@ductopenia and bile duct injury are not related .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@ductopenia and bile duct paucity are not related .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@ductopenia and ductopenia are not related .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@ductopenia and marked cholestasis are not related .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@ductopenia and portal inflammation are not related .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@marked cholestasis and bile duct injury are not related .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@marked cholestasis and bile duct paucity are not related .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@marked cholestasis and ductopenia are not related .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@marked cholestasis and marked cholestasis are not related .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@marked cholestasis and portal inflammation are not related .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@portal inflammation and bile duct injury are not related .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@portal inflammation and bile duct paucity are not related .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@portal inflammation and ductopenia are not related .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@portal inflammation and marked cholestasis are not related .
One patient who received clindamycin had liver biopsy findings of marked cholestasis , portal inflammation , bile duct injury and bile duct paucity ( ductopenia ) .@_@portal inflammation and portal inflammation are not related .
The second patient , who developed cholestasis after receiving trimethoprim - sulfamethoxazole , had marked duct paucity in the liver biopsy .@_@duct paucity and trimethoprim - sulfamethoxazole are Adverse-Effect relation .
The second patient , who developed cholestasis after receiving trimethoprim - sulfamethoxazole , had marked duct paucity in the liver biopsy .@_@cholestasis and trimethoprim - sulfamethoxazole are Adverse-Effect relation .
The second patient , who developed cholestasis after receiving trimethoprim - sulfamethoxazole , had marked duct paucity in the liver biopsy .@_@cholestasis and cholestasis are not related .
The second patient , who developed cholestasis after receiving trimethoprim - sulfamethoxazole , had marked duct paucity in the liver biopsy .@_@cholestasis and duct paucity are not related .
The second patient , who developed cholestasis after receiving trimethoprim - sulfamethoxazole , had marked duct paucity in the liver biopsy .@_@trimethoprim - sulfamethoxazole and cholestasis are not related .
The second patient , who developed cholestasis after receiving trimethoprim - sulfamethoxazole , had marked duct paucity in the liver biopsy .@_@trimethoprim - sulfamethoxazole and trimethoprim - sulfamethoxazole are not related .
The second patient , who developed cholestasis after receiving trimethoprim - sulfamethoxazole , had marked duct paucity in the liver biopsy .@_@trimethoprim - sulfamethoxazole and duct paucity are not related .
The second patient , who developed cholestasis after receiving trimethoprim - sulfamethoxazole , had marked duct paucity in the liver biopsy .@_@duct paucity and cholestasis are not related .
The second patient , who developed cholestasis after receiving trimethoprim - sulfamethoxazole , had marked duct paucity in the liver biopsy .@_@duct paucity and duct paucity are not related .
This is the first description , to our knowledge , of ductopenia apparently caused by clindamycin .@_@ductopenia and clindamycin are Adverse-Effect relation .
This is the first description , to our knowledge , of ductopenia apparently caused by clindamycin .@_@ductopenia and ductopenia are not related .
This is the first description , to our knowledge , of ductopenia apparently caused by clindamycin .@_@clindamycin and ductopenia are not related .
This is the first description , to our knowledge , of ductopenia apparently caused by clindamycin .@_@clindamycin and clindamycin are not related .
Three years later , treatment with ampicillin caused another episode of cholestatic hepatitis with cholestasis and duct paucity on rebiopsy .@_@duct paucity and ampicillin are Adverse-Effect relation .
Three years later , treatment with ampicillin caused another episode of cholestatic hepatitis with cholestasis and duct paucity on rebiopsy .@_@cholestatic hepatitis and ampicillin are Adverse-Effect relation .
Three years later , treatment with ampicillin caused another episode of cholestatic hepatitis with cholestasis and duct paucity on rebiopsy .@_@cholestasis and ampicillin are Adverse-Effect relation .
Three years later , treatment with ampicillin caused another episode of cholestatic hepatitis with cholestasis and duct paucity on rebiopsy .@_@cholestasis and cholestasis are not related .
Three years later , treatment with ampicillin caused another episode of cholestatic hepatitis with cholestasis and duct paucity on rebiopsy .@_@cholestasis and cholestatic hepatitis are not related .
Three years later , treatment with ampicillin caused another episode of cholestatic hepatitis with cholestasis and duct paucity on rebiopsy .@_@cholestasis and duct paucity are not related .
Three years later , treatment with ampicillin caused another episode of cholestatic hepatitis with cholestasis and duct paucity on rebiopsy .@_@ampicillin and cholestasis are not related .
Three years later , treatment with ampicillin caused another episode of cholestatic hepatitis with cholestasis and duct paucity on rebiopsy .@_@ampicillin and ampicillin are not related .
Three years later , treatment with ampicillin caused another episode of cholestatic hepatitis with cholestasis and duct paucity on rebiopsy .@_@ampicillin and cholestatic hepatitis are not related .
Three years later , treatment with ampicillin caused another episode of cholestatic hepatitis with cholestasis and duct paucity on rebiopsy .@_@ampicillin and duct paucity are not related .
Three years later , treatment with ampicillin caused another episode of cholestatic hepatitis with cholestasis and duct paucity on rebiopsy .@_@cholestatic hepatitis and cholestasis are not related .
Three years later , treatment with ampicillin caused another episode of cholestatic hepatitis with cholestasis and duct paucity on rebiopsy .@_@cholestatic hepatitis and cholestatic hepatitis are not related .
Three years later , treatment with ampicillin caused another episode of cholestatic hepatitis with cholestasis and duct paucity on rebiopsy .@_@cholestatic hepatitis and duct paucity are not related .
Three years later , treatment with ampicillin caused another episode of cholestatic hepatitis with cholestasis and duct paucity on rebiopsy .@_@duct paucity and cholestasis are not related .
Three years later , treatment with ampicillin caused another episode of cholestatic hepatitis with cholestasis and duct paucity on rebiopsy .@_@duct paucity and cholestatic hepatitis are not related .
Three years later , treatment with ampicillin caused another episode of cholestatic hepatitis with cholestasis and duct paucity on rebiopsy .@_@duct paucity and duct paucity are not related .
METHODS : A patient who developed dramatic , permanent vision loss after a 9-month course of treatment with ethambutol and isoniazid for pulmonary tuberculosis is presented .@_@vision loss and ethambutol are Adverse-Effect relation .
METHODS : A patient who developed dramatic , permanent vision loss after a 9-month course of treatment with ethambutol and isoniazid for pulmonary tuberculosis is presented .@_@vision loss and isoniazid are Adverse-Effect relation .
METHODS : A patient who developed dramatic , permanent vision loss after a 9-month course of treatment with ethambutol and isoniazid for pulmonary tuberculosis is presented .@_@vision loss and vision loss are not related .
METHODS : A patient who developed dramatic , permanent vision loss after a 9-month course of treatment with ethambutol and isoniazid for pulmonary tuberculosis is presented .@_@ethambutol and vision loss are not related .
METHODS : A patient who developed dramatic , permanent vision loss after a 9-month course of treatment with ethambutol and isoniazid for pulmonary tuberculosis is presented .@_@ethambutol and ethambutol are not related .
METHODS : A patient who developed dramatic , permanent vision loss after a 9-month course of treatment with ethambutol and isoniazid for pulmonary tuberculosis is presented .@_@ethambutol and isoniazid are not related .
METHODS : A patient who developed dramatic , permanent vision loss after a 9-month course of treatment with ethambutol and isoniazid for pulmonary tuberculosis is presented .@_@isoniazid and vision loss are not related .
METHODS : A patient who developed dramatic , permanent vision loss after a 9-month course of treatment with ethambutol and isoniazid for pulmonary tuberculosis is presented .@_@isoniazid and ethambutol are not related .
METHODS : A patient who developed dramatic , permanent vision loss after a 9-month course of treatment with ethambutol and isoniazid for pulmonary tuberculosis is presented .@_@isoniazid and isoniazid are not related .
RESULTS : Ethambutol , and to a lesser extent isoniazid , are both implicated in the development of visually related side effects .@_@development of visually related side effects and isoniazid are Adverse-Effect relation .
RESULTS : Ethambutol , and to a lesser extent isoniazid , are both implicated in the development of visually related side effects .@_@development of visually related side effects and Ethambutol are Adverse-Effect relation .
RESULTS : Ethambutol , and to a lesser extent isoniazid , are both implicated in the development of visually related side effects .@_@development of visually related side effects and development of visually related side effects are not related .
RESULTS : Ethambutol , and to a lesser extent isoniazid , are both implicated in the development of visually related side effects .@_@Ethambutol and development of visually related side effects are not related .
RESULTS : Ethambutol , and to a lesser extent isoniazid , are both implicated in the development of visually related side effects .@_@Ethambutol and Ethambutol are not related .
RESULTS : Ethambutol , and to a lesser extent isoniazid , are both implicated in the development of visually related side effects .@_@Ethambutol and isoniazid are not related .
RESULTS : Ethambutol , and to a lesser extent isoniazid , are both implicated in the development of visually related side effects .@_@isoniazid and development of visually related side effects are not related .
RESULTS : Ethambutol , and to a lesser extent isoniazid , are both implicated in the development of visually related side effects .@_@isoniazid and Ethambutol are not related .
RESULTS : Ethambutol , and to a lesser extent isoniazid , are both implicated in the development of visually related side effects .@_@isoniazid and isoniazid are not related .
There is documentation of ocular toxicity with ethambutol when administered at dosages generally pronounced as being safe .@_@ocular toxicity and ethambutol are Adverse-Effect relation .
There is documentation of ocular toxicity with ethambutol when administered at dosages generally pronounced as being safe .@_@ocular toxicity and ocular toxicity are not related .
There is documentation of ocular toxicity with ethambutol when administered at dosages generally pronounced as being safe .@_@ethambutol and ocular toxicity are not related .
There is documentation of ocular toxicity with ethambutol when administered at dosages generally pronounced as being safe .@_@ethambutol and ethambutol are not related .
Toxic optic neuropathy associated with ethambutol : implications for current therapy .@_@Toxic optic neuropathy and ethambutol are Adverse-Effect relation .
Toxic optic neuropathy associated with ethambutol : implications for current therapy .@_@Toxic optic neuropathy and Toxic optic neuropathy are not related .
Toxic optic neuropathy associated with ethambutol : implications for current therapy .@_@ethambutol and Toxic optic neuropathy are not related .
Toxic optic neuropathy associated with ethambutol : implications for current therapy .@_@ethambutol and ethambutol are not related .
Currently the use of zidovudine is one of the few specific measures available , and as a potentially teratogenic and fetotoxic agent , any decision for its use requires evaluation of the potential for fetal damage .@_@fetotoxic and zidovudine are Adverse-Effect relation .
Currently the use of zidovudine is one of the few specific measures available , and as a potentially teratogenic and fetotoxic agent , any decision for its use requires evaluation of the potential for fetal damage .@_@teratogenic and zidovudine are Adverse-Effect relation .
Currently the use of zidovudine is one of the few specific measures available , and as a potentially teratogenic and fetotoxic agent , any decision for its use requires evaluation of the potential for fetal damage .@_@fetal damage and zidovudine are Adverse-Effect relation .
Currently the use of zidovudine is one of the few specific measures available , and as a potentially teratogenic and fetotoxic agent , any decision for its use requires evaluation of the potential for fetal damage .@_@fetal damage and fetal damage are not related .
Currently the use of zidovudine is one of the few specific measures available , and as a potentially teratogenic and fetotoxic agent , any decision for its use requires evaluation of the potential for fetal damage .@_@fetal damage and fetotoxic are not related .
Currently the use of zidovudine is one of the few specific measures available , and as a potentially teratogenic and fetotoxic agent , any decision for its use requires evaluation of the potential for fetal damage .@_@fetal damage and teratogenic are not related .
Currently the use of zidovudine is one of the few specific measures available , and as a potentially teratogenic and fetotoxic agent , any decision for its use requires evaluation of the potential for fetal damage .@_@zidovudine and fetal damage are not related .
Currently the use of zidovudine is one of the few specific measures available , and as a potentially teratogenic and fetotoxic agent , any decision for its use requires evaluation of the potential for fetal damage .@_@zidovudine and zidovudine are not related .
Currently the use of zidovudine is one of the few specific measures available , and as a potentially teratogenic and fetotoxic agent , any decision for its use requires evaluation of the potential for fetal damage .@_@zidovudine and fetotoxic are not related .
Currently the use of zidovudine is one of the few specific measures available , and as a potentially teratogenic and fetotoxic agent , any decision for its use requires evaluation of the potential for fetal damage .@_@zidovudine and teratogenic are not related .
Currently the use of zidovudine is one of the few specific measures available , and as a potentially teratogenic and fetotoxic agent , any decision for its use requires evaluation of the potential for fetal damage .@_@fetotoxic and fetal damage are not related .
Currently the use of zidovudine is one of the few specific measures available , and as a potentially teratogenic and fetotoxic agent , any decision for its use requires evaluation of the potential for fetal damage .@_@fetotoxic and fetotoxic are not related .
Currently the use of zidovudine is one of the few specific measures available , and as a potentially teratogenic and fetotoxic agent , any decision for its use requires evaluation of the potential for fetal damage .@_@fetotoxic and teratogenic are not related .
Currently the use of zidovudine is one of the few specific measures available , and as a potentially teratogenic and fetotoxic agent , any decision for its use requires evaluation of the potential for fetal damage .@_@teratogenic and fetal damage are not related .
Currently the use of zidovudine is one of the few specific measures available , and as a potentially teratogenic and fetotoxic agent , any decision for its use requires evaluation of the potential for fetal damage .@_@teratogenic and fetotoxic are not related .
Currently the use of zidovudine is one of the few specific measures available , and as a potentially teratogenic and fetotoxic agent , any decision for its use requires evaluation of the potential for fetal damage .@_@teratogenic and teratogenic are not related .
In a series of 104 cases of intentional or inadvertent use of zidovudine at differing gestations in pregnancy , there were eight spontaneous first trimester abortions , eight therapeutic terminations , and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed .@_@first trimester abortions and zidovudine are Adverse-Effect relation .
In a series of 104 cases of intentional or inadvertent use of zidovudine at differing gestations in pregnancy , there were eight spontaneous first trimester abortions , eight therapeutic terminations , and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed .@_@fetal abnormality and zidovudine are Adverse-Effect relation .
In a series of 104 cases of intentional or inadvertent use of zidovudine at differing gestations in pregnancy , there were eight spontaneous first trimester abortions , eight therapeutic terminations , and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed .@_@fetal abnormality and fetal abnormality are not related .
In a series of 104 cases of intentional or inadvertent use of zidovudine at differing gestations in pregnancy , there were eight spontaneous first trimester abortions , eight therapeutic terminations , and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed .@_@fetal abnormality and first trimester abortions are not related .
In a series of 104 cases of intentional or inadvertent use of zidovudine at differing gestations in pregnancy , there were eight spontaneous first trimester abortions , eight therapeutic terminations , and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed .@_@zidovudine and fetal abnormality are not related .
In a series of 104 cases of intentional or inadvertent use of zidovudine at differing gestations in pregnancy , there were eight spontaneous first trimester abortions , eight therapeutic terminations , and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed .@_@zidovudine and zidovudine are not related .
In a series of 104 cases of intentional or inadvertent use of zidovudine at differing gestations in pregnancy , there were eight spontaneous first trimester abortions , eight therapeutic terminations , and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed .@_@zidovudine and first trimester abortions are not related .
In a series of 104 cases of intentional or inadvertent use of zidovudine at differing gestations in pregnancy , there were eight spontaneous first trimester abortions , eight therapeutic terminations , and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed .@_@first trimester abortions and fetal abnormality are not related .
In a series of 104 cases of intentional or inadvertent use of zidovudine at differing gestations in pregnancy , there were eight spontaneous first trimester abortions , eight therapeutic terminations , and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed .@_@first trimester abortions and first trimester abortions are not related .
Zidovudine use in pregnancy : a report on 104 cases and the occurrence of birth defects .@_@birth defects and Zidovudine are Adverse-Effect relation .
Zidovudine use in pregnancy : a report on 104 cases and the occurrence of birth defects .@_@birth defects and birth defects are not related .
Zidovudine use in pregnancy : a report on 104 cases and the occurrence of birth defects .@_@Zidovudine and birth defects are not related .
Zidovudine use in pregnancy : a report on 104 cases and the occurrence of birth defects .@_@Zidovudine and Zidovudine are not related .
Celiprolol pneumonitis .@_@pneumonitis and Celiprolol are Adverse-Effect relation .
Celiprolol pneumonitis .@_@pneumonitis and pneumonitis are not related .
Celiprolol pneumonitis .@_@Celiprolol and pneumonitis are not related .
Celiprolol pneumonitis .@_@Celiprolol and Celiprolol are not related .
Inadvertent subsequent rechallenge with celiprolol led to recurrence of the pneumonitis , 10 weeks after drug readministration .@_@pneumonitis and celiprolol are Adverse-Effect relation .
Inadvertent subsequent rechallenge with celiprolol led to recurrence of the pneumonitis , 10 weeks after drug readministration .@_@pneumonitis and pneumonitis are not related .
Inadvertent subsequent rechallenge with celiprolol led to recurrence of the pneumonitis , 10 weeks after drug readministration .@_@celiprolol and pneumonitis are not related .
Inadvertent subsequent rechallenge with celiprolol led to recurrence of the pneumonitis , 10 weeks after drug readministration .@_@celiprolol and celiprolol are not related .
We report on a patient who developed hypersensitivity pneumonitis during treatment with the beta - blocker , celiprolol .@_@hypersensitivity pneumonitis and celiprolol are Adverse-Effect relation .
We report on a patient who developed hypersensitivity pneumonitis during treatment with the beta - blocker , celiprolol .@_@hypersensitivity pneumonitis and hypersensitivity pneumonitis are not related .
We report on a patient who developed hypersensitivity pneumonitis during treatment with the beta - blocker , celiprolol .@_@celiprolol and hypersensitivity pneumonitis are not related .
We report on a patient who developed hypersensitivity pneumonitis during treatment with the beta - blocker , celiprolol .@_@celiprolol and celiprolol are not related .
Ibopamine - induced reversible leukopenia during treatment for congestive heart failure .@_@leukopenia and Ibopamine are Adverse-Effect relation .
Ibopamine - induced reversible leukopenia during treatment for congestive heart failure .@_@leukopenia and leukopenia are not related .
Ibopamine - induced reversible leukopenia during treatment for congestive heart failure .@_@Ibopamine and leukopenia are not related .
Ibopamine - induced reversible leukopenia during treatment for congestive heart failure .@_@Ibopamine and Ibopamine are not related .
Reversible leukopenia was documented in an 81-year - old woman treated with adjunctive ibopamine 100 mg t.i.d . for chronic congestive heart failure .@_@Reversible leukopenia and ibopamine are Adverse-Effect relation .
Reversible leukopenia was documented in an 81-year - old woman treated with adjunctive ibopamine 100 mg t.i.d . for chronic congestive heart failure .@_@Reversible leukopenia and Reversible leukopenia are not related .
Reversible leukopenia was documented in an 81-year - old woman treated with adjunctive ibopamine 100 mg t.i.d . for chronic congestive heart failure .@_@ibopamine and Reversible leukopenia are not related .
Reversible leukopenia was documented in an 81-year - old woman treated with adjunctive ibopamine 100 mg t.i.d . for chronic congestive heart failure .@_@ibopamine and ibopamine are not related .
Diphenylhydantoin apparently adversely affected both the clinical and biochemical parameters of the acute intermittent porphyria .@_@acute intermittent porphyria and Diphenylhydantoin are Adverse-Effect relation .
Diphenylhydantoin apparently adversely affected both the clinical and biochemical parameters of the acute intermittent porphyria .@_@acute intermittent porphyria and acute intermittent porphyria are not related .
Diphenylhydantoin apparently adversely affected both the clinical and biochemical parameters of the acute intermittent porphyria .@_@Diphenylhydantoin and acute intermittent porphyria are not related .
Diphenylhydantoin apparently adversely affected both the clinical and biochemical parameters of the acute intermittent porphyria .@_@Diphenylhydantoin and Diphenylhydantoin are not related .
Significant clinical improvement of the porphyria followed withdrawal of the diphenylhydantoin .@_@porphyria and diphenylhydantoin are Adverse-Effect relation .
Significant clinical improvement of the porphyria followed withdrawal of the diphenylhydantoin .@_@porphyria and porphyria are not related .
Significant clinical improvement of the porphyria followed withdrawal of the diphenylhydantoin .@_@diphenylhydantoin and porphyria are not related .
Significant clinical improvement of the porphyria followed withdrawal of the diphenylhydantoin .@_@diphenylhydantoin and diphenylhydantoin are not related .
A 53-year - old male , without any prior history of psychosis , developed schizophrenia 4 days after starting low - dose bromocriptine therapy for a macroprolactinoma .@_@schizophrenia and bromocriptine are Adverse-Effect relation .
A 53-year - old male , without any prior history of psychosis , developed schizophrenia 4 days after starting low - dose bromocriptine therapy for a macroprolactinoma .@_@schizophrenia and schizophrenia are not related .
A 53-year - old male , without any prior history of psychosis , developed schizophrenia 4 days after starting low - dose bromocriptine therapy for a macroprolactinoma .@_@bromocriptine and schizophrenia are not related .
A 53-year - old male , without any prior history of psychosis , developed schizophrenia 4 days after starting low - dose bromocriptine therapy for a macroprolactinoma .@_@bromocriptine and bromocriptine are not related .
Bromocriptine - induced schizophrenia .@_@schizophrenia and Bromocriptine are Adverse-Effect relation .
Bromocriptine - induced schizophrenia .@_@schizophrenia and schizophrenia are not related .
Bromocriptine - induced schizophrenia .@_@Bromocriptine and schizophrenia are not related .
Bromocriptine - induced schizophrenia .@_@Bromocriptine and Bromocriptine are not related .
Concurrent acute megaloblastic anaemia and pneumonitis : a severe side - effect of low - dose methotrexate therapy during rheumatoid arthritis .@_@Concurrent acute megaloblastic anaemia and methotrexate are Adverse-Effect relation .
Concurrent acute megaloblastic anaemia and pneumonitis : a severe side - effect of low - dose methotrexate therapy during rheumatoid arthritis .@_@pneumonitis and methotrexate are Adverse-Effect relation .
Concurrent acute megaloblastic anaemia and pneumonitis : a severe side - effect of low - dose methotrexate therapy during rheumatoid arthritis .@_@Concurrent acute megaloblastic anaemia and Concurrent acute megaloblastic anaemia are not related .
Concurrent acute megaloblastic anaemia and pneumonitis : a severe side - effect of low - dose methotrexate therapy during rheumatoid arthritis .@_@Concurrent acute megaloblastic anaemia and pneumonitis are not related .
Concurrent acute megaloblastic anaemia and pneumonitis : a severe side - effect of low - dose methotrexate therapy during rheumatoid arthritis .@_@methotrexate and Concurrent acute megaloblastic anaemia are not related .
Concurrent acute megaloblastic anaemia and pneumonitis : a severe side - effect of low - dose methotrexate therapy during rheumatoid arthritis .@_@methotrexate and methotrexate are not related .
Concurrent acute megaloblastic anaemia and pneumonitis : a severe side - effect of low - dose methotrexate therapy during rheumatoid arthritis .@_@methotrexate and pneumonitis are not related .
Concurrent acute megaloblastic anaemia and pneumonitis : a severe side - effect of low - dose methotrexate therapy during rheumatoid arthritis .@_@pneumonitis and Concurrent acute megaloblastic anaemia are not related .
Concurrent acute megaloblastic anaemia and pneumonitis : a severe side - effect of low - dose methotrexate therapy during rheumatoid arthritis .@_@pneumonitis and pneumonitis are not related .
In a patient suffering from rheumatoid arthritis , we report the first simultaneous occurrence of two side effects of low - dose methotrexate : an acute megaloblastic anaemia and a pneumonitis .@_@acute megaloblastic anaemia and methotrexate are Adverse-Effect relation .
In a patient suffering from rheumatoid arthritis , we report the first simultaneous occurrence of two side effects of low - dose methotrexate : an acute megaloblastic anaemia and a pneumonitis .@_@pneumonitis and methotrexate are Adverse-Effect relation .
In a patient suffering from rheumatoid arthritis , we report the first simultaneous occurrence of two side effects of low - dose methotrexate : an acute megaloblastic anaemia and a pneumonitis .@_@acute megaloblastic anaemia and acute megaloblastic anaemia are not related .
In a patient suffering from rheumatoid arthritis , we report the first simultaneous occurrence of two side effects of low - dose methotrexate : an acute megaloblastic anaemia and a pneumonitis .@_@acute megaloblastic anaemia and pneumonitis are not related .
In a patient suffering from rheumatoid arthritis , we report the first simultaneous occurrence of two side effects of low - dose methotrexate : an acute megaloblastic anaemia and a pneumonitis .@_@methotrexate and acute megaloblastic anaemia are not related .
In a patient suffering from rheumatoid arthritis , we report the first simultaneous occurrence of two side effects of low - dose methotrexate : an acute megaloblastic anaemia and a pneumonitis .@_@methotrexate and methotrexate are not related .
In a patient suffering from rheumatoid arthritis , we report the first simultaneous occurrence of two side effects of low - dose methotrexate : an acute megaloblastic anaemia and a pneumonitis .@_@methotrexate and pneumonitis are not related .
In a patient suffering from rheumatoid arthritis , we report the first simultaneous occurrence of two side effects of low - dose methotrexate : an acute megaloblastic anaemia and a pneumonitis .@_@pneumonitis and acute megaloblastic anaemia are not related .
In a patient suffering from rheumatoid arthritis , we report the first simultaneous occurrence of two side effects of low - dose methotrexate : an acute megaloblastic anaemia and a pneumonitis .@_@pneumonitis and pneumonitis are not related .
An 11-year - old boy who was treated with a relatively high dose of methotrimeprazine meleate ( Levemepromazine ) a phenothiazine antipsychotic drug , was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome .@_@respiratory distress syndrome and Levemepromazine are Adverse-Effect relation .
An 11-year - old boy who was treated with a relatively high dose of methotrimeprazine meleate ( Levemepromazine ) a phenothiazine antipsychotic drug , was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome .@_@respiratory distress syndrome and methotrimeprazine meleate are Adverse-Effect relation .
An 11-year - old boy who was treated with a relatively high dose of methotrimeprazine meleate ( Levemepromazine ) a phenothiazine antipsychotic drug , was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome .@_@respiratory distress syndrome and respiratory distress syndrome are not related .
An 11-year - old boy who was treated with a relatively high dose of methotrimeprazine meleate ( Levemepromazine ) a phenothiazine antipsychotic drug , was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome .@_@Levemepromazine and respiratory distress syndrome are not related .
An 11-year - old boy who was treated with a relatively high dose of methotrimeprazine meleate ( Levemepromazine ) a phenothiazine antipsychotic drug , was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome .@_@Levemepromazine and Levemepromazine are not related .
An 11-year - old boy who was treated with a relatively high dose of methotrimeprazine meleate ( Levemepromazine ) a phenothiazine antipsychotic drug , was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome .@_@Levemepromazine and methotrimeprazine meleate are not related .
An 11-year - old boy who was treated with a relatively high dose of methotrimeprazine meleate ( Levemepromazine ) a phenothiazine antipsychotic drug , was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome .@_@methotrimeprazine meleate and respiratory distress syndrome are not related .
An 11-year - old boy who was treated with a relatively high dose of methotrimeprazine meleate ( Levemepromazine ) a phenothiazine antipsychotic drug , was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome .@_@methotrimeprazine meleate and Levemepromazine are not related .
An 11-year - old boy who was treated with a relatively high dose of methotrimeprazine meleate ( Levemepromazine ) a phenothiazine antipsychotic drug , was admitted to the pediatric intensive care unit suffering from respiratory distress syndrome .@_@methotrimeprazine meleate and methotrimeprazine meleate are not related .
The association of phenothiazine overdose and respiratory distress syndrome merits consideration .@_@respiratory distress syndrome and phenothiazine are Adverse-Effect relation .
The association of phenothiazine overdose and respiratory distress syndrome merits consideration .@_@respiratory distress syndrome and respiratory distress syndrome are not related .
The association of phenothiazine overdose and respiratory distress syndrome merits consideration .@_@phenothiazine and respiratory distress syndrome are not related .
The association of phenothiazine overdose and respiratory distress syndrome merits consideration .@_@phenothiazine and phenothiazine are not related .
In two patients , apomorphine remained effective in the morning , but increased the intensity of the dyskinesias in the afternoon .@_@dyskinesias and apomorphine are Adverse-Effect relation .
In two patients , apomorphine remained effective in the morning , but increased the intensity of the dyskinesias in the afternoon .@_@dyskinesias and dyskinesias are not related .
In two patients , apomorphine remained effective in the morning , but increased the intensity of the dyskinesias in the afternoon .@_@apomorphine and dyskinesias are not related .
In two patients , apomorphine remained effective in the morning , but increased the intensity of the dyskinesias in the afternoon .@_@apomorphine and apomorphine are not related .
We report on three observations of parkinsonian patients with levo - dopa - induced diphasic dyskinesias , who received subcutaneous apomorphine to reduce the duration of abnormal movements .@_@diphasic dyskinesias and levo - dopa are Adverse-Effect relation .
We report on three observations of parkinsonian patients with levo - dopa - induced diphasic dyskinesias , who received subcutaneous apomorphine to reduce the duration of abnormal movements .@_@diphasic dyskinesias and diphasic dyskinesias are not related .
We report on three observations of parkinsonian patients with levo - dopa - induced diphasic dyskinesias , who received subcutaneous apomorphine to reduce the duration of abnormal movements .@_@levo - dopa and diphasic dyskinesias are not related .
We report on three observations of parkinsonian patients with levo - dopa - induced diphasic dyskinesias , who received subcutaneous apomorphine to reduce the duration of abnormal movements .@_@levo - dopa and levo - dopa are not related .
Fulminant hepatitis with severe lactate acidosis in HIV - infected patients on didanosine therapy .@_@Fulminant hepatitis and didanosine are Adverse-Effect relation .
Fulminant hepatitis with severe lactate acidosis in HIV - infected patients on didanosine therapy .@_@severe lactate acidosis and didanosine are Adverse-Effect relation .
Fulminant hepatitis with severe lactate acidosis in HIV - infected patients on didanosine therapy .@_@Fulminant hepatitis and Fulminant hepatitis are not related .
Fulminant hepatitis with severe lactate acidosis in HIV - infected patients on didanosine therapy .@_@Fulminant hepatitis and severe lactate acidosis are not related .
Fulminant hepatitis with severe lactate acidosis in HIV - infected patients on didanosine therapy .@_@didanosine and Fulminant hepatitis are not related .
Fulminant hepatitis with severe lactate acidosis in HIV - infected patients on didanosine therapy .@_@didanosine and didanosine are not related .
Fulminant hepatitis with severe lactate acidosis in HIV - infected patients on didanosine therapy .@_@didanosine and severe lactate acidosis are not related .
Fulminant hepatitis with severe lactate acidosis in HIV - infected patients on didanosine therapy .@_@severe lactate acidosis and Fulminant hepatitis are not related .
Fulminant hepatitis with severe lactate acidosis in HIV - infected patients on didanosine therapy .@_@severe lactate acidosis and severe lactate acidosis are not related .
This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients .@_@fulminant hepatitis and ddI are Adverse-Effect relation .
This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients .@_@fulminant hepatitis and fulminant hepatitis are not related .
This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients .@_@ddI and fulminant hepatitis are not related .
This prompted us to suspect that ddI might be responsible for fulminant hepatitis in all three AIDS patients .@_@ddI and ddI are not related .
We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine ( ddI ) .@_@fulminant hepatic failure and didanosine are Adverse-Effect relation .
We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine ( ddI ) .@_@fulminant hepatic failure and ddI are Adverse-Effect relation .
We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine ( ddI ) .@_@fulminant hepatic failure and fulminant hepatic failure are not related .
We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine ( ddI ) .@_@ddI and fulminant hepatic failure are not related .
We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine ( ddI ) .@_@ddI and ddI are not related .
We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine ( ddI ) .@_@ddI and didanosine are not related .
We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine ( ddI ) .@_@didanosine and fulminant hepatic failure are not related .
We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine ( ddI ) .@_@didanosine and ddI are not related .
We report two cases of fulminant hepatic failure in HIV-1-infected patients treated with didanosine ( ddI ) .@_@didanosine and didanosine are not related .
Generalized argyria after habitual use of AgNO3 .@_@Generalized argyria and AgNO3 are Adverse-Effect relation .
Generalized argyria after habitual use of AgNO3 .@_@Generalized argyria and Generalized argyria are not related .
Generalized argyria after habitual use of AgNO3 .@_@AgNO3 and Generalized argyria are not related .
Generalized argyria after habitual use of AgNO3 .@_@AgNO3 and AgNO3 are not related .
A case of fluoxetine induced seizures , in a person with Down syndrome , is described .@_@seizures and fluoxetine are Adverse-Effect relation .
A case of fluoxetine induced seizures , in a person with Down syndrome , is described .@_@seizures and seizures are not related .
A case of fluoxetine induced seizures , in a person with Down syndrome , is described .@_@fluoxetine and seizures are not related .
A case of fluoxetine induced seizures , in a person with Down syndrome , is described .@_@fluoxetine and fluoxetine are not related .
Seizures associated with fluoxetine therapy are uncommon .@_@Seizures and fluoxetine are Adverse-Effect relation .
Seizures associated with fluoxetine therapy are uncommon .@_@Seizures and Seizures are not related .
Seizures associated with fluoxetine therapy are uncommon .@_@fluoxetine and Seizures are not related .
Seizures associated with fluoxetine therapy are uncommon .@_@fluoxetine and fluoxetine are not related .
Seizures associated with fluoxetine therapy .@_@Seizures and fluoxetine are Adverse-Effect relation .
Seizures associated with fluoxetine therapy .@_@Seizures and Seizures are not related .
Seizures associated with fluoxetine therapy .@_@fluoxetine and Seizures are not related .
Seizures associated with fluoxetine therapy .@_@fluoxetine and fluoxetine are not related .
Although fluoxetine - induced headache occurred in one patient , the other five reported no side effects at the doses used .@_@headache and fluoxetine are Adverse-Effect relation .
Although fluoxetine - induced headache occurred in one patient , the other five reported no side effects at the doses used .@_@headache and headache are not related .
Although fluoxetine - induced headache occurred in one patient , the other five reported no side effects at the doses used .@_@fluoxetine and headache are not related .
Although fluoxetine - induced headache occurred in one patient , the other five reported no side effects at the doses used .@_@fluoxetine and fluoxetine are not related .
Sodium valproate and carbamazepine , antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions , should be added to the growing list of drugs that produce psoriasiform eruptions .@_@psoriasiform eruptions and Sodium valproate are Adverse-Effect relation .
Sodium valproate and carbamazepine , antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions , should be added to the growing list of drugs that produce psoriasiform eruptions .@_@psoriasiform eruptions and carbamazepine are Adverse-Effect relation .
Sodium valproate and carbamazepine , antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions , should be added to the growing list of drugs that produce psoriasiform eruptions .@_@psoriasiform eruptions and psoriasiform eruptions are not related .
Sodium valproate and carbamazepine , antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions , should be added to the growing list of drugs that produce psoriasiform eruptions .@_@carbamazepine and psoriasiform eruptions are not related .
Sodium valproate and carbamazepine , antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions , should be added to the growing list of drugs that produce psoriasiform eruptions .@_@carbamazepine and carbamazepine are not related .
Sodium valproate and carbamazepine , antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions , should be added to the growing list of drugs that produce psoriasiform eruptions .@_@carbamazepine and Sodium valproate are not related .
Sodium valproate and carbamazepine , antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions , should be added to the growing list of drugs that produce psoriasiform eruptions .@_@Sodium valproate and psoriasiform eruptions are not related .
Sodium valproate and carbamazepine , antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions , should be added to the growing list of drugs that produce psoriasiform eruptions .@_@Sodium valproate and carbamazepine are not related .
Sodium valproate and carbamazepine , antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions , should be added to the growing list of drugs that produce psoriasiform eruptions .@_@Sodium valproate and Sodium valproate are not related .
We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine .@_@psoriasiform eruption and carbamazepine are Adverse-Effect relation .
We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine .@_@psoriasiform eruption and sodium valproate are Adverse-Effect relation .
We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine .@_@psoriasiform eruption and psoriasiform eruption are not related .
We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine .@_@carbamazepine and psoriasiform eruption are not related .
We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine .@_@carbamazepine and carbamazepine are not related .
We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine .@_@carbamazepine and sodium valproate are not related .
We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine .@_@sodium valproate and psoriasiform eruption are not related .
We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine .@_@sodium valproate and carbamazepine are not related .
We present findings from three patients who experienced a psoriasiform eruption apparently due to the antiepileptic agents sodium valproate and carbamazepine .@_@sodium valproate and sodium valproate are not related .
Severe diffuse interstitial pneumonitis induced by carmustine ( BCNU ) .@_@Severe diffuse interstitial pneumonitis and carmustine are Adverse-Effect relation .
Severe diffuse interstitial pneumonitis induced by carmustine ( BCNU ) .@_@Severe diffuse interstitial pneumonitis and BCNU are Adverse-Effect relation .
Severe diffuse interstitial pneumonitis induced by carmustine ( BCNU ) .@_@Severe diffuse interstitial pneumonitis and Severe diffuse interstitial pneumonitis are not related .
Severe diffuse interstitial pneumonitis induced by carmustine ( BCNU ) .@_@BCNU and Severe diffuse interstitial pneumonitis are not related .
Severe diffuse interstitial pneumonitis induced by carmustine ( BCNU ) .@_@BCNU and BCNU are not related .
Severe diffuse interstitial pneumonitis induced by carmustine ( BCNU ) .@_@BCNU and carmustine are not related .
Severe diffuse interstitial pneumonitis induced by carmustine ( BCNU ) .@_@carmustine and Severe diffuse interstitial pneumonitis are not related .
Severe diffuse interstitial pneumonitis induced by carmustine ( BCNU ) .@_@carmustine and BCNU are not related .
Severe diffuse interstitial pneumonitis induced by carmustine ( BCNU ) .@_@carmustine and carmustine are not related .
We report a fatal case of acute interstitial pneumonitis in a patient treated with carmustine ( BCNU ) for a brain tumor .@_@fatal case of acute interstitial pneumonitis and carmustine are Adverse-Effect relation .
We report a fatal case of acute interstitial pneumonitis in a patient treated with carmustine ( BCNU ) for a brain tumor .@_@fatal case of acute interstitial pneumonitis and BCNU are Adverse-Effect relation .
We report a fatal case of acute interstitial pneumonitis in a patient treated with carmustine ( BCNU ) for a brain tumor .@_@fatal case of acute interstitial pneumonitis and fatal case of acute interstitial pneumonitis are not related .
We report a fatal case of acute interstitial pneumonitis in a patient treated with carmustine ( BCNU ) for a brain tumor .@_@BCNU and fatal case of acute interstitial pneumonitis are not related .
We report a fatal case of acute interstitial pneumonitis in a patient treated with carmustine ( BCNU ) for a brain tumor .@_@BCNU and BCNU are not related .
We report a fatal case of acute interstitial pneumonitis in a patient treated with carmustine ( BCNU ) for a brain tumor .@_@BCNU and carmustine are not related .
We report a fatal case of acute interstitial pneumonitis in a patient treated with carmustine ( BCNU ) for a brain tumor .@_@carmustine and fatal case of acute interstitial pneumonitis are not related .
We report a fatal case of acute interstitial pneumonitis in a patient treated with carmustine ( BCNU ) for a brain tumor .@_@carmustine and BCNU are not related .
We report a fatal case of acute interstitial pneumonitis in a patient treated with carmustine ( BCNU ) for a brain tumor .@_@carmustine and carmustine are not related .
A 78-year - old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy .@_@shocks and procainamide are Adverse-Effect relation .
A 78-year - old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy .@_@shocks and shocks are not related .
A 78-year - old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy .@_@procainamide and shocks are not related .
A 78-year - old man with a transvenous cardioverter defibrillator system developed frequent shocks during oral procainamide therapy .@_@procainamide and procainamide are not related .
Electrical proarrhythmia with procainamide : a new ICD - drug interaction .@_@Electrical proarrhythmia and procainamide are Adverse-Effect relation .
Electrical proarrhythmia with procainamide : a new ICD - drug interaction .@_@Electrical proarrhythmia and Electrical proarrhythmia are not related .
Electrical proarrhythmia with procainamide : a new ICD - drug interaction .@_@procainamide and Electrical proarrhythmia are not related .
Electrical proarrhythmia with procainamide : a new ICD - drug interaction .@_@procainamide and procainamide are not related .
The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported electrophysiologic effect of , or idiosyncratic response to , procainamide .@_@electrophysiologic effect and procainamide are Adverse-Effect relation .
The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported electrophysiologic effect of , or idiosyncratic response to , procainamide .@_@electrophysiologic effect and electrophysiologic effect are not related .
The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported electrophysiologic effect of , or idiosyncratic response to , procainamide .@_@procainamide and electrophysiologic effect are not related .
The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported electrophysiologic effect of , or idiosyncratic response to , procainamide .@_@procainamide and procainamide are not related .
Based on our experience and on previously published data , serum ammonia levels appear to be indicated in all ED patients on valproic acid therapy who present with altered mental status .@_@altered mental status and valproic acid are Adverse-Effect relation .
Based on our experience and on previously published data , serum ammonia levels appear to be indicated in all ED patients on valproic acid therapy who present with altered mental status .@_@altered mental status and altered mental status are not related .
Based on our experience and on previously published data , serum ammonia levels appear to be indicated in all ED patients on valproic acid therapy who present with altered mental status .@_@valproic acid and altered mental status are not related .
Based on our experience and on previously published data , serum ammonia levels appear to be indicated in all ED patients on valproic acid therapy who present with altered mental status .@_@valproic acid and valproic acid are not related .
Hyperammonemia has been described as a complication of valproic acid therapy but may often be overlooked as a cause of lethargy in the postictal patient who presents to the emergency department .@_@Hyperammonemia and valproic acid are Adverse-Effect relation .
Hyperammonemia has been described as a complication of valproic acid therapy but may often be overlooked as a cause of lethargy in the postictal patient who presents to the emergency department .@_@lethargy and valproic acid are Adverse-Effect relation .
Hyperammonemia has been described as a complication of valproic acid therapy but may often be overlooked as a cause of lethargy in the postictal patient who presents to the emergency department .@_@Hyperammonemia and Hyperammonemia are not related .
Hyperammonemia has been described as a complication of valproic acid therapy but may often be overlooked as a cause of lethargy in the postictal patient who presents to the emergency department .@_@Hyperammonemia and lethargy are not related .
Hyperammonemia has been described as a complication of valproic acid therapy but may often be overlooked as a cause of lethargy in the postictal patient who presents to the emergency department .@_@valproic acid and Hyperammonemia are not related .
Hyperammonemia has been described as a complication of valproic acid therapy but may often be overlooked as a cause of lethargy in the postictal patient who presents to the emergency department .@_@valproic acid and valproic acid are not related .
Hyperammonemia has been described as a complication of valproic acid therapy but may often be overlooked as a cause of lethargy in the postictal patient who presents to the emergency department .@_@valproic acid and lethargy are not related .
Hyperammonemia has been described as a complication of valproic acid therapy but may often be overlooked as a cause of lethargy in the postictal patient who presents to the emergency department .@_@lethargy and Hyperammonemia are not related .
Hyperammonemia has been described as a complication of valproic acid therapy but may often be overlooked as a cause of lethargy in the postictal patient who presents to the emergency department .@_@lethargy and lethargy are not related .
Hyperammonemia secondary to valproic acid as a cause of lethargy in a postictal patient .@_@lethargy and valproic acid are Adverse-Effect relation .
Hyperammonemia secondary to valproic acid as a cause of lethargy in a postictal patient .@_@Hyperammonemia and valproic acid are Adverse-Effect relation .
Hyperammonemia secondary to valproic acid as a cause of lethargy in a postictal patient .@_@Hyperammonemia and Hyperammonemia are not related .
Hyperammonemia secondary to valproic acid as a cause of lethargy in a postictal patient .@_@Hyperammonemia and lethargy are not related .
Hyperammonemia secondary to valproic acid as a cause of lethargy in a postictal patient .@_@valproic acid and Hyperammonemia are not related .
Hyperammonemia secondary to valproic acid as a cause of lethargy in a postictal patient .@_@valproic acid and valproic acid are not related .
Hyperammonemia secondary to valproic acid as a cause of lethargy in a postictal patient .@_@valproic acid and lethargy are not related .
Hyperammonemia secondary to valproic acid as a cause of lethargy in a postictal patient .@_@lethargy and Hyperammonemia are not related .
Hyperammonemia secondary to valproic acid as a cause of lethargy in a postictal patient .@_@lethargy and lethargy are not related .
We present the case of a postictal patient with lethargy , hyperammonemia , otherwise normal liver function tests , and a therapeutic valproic acid level .@_@lethargy and valproic acid are Adverse-Effect relation .
We present the case of a postictal patient with lethargy , hyperammonemia , otherwise normal liver function tests , and a therapeutic valproic acid level .@_@hyperammonemia and valproic acid are Adverse-Effect relation .
We present the case of a postictal patient with lethargy , hyperammonemia , otherwise normal liver function tests , and a therapeutic valproic acid level .@_@hyperammonemia and hyperammonemia are not related .
We present the case of a postictal patient with lethargy , hyperammonemia , otherwise normal liver function tests , and a therapeutic valproic acid level .@_@hyperammonemia and lethargy are not related .
We present the case of a postictal patient with lethargy , hyperammonemia , otherwise normal liver function tests , and a therapeutic valproic acid level .@_@valproic acid and hyperammonemia are not related .
We present the case of a postictal patient with lethargy , hyperammonemia , otherwise normal liver function tests , and a therapeutic valproic acid level .@_@valproic acid and valproic acid are not related .
We present the case of a postictal patient with lethargy , hyperammonemia , otherwise normal liver function tests , and a therapeutic valproic acid level .@_@valproic acid and lethargy are not related .
We present the case of a postictal patient with lethargy , hyperammonemia , otherwise normal liver function tests , and a therapeutic valproic acid level .@_@lethargy and hyperammonemia are not related .
We present the case of a postictal patient with lethargy , hyperammonemia , otherwise normal liver function tests , and a therapeutic valproic acid level .@_@lethargy and lethargy are not related .
Central nervous system toxicity associated with meperidine use in hepatic disease .@_@Central nervous system toxicity and meperidine are Adverse-Effect relation .
Central nervous system toxicity associated with meperidine use in hepatic disease .@_@Central nervous system toxicity and Central nervous system toxicity are not related .
Central nervous system toxicity associated with meperidine use in hepatic disease .@_@meperidine and Central nervous system toxicity are not related .
Central nervous system toxicity associated with meperidine use in hepatic disease .@_@meperidine and meperidine are not related .
In patients with cirrhosis , the metabolism of meperidine is decreased , leading to accumulation of the parent drug and possible CNS depressive effects similar to hepatic encephalopathy .@_@accumulation of the parent drug and meperidine are Adverse-Effect relation .
In patients with cirrhosis , the metabolism of meperidine is decreased , leading to accumulation of the parent drug and possible CNS depressive effects similar to hepatic encephalopathy .@_@CNS depressive effects and meperidine are Adverse-Effect relation .
In patients with cirrhosis , the metabolism of meperidine is decreased , leading to accumulation of the parent drug and possible CNS depressive effects similar to hepatic encephalopathy .@_@accumulation of the parent drug and accumulation of the parent drug are not related .
In patients with cirrhosis , the metabolism of meperidine is decreased , leading to accumulation of the parent drug and possible CNS depressive effects similar to hepatic encephalopathy .@_@accumulation of the parent drug and CNS depressive effects are not related .
In patients with cirrhosis , the metabolism of meperidine is decreased , leading to accumulation of the parent drug and possible CNS depressive effects similar to hepatic encephalopathy .@_@meperidine and accumulation of the parent drug are not related .
In patients with cirrhosis , the metabolism of meperidine is decreased , leading to accumulation of the parent drug and possible CNS depressive effects similar to hepatic encephalopathy .@_@meperidine and meperidine are not related .
In patients with cirrhosis , the metabolism of meperidine is decreased , leading to accumulation of the parent drug and possible CNS depressive effects similar to hepatic encephalopathy .@_@meperidine and CNS depressive effects are not related .
In patients with cirrhosis , the metabolism of meperidine is decreased , leading to accumulation of the parent drug and possible CNS depressive effects similar to hepatic encephalopathy .@_@CNS depressive effects and accumulation of the parent drug are not related .
In patients with cirrhosis , the metabolism of meperidine is decreased , leading to accumulation of the parent drug and possible CNS depressive effects similar to hepatic encephalopathy .@_@CNS depressive effects and CNS depressive effects are not related .
Meperidine - associated central nervous system ( CNS ) excitatory toxicities are believed to be caused by accumulation of the active metabolite normeperidine .@_@accumulation of the active metabolite normeperidine and Meperidine are Adverse-Effect relation .
Meperidine - associated central nervous system ( CNS ) excitatory toxicities are believed to be caused by accumulation of the active metabolite normeperidine .@_@central nervous system ( CNS ) excitatory toxicities and Meperidine are Adverse-Effect relation .
Meperidine - associated central nervous system ( CNS ) excitatory toxicities are believed to be caused by accumulation of the active metabolite normeperidine .@_@accumulation of the active metabolite normeperidine and accumulation of the active metabolite normeperidine are not related .
Meperidine - associated central nervous system ( CNS ) excitatory toxicities are believed to be caused by accumulation of the active metabolite normeperidine .@_@accumulation of the active metabolite normeperidine and central nervous system ( CNS ) excitatory toxicities are not related .
Meperidine - associated central nervous system ( CNS ) excitatory toxicities are believed to be caused by accumulation of the active metabolite normeperidine .@_@Meperidine and accumulation of the active metabolite normeperidine are not related .
Meperidine - associated central nervous system ( CNS ) excitatory toxicities are believed to be caused by accumulation of the active metabolite normeperidine .@_@Meperidine and Meperidine are not related .
Meperidine - associated central nervous system ( CNS ) excitatory toxicities are believed to be caused by accumulation of the active metabolite normeperidine .@_@Meperidine and central nervous system ( CNS ) excitatory toxicities are not related .
Meperidine - associated central nervous system ( CNS ) excitatory toxicities are believed to be caused by accumulation of the active metabolite normeperidine .@_@central nervous system ( CNS ) excitatory toxicities and accumulation of the active metabolite normeperidine are not related .
Meperidine - associated central nervous system ( CNS ) excitatory toxicities are believed to be caused by accumulation of the active metabolite normeperidine .@_@central nervous system ( CNS ) excitatory toxicities and central nervous system ( CNS ) excitatory toxicities are not related .
She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure .@_@intracerebral hemorrhage and morphine are Adverse-Effect relation .
She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure .@_@status epilepticus and morphine are Adverse-Effect relation .
She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure .@_@hypertension and morphine are Adverse-Effect relation .
She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure .@_@respiratory failure and morphine are Adverse-Effect relation .
She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure .@_@hypertension and hypertension are not related .
She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure .@_@hypertension and intracerebral hemorrhage are not related .
She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure .@_@hypertension and respiratory failure are not related .
She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure .@_@hypertension and status epilepticus are not related .
She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure .@_@morphine and hypertension are not related .
She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure .@_@morphine and morphine are not related .
She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure .@_@morphine and intracerebral hemorrhage are not related .
She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure .@_@morphine and respiratory failure are not related .
She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure .@_@morphine and status epilepticus are not related .
She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure .@_@intracerebral hemorrhage and hypertension are not related .
She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure .@_@intracerebral hemorrhage and intracerebral hemorrhage are not related .
She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure .@_@intracerebral hemorrhage and respiratory failure are not related .
She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure .@_@intracerebral hemorrhage and status epilepticus are not related .
She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure .@_@respiratory failure and hypertension are not related .
She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure .@_@respiratory failure and intracerebral hemorrhage are not related .
She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure .@_@respiratory failure and respiratory failure are not related .
She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure .@_@respiratory failure and status epilepticus are not related .
She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure .@_@status epilepticus and hypertension are not related .
She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure .@_@status epilepticus and intracerebral hemorrhage are not related .
She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure .@_@status epilepticus and respiratory failure are not related .
She received an accidental 450-mg bolus injection of morphine intrathecally and developed hypertension , status epilepticus , intracerebral hemorrhage , and respiratory failure .@_@status epilepticus and status epilepticus are not related .
Mitomycin C ( MMC ) is an alkylating agent that has been recently associated with the hemolytic - uremic syndrome ( HUS ) .@_@hemolytic - uremic syndrome and MMC are Adverse-Effect relation .
Mitomycin C ( MMC ) is an alkylating agent that has been recently associated with the hemolytic - uremic syndrome ( HUS ) .@_@HUS and Mitomycin C are Adverse-Effect relation .
Mitomycin C ( MMC ) is an alkylating agent that has been recently associated with the hemolytic - uremic syndrome ( HUS ) .@_@hemolytic - uremic syndrome and Mitomycin C are Adverse-Effect relation .
Mitomycin C ( MMC ) is an alkylating agent that has been recently associated with the hemolytic - uremic syndrome ( HUS ) .@_@HUS and MMC are Adverse-Effect relation .
Mitomycin C ( MMC ) is an alkylating agent that has been recently associated with the hemolytic - uremic syndrome ( HUS ) .@_@hemolytic - uremic syndrome and hemolytic - uremic syndrome are not related .
Mitomycin C ( MMC ) is an alkylating agent that has been recently associated with the hemolytic - uremic syndrome ( HUS ) .@_@hemolytic - uremic syndrome and HUS are not related .
Mitomycin C ( MMC ) is an alkylating agent that has been recently associated with the hemolytic - uremic syndrome ( HUS ) .@_@Mitomycin C and hemolytic - uremic syndrome are not related .
Mitomycin C ( MMC ) is an alkylating agent that has been recently associated with the hemolytic - uremic syndrome ( HUS ) .@_@Mitomycin C and Mitomycin C are not related .
Mitomycin C ( MMC ) is an alkylating agent that has been recently associated with the hemolytic - uremic syndrome ( HUS ) .@_@Mitomycin C and MMC are not related .
Mitomycin C ( MMC ) is an alkylating agent that has been recently associated with the hemolytic - uremic syndrome ( HUS ) .@_@Mitomycin C and HUS are not related .
Mitomycin C ( MMC ) is an alkylating agent that has been recently associated with the hemolytic - uremic syndrome ( HUS ) .@_@MMC and hemolytic - uremic syndrome are not related .
Mitomycin C ( MMC ) is an alkylating agent that has been recently associated with the hemolytic - uremic syndrome ( HUS ) .@_@MMC and Mitomycin C are not related .
Mitomycin C ( MMC ) is an alkylating agent that has been recently associated with the hemolytic - uremic syndrome ( HUS ) .@_@MMC and MMC are not related .
Mitomycin C ( MMC ) is an alkylating agent that has been recently associated with the hemolytic - uremic syndrome ( HUS ) .@_@MMC and HUS are not related .
Mitomycin C ( MMC ) is an alkylating agent that has been recently associated with the hemolytic - uremic syndrome ( HUS ) .@_@HUS and hemolytic - uremic syndrome are not related .
Mitomycin C ( MMC ) is an alkylating agent that has been recently associated with the hemolytic - uremic syndrome ( HUS ) .@_@HUS and HUS are not related .
Pulmonary hemorrhage as a clinical manifestation of hemolytic - uremic syndrome associated with mitomycin C therapy .@_@hemolytic - uremic syndrome and mitomycin C are Adverse-Effect relation .
Pulmonary hemorrhage as a clinical manifestation of hemolytic - uremic syndrome associated with mitomycin C therapy .@_@Pulmonary hemorrhage and mitomycin C are Adverse-Effect relation .
Pulmonary hemorrhage as a clinical manifestation of hemolytic - uremic syndrome associated with mitomycin C therapy .@_@hemolytic - uremic syndrome and hemolytic - uremic syndrome are not related .
Pulmonary hemorrhage as a clinical manifestation of hemolytic - uremic syndrome associated with mitomycin C therapy .@_@hemolytic - uremic syndrome and Pulmonary hemorrhage are not related .
Pulmonary hemorrhage as a clinical manifestation of hemolytic - uremic syndrome associated with mitomycin C therapy .@_@mitomycin C and hemolytic - uremic syndrome are not related .
Pulmonary hemorrhage as a clinical manifestation of hemolytic - uremic syndrome associated with mitomycin C therapy .@_@mitomycin C and mitomycin C are not related .
Pulmonary hemorrhage as a clinical manifestation of hemolytic - uremic syndrome associated with mitomycin C therapy .@_@mitomycin C and Pulmonary hemorrhage are not related .
Pulmonary hemorrhage as a clinical manifestation of hemolytic - uremic syndrome associated with mitomycin C therapy .@_@Pulmonary hemorrhage and hemolytic - uremic syndrome are not related .
Pulmonary hemorrhage as a clinical manifestation of hemolytic - uremic syndrome associated with mitomycin C therapy .@_@Pulmonary hemorrhage and Pulmonary hemorrhage are not related .
Pulmonary hemorrhage is an uncommon feature in the HUS , and seems to appear especially in the HUS associated with MMC therapy .@_@HUS and MMC are Adverse-Effect relation .
Pulmonary hemorrhage is an uncommon feature in the HUS , and seems to appear especially in the HUS associated with MMC therapy .@_@Pulmonary hemorrhage and MMC are Adverse-Effect relation .
Pulmonary hemorrhage is an uncommon feature in the HUS , and seems to appear especially in the HUS associated with MMC therapy .@_@HUS and HUS are not related .
Pulmonary hemorrhage is an uncommon feature in the HUS , and seems to appear especially in the HUS associated with MMC therapy .@_@HUS and Pulmonary hemorrhage are not related .
Pulmonary hemorrhage is an uncommon feature in the HUS , and seems to appear especially in the HUS associated with MMC therapy .@_@MMC and HUS are not related .
Pulmonary hemorrhage is an uncommon feature in the HUS , and seems to appear especially in the HUS associated with MMC therapy .@_@MMC and MMC are not related .
Pulmonary hemorrhage is an uncommon feature in the HUS , and seems to appear especially in the HUS associated with MMC therapy .@_@MMC and Pulmonary hemorrhage are not related .
Pulmonary hemorrhage is an uncommon feature in the HUS , and seems to appear especially in the HUS associated with MMC therapy .@_@Pulmonary hemorrhage and HUS are not related .
Pulmonary hemorrhage is an uncommon feature in the HUS , and seems to appear especially in the HUS associated with MMC therapy .@_@Pulmonary hemorrhage and Pulmonary hemorrhage are not related .
We describe two women who developed HUS after MMC therapy and presented massive pulmonary bleeding .@_@HUS and MMC are Adverse-Effect relation .
We describe two women who developed HUS after MMC therapy and presented massive pulmonary bleeding .@_@massive pulmonary bleeding and MMC are Adverse-Effect relation .
We describe two women who developed HUS after MMC therapy and presented massive pulmonary bleeding .@_@HUS and HUS are not related .
We describe two women who developed HUS after MMC therapy and presented massive pulmonary bleeding .@_@HUS and massive pulmonary bleeding are not related .
We describe two women who developed HUS after MMC therapy and presented massive pulmonary bleeding .@_@MMC and HUS are not related .
We describe two women who developed HUS after MMC therapy and presented massive pulmonary bleeding .@_@MMC and MMC are not related .
We describe two women who developed HUS after MMC therapy and presented massive pulmonary bleeding .@_@MMC and massive pulmonary bleeding are not related .
We describe two women who developed HUS after MMC therapy and presented massive pulmonary bleeding .@_@massive pulmonary bleeding and HUS are not related .
We describe two women who developed HUS after MMC therapy and presented massive pulmonary bleeding .@_@massive pulmonary bleeding and massive pulmonary bleeding are not related .
Clonidine - induced bradycardia in patients with spinal cord injury .@_@bradycardia and Clonidine are Adverse-Effect relation .
Clonidine - induced bradycardia in patients with spinal cord injury .@_@bradycardia and bradycardia are not related .
Clonidine - induced bradycardia in patients with spinal cord injury .@_@Clonidine and bradycardia are not related .
Clonidine - induced bradycardia in patients with spinal cord injury .@_@Clonidine and Clonidine are not related .
Possible mechanisms by which clonidine decreases spasticity are described , probable mechanisms of induced bradycardia are reviewed , and specific treatment recommendations for the use of clonidine in spinal cord injured patients are presented .@_@bradycardia and clonidine are Adverse-Effect relation .
Possible mechanisms by which clonidine decreases spasticity are described , probable mechanisms of induced bradycardia are reviewed , and specific treatment recommendations for the use of clonidine in spinal cord injured patients are presented .@_@bradycardia and bradycardia are not related .
Possible mechanisms by which clonidine decreases spasticity are described , probable mechanisms of induced bradycardia are reviewed , and specific treatment recommendations for the use of clonidine in spinal cord injured patients are presented .@_@clonidine and bradycardia are not related .
Possible mechanisms by which clonidine decreases spasticity are described , probable mechanisms of induced bradycardia are reviewed , and specific treatment recommendations for the use of clonidine in spinal cord injured patients are presented .@_@clonidine and clonidine are not related .
Though hypotension , dry mouth , and constipation are well - documented possible adverse effects , the possibility of clonidine - induced bradycardia is less well recognized and is rare .@_@constipation and clonidine are Adverse-Effect relation .
Though hypotension , dry mouth , and constipation are well - documented possible adverse effects , the possibility of clonidine - induced bradycardia is less well recognized and is rare .@_@bradycardia and clonidine are Adverse-Effect relation .
Though hypotension , dry mouth , and constipation are well - documented possible adverse effects , the possibility of clonidine - induced bradycardia is less well recognized and is rare .@_@dry mouth and clonidine are Adverse-Effect relation .
Though hypotension , dry mouth , and constipation are well - documented possible adverse effects , the possibility of clonidine - induced bradycardia is less well recognized and is rare .@_@hypotension and clonidine are Adverse-Effect relation .
Though hypotension , dry mouth , and constipation are well - documented possible adverse effects , the possibility of clonidine - induced bradycardia is less well recognized and is rare .@_@bradycardia and bradycardia are not related .
Though hypotension , dry mouth , and constipation are well - documented possible adverse effects , the possibility of clonidine - induced bradycardia is less well recognized and is rare .@_@bradycardia and constipation are not related .
Though hypotension , dry mouth , and constipation are well - documented possible adverse effects , the possibility of clonidine - induced bradycardia is less well recognized and is rare .@_@bradycardia and dry mouth are not related .
Though hypotension , dry mouth , and constipation are well - documented possible adverse effects , the possibility of clonidine - induced bradycardia is less well recognized and is rare .@_@bradycardia and hypotension are not related .
Though hypotension , dry mouth , and constipation are well - documented possible adverse effects , the possibility of clonidine - induced bradycardia is less well recognized and is rare .@_@clonidine and bradycardia are not related .
Though hypotension , dry mouth , and constipation are well - documented possible adverse effects , the possibility of clonidine - induced bradycardia is less well recognized and is rare .@_@clonidine and clonidine are not related .
Though hypotension , dry mouth , and constipation are well - documented possible adverse effects , the possibility of clonidine - induced bradycardia is less well recognized and is rare .@_@clonidine and constipation are not related .
Though hypotension , dry mouth , and constipation are well - documented possible adverse effects , the possibility of clonidine - induced bradycardia is less well recognized and is rare .@_@clonidine and dry mouth are not related .
Though hypotension , dry mouth , and constipation are well - documented possible adverse effects , the possibility of clonidine - induced bradycardia is less well recognized and is rare .@_@clonidine and hypotension are not related .
Though hypotension , dry mouth , and constipation are well - documented possible adverse effects , the possibility of clonidine - induced bradycardia is less well recognized and is rare .@_@constipation and bradycardia are not related .
Though hypotension , dry mouth , and constipation are well - documented possible adverse effects , the possibility of clonidine - induced bradycardia is less well recognized and is rare .@_@constipation and constipation are not related .
Though hypotension , dry mouth , and constipation are well - documented possible adverse effects , the possibility of clonidine - induced bradycardia is less well recognized and is rare .@_@constipation and dry mouth are not related .
Though hypotension , dry mouth , and constipation are well - documented possible adverse effects , the possibility of clonidine - induced bradycardia is less well recognized and is rare .@_@constipation and hypotension are not related .
Though hypotension , dry mouth , and constipation are well - documented possible adverse effects , the possibility of clonidine - induced bradycardia is less well recognized and is rare .@_@dry mouth and bradycardia are not related .
Though hypotension , dry mouth , and constipation are well - documented possible adverse effects , the possibility of clonidine - induced bradycardia is less well recognized and is rare .@_@dry mouth and constipation are not related .
Though hypotension , dry mouth , and constipation are well - documented possible adverse effects , the possibility of clonidine - induced bradycardia is less well recognized and is rare .@_@dry mouth and dry mouth are not related .
Though hypotension , dry mouth , and constipation are well - documented possible adverse effects , the possibility of clonidine - induced bradycardia is less well recognized and is rare .@_@dry mouth and hypotension are not related .
Though hypotension , dry mouth , and constipation are well - documented possible adverse effects , the possibility of clonidine - induced bradycardia is less well recognized and is rare .@_@hypotension and bradycardia are not related .
Though hypotension , dry mouth , and constipation are well - documented possible adverse effects , the possibility of clonidine - induced bradycardia is less well recognized and is rare .@_@hypotension and constipation are not related .
Though hypotension , dry mouth , and constipation are well - documented possible adverse effects , the possibility of clonidine - induced bradycardia is less well recognized and is rare .@_@hypotension and dry mouth are not related .
Though hypotension , dry mouth , and constipation are well - documented possible adverse effects , the possibility of clonidine - induced bradycardia is less well recognized and is rare .@_@hypotension and hypotension are not related .
A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .@_@hyperkalaemia and cotrimoxazole are Adverse-Effect relation .
A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .@_@increased urinary N - acetyl glucosaminase and cotrimoxazole are Adverse-Effect relation .
A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .@_@elevation of serum creatinine and blood urea and cotrimoxazole are Adverse-Effect relation .
A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .@_@one patient became unconscious and cotrimoxazole are Adverse-Effect relation .
A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .@_@elevation of serum creatinine and blood urea and elevation of serum creatinine and blood urea are not related .
A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .@_@elevation of serum creatinine and blood urea and hyperkalaemia are not related .
A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .@_@elevation of serum creatinine and blood urea and increased urinary N - acetyl glucosaminase are not related .
A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .@_@elevation of serum creatinine and blood urea and one patient became unconscious are not related .
A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .@_@cotrimoxazole and elevation of serum creatinine and blood urea are not related .
A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .@_@cotrimoxazole and cotrimoxazole are not related .
A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .@_@cotrimoxazole and hyperkalaemia are not related .
A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .@_@cotrimoxazole and increased urinary N - acetyl glucosaminase are not related .
A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .@_@cotrimoxazole and one patient became unconscious are not related .
A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .@_@hyperkalaemia and elevation of serum creatinine and blood urea are not related .
A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .@_@hyperkalaemia and hyperkalaemia are not related .
A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .@_@hyperkalaemia and increased urinary N - acetyl glucosaminase are not related .
A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .@_@hyperkalaemia and one patient became unconscious are not related .
A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .@_@increased urinary N - acetyl glucosaminase and elevation of serum creatinine and blood urea are not related .
A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .@_@increased urinary N - acetyl glucosaminase and hyperkalaemia are not related .
A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .@_@increased urinary N - acetyl glucosaminase and increased urinary N - acetyl glucosaminase are not related .
A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .@_@increased urinary N - acetyl glucosaminase and one patient became unconscious are not related .
A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .@_@one patient became unconscious and elevation of serum creatinine and blood urea are not related .
A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .@_@one patient became unconscious and hyperkalaemia are not related .
A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .@_@one patient became unconscious and increased urinary N - acetyl glucosaminase are not related .
A high dose of cotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious .@_@one patient became unconscious and one patient became unconscious are not related .
Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy , who developed Pneumocystis carinii pneumonia and improved .@_@renal tubular dysfunction and sulfamethoxazole - trimethoprim are Adverse-Effect relation .
Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy , who developed Pneumocystis carinii pneumonia and improved .@_@Hyperkalaemia and co - trimoxazole are Adverse-Effect relation .
Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy , who developed Pneumocystis carinii pneumonia and improved .@_@renal tubular dysfunction and co - trimoxazole are Adverse-Effect relation .
Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy , who developed Pneumocystis carinii pneumonia and improved .@_@Hyperkalaemia and sulfamethoxazole - trimethoprim are Adverse-Effect relation .
Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy , who developed Pneumocystis carinii pneumonia and improved .@_@Hyperkalaemia and Hyperkalaemia are not related .
Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy , who developed Pneumocystis carinii pneumonia and improved .@_@Hyperkalaemia and renal tubular dysfunction are not related .
Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy , who developed Pneumocystis carinii pneumonia and improved .@_@co - trimoxazole and Hyperkalaemia are not related .
Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy , who developed Pneumocystis carinii pneumonia and improved .@_@co - trimoxazole and co - trimoxazole are not related .
Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy , who developed Pneumocystis carinii pneumonia and improved .@_@co - trimoxazole and sulfamethoxazole - trimethoprim are not related .
Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy , who developed Pneumocystis carinii pneumonia and improved .@_@co - trimoxazole and renal tubular dysfunction are not related .
Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy , who developed Pneumocystis carinii pneumonia and improved .@_@sulfamethoxazole - trimethoprim and Hyperkalaemia are not related .
Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy , who developed Pneumocystis carinii pneumonia and improved .@_@sulfamethoxazole - trimethoprim and co - trimoxazole are not related .
Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy , who developed Pneumocystis carinii pneumonia and improved .@_@sulfamethoxazole - trimethoprim and sulfamethoxazole - trimethoprim are not related .
Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy , who developed Pneumocystis carinii pneumonia and improved .@_@sulfamethoxazole - trimethoprim and renal tubular dysfunction are not related .
Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy , who developed Pneumocystis carinii pneumonia and improved .@_@renal tubular dysfunction and Hyperkalaemia are not related .
Hyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy , who developed Pneumocystis carinii pneumonia and improved .@_@renal tubular dysfunction and renal tubular dysfunction are not related .
Hyperkalaemia with renal tubular dysfunction by sulfamethoxazole - trimethoprim for Pneumocystis carinii pneumonia in patients with lymphoid malignancy .@_@Hyperkalaemia and sulfamethoxazole - trimethoprim are Adverse-Effect relation .
Hyperkalaemia with renal tubular dysfunction by sulfamethoxazole - trimethoprim for Pneumocystis carinii pneumonia in patients with lymphoid malignancy .@_@renal tubular dysfunction and sulfamethoxazole - trimethoprim are Adverse-Effect relation .
Hyperkalaemia with renal tubular dysfunction by sulfamethoxazole - trimethoprim for Pneumocystis carinii pneumonia in patients with lymphoid malignancy .@_@Hyperkalaemia and Hyperkalaemia are not related .
Hyperkalaemia with renal tubular dysfunction by sulfamethoxazole - trimethoprim for Pneumocystis carinii pneumonia in patients with lymphoid malignancy .@_@Hyperkalaemia and renal tubular dysfunction are not related .
Hyperkalaemia with renal tubular dysfunction by sulfamethoxazole - trimethoprim for Pneumocystis carinii pneumonia in patients with lymphoid malignancy .@_@sulfamethoxazole - trimethoprim and Hyperkalaemia are not related .
Hyperkalaemia with renal tubular dysfunction by sulfamethoxazole - trimethoprim for Pneumocystis carinii pneumonia in patients with lymphoid malignancy .@_@sulfamethoxazole - trimethoprim and sulfamethoxazole - trimethoprim are not related .
Hyperkalaemia with renal tubular dysfunction by sulfamethoxazole - trimethoprim for Pneumocystis carinii pneumonia in patients with lymphoid malignancy .@_@sulfamethoxazole - trimethoprim and renal tubular dysfunction are not related .
Hyperkalaemia with renal tubular dysfunction by sulfamethoxazole - trimethoprim for Pneumocystis carinii pneumonia in patients with lymphoid malignancy .@_@renal tubular dysfunction and Hyperkalaemia are not related .
Hyperkalaemia with renal tubular dysfunction by sulfamethoxazole - trimethoprim for Pneumocystis carinii pneumonia in patients with lymphoid malignancy .@_@renal tubular dysfunction and renal tubular dysfunction are not related .
Five cases ( four from the literature and one new case ) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia .@_@subacute combined degeneration of the spinal cord and nitrous oxide are Adverse-Effect relation .
Five cases ( four from the literature and one new case ) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia .@_@subacute combined degeneration of the spinal cord and subacute combined degeneration of the spinal cord are not related .
Five cases ( four from the literature and one new case ) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia .@_@nitrous oxide and subacute combined degeneration of the spinal cord are not related .
Five cases ( four from the literature and one new case ) are presented in which patients unsuspected of having vitamin B12 deficiency developed subacute combined degeneration of the spinal cord following nitrous oxide anesthesia .@_@nitrous oxide and nitrous oxide are not related .
Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency .@_@Neurologic degeneration and nitrous oxide are Adverse-Effect relation .
Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency .@_@Neurologic degeneration and Neurologic degeneration are not related .
Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency .@_@nitrous oxide and Neurologic degeneration are not related .
Neurologic degeneration associated with nitrous oxide anesthesia in patients with vitamin B12 deficiency .@_@nitrous oxide and nitrous oxide are not related .
Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia .@_@neurologic deterioration and nitrous oxide are Adverse-Effect relation .
Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia .@_@neurologic deterioration and neurologic deterioration are not related .
Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia .@_@nitrous oxide and neurologic deterioration are not related .
Patients with vitamin B12 deficiency are exceedingly sensitive to neurologic deterioration following nitrous oxide anesthesia .@_@nitrous oxide and nitrous oxide are not related .
BACKGROUND : Fluoxetine , a highly specific serotonin reuptake inhibitor , has been reported to cause sexual dysfunction in a minority of patients .@_@sexual dysfunction and Fluoxetine are Adverse-Effect relation .
BACKGROUND : Fluoxetine , a highly specific serotonin reuptake inhibitor , has been reported to cause sexual dysfunction in a minority of patients .@_@sexual dysfunction and sexual dysfunction are not related .
BACKGROUND : Fluoxetine , a highly specific serotonin reuptake inhibitor , has been reported to cause sexual dysfunction in a minority of patients .@_@Fluoxetine and sexual dysfunction are not related .
BACKGROUND : Fluoxetine , a highly specific serotonin reuptake inhibitor , has been reported to cause sexual dysfunction in a minority of patients .@_@Fluoxetine and Fluoxetine are not related .
Captopril - induced bone marrow suppression in two cardiac patients with trisomy 21 .@_@bone marrow suppression and Captopril are Adverse-Effect relation .
Captopril - induced bone marrow suppression in two cardiac patients with trisomy 21 .@_@bone marrow suppression and bone marrow suppression are not related .
Captopril - induced bone marrow suppression in two cardiac patients with trisomy 21 .@_@Captopril and bone marrow suppression are not related .
Captopril - induced bone marrow suppression in two cardiac patients with trisomy 21 .@_@Captopril and Captopril are not related .
Neutropenia is an infrequent complication following administration of the angiotensin - converting enzyme ( ACE ) inhibitor , captopril .@_@Neutropenia and captopril are Adverse-Effect relation .
Neutropenia is an infrequent complication following administration of the angiotensin - converting enzyme ( ACE ) inhibitor , captopril .@_@Neutropenia and Neutropenia are not related .
Neutropenia is an infrequent complication following administration of the angiotensin - converting enzyme ( ACE ) inhibitor , captopril .@_@captopril and Neutropenia are not related .
Neutropenia is an infrequent complication following administration of the angiotensin - converting enzyme ( ACE ) inhibitor , captopril .@_@captopril and captopril are not related .
We report two cases of neutropenia following captopril use in cardiac patients with trisomy 21 .@_@neutropenia and captopril are Adverse-Effect relation .
We report two cases of neutropenia following captopril use in cardiac patients with trisomy 21 .@_@neutropenia and neutropenia are not related .
We report two cases of neutropenia following captopril use in cardiac patients with trisomy 21 .@_@captopril and neutropenia are not related .
We report two cases of neutropenia following captopril use in cardiac patients with trisomy 21 .@_@captopril and captopril are not related .
Can magnesium sulfate therapy impact lactogenesis ?@_@lactogenesis and magnesium sulfate are Adverse-Effect relation .
Can magnesium sulfate therapy impact lactogenesis ?@_@lactogenesis and lactogenesis are not related .
Can magnesium sulfate therapy impact lactogenesis ?@_@magnesium sulfate and lactogenesis are not related .
Can magnesium sulfate therapy impact lactogenesis ?@_@magnesium sulfate and magnesium sulfate are not related .
No explanation for this delay was found , other than the possibility that magnesium sulfate treatment impeded lactogenesis .@_@impeded lactogenesis and magnesium sulfate are Adverse-Effect relation .
No explanation for this delay was found , other than the possibility that magnesium sulfate treatment impeded lactogenesis .@_@impeded lactogenesis and impeded lactogenesis are not related .
No explanation for this delay was found , other than the possibility that magnesium sulfate treatment impeded lactogenesis .@_@magnesium sulfate and impeded lactogenesis are not related .
No explanation for this delay was found , other than the possibility that magnesium sulfate treatment impeded lactogenesis .@_@magnesium sulfate and magnesium sulfate are not related .
Four days after the initial injection of 3.6 mg of goserelin acetate , severe dyspnea developed due to worsening pleuritis carcinomatosa , which was considered as a flare - up .@_@flare - up and goserelin acetate are Adverse-Effect relation .
Four days after the initial injection of 3.6 mg of goserelin acetate , severe dyspnea developed due to worsening pleuritis carcinomatosa , which was considered as a flare - up .@_@severe dyspnea and goserelin acetate are Adverse-Effect relation .
Four days after the initial injection of 3.6 mg of goserelin acetate , severe dyspnea developed due to worsening pleuritis carcinomatosa , which was considered as a flare - up .@_@worsening pleuritis carcinomatosa and goserelin acetate are Adverse-Effect relation .
Four days after the initial injection of 3.6 mg of goserelin acetate , severe dyspnea developed due to worsening pleuritis carcinomatosa , which was considered as a flare - up .@_@flare - up and flare - up are not related .
Four days after the initial injection of 3.6 mg of goserelin acetate , severe dyspnea developed due to worsening pleuritis carcinomatosa , which was considered as a flare - up .@_@flare - up and severe dyspnea are not related .
Four days after the initial injection of 3.6 mg of goserelin acetate , severe dyspnea developed due to worsening pleuritis carcinomatosa , which was considered as a flare - up .@_@flare - up and worsening pleuritis carcinomatosa are not related .
Four days after the initial injection of 3.6 mg of goserelin acetate , severe dyspnea developed due to worsening pleuritis carcinomatosa , which was considered as a flare - up .@_@goserelin acetate and flare - up are not related .
Four days after the initial injection of 3.6 mg of goserelin acetate , severe dyspnea developed due to worsening pleuritis carcinomatosa , which was considered as a flare - up .@_@goserelin acetate and goserelin acetate are not related .
Four days after the initial injection of 3.6 mg of goserelin acetate , severe dyspnea developed due to worsening pleuritis carcinomatosa , which was considered as a flare - up .@_@goserelin acetate and severe dyspnea are not related .
Four days after the initial injection of 3.6 mg of goserelin acetate , severe dyspnea developed due to worsening pleuritis carcinomatosa , which was considered as a flare - up .@_@goserelin acetate and worsening pleuritis carcinomatosa are not related .
Four days after the initial injection of 3.6 mg of goserelin acetate , severe dyspnea developed due to worsening pleuritis carcinomatosa , which was considered as a flare - up .@_@severe dyspnea and flare - up are not related .
Four days after the initial injection of 3.6 mg of goserelin acetate , severe dyspnea developed due to worsening pleuritis carcinomatosa , which was considered as a flare - up .@_@severe dyspnea and severe dyspnea are not related .
Four days after the initial injection of 3.6 mg of goserelin acetate , severe dyspnea developed due to worsening pleuritis carcinomatosa , which was considered as a flare - up .@_@severe dyspnea and worsening pleuritis carcinomatosa are not related .
Four days after the initial injection of 3.6 mg of goserelin acetate , severe dyspnea developed due to worsening pleuritis carcinomatosa , which was considered as a flare - up .@_@worsening pleuritis carcinomatosa and flare - up are not related .
Four days after the initial injection of 3.6 mg of goserelin acetate , severe dyspnea developed due to worsening pleuritis carcinomatosa , which was considered as a flare - up .@_@worsening pleuritis carcinomatosa and severe dyspnea are not related .
Four days after the initial injection of 3.6 mg of goserelin acetate , severe dyspnea developed due to worsening pleuritis carcinomatosa , which was considered as a flare - up .@_@worsening pleuritis carcinomatosa and worsening pleuritis carcinomatosa are not related .
Imidazoline intoxication due to overdose or accidental ingestion but also after normal therapeutic usage is frequent in children .@_@Imidazoline intoxication and Imidazoline are Adverse-Effect relation .
Imidazoline intoxication due to overdose or accidental ingestion but also after normal therapeutic usage is frequent in children .@_@Imidazoline intoxication and Imidazoline intoxication are not related .
Imidazoline intoxication due to overdose or accidental ingestion but also after normal therapeutic usage is frequent in children .@_@Imidazoline and Imidazoline intoxication are not related .
Imidazoline intoxication due to overdose or accidental ingestion but also after normal therapeutic usage is frequent in children .@_@Imidazoline and Imidazoline are not related .
Imidazoline intoxication in children .@_@Imidazoline intoxication and Imidazoline are Adverse-Effect relation .
Imidazoline intoxication in children .@_@Imidazoline intoxication and Imidazoline intoxication are not related .
Imidazoline intoxication in children .@_@Imidazoline and Imidazoline intoxication are not related .
Imidazoline intoxication in children .@_@Imidazoline and Imidazoline are not related .
Cerebrovascular complications of L - asparaginase therapy in children with leukemia : aphasia and other neuropsychological deficits .@_@aphasia and L - asparaginase are Adverse-Effect relation .
Cerebrovascular complications of L - asparaginase therapy in children with leukemia : aphasia and other neuropsychological deficits .@_@Cerebrovascular complications and L - asparaginase are Adverse-Effect relation .
Cerebrovascular complications of L - asparaginase therapy in children with leukemia : aphasia and other neuropsychological deficits .@_@neuropsychological deficits and L - asparaginase are Adverse-Effect relation .
Cerebrovascular complications of L - asparaginase therapy in children with leukemia : aphasia and other neuropsychological deficits .@_@aphasia and aphasia are not related .
Cerebrovascular complications of L - asparaginase therapy in children with leukemia : aphasia and other neuropsychological deficits .@_@aphasia and Cerebrovascular complications are not related .
Cerebrovascular complications of L - asparaginase therapy in children with leukemia : aphasia and other neuropsychological deficits .@_@aphasia and neuropsychological deficits are not related .
Cerebrovascular complications of L - asparaginase therapy in children with leukemia : aphasia and other neuropsychological deficits .@_@L - asparaginase and aphasia are not related .
Cerebrovascular complications of L - asparaginase therapy in children with leukemia : aphasia and other neuropsychological deficits .@_@L - asparaginase and L - asparaginase are not related .
Cerebrovascular complications of L - asparaginase therapy in children with leukemia : aphasia and other neuropsychological deficits .@_@L - asparaginase and Cerebrovascular complications are not related .
Cerebrovascular complications of L - asparaginase therapy in children with leukemia : aphasia and other neuropsychological deficits .@_@L - asparaginase and neuropsychological deficits are not related .
Cerebrovascular complications of L - asparaginase therapy in children with leukemia : aphasia and other neuropsychological deficits .@_@Cerebrovascular complications and aphasia are not related .
Cerebrovascular complications of L - asparaginase therapy in children with leukemia : aphasia and other neuropsychological deficits .@_@Cerebrovascular complications and Cerebrovascular complications are not related .
Cerebrovascular complications of L - asparaginase therapy in children with leukemia : aphasia and other neuropsychological deficits .@_@Cerebrovascular complications and neuropsychological deficits are not related .
Cerebrovascular complications of L - asparaginase therapy in children with leukemia : aphasia and other neuropsychological deficits .@_@neuropsychological deficits and aphasia are not related .
Cerebrovascular complications of L - asparaginase therapy in children with leukemia : aphasia and other neuropsychological deficits .@_@neuropsychological deficits and Cerebrovascular complications are not related .
Cerebrovascular complications of L - asparaginase therapy in children with leukemia : aphasia and other neuropsychological deficits .@_@neuropsychological deficits and neuropsychological deficits are not related .
Children with acute lymphoblastic leukemia ( ALL ) , treated with L - asparaginase are at risk for cerebral thrombosis or hemorrhage because of coagulation protein deficiencies .@_@hemorrhage and L - asparaginase are Adverse-Effect relation .
Children with acute lymphoblastic leukemia ( ALL ) , treated with L - asparaginase are at risk for cerebral thrombosis or hemorrhage because of coagulation protein deficiencies .@_@cerebral thrombosis and L - asparaginase are Adverse-Effect relation .
Children with acute lymphoblastic leukemia ( ALL ) , treated with L - asparaginase are at risk for cerebral thrombosis or hemorrhage because of coagulation protein deficiencies .@_@coagulation protein deficiencies and L - asparaginase are Adverse-Effect relation .
Children with acute lymphoblastic leukemia ( ALL ) , treated with L - asparaginase are at risk for cerebral thrombosis or hemorrhage because of coagulation protein deficiencies .@_@cerebral thrombosis and cerebral thrombosis are not related .
Children with acute lymphoblastic leukemia ( ALL ) , treated with L - asparaginase are at risk for cerebral thrombosis or hemorrhage because of coagulation protein deficiencies .@_@cerebral thrombosis and coagulation protein deficiencies are not related .
Children with acute lymphoblastic leukemia ( ALL ) , treated with L - asparaginase are at risk for cerebral thrombosis or hemorrhage because of coagulation protein deficiencies .@_@cerebral thrombosis and hemorrhage are not related .
Children with acute lymphoblastic leukemia ( ALL ) , treated with L - asparaginase are at risk for cerebral thrombosis or hemorrhage because of coagulation protein deficiencies .@_@L - asparaginase and cerebral thrombosis are not related .
Children with acute lymphoblastic leukemia ( ALL ) , treated with L - asparaginase are at risk for cerebral thrombosis or hemorrhage because of coagulation protein deficiencies .@_@L - asparaginase and L - asparaginase are not related .
Children with acute lymphoblastic leukemia ( ALL ) , treated with L - asparaginase are at risk for cerebral thrombosis or hemorrhage because of coagulation protein deficiencies .@_@L - asparaginase and coagulation protein deficiencies are not related .
Children with acute lymphoblastic leukemia ( ALL ) , treated with L - asparaginase are at risk for cerebral thrombosis or hemorrhage because of coagulation protein deficiencies .@_@L - asparaginase and hemorrhage are not related .
Children with acute lymphoblastic leukemia ( ALL ) , treated with L - asparaginase are at risk for cerebral thrombosis or hemorrhage because of coagulation protein deficiencies .@_@coagulation protein deficiencies and cerebral thrombosis are not related .
Children with acute lymphoblastic leukemia ( ALL ) , treated with L - asparaginase are at risk for cerebral thrombosis or hemorrhage because of coagulation protein deficiencies .@_@coagulation protein deficiencies and coagulation protein deficiencies are not related .
Children with acute lymphoblastic leukemia ( ALL ) , treated with L - asparaginase are at risk for cerebral thrombosis or hemorrhage because of coagulation protein deficiencies .@_@coagulation protein deficiencies and hemorrhage are not related .
Children with acute lymphoblastic leukemia ( ALL ) , treated with L - asparaginase are at risk for cerebral thrombosis or hemorrhage because of coagulation protein deficiencies .@_@hemorrhage and cerebral thrombosis are not related .
Children with acute lymphoblastic leukemia ( ALL ) , treated with L - asparaginase are at risk for cerebral thrombosis or hemorrhage because of coagulation protein deficiencies .@_@hemorrhage and coagulation protein deficiencies are not related .
Children with acute lymphoblastic leukemia ( ALL ) , treated with L - asparaginase are at risk for cerebral thrombosis or hemorrhage because of coagulation protein deficiencies .@_@hemorrhage and hemorrhage are not related .
Myoclonus and seizures disappeared after discontinuation of L - dopa and the introduction of valproate sodium ( VPA ) .@_@seizures and L - dopa are Adverse-Effect relation .
Myoclonus and seizures disappeared after discontinuation of L - dopa and the introduction of valproate sodium ( VPA ) .@_@Myoclonus and L - dopa are Adverse-Effect relation .
Myoclonus and seizures disappeared after discontinuation of L - dopa and the introduction of valproate sodium ( VPA ) .@_@Myoclonus and Myoclonus are not related .
Myoclonus and seizures disappeared after discontinuation of L - dopa and the introduction of valproate sodium ( VPA ) .@_@Myoclonus and seizures are not related .
Myoclonus and seizures disappeared after discontinuation of L - dopa and the introduction of valproate sodium ( VPA ) .@_@L - dopa and Myoclonus are not related .
Myoclonus and seizures disappeared after discontinuation of L - dopa and the introduction of valproate sodium ( VPA ) .@_@L - dopa and L - dopa are not related .
Myoclonus and seizures disappeared after discontinuation of L - dopa and the introduction of valproate sodium ( VPA ) .@_@L - dopa and seizures are not related .
Myoclonus and seizures disappeared after discontinuation of L - dopa and the introduction of valproate sodium ( VPA ) .@_@seizures and Myoclonus are not related .
Myoclonus and seizures disappeared after discontinuation of L - dopa and the introduction of valproate sodium ( VPA ) .@_@seizures and seizures are not related .
Myoclonus and seizures in a patient with parkinsonism : induction by levodopa and its confirmation on SEPs .@_@seizures and levodopa are Adverse-Effect relation .
Myoclonus and seizures in a patient with parkinsonism : induction by levodopa and its confirmation on SEPs .@_@Myoclonus and levodopa are Adverse-Effect relation .
Myoclonus and seizures in a patient with parkinsonism : induction by levodopa and its confirmation on SEPs .@_@Myoclonus and Myoclonus are not related .
Myoclonus and seizures in a patient with parkinsonism : induction by levodopa and its confirmation on SEPs .@_@Myoclonus and seizures are not related .
Myoclonus and seizures in a patient with parkinsonism : induction by levodopa and its confirmation on SEPs .@_@levodopa and Myoclonus are not related .
Myoclonus and seizures in a patient with parkinsonism : induction by levodopa and its confirmation on SEPs .@_@levodopa and levodopa are not related .
Myoclonus and seizures in a patient with parkinsonism : induction by levodopa and its confirmation on SEPs .@_@levodopa and seizures are not related .
Myoclonus and seizures in a patient with parkinsonism : induction by levodopa and its confirmation on SEPs .@_@seizures and Myoclonus are not related .
Myoclonus and seizures in a patient with parkinsonism : induction by levodopa and its confirmation on SEPs .@_@seizures and seizures are not related .
Myoclonus was induced and enhanced by L - dopa , developing into generalized seizures .@_@generalized seizures and L - dopa are Adverse-Effect relation .
Myoclonus was induced and enhanced by L - dopa , developing into generalized seizures .@_@Myoclonus and L - dopa are Adverse-Effect relation .
Myoclonus was induced and enhanced by L - dopa , developing into generalized seizures .@_@generalized seizures and generalized seizures are not related .
Myoclonus was induced and enhanced by L - dopa , developing into generalized seizures .@_@generalized seizures and Myoclonus are not related .
Myoclonus was induced and enhanced by L - dopa , developing into generalized seizures .@_@L - dopa and generalized seizures are not related .
Myoclonus was induced and enhanced by L - dopa , developing into generalized seizures .@_@L - dopa and L - dopa are not related .
Myoclonus was induced and enhanced by L - dopa , developing into generalized seizures .@_@L - dopa and Myoclonus are not related .
Myoclonus was induced and enhanced by L - dopa , developing into generalized seizures .@_@Myoclonus and generalized seizures are not related .
Myoclonus was induced and enhanced by L - dopa , developing into generalized seizures .@_@Myoclonus and Myoclonus are not related .
We described the occurrence of L - dopa - induced myoclonus and seizures in a case of parkinsonism with its SEPs findings .@_@seizures and L - dopa are Adverse-Effect relation .
We described the occurrence of L - dopa - induced myoclonus and seizures in a case of parkinsonism with its SEPs findings .@_@myoclonus and L - dopa are Adverse-Effect relation .
We described the occurrence of L - dopa - induced myoclonus and seizures in a case of parkinsonism with its SEPs findings .@_@myoclonus and myoclonus are not related .
We described the occurrence of L - dopa - induced myoclonus and seizures in a case of parkinsonism with its SEPs findings .@_@myoclonus and seizures are not related .
We described the occurrence of L - dopa - induced myoclonus and seizures in a case of parkinsonism with its SEPs findings .@_@L - dopa and myoclonus are not related .
We described the occurrence of L - dopa - induced myoclonus and seizures in a case of parkinsonism with its SEPs findings .@_@L - dopa and L - dopa are not related .
We described the occurrence of L - dopa - induced myoclonus and seizures in a case of parkinsonism with its SEPs findings .@_@L - dopa and seizures are not related .
We described the occurrence of L - dopa - induced myoclonus and seizures in a case of parkinsonism with its SEPs findings .@_@seizures and myoclonus are not related .
We described the occurrence of L - dopa - induced myoclonus and seizures in a case of parkinsonism with its SEPs findings .@_@seizures and seizures are not related .
Unintended exposure to acyclovir early in pregnancy , which is not uncommon , may cause excessive maternal and physician anxiety .@_@excessive maternal and physician anxiety and acyclovir are Adverse-Effect relation .
Unintended exposure to acyclovir early in pregnancy , which is not uncommon , may cause excessive maternal and physician anxiety .@_@excessive maternal and physician anxiety and excessive maternal and physician anxiety are not related .
Unintended exposure to acyclovir early in pregnancy , which is not uncommon , may cause excessive maternal and physician anxiety .@_@acyclovir and excessive maternal and physician anxiety are not related .
Unintended exposure to acyclovir early in pregnancy , which is not uncommon , may cause excessive maternal and physician anxiety .@_@acyclovir and acyclovir are not related .
A severe form of exophthalmos resulting from lithium therapy has not been described in the literature .@_@exophthalmos and lithium are Adverse-Effect relation .
A severe form of exophthalmos resulting from lithium therapy has not been described in the literature .@_@exophthalmos and exophthalmos are not related .
A severe form of exophthalmos resulting from lithium therapy has not been described in the literature .@_@lithium and exophthalmos are not related .
A severe form of exophthalmos resulting from lithium therapy has not been described in the literature .@_@lithium and lithium are not related .
Lithium therapy was discontinued because of poor compliance to the medication and intolerable polyuria .@_@polyuria and Lithium are Adverse-Effect relation .
Lithium therapy was discontinued because of poor compliance to the medication and intolerable polyuria .@_@polyuria and polyuria are not related .
Lithium therapy was discontinued because of poor compliance to the medication and intolerable polyuria .@_@Lithium and polyuria are not related .
Lithium therapy was discontinued because of poor compliance to the medication and intolerable polyuria .@_@Lithium and Lithium are not related .
Regression of thyrotoxic ophthalmopathy following lithium withdrawal .@_@thyrotoxic ophthalmopathy and lithium are Adverse-Effect relation .
Regression of thyrotoxic ophthalmopathy following lithium withdrawal .@_@thyrotoxic ophthalmopathy and thyrotoxic ophthalmopathy are not related .
Regression of thyrotoxic ophthalmopathy following lithium withdrawal .@_@lithium and thyrotoxic ophthalmopathy are not related .
Regression of thyrotoxic ophthalmopathy following lithium withdrawal .@_@lithium and lithium are not related .
The case of a bipolar patient who developed thyrotoxicosis with severe exophthalmos while on lithium therapy is described .@_@severe exophthalmos and lithium are Adverse-Effect relation .
The case of a bipolar patient who developed thyrotoxicosis with severe exophthalmos while on lithium therapy is described .@_@thyrotoxicosis and lithium are Adverse-Effect relation .
The case of a bipolar patient who developed thyrotoxicosis with severe exophthalmos while on lithium therapy is described .@_@severe exophthalmos and severe exophthalmos are not related .
The case of a bipolar patient who developed thyrotoxicosis with severe exophthalmos while on lithium therapy is described .@_@severe exophthalmos and thyrotoxicosis are not related .
The case of a bipolar patient who developed thyrotoxicosis with severe exophthalmos while on lithium therapy is described .@_@lithium and severe exophthalmos are not related .
The case of a bipolar patient who developed thyrotoxicosis with severe exophthalmos while on lithium therapy is described .@_@lithium and lithium are not related .
The case of a bipolar patient who developed thyrotoxicosis with severe exophthalmos while on lithium therapy is described .@_@lithium and thyrotoxicosis are not related .
The case of a bipolar patient who developed thyrotoxicosis with severe exophthalmos while on lithium therapy is described .@_@thyrotoxicosis and severe exophthalmos are not related .
The case of a bipolar patient who developed thyrotoxicosis with severe exophthalmos while on lithium therapy is described .@_@thyrotoxicosis and thyrotoxicosis are not related .
The exophthalmos improved dramatically within 72 hours of the withdrawal of lithium .@_@exophthalmos and lithium are Adverse-Effect relation .
The exophthalmos improved dramatically within 72 hours of the withdrawal of lithium .@_@exophthalmos and exophthalmos are not related .
The exophthalmos improved dramatically within 72 hours of the withdrawal of lithium .@_@lithium and exophthalmos are not related .
The exophthalmos improved dramatically within 72 hours of the withdrawal of lithium .@_@lithium and lithium are not related .
Severe abdominal pain in low dosage clofazimine .@_@abdominal pain and clofazimine are Adverse-Effect relation .
Severe abdominal pain in low dosage clofazimine .@_@abdominal pain and abdominal pain are not related .
Severe abdominal pain in low dosage clofazimine .@_@clofazimine and abdominal pain are not related .
Severe abdominal pain in low dosage clofazimine .@_@clofazimine and clofazimine are not related .
We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain .@_@abdominal pain and clofazimine are Adverse-Effect relation .
We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain .@_@abdominal pain and abdominal pain are not related .
We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain .@_@clofazimine and abdominal pain are not related .
We describe a 41 yr old leprosy patient treated for 10 yrs with clofazimine who underwent laparotomy for severe abdominal pain .@_@clofazimine and clofazimine are not related .
Amphotericin B overdose in pediatric patients with associated cardiac arrest .@_@cardiac arrest and Amphotericin B are Adverse-Effect relation .
Amphotericin B overdose in pediatric patients with associated cardiac arrest .@_@cardiac arrest and cardiac arrest are not related .
Amphotericin B overdose in pediatric patients with associated cardiac arrest .@_@Amphotericin B and cardiac arrest are not related .
Amphotericin B overdose in pediatric patients with associated cardiac arrest .@_@Amphotericin B and Amphotericin B are not related .
CONCLUSIONS : Amphotericin B overdose can be fatal in children and infants .@_@fatal and Amphotericin B are Adverse-Effect relation .
CONCLUSIONS : Amphotericin B overdose can be fatal in children and infants .@_@fatal and fatal are not related .
CONCLUSIONS : Amphotericin B overdose can be fatal in children and infants .@_@Amphotericin B and fatal are not related .
CONCLUSIONS : Amphotericin B overdose can be fatal in children and infants .@_@Amphotericin B and Amphotericin B are not related .
Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses .@_@cardiac arrhythmias and amphotericin B are Adverse-Effect relation .
Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses .@_@mortality and amphotericin B are Adverse-Effect relation .
Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses .@_@cardiac arrhythmias and cardiac arrhythmias are not related .
Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses .@_@cardiac arrhythmias and mortality are not related .
Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses .@_@amphotericin B and cardiac arrhythmias are not related .
Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses .@_@amphotericin B and amphotericin B are not related .
Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses .@_@amphotericin B and mortality are not related .
Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses .@_@mortality and cardiac arrhythmias are not related .
Hydrocortisone may decrease the incidence of mortality associated with cardiac arrhythmias in children receiving amphotericin B overdoses .@_@mortality and mortality are not related .
INTERVENTIONS AND RESULTS : Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg / kg / d of amphotericin B .@_@Cardiac complications and amphotericin B are Adverse-Effect relation .
INTERVENTIONS AND RESULTS : Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg / kg / d of amphotericin B .@_@Cardiac complications and Cardiac complications are not related .
INTERVENTIONS AND RESULTS : Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg / kg / d of amphotericin B .@_@amphotericin B and Cardiac complications are not related .
INTERVENTIONS AND RESULTS : Cardiac complications were observed in five pediatric patients who received between 4.6 and 40.8 mg / kg / d of amphotericin B .@_@amphotericin B and amphotericin B are not related .
OBJECTIVE : To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population .@_@cardiac complications and amphotericin B are Adverse-Effect relation .
OBJECTIVE : To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population .@_@cardiac complications and cardiac complications are not related .
OBJECTIVE : To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population .@_@amphotericin B and cardiac complications are not related .
OBJECTIVE : To report the first five cases of amphotericin B overdose with secondary cardiac complications in a pediatric population .@_@amphotericin B and amphotericin B are not related .
Hypertension develops in most patients after transplantation when immunosuppression is based on cyclosporine and prednisone .@_@Hypertension and cyclosporine are Adverse-Effect relation .
Hypertension develops in most patients after transplantation when immunosuppression is based on cyclosporine and prednisone .@_@Hypertension and prednisone are Adverse-Effect relation .
Hypertension develops in most patients after transplantation when immunosuppression is based on cyclosporine and prednisone .@_@Hypertension and Hypertension are not related .
Hypertension develops in most patients after transplantation when immunosuppression is based on cyclosporine and prednisone .@_@cyclosporine and Hypertension are not related .
Hypertension develops in most patients after transplantation when immunosuppression is based on cyclosporine and prednisone .@_@cyclosporine and cyclosporine are not related .
Hypertension develops in most patients after transplantation when immunosuppression is based on cyclosporine and prednisone .@_@cyclosporine and prednisone are not related .
Hypertension develops in most patients after transplantation when immunosuppression is based on cyclosporine and prednisone .@_@prednisone and Hypertension are not related .
Hypertension develops in most patients after transplantation when immunosuppression is based on cyclosporine and prednisone .@_@prednisone and cyclosporine are not related .
Hypertension develops in most patients after transplantation when immunosuppression is based on cyclosporine and prednisone .@_@prednisone and prednisone are not related .
Sudden death in an infant from methemoglobinemia after administration of " sweet spirits of nitre " .@_@Sudden death and sweet spirits of nitre are Adverse-Effect relation .
Sudden death in an infant from methemoglobinemia after administration of " sweet spirits of nitre " .@_@Sudden death and Sudden death are not related .
Sudden death in an infant from methemoglobinemia after administration of " sweet spirits of nitre " .@_@sweet spirits of nitre and Sudden death are not related .
Sudden death in an infant from methemoglobinemia after administration of " sweet spirits of nitre " .@_@sweet spirits of nitre and sweet spirits of nitre are not related .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@acute methemoglobinemia and 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol are Adverse-Effect relation .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@hypoxemia and sweet spirits of nitre are Adverse-Effect relation .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@hypoxemia and 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol are Adverse-Effect relation .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@severe anoxic metabolic acidosis and sweet spirits of nitre are Adverse-Effect relation .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@severe anoxic metabolic acidosis and 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol are Adverse-Effect relation .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@acute methemoglobinemia and sweet spirits of nitre are Adverse-Effect relation .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@died and sweet spirits of nitre are Adverse-Effect relation .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@died and 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol are Adverse-Effect relation .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@acute methemoglobinemia and acute methemoglobinemia are not related .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@acute methemoglobinemia and died are not related .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@acute methemoglobinemia and hypoxemia are not related .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@acute methemoglobinemia and severe anoxic metabolic acidosis are not related .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol and acute methemoglobinemia are not related .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol and 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol are not related .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol and sweet spirits of nitre are not related .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol and died are not related .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol and hypoxemia are not related .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol and severe anoxic metabolic acidosis are not related .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@sweet spirits of nitre and acute methemoglobinemia are not related .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@sweet spirits of nitre and 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol are not related .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@sweet spirits of nitre and sweet spirits of nitre are not related .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@sweet spirits of nitre and died are not related .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@sweet spirits of nitre and hypoxemia are not related .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@sweet spirits of nitre and severe anoxic metabolic acidosis are not related .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@died and acute methemoglobinemia are not related .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@died and died are not related .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@died and hypoxemia are not related .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@died and severe anoxic metabolic acidosis are not related .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@hypoxemia and acute methemoglobinemia are not related .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@hypoxemia and died are not related .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@hypoxemia and hypoxemia are not related .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@hypoxemia and severe anoxic metabolic acidosis are not related .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@severe anoxic metabolic acidosis and acute methemoglobinemia are not related .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@severe anoxic metabolic acidosis and died are not related .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@severe anoxic metabolic acidosis and hypoxemia are not related .
The administration of " sweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins , Methylene blue administration reversed methemoglobinemia in both , but one twin died from the consequences of hypoxemia .@_@severe anoxic metabolic acidosis and severe anoxic metabolic acidosis are not related .
Hepatotoxic effects in a child receiving valproate and carnitine .@_@Hepatotoxic effects and carnitine are Adverse-Effect relation .
Hepatotoxic effects in a child receiving valproate and carnitine .@_@Hepatotoxic effects and valproate are Adverse-Effect relation .
Hepatotoxic effects in a child receiving valproate and carnitine .@_@Hepatotoxic effects and Hepatotoxic effects are not related .
Hepatotoxic effects in a child receiving valproate and carnitine .@_@carnitine and Hepatotoxic effects are not related .
Hepatotoxic effects in a child receiving valproate and carnitine .@_@carnitine and carnitine are not related .
Hepatotoxic effects in a child receiving valproate and carnitine .@_@carnitine and valproate are not related .
Hepatotoxic effects in a child receiving valproate and carnitine .@_@valproate and Hepatotoxic effects are not related .
Hepatotoxic effects in a child receiving valproate and carnitine .@_@valproate and carnitine are not related .
Hepatotoxic effects in a child receiving valproate and carnitine .@_@valproate and valproate are not related .
L - Carnitine supplementation has been recommended to prevent the fatal hepatotoxic effects associated with valproic acid .@_@fatal hepatotoxic effects and valproic acid are Adverse-Effect relation .
L - Carnitine supplementation has been recommended to prevent the fatal hepatotoxic effects associated with valproic acid .@_@fatal hepatotoxic effects and fatal hepatotoxic effects are not related .
L - Carnitine supplementation has been recommended to prevent the fatal hepatotoxic effects associated with valproic acid .@_@valproic acid and fatal hepatotoxic effects are not related .
L - Carnitine supplementation has been recommended to prevent the fatal hepatotoxic effects associated with valproic acid .@_@valproic acid and valproic acid are not related .
We report on a child with fatal valproate - related hepatotoxic effects despite this supplementation .@_@hepatotoxic effects and valproate are Adverse-Effect relation .
We report on a child with fatal valproate - related hepatotoxic effects despite this supplementation .@_@fatal and valproate are Adverse-Effect relation .
We report on a child with fatal valproate - related hepatotoxic effects despite this supplementation .@_@fatal and fatal are not related .
We report on a child with fatal valproate - related hepatotoxic effects despite this supplementation .@_@fatal and hepatotoxic effects are not related .
We report on a child with fatal valproate - related hepatotoxic effects despite this supplementation .@_@valproate and fatal are not related .
We report on a child with fatal valproate - related hepatotoxic effects despite this supplementation .@_@valproate and valproate are not related .
We report on a child with fatal valproate - related hepatotoxic effects despite this supplementation .@_@valproate and hepatotoxic effects are not related .
We report on a child with fatal valproate - related hepatotoxic effects despite this supplementation .@_@hepatotoxic effects and fatal are not related .
We report on a child with fatal valproate - related hepatotoxic effects despite this supplementation .@_@hepatotoxic effects and hepatotoxic effects are not related .
A case is reported of a 40 year old woman treated with intraventricular IL-2 for leptomeningeal disease who developed progressive cognitive dysfunction .@_@cognitive dysfunction and IL-2 are Adverse-Effect relation .
A case is reported of a 40 year old woman treated with intraventricular IL-2 for leptomeningeal disease who developed progressive cognitive dysfunction .@_@cognitive dysfunction and cognitive dysfunction are not related .
A case is reported of a 40 year old woman treated with intraventricular IL-2 for leptomeningeal disease who developed progressive cognitive dysfunction .@_@IL-2 and cognitive dysfunction are not related .
A case is reported of a 40 year old woman treated with intraventricular IL-2 for leptomeningeal disease who developed progressive cognitive dysfunction .@_@IL-2 and IL-2 are not related .
Delayed neurotoxicity of intraventricular interleukin-2 : a case report .@_@neurotoxicity and interleukin-2 are Adverse-Effect relation .
Delayed neurotoxicity of intraventricular interleukin-2 : a case report .@_@neurotoxicity and neurotoxicity are not related .
Delayed neurotoxicity of intraventricular interleukin-2 : a case report .@_@interleukin-2 and neurotoxicity are not related .
Delayed neurotoxicity of intraventricular interleukin-2 : a case report .@_@interleukin-2 and interleukin-2 are not related .
The potential for progressive brain injury and subsequent disability related to intraventricular IL-2 therapy is discussed .@_@brain injury and IL-2 are Adverse-Effect relation .
The potential for progressive brain injury and subsequent disability related to intraventricular IL-2 therapy is discussed .@_@disability and IL-2 are Adverse-Effect relation .
The potential for progressive brain injury and subsequent disability related to intraventricular IL-2 therapy is discussed .@_@brain injury and brain injury are not related .
The potential for progressive brain injury and subsequent disability related to intraventricular IL-2 therapy is discussed .@_@brain injury and disability are not related .
The potential for progressive brain injury and subsequent disability related to intraventricular IL-2 therapy is discussed .@_@IL-2 and brain injury are not related .
The potential for progressive brain injury and subsequent disability related to intraventricular IL-2 therapy is discussed .@_@IL-2 and IL-2 are not related .
The potential for progressive brain injury and subsequent disability related to intraventricular IL-2 therapy is discussed .@_@IL-2 and disability are not related .
The potential for progressive brain injury and subsequent disability related to intraventricular IL-2 therapy is discussed .@_@disability and brain injury are not related .
The potential for progressive brain injury and subsequent disability related to intraventricular IL-2 therapy is discussed .@_@disability and disability are not related .
Albeit rare among Western patients , such lithium - associated thyroid dysfunctions appeared to be more likely to occur in Hong Kong Chinese .@_@thyroid dysfunctions and lithium are Adverse-Effect relation .
Albeit rare among Western patients , such lithium - associated thyroid dysfunctions appeared to be more likely to occur in Hong Kong Chinese .@_@thyroid dysfunctions and thyroid dysfunctions are not related .
Albeit rare among Western patients , such lithium - associated thyroid dysfunctions appeared to be more likely to occur in Hong Kong Chinese .@_@lithium and thyroid dysfunctions are not related .
Albeit rare among Western patients , such lithium - associated thyroid dysfunctions appeared to be more likely to occur in Hong Kong Chinese .@_@lithium and lithium are not related .
Four Chinese female patients who suffered from manic - depressive disorder and underlying autoimmune thyroiditis developed transient episodes of thyrotoxicosis during maintenance lithium therapy .@_@thyrotoxicosis and lithium are Adverse-Effect relation .
Four Chinese female patients who suffered from manic - depressive disorder and underlying autoimmune thyroiditis developed transient episodes of thyrotoxicosis during maintenance lithium therapy .@_@thyrotoxicosis and thyrotoxicosis are not related .
Four Chinese female patients who suffered from manic - depressive disorder and underlying autoimmune thyroiditis developed transient episodes of thyrotoxicosis during maintenance lithium therapy .@_@lithium and thyrotoxicosis are not related .
Four Chinese female patients who suffered from manic - depressive disorder and underlying autoimmune thyroiditis developed transient episodes of thyrotoxicosis during maintenance lithium therapy .@_@lithium and lithium are not related .
Lithium - associated transient thyrotoxicosis in 4 Chinese women with autoimmune thyroiditis .@_@transient thyrotoxicosis and Lithium are Adverse-Effect relation .
Lithium - associated transient thyrotoxicosis in 4 Chinese women with autoimmune thyroiditis .@_@transient thyrotoxicosis and transient thyrotoxicosis are not related .
Lithium - associated transient thyrotoxicosis in 4 Chinese women with autoimmune thyroiditis .@_@Lithium and transient thyrotoxicosis are not related .
Lithium - associated transient thyrotoxicosis in 4 Chinese women with autoimmune thyroiditis .@_@Lithium and Lithium are not related .
They seemed to involve multiple aetiological factors , such as autoimmune thyroid disease , the toxic and immunomodulatory roles of lithium and perhaps genetic and dietary factors .@_@toxic and immunomodulatory roles and lithium are Adverse-Effect relation .
They seemed to involve multiple aetiological factors , such as autoimmune thyroid disease , the toxic and immunomodulatory roles of lithium and perhaps genetic and dietary factors .@_@toxic and immunomodulatory roles and toxic and immunomodulatory roles are not related .
They seemed to involve multiple aetiological factors , such as autoimmune thyroid disease , the toxic and immunomodulatory roles of lithium and perhaps genetic and dietary factors .@_@lithium and toxic and immunomodulatory roles are not related .
They seemed to involve multiple aetiological factors , such as autoimmune thyroid disease , the toxic and immunomodulatory roles of lithium and perhaps genetic and dietary factors .@_@lithium and lithium are not related .
Although retinoic acid is well tolerated by the majority of patients with this disease , a potentially fatal complication of this kind of treatment has been reported : " the retinoic acid syndrome " .@_@retinoic acid syndrome and retinoic acid are Adverse-Effect relation .
Although retinoic acid is well tolerated by the majority of patients with this disease , a potentially fatal complication of this kind of treatment has been reported : " the retinoic acid syndrome " .@_@fatal complication and retinoic acid are Adverse-Effect relation .
Although retinoic acid is well tolerated by the majority of patients with this disease , a potentially fatal complication of this kind of treatment has been reported : " the retinoic acid syndrome " .@_@fatal complication and fatal complication are not related .
Although retinoic acid is well tolerated by the majority of patients with this disease , a potentially fatal complication of this kind of treatment has been reported : " the retinoic acid syndrome " .@_@fatal complication and retinoic acid syndrome are not related .
Although retinoic acid is well tolerated by the majority of patients with this disease , a potentially fatal complication of this kind of treatment has been reported : " the retinoic acid syndrome " .@_@retinoic acid and fatal complication are not related .
Although retinoic acid is well tolerated by the majority of patients with this disease , a potentially fatal complication of this kind of treatment has been reported : " the retinoic acid syndrome " .@_@retinoic acid and retinoic acid are not related .
Although retinoic acid is well tolerated by the majority of patients with this disease , a potentially fatal complication of this kind of treatment has been reported : " the retinoic acid syndrome " .@_@retinoic acid and retinoic acid syndrome are not related .
Although retinoic acid is well tolerated by the majority of patients with this disease , a potentially fatal complication of this kind of treatment has been reported : " the retinoic acid syndrome " .@_@retinoic acid syndrome and fatal complication are not related .
Although retinoic acid is well tolerated by the majority of patients with this disease , a potentially fatal complication of this kind of treatment has been reported : " the retinoic acid syndrome " .@_@retinoic acid syndrome and retinoic acid syndrome are not related .
CONCLUSIONS : It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient .@_@electrolyte disorders and foscarnet are Adverse-Effect relation .
CONCLUSIONS : It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient .@_@electrolyte disorders and electrolyte disorders are not related .
CONCLUSIONS : It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient .@_@foscarnet and electrolyte disorders are not related .
CONCLUSIONS : It is probable that foscarnet contributed to the electrolyte disorders and symptomatology in this patient .@_@foscarnet and foscarnet are not related .
DISCUSSION : Electrolyte disorders associated with foscarnet are reviewed .@_@Electrolyte disorders and foscarnet are Adverse-Effect relation .
DISCUSSION : Electrolyte disorders associated with foscarnet are reviewed .@_@Electrolyte disorders and Electrolyte disorders are not related .
DISCUSSION : Electrolyte disorders associated with foscarnet are reviewed .@_@foscarnet and Electrolyte disorders are not related .
DISCUSSION : Electrolyte disorders associated with foscarnet are reviewed .@_@foscarnet and foscarnet are not related .
Foscarnet - induced severe hypomagnesemia and other electrolyte disorders .@_@electrolyte disorders and Foscarnet are Adverse-Effect relation .
Foscarnet - induced severe hypomagnesemia and other electrolyte disorders .@_@severe hypomagnesemia and Foscarnet are Adverse-Effect relation .
Foscarnet - induced severe hypomagnesemia and other electrolyte disorders .@_@electrolyte disorders and electrolyte disorders are not related .
Foscarnet - induced severe hypomagnesemia and other electrolyte disorders .@_@electrolyte disorders and severe hypomagnesemia are not related .
Foscarnet - induced severe hypomagnesemia and other electrolyte disorders .@_@Foscarnet and electrolyte disorders are not related .
Foscarnet - induced severe hypomagnesemia and other electrolyte disorders .@_@Foscarnet and Foscarnet are not related .
Foscarnet - induced severe hypomagnesemia and other electrolyte disorders .@_@Foscarnet and severe hypomagnesemia are not related .
Foscarnet - induced severe hypomagnesemia and other electrolyte disorders .@_@severe hypomagnesemia and electrolyte disorders are not related .
Foscarnet - induced severe hypomagnesemia and other electrolyte disorders .@_@severe hypomagnesemia and severe hypomagnesemia are not related .
OBJECTIVE : To report a case of possible foscarnet - induced severe hypomagnesemia and other electrolyte disorders .@_@severe hypomagnesemia and foscarnet are Adverse-Effect relation .
OBJECTIVE : To report a case of possible foscarnet - induced severe hypomagnesemia and other electrolyte disorders .@_@electrolyte disorders and foscarnet are Adverse-Effect relation .
OBJECTIVE : To report a case of possible foscarnet - induced severe hypomagnesemia and other electrolyte disorders .@_@electrolyte disorders and electrolyte disorders are not related .
OBJECTIVE : To report a case of possible foscarnet - induced severe hypomagnesemia and other electrolyte disorders .@_@electrolyte disorders and severe hypomagnesemia are not related .
OBJECTIVE : To report a case of possible foscarnet - induced severe hypomagnesemia and other electrolyte disorders .@_@foscarnet and electrolyte disorders are not related .
OBJECTIVE : To report a case of possible foscarnet - induced severe hypomagnesemia and other electrolyte disorders .@_@foscarnet and foscarnet are not related .
OBJECTIVE : To report a case of possible foscarnet - induced severe hypomagnesemia and other electrolyte disorders .@_@foscarnet and severe hypomagnesemia are not related .
OBJECTIVE : To report a case of possible foscarnet - induced severe hypomagnesemia and other electrolyte disorders .@_@severe hypomagnesemia and electrolyte disorders are not related .
OBJECTIVE : To report a case of possible foscarnet - induced severe hypomagnesemia and other electrolyte disorders .@_@severe hypomagnesemia and severe hypomagnesemia are not related .
The patient experienced muscle twitches , tremulousness , and anxiety on day 17 of foscarnet therapy .@_@tremulousness and foscarnet are Adverse-Effect relation .
The patient experienced muscle twitches , tremulousness , and anxiety on day 17 of foscarnet therapy .@_@muscle twitches and foscarnet are Adverse-Effect relation .
The patient experienced muscle twitches , tremulousness , and anxiety on day 17 of foscarnet therapy .@_@anxiety and foscarnet are Adverse-Effect relation .
The patient experienced muscle twitches , tremulousness , and anxiety on day 17 of foscarnet therapy .@_@anxiety and anxiety are not related .
The patient experienced muscle twitches , tremulousness , and anxiety on day 17 of foscarnet therapy .@_@anxiety and muscle twitches are not related .
The patient experienced muscle twitches , tremulousness , and anxiety on day 17 of foscarnet therapy .@_@anxiety and tremulousness are not related .
The patient experienced muscle twitches , tremulousness , and anxiety on day 17 of foscarnet therapy .@_@foscarnet and anxiety are not related .
The patient experienced muscle twitches , tremulousness , and anxiety on day 17 of foscarnet therapy .@_@foscarnet and foscarnet are not related .
The patient experienced muscle twitches , tremulousness , and anxiety on day 17 of foscarnet therapy .@_@foscarnet and muscle twitches are not related .
The patient experienced muscle twitches , tremulousness , and anxiety on day 17 of foscarnet therapy .@_@foscarnet and tremulousness are not related .
The patient experienced muscle twitches , tremulousness , and anxiety on day 17 of foscarnet therapy .@_@muscle twitches and anxiety are not related .
The patient experienced muscle twitches , tremulousness , and anxiety on day 17 of foscarnet therapy .@_@muscle twitches and muscle twitches are not related .
The patient experienced muscle twitches , tremulousness , and anxiety on day 17 of foscarnet therapy .@_@muscle twitches and tremulousness are not related .
The patient experienced muscle twitches , tremulousness , and anxiety on day 17 of foscarnet therapy .@_@tremulousness and anxiety are not related .
The patient experienced muscle twitches , tremulousness , and anxiety on day 17 of foscarnet therapy .@_@tremulousness and muscle twitches are not related .
The patient experienced muscle twitches , tremulousness , and anxiety on day 17 of foscarnet therapy .@_@tremulousness and tremulousness are not related .
Interference with the cortisol axis by the microtubule antagonist , CPH82 .@_@Interference with the cortisol axis and CPH82 are Adverse-Effect relation .
Interference with the cortisol axis by the microtubule antagonist , CPH82 .@_@Interference with the cortisol axis and Interference with the cortisol axis are not related .
Interference with the cortisol axis by the microtubule antagonist , CPH82 .@_@CPH82 and Interference with the cortisol axis are not related .
Interference with the cortisol axis by the microtubule antagonist , CPH82 .@_@CPH82 and CPH82 are not related .
The results clearly demonstrate that CPH82 was associated with suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical hypercortisolism .@_@hypercortisolism and CPH82 are Adverse-Effect relation .
The results clearly demonstrate that CPH82 was associated with suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical hypercortisolism .@_@suppression of the endogeneous production of ACTH and cortisol and CPH82 are Adverse-Effect relation .
The results clearly demonstrate that CPH82 was associated with suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical hypercortisolism .@_@hypercortisolism and hypercortisolism are not related .
The results clearly demonstrate that CPH82 was associated with suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical hypercortisolism .@_@hypercortisolism and suppression of the endogeneous production of ACTH and cortisol are not related .
The results clearly demonstrate that CPH82 was associated with suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical hypercortisolism .@_@CPH82 and hypercortisolism are not related .
The results clearly demonstrate that CPH82 was associated with suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical hypercortisolism .@_@CPH82 and CPH82 are not related .
The results clearly demonstrate that CPH82 was associated with suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical hypercortisolism .@_@CPH82 and suppression of the endogeneous production of ACTH and cortisol are not related .
The results clearly demonstrate that CPH82 was associated with suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical hypercortisolism .@_@suppression of the endogeneous production of ACTH and cortisol and hypercortisolism are not related .
The results clearly demonstrate that CPH82 was associated with suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical hypercortisolism .@_@suppression of the endogeneous production of ACTH and cortisol and suppression of the endogeneous production of ACTH and cortisol are not related .
A variety of movement disorders are known to occur in association with carbamazepine ( CBZ ) therapy in adults and children , but development of tics has been described infrequently and only in patients with underlying Tourette 's syndrome or other movement disorders .@_@movement disorders and carbamazepine are Adverse-Effect relation .
A variety of movement disorders are known to occur in association with carbamazepine ( CBZ ) therapy in adults and children , but development of tics has been described infrequently and only in patients with underlying Tourette 's syndrome or other movement disorders .@_@tics and carbamazepine are Adverse-Effect relation .
A variety of movement disorders are known to occur in association with carbamazepine ( CBZ ) therapy in adults and children , but development of tics has been described infrequently and only in patients with underlying Tourette 's syndrome or other movement disorders .@_@movement disorders and CBZ are Adverse-Effect relation .
A variety of movement disorders are known to occur in association with carbamazepine ( CBZ ) therapy in adults and children , but development of tics has been described infrequently and only in patients with underlying Tourette 's syndrome or other movement disorders .@_@tics and CBZ are Adverse-Effect relation .
A variety of movement disorders are known to occur in association with carbamazepine ( CBZ ) therapy in adults and children , but development of tics has been described infrequently and only in patients with underlying Tourette 's syndrome or other movement disorders .@_@movement disorders and movement disorders are not related .
A variety of movement disorders are known to occur in association with carbamazepine ( CBZ ) therapy in adults and children , but development of tics has been described infrequently and only in patients with underlying Tourette 's syndrome or other movement disorders .@_@movement disorders and tics are not related .
A variety of movement disorders are known to occur in association with carbamazepine ( CBZ ) therapy in adults and children , but development of tics has been described infrequently and only in patients with underlying Tourette 's syndrome or other movement disorders .@_@carbamazepine and movement disorders are not related .
A variety of movement disorders are known to occur in association with carbamazepine ( CBZ ) therapy in adults and children , but development of tics has been described infrequently and only in patients with underlying Tourette 's syndrome or other movement disorders .@_@carbamazepine and carbamazepine are not related .
A variety of movement disorders are known to occur in association with carbamazepine ( CBZ ) therapy in adults and children , but development of tics has been described infrequently and only in patients with underlying Tourette 's syndrome or other movement disorders .@_@carbamazepine and CBZ are not related .
A variety of movement disorders are known to occur in association with carbamazepine ( CBZ ) therapy in adults and children , but development of tics has been described infrequently and only in patients with underlying Tourette 's syndrome or other movement disorders .@_@carbamazepine and tics are not related .
A variety of movement disorders are known to occur in association with carbamazepine ( CBZ ) therapy in adults and children , but development of tics has been described infrequently and only in patients with underlying Tourette 's syndrome or other movement disorders .@_@CBZ and movement disorders are not related .
A variety of movement disorders are known to occur in association with carbamazepine ( CBZ ) therapy in adults and children , but development of tics has been described infrequently and only in patients with underlying Tourette 's syndrome or other movement disorders .@_@CBZ and carbamazepine are not related .
A variety of movement disorders are known to occur in association with carbamazepine ( CBZ ) therapy in adults and children , but development of tics has been described infrequently and only in patients with underlying Tourette 's syndrome or other movement disorders .@_@CBZ and CBZ are not related .
A variety of movement disorders are known to occur in association with carbamazepine ( CBZ ) therapy in adults and children , but development of tics has been described infrequently and only in patients with underlying Tourette 's syndrome or other movement disorders .@_@CBZ and tics are not related .
A variety of movement disorders are known to occur in association with carbamazepine ( CBZ ) therapy in adults and children , but development of tics has been described infrequently and only in patients with underlying Tourette 's syndrome or other movement disorders .@_@tics and movement disorders are not related .
A variety of movement disorders are known to occur in association with carbamazepine ( CBZ ) therapy in adults and children , but development of tics has been described infrequently and only in patients with underlying Tourette 's syndrome or other movement disorders .@_@tics and tics are not related .
Carbamazepine - induced tics .@_@tics and Carbamazepine are Adverse-Effect relation .
Carbamazepine - induced tics .@_@tics and tics are not related .
Carbamazepine - induced tics .@_@Carbamazepine and tics are not related .
Carbamazepine - induced tics .@_@Carbamazepine and Carbamazepine are not related .
In the third child , the tics ceased after CBZ discontinuation .@_@tics and CBZ are Adverse-Effect relation .
In the third child , the tics ceased after CBZ discontinuation .@_@tics and tics are not related .
In the third child , the tics ceased after CBZ discontinuation .@_@CBZ and tics are not related .
In the third child , the tics ceased after CBZ discontinuation .@_@CBZ and CBZ are not related .
These cases demonstrate that CBZ can induce simple motor tics in children .@_@motor tics and CBZ are Adverse-Effect relation .
These cases demonstrate that CBZ can induce simple motor tics in children .@_@motor tics and motor tics are not related .
These cases demonstrate that CBZ can induce simple motor tics in children .@_@CBZ and motor tics are not related .
These cases demonstrate that CBZ can induce simple motor tics in children .@_@CBZ and CBZ are not related .
We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures .@_@facial motor tics and CBZ are Adverse-Effect relation .
We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures .@_@facial motor tics and facial motor tics are not related .
We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures .@_@CBZ and facial motor tics are not related .
We report 3 children with epilepsy who developed facial motor tics after initiation of CBZ for complex partial seizures .@_@CBZ and CBZ are not related .
Acyclovir - induced neurotoxicity : concentration - side effect relationship in acyclovir overdose .@_@neurotoxicity and Acyclovir are Adverse-Effect relation .
Acyclovir - induced neurotoxicity : concentration - side effect relationship in acyclovir overdose .@_@neurotoxicity and neurotoxicity are not related .
Acyclovir - induced neurotoxicity : concentration - side effect relationship in acyclovir overdose .@_@Acyclovir and neurotoxicity are not related .
Acyclovir - induced neurotoxicity : concentration - side effect relationship in acyclovir overdose .@_@Acyclovir and Acyclovir are not related .
CONCLUSIONS : The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases .@_@neurotoxicity and acyclovir are Adverse-Effect relation .
CONCLUSIONS : The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases .@_@neurotoxicity and neurotoxicity are not related .
CONCLUSIONS : The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases .@_@acyclovir and neurotoxicity are not related .
CONCLUSIONS : The observation that neurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases .@_@acyclovir and acyclovir are not related .
METHODS : Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure .@_@nonoliguric renal failure and acyclovir are Adverse-Effect relation .
METHODS : Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure .@_@coma and acyclovir are Adverse-Effect relation .
METHODS : Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure .@_@coma and coma are not related .
METHODS : Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure .@_@coma and nonoliguric renal failure are not related .
METHODS : Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure .@_@acyclovir and coma are not related .
METHODS : Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure .@_@acyclovir and acyclovir are not related .
METHODS : Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure .@_@acyclovir and nonoliguric renal failure are not related .
METHODS : Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure .@_@nonoliguric renal failure and coma are not related .
METHODS : Repeated blood samples were drawn in a patient with severe acyclovir overdose who developed coma and nonoliguric renal failure .@_@nonoliguric renal failure and nonoliguric renal failure are not related .
PURPOSE : To investigate the concentration - side effect relationship in a patient with severe acyclovir - induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir .@_@neurotoxicity and acyclovir are Adverse-Effect relation .
PURPOSE : To investigate the concentration - side effect relationship in a patient with severe acyclovir - induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir .@_@central nervous system side effects and acyclovir are Adverse-Effect relation .
PURPOSE : To investigate the concentration - side effect relationship in a patient with severe acyclovir - induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir .@_@central nervous system side effects and central nervous system side effects are not related .
PURPOSE : To investigate the concentration - side effect relationship in a patient with severe acyclovir - induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir .@_@central nervous system side effects and neurotoxicity are not related .
PURPOSE : To investigate the concentration - side effect relationship in a patient with severe acyclovir - induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir .@_@acyclovir and central nervous system side effects are not related .
PURPOSE : To investigate the concentration - side effect relationship in a patient with severe acyclovir - induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir .@_@acyclovir and acyclovir are not related .
PURPOSE : To investigate the concentration - side effect relationship in a patient with severe acyclovir - induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir .@_@acyclovir and neurotoxicity are not related .
PURPOSE : To investigate the concentration - side effect relationship in a patient with severe acyclovir - induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir .@_@neurotoxicity and central nervous system side effects are not related .
PURPOSE : To investigate the concentration - side effect relationship in a patient with severe acyclovir - induced neurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir .@_@neurotoxicity and neurotoxicity are not related .
A 16-year - old white male with acute biphenotypic leukemia developed evidence of the eosinophilia myalgia syndrome associated with total parenteral nutritional support with solutions containing tryptophan , which were given during his initial induction chemotherapy and also after autologous marrow transplantation .@_@eosinophilia myalgia syndrome and tryptophan are Adverse-Effect relation .
A 16-year - old white male with acute biphenotypic leukemia developed evidence of the eosinophilia myalgia syndrome associated with total parenteral nutritional support with solutions containing tryptophan , which were given during his initial induction chemotherapy and also after autologous marrow transplantation .@_@eosinophilia myalgia syndrome and eosinophilia myalgia syndrome are not related .
A 16-year - old white male with acute biphenotypic leukemia developed evidence of the eosinophilia myalgia syndrome associated with total parenteral nutritional support with solutions containing tryptophan , which were given during his initial induction chemotherapy and also after autologous marrow transplantation .@_@tryptophan and eosinophilia myalgia syndrome are not related .
A 16-year - old white male with acute biphenotypic leukemia developed evidence of the eosinophilia myalgia syndrome associated with total parenteral nutritional support with solutions containing tryptophan , which were given during his initial induction chemotherapy and also after autologous marrow transplantation .@_@tryptophan and tryptophan are not related .
Fatal eosinophilia myalgia syndrome in a marrow transplant patient attributed to total parenteral nutrition with a solution containing tryptophan .@_@Fatal eosinophilia myalgia syndrome and tryptophan are Adverse-Effect relation .
Fatal eosinophilia myalgia syndrome in a marrow transplant patient attributed to total parenteral nutrition with a solution containing tryptophan .@_@Fatal eosinophilia myalgia syndrome and Fatal eosinophilia myalgia syndrome are not related .
Fatal eosinophilia myalgia syndrome in a marrow transplant patient attributed to total parenteral nutrition with a solution containing tryptophan .@_@tryptophan and Fatal eosinophilia myalgia syndrome are not related .
Fatal eosinophilia myalgia syndrome in a marrow transplant patient attributed to total parenteral nutrition with a solution containing tryptophan .@_@tryptophan and tryptophan are not related .
Thus , the eosinophilia myalgia syndrome can be associated with parenteral tryptophan administration .@_@eosinophilia myalgia syndrome and tryptophan are Adverse-Effect relation .
Thus , the eosinophilia myalgia syndrome can be associated with parenteral tryptophan administration .@_@eosinophilia myalgia syndrome and eosinophilia myalgia syndrome are not related .
Thus , the eosinophilia myalgia syndrome can be associated with parenteral tryptophan administration .@_@tryptophan and eosinophilia myalgia syndrome are not related .
Thus , the eosinophilia myalgia syndrome can be associated with parenteral tryptophan administration .@_@tryptophan and tryptophan are not related .
A patient with acute esophageal variceal bleeding developed fatal rhabdomyolysis during treatment with a continuous intravenous infusion of vasopressin .@_@fatal rhabdomyolysis and vasopressin are Adverse-Effect relation .
A patient with acute esophageal variceal bleeding developed fatal rhabdomyolysis during treatment with a continuous intravenous infusion of vasopressin .@_@fatal rhabdomyolysis and fatal rhabdomyolysis are not related .
A patient with acute esophageal variceal bleeding developed fatal rhabdomyolysis during treatment with a continuous intravenous infusion of vasopressin .@_@vasopressin and fatal rhabdomyolysis are not related .
A patient with acute esophageal variceal bleeding developed fatal rhabdomyolysis during treatment with a continuous intravenous infusion of vasopressin .@_@vasopressin and vasopressin are not related .
Idiosyncratic factors involving vasopressin receptor affinity and distribution , vasopressin - associated vasodilation in some vascular beds , and the effect of vasopressin on the renin - angiotensin system may further contribute to impaired tissue perfusion .@_@vasodilation and vasopressin are Adverse-Effect relation .
Idiosyncratic factors involving vasopressin receptor affinity and distribution , vasopressin - associated vasodilation in some vascular beds , and the effect of vasopressin on the renin - angiotensin system may further contribute to impaired tissue perfusion .@_@impaired tissue perfusion and vasopressin are Adverse-Effect relation .
Idiosyncratic factors involving vasopressin receptor affinity and distribution , vasopressin - associated vasodilation in some vascular beds , and the effect of vasopressin on the renin - angiotensin system may further contribute to impaired tissue perfusion .@_@impaired tissue perfusion and impaired tissue perfusion are not related .
Idiosyncratic factors involving vasopressin receptor affinity and distribution , vasopressin - associated vasodilation in some vascular beds , and the effect of vasopressin on the renin - angiotensin system may further contribute to impaired tissue perfusion .@_@impaired tissue perfusion and vasodilation are not related .
Idiosyncratic factors involving vasopressin receptor affinity and distribution , vasopressin - associated vasodilation in some vascular beds , and the effect of vasopressin on the renin - angiotensin system may further contribute to impaired tissue perfusion .@_@vasopressin and impaired tissue perfusion are not related .
Idiosyncratic factors involving vasopressin receptor affinity and distribution , vasopressin - associated vasodilation in some vascular beds , and the effect of vasopressin on the renin - angiotensin system may further contribute to impaired tissue perfusion .@_@vasopressin and vasopressin are not related .
Idiosyncratic factors involving vasopressin receptor affinity and distribution , vasopressin - associated vasodilation in some vascular beds , and the effect of vasopressin on the renin - angiotensin system may further contribute to impaired tissue perfusion .@_@vasopressin and vasodilation are not related .
Idiosyncratic factors involving vasopressin receptor affinity and distribution , vasopressin - associated vasodilation in some vascular beds , and the effect of vasopressin on the renin - angiotensin system may further contribute to impaired tissue perfusion .@_@vasodilation and impaired tissue perfusion are not related .
Idiosyncratic factors involving vasopressin receptor affinity and distribution , vasopressin - associated vasodilation in some vascular beds , and the effect of vasopressin on the renin - angiotensin system may further contribute to impaired tissue perfusion .@_@vasodilation and vasodilation are not related .
Rhabdomyolysis associated with the use of intravenous vasopressin .@_@Rhabdomyolysis and vasopressin are Adverse-Effect relation .
Rhabdomyolysis associated with the use of intravenous vasopressin .@_@Rhabdomyolysis and Rhabdomyolysis are not related .
Rhabdomyolysis associated with the use of intravenous vasopressin .@_@vasopressin and Rhabdomyolysis are not related .
Rhabdomyolysis associated with the use of intravenous vasopressin .@_@vasopressin and vasopressin are not related .
These multiple overlapping factors probably lead to rhabdomyolysis in a minority of patients receiving vasopressin infusion .@_@rhabdomyolysis and vasopressin are Adverse-Effect relation .
These multiple overlapping factors probably lead to rhabdomyolysis in a minority of patients receiving vasopressin infusion .@_@rhabdomyolysis and rhabdomyolysis are not related .
These multiple overlapping factors probably lead to rhabdomyolysis in a minority of patients receiving vasopressin infusion .@_@vasopressin and rhabdomyolysis are not related .
These multiple overlapping factors probably lead to rhabdomyolysis in a minority of patients receiving vasopressin infusion .@_@vasopressin and vasopressin are not related .
In one case , disulfiram was the only potential teratogen exposed to the fetus .@_@teratogen and disulfiram are Adverse-Effect relation .
In one case , disulfiram was the only potential teratogen exposed to the fetus .@_@teratogen and teratogen are not related .
In one case , disulfiram was the only potential teratogen exposed to the fetus .@_@disulfiram and teratogen are not related .
In one case , disulfiram was the only potential teratogen exposed to the fetus .@_@disulfiram and disulfiram are not related .
Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies .@_@significant abnormalities and disulfiram are Adverse-Effect relation .
Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies .@_@significant abnormalities and significant abnormalities are not related .
Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies .@_@disulfiram and significant abnormalities are not related .
Nonspecific but significant abnormalities have been described in the infants of women treated with disulfiram in the first trimester of their pregnancies .@_@disulfiram and disulfiram are not related .
Although the essential cause of PV is unclear , its onset has occasionally been associated with drug therapy , in particular penicillamine .@_@PV and penicillamine are Adverse-Effect relation .
Although the essential cause of PV is unclear , its onset has occasionally been associated with drug therapy , in particular penicillamine .@_@PV and PV are not related .
Although the essential cause of PV is unclear , its onset has occasionally been associated with drug therapy , in particular penicillamine .@_@penicillamine and PV are not related .
Although the essential cause of PV is unclear , its onset has occasionally been associated with drug therapy , in particular penicillamine .@_@penicillamine and penicillamine are not related .
Pemphigus vulgaris precipitated by glibenclamide therapy .@_@Pemphigus vulgaris and glibenclamide are Adverse-Effect relation .
Pemphigus vulgaris precipitated by glibenclamide therapy .@_@Pemphigus vulgaris and Pemphigus vulgaris are not related .
Pemphigus vulgaris precipitated by glibenclamide therapy .@_@glibenclamide and Pemphigus vulgaris are not related .
Pemphigus vulgaris precipitated by glibenclamide therapy .@_@glibenclamide and glibenclamide are not related .
The patient described in this paper was a 78-year - old diabetic man who developed oral lesions of PV following institution of glibenclamide therapy .@_@oral lesions of PV and glibenclamide are Adverse-Effect relation .
The patient described in this paper was a 78-year - old diabetic man who developed oral lesions of PV following institution of glibenclamide therapy .@_@oral lesions of PV and oral lesions of PV are not related .
The patient described in this paper was a 78-year - old diabetic man who developed oral lesions of PV following institution of glibenclamide therapy .@_@glibenclamide and oral lesions of PV are not related .
The patient described in this paper was a 78-year - old diabetic man who developed oral lesions of PV following institution of glibenclamide therapy .@_@glibenclamide and glibenclamide are not related .
Piritrexim - induced pulmonary toxicity .@_@pulmonary toxicity and Piritrexim are Adverse-Effect relation .
Piritrexim - induced pulmonary toxicity .@_@pulmonary toxicity and pulmonary toxicity are not related .
Piritrexim - induced pulmonary toxicity .@_@Piritrexim and pulmonary toxicity are not related .
Piritrexim - induced pulmonary toxicity .@_@Piritrexim and Piritrexim are not related .
The pulmonary toxicity is probably induced by piritrexim .@_@pulmonary toxicity and piritrexim are Adverse-Effect relation .
The pulmonary toxicity is probably induced by piritrexim .@_@pulmonary toxicity and pulmonary toxicity are not related .
The pulmonary toxicity is probably induced by piritrexim .@_@piritrexim and pulmonary toxicity are not related .
The pulmonary toxicity is probably induced by piritrexim .@_@piritrexim and piritrexim are not related .
We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x - ray with diffuse interstitial opacities while on chemotherapy with piritrexim , a methotrexate analog .@_@abnormal chest x - ray with diffuse interstitial opacities and piritrexim are Adverse-Effect relation .
We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x - ray with diffuse interstitial opacities while on chemotherapy with piritrexim , a methotrexate analog .@_@respiratory dysfunction and piritrexim are Adverse-Effect relation .
We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x - ray with diffuse interstitial opacities while on chemotherapy with piritrexim , a methotrexate analog .@_@abnormal chest x - ray with diffuse interstitial opacities and abnormal chest x - ray with diffuse interstitial opacities are not related .
We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x - ray with diffuse interstitial opacities while on chemotherapy with piritrexim , a methotrexate analog .@_@abnormal chest x - ray with diffuse interstitial opacities and respiratory dysfunction are not related .
We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x - ray with diffuse interstitial opacities while on chemotherapy with piritrexim , a methotrexate analog .@_@piritrexim and abnormal chest x - ray with diffuse interstitial opacities are not related .
We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x - ray with diffuse interstitial opacities while on chemotherapy with piritrexim , a methotrexate analog .@_@piritrexim and piritrexim are not related .
We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x - ray with diffuse interstitial opacities while on chemotherapy with piritrexim , a methotrexate analog .@_@piritrexim and respiratory dysfunction are not related .
We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x - ray with diffuse interstitial opacities while on chemotherapy with piritrexim , a methotrexate analog .@_@respiratory dysfunction and abnormal chest x - ray with diffuse interstitial opacities are not related .
We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an abnormal chest x - ray with diffuse interstitial opacities while on chemotherapy with piritrexim , a methotrexate analog .@_@respiratory dysfunction and respiratory dysfunction are not related .
A 12 year old patient with atrial flutter is presented , in whom intravenous adenosine was followed by acceleration of the heart rate to a potentially dangerous arrhythmia .@_@acceleration of the heart rate and adenosine are Adverse-Effect relation .
A 12 year old patient with atrial flutter is presented , in whom intravenous adenosine was followed by acceleration of the heart rate to a potentially dangerous arrhythmia .@_@arrhythmia and adenosine are Adverse-Effect relation .
A 12 year old patient with atrial flutter is presented , in whom intravenous adenosine was followed by acceleration of the heart rate to a potentially dangerous arrhythmia .@_@acceleration of the heart rate and acceleration of the heart rate are not related .
A 12 year old patient with atrial flutter is presented , in whom intravenous adenosine was followed by acceleration of the heart rate to a potentially dangerous arrhythmia .@_@acceleration of the heart rate and arrhythmia are not related .
A 12 year old patient with atrial flutter is presented , in whom intravenous adenosine was followed by acceleration of the heart rate to a potentially dangerous arrhythmia .@_@adenosine and acceleration of the heart rate are not related .
A 12 year old patient with atrial flutter is presented , in whom intravenous adenosine was followed by acceleration of the heart rate to a potentially dangerous arrhythmia .@_@adenosine and adenosine are not related .
A 12 year old patient with atrial flutter is presented , in whom intravenous adenosine was followed by acceleration of the heart rate to a potentially dangerous arrhythmia .@_@adenosine and arrhythmia are not related .
A 12 year old patient with atrial flutter is presented , in whom intravenous adenosine was followed by acceleration of the heart rate to a potentially dangerous arrhythmia .@_@arrhythmia and acceleration of the heart rate are not related .
A 12 year old patient with atrial flutter is presented , in whom intravenous adenosine was followed by acceleration of the heart rate to a potentially dangerous arrhythmia .@_@arrhythmia and arrhythmia are not related .
Acceleration of ventricular response to atrial flutter after intravenous adenosine .@_@Acceleration of ventricular response and adenosine are Adverse-Effect relation .
Acceleration of ventricular response to atrial flutter after intravenous adenosine .@_@Acceleration of ventricular response and Acceleration of ventricular response are not related .
Acceleration of ventricular response to atrial flutter after intravenous adenosine .@_@adenosine and Acceleration of ventricular response are not related .
Acceleration of ventricular response to atrial flutter after intravenous adenosine .@_@adenosine and adenosine are not related .
Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate .@_@Lymphoma and methotrexate are Adverse-Effect relation .
Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate .@_@Lymphoma and Lymphoma are not related .
Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate .@_@methotrexate and Lymphoma are not related .
Lymphoma developing in a patient with rheumatoid arthritis taking methotrexate .@_@methotrexate and methotrexate are not related .
The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases , but coincidence can not be excluded .@_@lymphoproliferative diseases and methotrexate are Adverse-Effect relation .
The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases , but coincidence can not be excluded .@_@lymphoproliferative diseases and lymphoproliferative diseases are not related .
The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases , but coincidence can not be excluded .@_@methotrexate and lymphoproliferative diseases are not related .
The mild immunosuppression that occurs with methotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing lymphoproliferative diseases , but coincidence can not be excluded .@_@methotrexate and methotrexate are not related .
We report one case of non - Hodgkin lymphoma in a patient , with a 30-year history of rheumatoid arthritis , taking low dose methotrexate weekly over a 10-month period .@_@non - Hodgkin lymphoma and methotrexate are Adverse-Effect relation .
We report one case of non - Hodgkin lymphoma in a patient , with a 30-year history of rheumatoid arthritis , taking low dose methotrexate weekly over a 10-month period .@_@non - Hodgkin lymphoma and non - Hodgkin lymphoma are not related .
We report one case of non - Hodgkin lymphoma in a patient , with a 30-year history of rheumatoid arthritis , taking low dose methotrexate weekly over a 10-month period .@_@methotrexate and non - Hodgkin lymphoma are not related .
We report one case of non - Hodgkin lymphoma in a patient , with a 30-year history of rheumatoid arthritis , taking low dose methotrexate weekly over a 10-month period .@_@methotrexate and methotrexate are not related .
Hepatotoxicity of paracetamol enhanced by ingestion of alcohol : report of two cases .@_@Hepatotoxicity and paracetamol are Adverse-Effect relation .
Hepatotoxicity of paracetamol enhanced by ingestion of alcohol : report of two cases .@_@Hepatotoxicity and Hepatotoxicity are not related .
Hepatotoxicity of paracetamol enhanced by ingestion of alcohol : report of two cases .@_@paracetamol and Hepatotoxicity are not related .
Hepatotoxicity of paracetamol enhanced by ingestion of alcohol : report of two cases .@_@paracetamol and paracetamol are not related .
The biochemistry of paracetamol hepatotoxicity is outlined and the increased susceptibility of alcoholic patients to the hepatotoxic effects of paracetamol is remarked upon .@_@hepatotoxicity and paracetamol are Adverse-Effect relation .
The biochemistry of paracetamol hepatotoxicity is outlined and the increased susceptibility of alcoholic patients to the hepatotoxic effects of paracetamol is remarked upon .@_@hepatotoxic effects and paracetamol are Adverse-Effect relation .
The biochemistry of paracetamol hepatotoxicity is outlined and the increased susceptibility of alcoholic patients to the hepatotoxic effects of paracetamol is remarked upon .@_@hepatotoxic effects and hepatotoxic effects are not related .
The biochemistry of paracetamol hepatotoxicity is outlined and the increased susceptibility of alcoholic patients to the hepatotoxic effects of paracetamol is remarked upon .@_@hepatotoxic effects and hepatotoxicity are not related .
The biochemistry of paracetamol hepatotoxicity is outlined and the increased susceptibility of alcoholic patients to the hepatotoxic effects of paracetamol is remarked upon .@_@paracetamol and hepatotoxic effects are not related .
The biochemistry of paracetamol hepatotoxicity is outlined and the increased susceptibility of alcoholic patients to the hepatotoxic effects of paracetamol is remarked upon .@_@paracetamol and paracetamol are not related .
The biochemistry of paracetamol hepatotoxicity is outlined and the increased susceptibility of alcoholic patients to the hepatotoxic effects of paracetamol is remarked upon .@_@paracetamol and hepatotoxicity are not related .
The biochemistry of paracetamol hepatotoxicity is outlined and the increased susceptibility of alcoholic patients to the hepatotoxic effects of paracetamol is remarked upon .@_@hepatotoxicity and hepatotoxic effects are not related .
The biochemistry of paracetamol hepatotoxicity is outlined and the increased susceptibility of alcoholic patients to the hepatotoxic effects of paracetamol is remarked upon .@_@hepatotoxicity and hepatotoxicity are not related .
Two fatal cases of poisoning by paracetamol are described .@_@fatal and paracetamol are Adverse-Effect relation .
Two fatal cases of poisoning by paracetamol are described .@_@fatal and fatal are not related .
Two fatal cases of poisoning by paracetamol are described .@_@paracetamol and fatal are not related .
Two fatal cases of poisoning by paracetamol are described .@_@paracetamol and paracetamol are not related .
We report a case of drug - induced Kaposi 's sarcoma ( KS ) on the sole of the right foot in a 71-year - old man , treated for 6 months with corticosteroid therapy ( prednisolone 25 mg / day ) for pericardial effusion .@_@Kaposi 's sarcoma and prednisolone are Adverse-Effect relation .
We report a case of drug - induced Kaposi 's sarcoma ( KS ) on the sole of the right foot in a 71-year - old man , treated for 6 months with corticosteroid therapy ( prednisolone 25 mg / day ) for pericardial effusion .@_@Kaposi 's sarcoma and Kaposi 's sarcoma are not related .
We report a case of drug - induced Kaposi 's sarcoma ( KS ) on the sole of the right foot in a 71-year - old man , treated for 6 months with corticosteroid therapy ( prednisolone 25 mg / day ) for pericardial effusion .@_@prednisolone and Kaposi 's sarcoma are not related .
We report a case of drug - induced Kaposi 's sarcoma ( KS ) on the sole of the right foot in a 71-year - old man , treated for 6 months with corticosteroid therapy ( prednisolone 25 mg / day ) for pericardial effusion .@_@prednisolone and prednisolone are not related .
Acute dystonic reaction with low - dose pimozide .@_@Acute dystonic reaction and pimozide are Adverse-Effect relation .
Acute dystonic reaction with low - dose pimozide .@_@Acute dystonic reaction and Acute dystonic reaction are not related .
Acute dystonic reaction with low - dose pimozide .@_@pimozide and Acute dystonic reaction are not related .
Acute dystonic reaction with low - dose pimozide .@_@pimozide and pimozide are not related .
This paper reports on a 6.9-year - old autistic male who developed repeated episodes of acute dystonic reactions associated with pimozide administration at the doses of 0.096 mg / kg / day and 0.032 mg / kg / day and 32 hours following pimozide withdrawal , as well as during subsequent thioridazine administration .@_@acute dystonic reactions and pimozide are Adverse-Effect relation .
This paper reports on a 6.9-year - old autistic male who developed repeated episodes of acute dystonic reactions associated with pimozide administration at the doses of 0.096 mg / kg / day and 0.032 mg / kg / day and 32 hours following pimozide withdrawal , as well as during subsequent thioridazine administration .@_@acute dystonic reactions and thioridazine are Adverse-Effect relation .
This paper reports on a 6.9-year - old autistic male who developed repeated episodes of acute dystonic reactions associated with pimozide administration at the doses of 0.096 mg / kg / day and 0.032 mg / kg / day and 32 hours following pimozide withdrawal , as well as during subsequent thioridazine administration .@_@acute dystonic reactions and acute dystonic reactions are not related .
This paper reports on a 6.9-year - old autistic male who developed repeated episodes of acute dystonic reactions associated with pimozide administration at the doses of 0.096 mg / kg / day and 0.032 mg / kg / day and 32 hours following pimozide withdrawal , as well as during subsequent thioridazine administration .@_@pimozide and acute dystonic reactions are not related .
This paper reports on a 6.9-year - old autistic male who developed repeated episodes of acute dystonic reactions associated with pimozide administration at the doses of 0.096 mg / kg / day and 0.032 mg / kg / day and 32 hours following pimozide withdrawal , as well as during subsequent thioridazine administration .@_@pimozide and pimozide are not related .
This paper reports on a 6.9-year - old autistic male who developed repeated episodes of acute dystonic reactions associated with pimozide administration at the doses of 0.096 mg / kg / day and 0.032 mg / kg / day and 32 hours following pimozide withdrawal , as well as during subsequent thioridazine administration .@_@pimozide and thioridazine are not related .
This paper reports on a 6.9-year - old autistic male who developed repeated episodes of acute dystonic reactions associated with pimozide administration at the doses of 0.096 mg / kg / day and 0.032 mg / kg / day and 32 hours following pimozide withdrawal , as well as during subsequent thioridazine administration .@_@thioridazine and acute dystonic reactions are not related .
This paper reports on a 6.9-year - old autistic male who developed repeated episodes of acute dystonic reactions associated with pimozide administration at the doses of 0.096 mg / kg / day and 0.032 mg / kg / day and 32 hours following pimozide withdrawal , as well as during subsequent thioridazine administration .@_@thioridazine and pimozide are not related .
This paper reports on a 6.9-year - old autistic male who developed repeated episodes of acute dystonic reactions associated with pimozide administration at the doses of 0.096 mg / kg / day and 0.032 mg / kg / day and 32 hours following pimozide withdrawal , as well as during subsequent thioridazine administration .@_@thioridazine and thioridazine are not related .
Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .@_@atheroembolic acute renal failure and t - PA are Adverse-Effect relation .
Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .@_@extrarenal manifestations and t - PA are Adverse-Effect relation .
Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .@_@cholesterol crystal embolization and t - PA are Adverse-Effect relation .
Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .@_@atheroembolic acute renal failure and atheroembolic acute renal failure are not related .
Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .@_@atheroembolic acute renal failure and cholesterol crystal embolization are not related .
Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .@_@atheroembolic acute renal failure and extrarenal manifestations are not related .
Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .@_@t - PA and atheroembolic acute renal failure are not related .
Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .@_@t - PA and t - PA are not related .
Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .@_@t - PA and cholesterol crystal embolization are not related .
Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .@_@t - PA and extrarenal manifestations are not related .
Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .@_@cholesterol crystal embolization and atheroembolic acute renal failure are not related .
Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .@_@cholesterol crystal embolization and cholesterol crystal embolization are not related .
Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .@_@cholesterol crystal embolization and extrarenal manifestations are not related .
Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .@_@extrarenal manifestations and atheroembolic acute renal failure are not related .
Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .@_@extrarenal manifestations and cholesterol crystal embolization are not related .
Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321:1270 , 1989 ) , this is the first reported case of atheroembolic acute renal failure following t - PA therapy .@_@extrarenal manifestations and extrarenal manifestations are not related .
Cholesterol crystal embolization - associated renal failure after therapy with recombinant tissue - type plasminogen activator .@_@renal failure and tissue - type plasminogen activator are Adverse-Effect relation .
Cholesterol crystal embolization - associated renal failure after therapy with recombinant tissue - type plasminogen activator .@_@Cholesterol crystal embolization and tissue - type plasminogen activator are Adverse-Effect relation .
Cholesterol crystal embolization - associated renal failure after therapy with recombinant tissue - type plasminogen activator .@_@Cholesterol crystal embolization and Cholesterol crystal embolization are not related .
Cholesterol crystal embolization - associated renal failure after therapy with recombinant tissue - type plasminogen activator .@_@Cholesterol crystal embolization and renal failure are not related .
Cholesterol crystal embolization - associated renal failure after therapy with recombinant tissue - type plasminogen activator .@_@tissue - type plasminogen activator and Cholesterol crystal embolization are not related .
Cholesterol crystal embolization - associated renal failure after therapy with recombinant tissue - type plasminogen activator .@_@tissue - type plasminogen activator and tissue - type plasminogen activator are not related .
Cholesterol crystal embolization - associated renal failure after therapy with recombinant tissue - type plasminogen activator .@_@tissue - type plasminogen activator and renal failure are not related .
Cholesterol crystal embolization - associated renal failure after therapy with recombinant tissue - type plasminogen activator .@_@renal failure and Cholesterol crystal embolization are not related .
Cholesterol crystal embolization - associated renal failure after therapy with recombinant tissue - type plasminogen activator .@_@renal failure and renal failure are not related .
We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA ) .@_@cholesterol crystal embolization and t - PA are Adverse-Effect relation .
We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA ) .@_@renal failure and recombinant tissue - type plasminogen activator are Adverse-Effect relation .
We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA ) .@_@renal failure and t - PA are Adverse-Effect relation .
We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA ) .@_@cholesterol crystal embolization and recombinant tissue - type plasminogen activator are Adverse-Effect relation .
We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA ) .@_@cholesterol crystal embolization and cholesterol crystal embolization are not related .
We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA ) .@_@cholesterol crystal embolization and renal failure are not related .
We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA ) .@_@recombinant tissue - type plasminogen activator and cholesterol crystal embolization are not related .
We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA ) .@_@recombinant tissue - type plasminogen activator and recombinant tissue - type plasminogen activator are not related .
We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA ) .@_@recombinant tissue - type plasminogen activator and t - PA are not related .
We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA ) .@_@recombinant tissue - type plasminogen activator and renal failure are not related .
We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA ) .@_@t - PA and cholesterol crystal embolization are not related .
We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA ) .@_@t - PA and recombinant tissue - type plasminogen activator are not related .
We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA ) .@_@t - PA and t - PA are not related .
We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA ) .@_@t - PA and renal failure are not related .
We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA ) .@_@renal failure and cholesterol crystal embolization are not related .
We report the occurrence of renal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( t - PA ) .@_@renal failure and renal failure are not related .
Intravenous haloperidol is generally well tolerated , but multiform ventricular tachycardia has been reported .@_@multiform ventricular tachycardia and haloperidol are Adverse-Effect relation .
Intravenous haloperidol is generally well tolerated , but multiform ventricular tachycardia has been reported .@_@multiform ventricular tachycardia and multiform ventricular tachycardia are not related .
Intravenous haloperidol is generally well tolerated , but multiform ventricular tachycardia has been reported .@_@haloperidol and multiform ventricular tachycardia are not related .
Intravenous haloperidol is generally well tolerated , but multiform ventricular tachycardia has been reported .@_@haloperidol and haloperidol are not related .
All developed mucocutaneous side effects within 20 weeks of beginning i m gold therapy , at a time when RA had improved markedly compared to pretreatment status .@_@mucocutaneous side effects and gold are Adverse-Effect relation .
All developed mucocutaneous side effects within 20 weeks of beginning i m gold therapy , at a time when RA had improved markedly compared to pretreatment status .@_@mucocutaneous side effects and mucocutaneous side effects are not related .
All developed mucocutaneous side effects within 20 weeks of beginning i m gold therapy , at a time when RA had improved markedly compared to pretreatment status .@_@gold and mucocutaneous side effects are not related .
All developed mucocutaneous side effects within 20 weeks of beginning i m gold therapy , at a time when RA had improved markedly compared to pretreatment status .@_@gold and gold are not related .
How low can you go ? Use of very low dosage of gold in patients with mucocutaneous reactions .@_@mucocutaneous reactions and gold are Adverse-Effect relation .
How low can you go ? Use of very low dosage of gold in patients with mucocutaneous reactions .@_@mucocutaneous reactions and mucocutaneous reactions are not related .
How low can you go ? Use of very low dosage of gold in patients with mucocutaneous reactions .@_@gold and mucocutaneous reactions are not related .
How low can you go ? Use of very low dosage of gold in patients with mucocutaneous reactions .@_@gold and gold are not related .
Anterior spinal artery syndrome -- a complication of cervical intrathecal phenol injection .@_@Anterior spinal artery syndrome and phenol are Adverse-Effect relation .
Anterior spinal artery syndrome -- a complication of cervical intrathecal phenol injection .@_@Anterior spinal artery syndrome and Anterior spinal artery syndrome are not related .
Anterior spinal artery syndrome -- a complication of cervical intrathecal phenol injection .@_@phenol and Anterior spinal artery syndrome are not related .
Anterior spinal artery syndrome -- a complication of cervical intrathecal phenol injection .@_@phenol and phenol are not related .
We have seen a case of terminal malignant melanoma in which clinical manifestations , indicative of anterior spinal artery syndrome , developed following the injection of 0.3 ml of 10 % phenol - glycerine into the cervical subarachnoid space at the C4 - -C5 level for the control of severe right arm pain .@_@anterior spinal artery syndrome and phenol - glycerine are Adverse-Effect relation .
We have seen a case of terminal malignant melanoma in which clinical manifestations , indicative of anterior spinal artery syndrome , developed following the injection of 0.3 ml of 10 % phenol - glycerine into the cervical subarachnoid space at the C4 - -C5 level for the control of severe right arm pain .@_@anterior spinal artery syndrome and anterior spinal artery syndrome are not related .
We have seen a case of terminal malignant melanoma in which clinical manifestations , indicative of anterior spinal artery syndrome , developed following the injection of 0.3 ml of 10 % phenol - glycerine into the cervical subarachnoid space at the C4 - -C5 level for the control of severe right arm pain .@_@phenol - glycerine and anterior spinal artery syndrome are not related .
We have seen a case of terminal malignant melanoma in which clinical manifestations , indicative of anterior spinal artery syndrome , developed following the injection of 0.3 ml of 10 % phenol - glycerine into the cervical subarachnoid space at the C4 - -C5 level for the control of severe right arm pain .@_@phenol - glycerine and phenol - glycerine are not related .
One patient required nursing home placement and a feeding gastrostomy as a result of the worsening parkinsonism during risperidone treatment , but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine .@_@worsening parkinsonism and risperidone are Adverse-Effect relation .
One patient required nursing home placement and a feeding gastrostomy as a result of the worsening parkinsonism during risperidone treatment , but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine .@_@feeding gastrostomy and risperidone are Adverse-Effect relation .
One patient required nursing home placement and a feeding gastrostomy as a result of the worsening parkinsonism during risperidone treatment , but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine .@_@feeding gastrostomy and feeding gastrostomy are not related .
One patient required nursing home placement and a feeding gastrostomy as a result of the worsening parkinsonism during risperidone treatment , but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine .@_@feeding gastrostomy and worsening parkinsonism are not related .
One patient required nursing home placement and a feeding gastrostomy as a result of the worsening parkinsonism during risperidone treatment , but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine .@_@risperidone and feeding gastrostomy are not related .
One patient required nursing home placement and a feeding gastrostomy as a result of the worsening parkinsonism during risperidone treatment , but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine .@_@risperidone and risperidone are not related .
One patient required nursing home placement and a feeding gastrostomy as a result of the worsening parkinsonism during risperidone treatment , but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine .@_@risperidone and worsening parkinsonism are not related .
One patient required nursing home placement and a feeding gastrostomy as a result of the worsening parkinsonism during risperidone treatment , but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine .@_@worsening parkinsonism and feeding gastrostomy are not related .
One patient required nursing home placement and a feeding gastrostomy as a result of the worsening parkinsonism during risperidone treatment , but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine .@_@worsening parkinsonism and worsening parkinsonism are not related .
Two of the five patients who worsened motorically also developed encephalopathy during risperidone treatment ; the encephalopathy resolved when the patients were switched to clozapine treatment .@_@encephalopathy and risperidone are Adverse-Effect relation .
Two of the five patients who worsened motorically also developed encephalopathy during risperidone treatment ; the encephalopathy resolved when the patients were switched to clozapine treatment .@_@worsened motorically and risperidone are Adverse-Effect relation .
Two of the five patients who worsened motorically also developed encephalopathy during risperidone treatment ; the encephalopathy resolved when the patients were switched to clozapine treatment .@_@encephalopathy and encephalopathy are not related .
Two of the five patients who worsened motorically also developed encephalopathy during risperidone treatment ; the encephalopathy resolved when the patients were switched to clozapine treatment .@_@encephalopathy and worsened motorically are not related .
Two of the five patients who worsened motorically also developed encephalopathy during risperidone treatment ; the encephalopathy resolved when the patients were switched to clozapine treatment .@_@risperidone and encephalopathy are not related .
Two of the five patients who worsened motorically also developed encephalopathy during risperidone treatment ; the encephalopathy resolved when the patients were switched to clozapine treatment .@_@risperidone and risperidone are not related .
Two of the five patients who worsened motorically also developed encephalopathy during risperidone treatment ; the encephalopathy resolved when the patients were switched to clozapine treatment .@_@risperidone and worsened motorically are not related .
Two of the five patients who worsened motorically also developed encephalopathy during risperidone treatment ; the encephalopathy resolved when the patients were switched to clozapine treatment .@_@worsened motorically and encephalopathy are not related .
Two of the five patients who worsened motorically also developed encephalopathy during risperidone treatment ; the encephalopathy resolved when the patients were switched to clozapine treatment .@_@worsened motorically and worsened motorically are not related .
Azathioprine can cause severe myelosuppression .@_@myelosuppression and Azathioprine are Adverse-Effect relation .
Azathioprine can cause severe myelosuppression .@_@myelosuppression and myelosuppression are not related .
Azathioprine can cause severe myelosuppression .@_@Azathioprine and myelosuppression are not related .
Azathioprine can cause severe myelosuppression .@_@Azathioprine and Azathioprine are not related .
Azathioprine - induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis .@_@myelosuppression and Azathioprine are Adverse-Effect relation .
Azathioprine - induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis .@_@myelosuppression and myelosuppression are not related .
Azathioprine - induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis .@_@Azathioprine and myelosuppression are not related .
Azathioprine - induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis .@_@Azathioprine and Azathioprine are not related .
The azathioprine dose was low ( 1 mg / kg ) and pancytopenia occurred after 56 days therapy .@_@pancytopenia and azathioprine are Adverse-Effect relation .
The azathioprine dose was low ( 1 mg / kg ) and pancytopenia occurred after 56 days therapy .@_@pancytopenia and pancytopenia are not related .
The azathioprine dose was low ( 1 mg / kg ) and pancytopenia occurred after 56 days therapy .@_@azathioprine and pancytopenia are not related .
The azathioprine dose was low ( 1 mg / kg ) and pancytopenia occurred after 56 days therapy .@_@azathioprine and azathioprine are not related .
Thiopurine methyltransferase deficiency occurs at a frequency of one in 300 and is associated with profound myelosuppression after a short course of azathioprine .@_@myelosuppression and azathioprine are Adverse-Effect relation .
Thiopurine methyltransferase deficiency occurs at a frequency of one in 300 and is associated with profound myelosuppression after a short course of azathioprine .@_@myelosuppression and myelosuppression are not related .
Thiopurine methyltransferase deficiency occurs at a frequency of one in 300 and is associated with profound myelosuppression after a short course of azathioprine .@_@azathioprine and myelosuppression are not related .
Thiopurine methyltransferase deficiency occurs at a frequency of one in 300 and is associated with profound myelosuppression after a short course of azathioprine .@_@azathioprine and azathioprine are not related .
We describe the first documented case of azathioprine - induced severe myelosuppression due to thiopurine methyltransferase deficiency in autoimmune liver disease .@_@myelosuppression and azathioprine are Adverse-Effect relation .
We describe the first documented case of azathioprine - induced severe myelosuppression due to thiopurine methyltransferase deficiency in autoimmune liver disease .@_@myelosuppression and myelosuppression are not related .
We describe the first documented case of azathioprine - induced severe myelosuppression due to thiopurine methyltransferase deficiency in autoimmune liver disease .@_@azathioprine and myelosuppression are not related .
We describe the first documented case of azathioprine - induced severe myelosuppression due to thiopurine methyltransferase deficiency in autoimmune liver disease .@_@azathioprine and azathioprine are not related .
Nabumetone - associated interstitial nephritis .@_@interstitial nephritis and Nabumetone are Adverse-Effect relation .
Nabumetone - associated interstitial nephritis .@_@interstitial nephritis and interstitial nephritis are not related .
Nabumetone - associated interstitial nephritis .@_@Nabumetone and interstitial nephritis are not related .
Nabumetone - associated interstitial nephritis .@_@Nabumetone and Nabumetone are not related .
She had been taking nabumetone for 6 months , but had discontinued the agent 2 weeks before admission due to progressive edema .@_@edema and nabumetone are Adverse-Effect relation .
She had been taking nabumetone for 6 months , but had discontinued the agent 2 weeks before admission due to progressive edema .@_@edema and edema are not related .
She had been taking nabumetone for 6 months , but had discontinued the agent 2 weeks before admission due to progressive edema .@_@nabumetone and edema are not related .
She had been taking nabumetone for 6 months , but had discontinued the agent 2 weeks before admission due to progressive edema .@_@nabumetone and nabumetone are not related .
Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea .@_@Acute myeloid leukemia and hydroxyurea are Adverse-Effect relation .
Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea .@_@Acute myeloid leukemia and Acute myeloid leukemia are not related .
Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea .@_@hydroxyurea and Acute myeloid leukemia are not related .
Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea .@_@hydroxyurea and hydroxyurea are not related .
In this report , two cases of ET which evolved into AL without prior exposure to radiation or alkylating agents , and which were treated with long - term hydroxyurea therapy , are described .@_@AL and hydroxyurea are Adverse-Effect relation .
In this report , two cases of ET which evolved into AL without prior exposure to radiation or alkylating agents , and which were treated with long - term hydroxyurea therapy , are described .@_@AL and AL are not related .
In this report , two cases of ET which evolved into AL without prior exposure to radiation or alkylating agents , and which were treated with long - term hydroxyurea therapy , are described .@_@hydroxyurea and AL are not related .
In this report , two cases of ET which evolved into AL without prior exposure to radiation or alkylating agents , and which were treated with long - term hydroxyurea therapy , are described .@_@hydroxyurea and hydroxyurea are not related .
Prolonged used of hydroxyurea in patients with ET may lead to therapy - associated acute leukemia .@_@acute leukemia and hydroxyurea are Adverse-Effect relation .
Prolonged used of hydroxyurea in patients with ET may lead to therapy - associated acute leukemia .@_@acute leukemia and acute leukemia are not related .
Prolonged used of hydroxyurea in patients with ET may lead to therapy - associated acute leukemia .@_@hydroxyurea and acute leukemia are not related .
Prolonged used of hydroxyurea in patients with ET may lead to therapy - associated acute leukemia .@_@hydroxyurea and hydroxyurea are not related .
However , in 1993 , a clinical study involving 400 patients on the Thai - Burmese border revealed cardiac effects of antimalarial treatment with halofantrine , including one sudden death after the treatment .@_@sudden death and halofantrine are Adverse-Effect relation .
However , in 1993 , a clinical study involving 400 patients on the Thai - Burmese border revealed cardiac effects of antimalarial treatment with halofantrine , including one sudden death after the treatment .@_@cardiac effects and halofantrine are Adverse-Effect relation .
However , in 1993 , a clinical study involving 400 patients on the Thai - Burmese border revealed cardiac effects of antimalarial treatment with halofantrine , including one sudden death after the treatment .@_@cardiac effects and cardiac effects are not related .
However , in 1993 , a clinical study involving 400 patients on the Thai - Burmese border revealed cardiac effects of antimalarial treatment with halofantrine , including one sudden death after the treatment .@_@cardiac effects and sudden death are not related .
However , in 1993 , a clinical study involving 400 patients on the Thai - Burmese border revealed cardiac effects of antimalarial treatment with halofantrine , including one sudden death after the treatment .@_@halofantrine and cardiac effects are not related .
However , in 1993 , a clinical study involving 400 patients on the Thai - Burmese border revealed cardiac effects of antimalarial treatment with halofantrine , including one sudden death after the treatment .@_@halofantrine and halofantrine are not related .
However , in 1993 , a clinical study involving 400 patients on the Thai - Burmese border revealed cardiac effects of antimalarial treatment with halofantrine , including one sudden death after the treatment .@_@halofantrine and sudden death are not related .
However , in 1993 , a clinical study involving 400 patients on the Thai - Burmese border revealed cardiac effects of antimalarial treatment with halofantrine , including one sudden death after the treatment .@_@sudden death and cardiac effects are not related .
However , in 1993 , a clinical study involving 400 patients on the Thai - Burmese border revealed cardiac effects of antimalarial treatment with halofantrine , including one sudden death after the treatment .@_@sudden death and sudden death are not related .
In the present paper , we discuss the first Japanese vivax malaria patient whose QT interval was prolonged after treatment with halofantrine .@_@QT interval was prolonged and halofantrine are Adverse-Effect relation .
In the present paper , we discuss the first Japanese vivax malaria patient whose QT interval was prolonged after treatment with halofantrine .@_@QT interval was prolonged and QT interval was prolonged are not related .
In the present paper , we discuss the first Japanese vivax malaria patient whose QT interval was prolonged after treatment with halofantrine .@_@halofantrine and QT interval was prolonged are not related .
In the present paper , we discuss the first Japanese vivax malaria patient whose QT interval was prolonged after treatment with halofantrine .@_@halofantrine and halofantrine are not related .
Prolongation of the QT interval observed in a Japanese patient with vivax malaria following treatment with halofantrine .@_@Prolongation of the QT interval and halofantrine are Adverse-Effect relation .
Prolongation of the QT interval observed in a Japanese patient with vivax malaria following treatment with halofantrine .@_@Prolongation of the QT interval and Prolongation of the QT interval are not related .
Prolongation of the QT interval observed in a Japanese patient with vivax malaria following treatment with halofantrine .@_@halofantrine and Prolongation of the QT interval are not related .
Prolongation of the QT interval observed in a Japanese patient with vivax malaria following treatment with halofantrine .@_@halofantrine and halofantrine are not related .
The pharmaceutical company producing Halfan has reported 8 cardiac arrests , leading to 6 deaths , when a higher dose than recommended was used , there was recent or concomitant treatment with mefloquine , there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency .@_@deaths and Halfan are Adverse-Effect relation .
The pharmaceutical company producing Halfan has reported 8 cardiac arrests , leading to 6 deaths , when a higher dose than recommended was used , there was recent or concomitant treatment with mefloquine , there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency .@_@cardiac arrests and Halfan are Adverse-Effect relation .
The pharmaceutical company producing Halfan has reported 8 cardiac arrests , leading to 6 deaths , when a higher dose than recommended was used , there was recent or concomitant treatment with mefloquine , there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency .@_@cardiac arrests and mefloquine are Adverse-Effect relation .
The pharmaceutical company producing Halfan has reported 8 cardiac arrests , leading to 6 deaths , when a higher dose than recommended was used , there was recent or concomitant treatment with mefloquine , there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency .@_@deaths and mefloquine are Adverse-Effect relation .
The pharmaceutical company producing Halfan has reported 8 cardiac arrests , leading to 6 deaths , when a higher dose than recommended was used , there was recent or concomitant treatment with mefloquine , there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency .@_@cardiac arrests and cardiac arrests are not related .
The pharmaceutical company producing Halfan has reported 8 cardiac arrests , leading to 6 deaths , when a higher dose than recommended was used , there was recent or concomitant treatment with mefloquine , there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency .@_@cardiac arrests and deaths are not related .
The pharmaceutical company producing Halfan has reported 8 cardiac arrests , leading to 6 deaths , when a higher dose than recommended was used , there was recent or concomitant treatment with mefloquine , there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency .@_@Halfan and cardiac arrests are not related .
The pharmaceutical company producing Halfan has reported 8 cardiac arrests , leading to 6 deaths , when a higher dose than recommended was used , there was recent or concomitant treatment with mefloquine , there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency .@_@Halfan and Halfan are not related .
The pharmaceutical company producing Halfan has reported 8 cardiac arrests , leading to 6 deaths , when a higher dose than recommended was used , there was recent or concomitant treatment with mefloquine , there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency .@_@Halfan and mefloquine are not related .
The pharmaceutical company producing Halfan has reported 8 cardiac arrests , leading to 6 deaths , when a higher dose than recommended was used , there was recent or concomitant treatment with mefloquine , there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency .@_@Halfan and deaths are not related .
The pharmaceutical company producing Halfan has reported 8 cardiac arrests , leading to 6 deaths , when a higher dose than recommended was used , there was recent or concomitant treatment with mefloquine , there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency .@_@mefloquine and cardiac arrests are not related .
The pharmaceutical company producing Halfan has reported 8 cardiac arrests , leading to 6 deaths , when a higher dose than recommended was used , there was recent or concomitant treatment with mefloquine , there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency .@_@mefloquine and Halfan are not related .
The pharmaceutical company producing Halfan has reported 8 cardiac arrests , leading to 6 deaths , when a higher dose than recommended was used , there was recent or concomitant treatment with mefloquine , there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency .@_@mefloquine and mefloquine are not related .
The pharmaceutical company producing Halfan has reported 8 cardiac arrests , leading to 6 deaths , when a higher dose than recommended was used , there was recent or concomitant treatment with mefloquine , there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency .@_@mefloquine and deaths are not related .
The pharmaceutical company producing Halfan has reported 8 cardiac arrests , leading to 6 deaths , when a higher dose than recommended was used , there was recent or concomitant treatment with mefloquine , there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency .@_@deaths and cardiac arrests are not related .
The pharmaceutical company producing Halfan has reported 8 cardiac arrests , leading to 6 deaths , when a higher dose than recommended was used , there was recent or concomitant treatment with mefloquine , there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency .@_@deaths and deaths are not related .
Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 ( Ki-1 ) - positive anaplastic large - cell lymphoma .@_@Supravenous hyperpigmentation and CHOP are Adverse-Effect relation .
Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 ( Ki-1 ) - positive anaplastic large - cell lymphoma .@_@Supravenous hyperpigmentation and Supravenous hyperpigmentation are not related .
Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 ( Ki-1 ) - positive anaplastic large - cell lymphoma .@_@CHOP and Supravenous hyperpigmentation are not related .
Supravenous hyperpigmentation in association with CHOP chemotherapy of a CD30 ( Ki-1 ) - positive anaplastic large - cell lymphoma .@_@CHOP and CHOP are not related .
We report an unusual pattern of supravenous hyperpigmentation occurring after CHOP chemotherapy .@_@supravenous hyperpigmentation and CHOP are Adverse-Effect relation .
We report an unusual pattern of supravenous hyperpigmentation occurring after CHOP chemotherapy .@_@supravenous hyperpigmentation and supravenous hyperpigmentation are not related .
We report an unusual pattern of supravenous hyperpigmentation occurring after CHOP chemotherapy .@_@CHOP and supravenous hyperpigmentation are not related .
We report an unusual pattern of supravenous hyperpigmentation occurring after CHOP chemotherapy .@_@CHOP and CHOP are not related .
Phenytoin toxicity due to concomitant antituberculosis therapy .@_@Phenytoin toxicity and Phenytoin are Adverse-Effect relation .
Phenytoin toxicity due to concomitant antituberculosis therapy .@_@Phenytoin toxicity and Phenytoin toxicity are not related .
Phenytoin toxicity due to concomitant antituberculosis therapy .@_@Phenytoin and Phenytoin toxicity are not related .
Phenytoin toxicity due to concomitant antituberculosis therapy .@_@Phenytoin and Phenytoin are not related .
Seventy - four per cent of patients with epileptogenic disorders seen at the Emergency Unit at Groote Schuur Hospital were on phenytoin and 11.6 % of these had blood levels in the toxic range .@_@blood levels in the toxic range and phenytoin are Adverse-Effect relation .
Seventy - four per cent of patients with epileptogenic disorders seen at the Emergency Unit at Groote Schuur Hospital were on phenytoin and 11.6 % of these had blood levels in the toxic range .@_@blood levels in the toxic range and blood levels in the toxic range are not related .
Seventy - four per cent of patients with epileptogenic disorders seen at the Emergency Unit at Groote Schuur Hospital were on phenytoin and 11.6 % of these had blood levels in the toxic range .@_@phenytoin and blood levels in the toxic range are not related .
Seventy - four per cent of patients with epileptogenic disorders seen at the Emergency Unit at Groote Schuur Hospital were on phenytoin and 11.6 % of these had blood levels in the toxic range .@_@phenytoin and phenytoin are not related .
Slow acetylators , who comprise roughly 50 % of the South African population , are likely to develop clinical and biochemical features of phenytoin toxicity when this drug is given together with antituberculosis therapy .@_@phenytoin toxicity and phenytoin are Adverse-Effect relation .
Slow acetylators , who comprise roughly 50 % of the South African population , are likely to develop clinical and biochemical features of phenytoin toxicity when this drug is given together with antituberculosis therapy .@_@phenytoin toxicity and phenytoin toxicity are not related .
Slow acetylators , who comprise roughly 50 % of the South African population , are likely to develop clinical and biochemical features of phenytoin toxicity when this drug is given together with antituberculosis therapy .@_@phenytoin and phenytoin toxicity are not related .
Slow acetylators , who comprise roughly 50 % of the South African population , are likely to develop clinical and biochemical features of phenytoin toxicity when this drug is given together with antituberculosis therapy .@_@phenytoin and phenytoin are not related .
The wide use of phenytoin during the recent tuberculosis epidemic makes it imperative to suspect this drug interaction in patients exhibiting clinical features that might be related to phenytoin toxicity .@_@phenytoin toxicity and phenytoin are Adverse-Effect relation .
The wide use of phenytoin during the recent tuberculosis epidemic makes it imperative to suspect this drug interaction in patients exhibiting clinical features that might be related to phenytoin toxicity .@_@phenytoin toxicity and phenytoin toxicity are not related .
The wide use of phenytoin during the recent tuberculosis epidemic makes it imperative to suspect this drug interaction in patients exhibiting clinical features that might be related to phenytoin toxicity .@_@phenytoin and phenytoin toxicity are not related .
The wide use of phenytoin during the recent tuberculosis epidemic makes it imperative to suspect this drug interaction in patients exhibiting clinical features that might be related to phenytoin toxicity .@_@phenytoin and phenytoin are not related .
Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy .@_@Nephrogenic diabetes insipidus and foscarnet are Adverse-Effect relation .
Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy .@_@renal tubular acidosis and foscarnet are Adverse-Effect relation .
Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy .@_@Nephrogenic diabetes insipidus and Nephrogenic diabetes insipidus are not related .
Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy .@_@Nephrogenic diabetes insipidus and renal tubular acidosis are not related .
Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy .@_@foscarnet and Nephrogenic diabetes insipidus are not related .
Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy .@_@foscarnet and foscarnet are not related .
Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy .@_@foscarnet and renal tubular acidosis are not related .
Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy .@_@renal tubular acidosis and Nephrogenic diabetes insipidus are not related .
Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy .@_@renal tubular acidosis and renal tubular acidosis are not related .
No cases of renal acidosis , and only one case of nephrogenic diabetes insipidus , has been previously reported as a complication of foscarnet treatment .@_@nephrogenic diabetes insipidus and foscarnet are Adverse-Effect relation .
No cases of renal acidosis , and only one case of nephrogenic diabetes insipidus , has been previously reported as a complication of foscarnet treatment .@_@nephrogenic diabetes insipidus and nephrogenic diabetes insipidus are not related .
No cases of renal acidosis , and only one case of nephrogenic diabetes insipidus , has been previously reported as a complication of foscarnet treatment .@_@foscarnet and nephrogenic diabetes insipidus are not related .
No cases of renal acidosis , and only one case of nephrogenic diabetes insipidus , has been previously reported as a complication of foscarnet treatment .@_@foscarnet and foscarnet are not related .
Our patient developed both nephrogenic diabetes insipidus and renal tubular acidosis with a temporal pattern that demonstrated a link between foscarnet therapy and these abnormalities .@_@renal tubular acidosis and foscarnet are Adverse-Effect relation .
Our patient developed both nephrogenic diabetes insipidus and renal tubular acidosis with a temporal pattern that demonstrated a link between foscarnet therapy and these abnormalities .@_@nephrogenic diabetes insipidus and foscarnet are Adverse-Effect relation .
Our patient developed both nephrogenic diabetes insipidus and renal tubular acidosis with a temporal pattern that demonstrated a link between foscarnet therapy and these abnormalities .@_@nephrogenic diabetes insipidus and nephrogenic diabetes insipidus are not related .
Our patient developed both nephrogenic diabetes insipidus and renal tubular acidosis with a temporal pattern that demonstrated a link between foscarnet therapy and these abnormalities .@_@nephrogenic diabetes insipidus and renal tubular acidosis are not related .
Our patient developed both nephrogenic diabetes insipidus and renal tubular acidosis with a temporal pattern that demonstrated a link between foscarnet therapy and these abnormalities .@_@foscarnet and nephrogenic diabetes insipidus are not related .
Our patient developed both nephrogenic diabetes insipidus and renal tubular acidosis with a temporal pattern that demonstrated a link between foscarnet therapy and these abnormalities .@_@foscarnet and foscarnet are not related .
Our patient developed both nephrogenic diabetes insipidus and renal tubular acidosis with a temporal pattern that demonstrated a link between foscarnet therapy and these abnormalities .@_@foscarnet and renal tubular acidosis are not related .
Our patient developed both nephrogenic diabetes insipidus and renal tubular acidosis with a temporal pattern that demonstrated a link between foscarnet therapy and these abnormalities .@_@renal tubular acidosis and nephrogenic diabetes insipidus are not related .
Our patient developed both nephrogenic diabetes insipidus and renal tubular acidosis with a temporal pattern that demonstrated a link between foscarnet therapy and these abnormalities .@_@renal tubular acidosis and renal tubular acidosis are not related .
We present a patient with human immunodeficiency virus infection under treatment with foscarnet for CMV retinitis who complained of thirst and polyuria .@_@thirst and foscarnet are Adverse-Effect relation .
We present a patient with human immunodeficiency virus infection under treatment with foscarnet for CMV retinitis who complained of thirst and polyuria .@_@polyuria and foscarnet are Adverse-Effect relation .
We present a patient with human immunodeficiency virus infection under treatment with foscarnet for CMV retinitis who complained of thirst and polyuria .@_@polyuria and polyuria are not related .
We present a patient with human immunodeficiency virus infection under treatment with foscarnet for CMV retinitis who complained of thirst and polyuria .@_@polyuria and thirst are not related .
We present a patient with human immunodeficiency virus infection under treatment with foscarnet for CMV retinitis who complained of thirst and polyuria .@_@foscarnet and polyuria are not related .
We present a patient with human immunodeficiency virus infection under treatment with foscarnet for CMV retinitis who complained of thirst and polyuria .@_@foscarnet and foscarnet are not related .
We present a patient with human immunodeficiency virus infection under treatment with foscarnet for CMV retinitis who complained of thirst and polyuria .@_@foscarnet and thirst are not related .
We present a patient with human immunodeficiency virus infection under treatment with foscarnet for CMV retinitis who complained of thirst and polyuria .@_@thirst and polyuria are not related .
We present a patient with human immunodeficiency virus infection under treatment with foscarnet for CMV retinitis who complained of thirst and polyuria .@_@thirst and thirst are not related .
Choroidal hemorrhage associated with systemic tissue plasminogen activator .@_@Choroidal hemorrhage and tissue plasminogen activator are Adverse-Effect relation .
Choroidal hemorrhage associated with systemic tissue plasminogen activator .@_@Choroidal hemorrhage and Choroidal hemorrhage are not related .
Choroidal hemorrhage associated with systemic tissue plasminogen activator .@_@tissue plasminogen activator and Choroidal hemorrhage are not related .
Choroidal hemorrhage associated with systemic tissue plasminogen activator .@_@tissue plasminogen activator and tissue plasminogen activator are not related .
CONCLUSION : The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment .@_@hemorrhagic choroidal detachment and tissue plasminogen activator are Adverse-Effect relation .
CONCLUSION : The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment .@_@hemorrhage and tissue plasminogen activator are Adverse-Effect relation .
CONCLUSION : The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment .@_@hemorrhage and hemorrhage are not related .
CONCLUSION : The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment .@_@hemorrhage and hemorrhagic choroidal detachment are not related .
CONCLUSION : The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment .@_@tissue plasminogen activator and hemorrhage are not related .
CONCLUSION : The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment .@_@tissue plasminogen activator and tissue plasminogen activator are not related .
CONCLUSION : The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment .@_@tissue plasminogen activator and hemorrhagic choroidal detachment are not related .
CONCLUSION : The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment .@_@hemorrhagic choroidal detachment and hemorrhage are not related .
CONCLUSION : The administration of tissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment .@_@hemorrhagic choroidal detachment and hemorrhagic choroidal detachment are not related .
PURPOSE : To determine the cause of spontaneous choroidal hemorrhage in a 67-year - old man after a myocardial infarction and administration of tissue plasminogen activator .@_@spontaneous choroidal hemorrhage and tissue plasminogen activator are Adverse-Effect relation .
PURPOSE : To determine the cause of spontaneous choroidal hemorrhage in a 67-year - old man after a myocardial infarction and administration of tissue plasminogen activator .@_@spontaneous choroidal hemorrhage and spontaneous choroidal hemorrhage are not related .
PURPOSE : To determine the cause of spontaneous choroidal hemorrhage in a 67-year - old man after a myocardial infarction and administration of tissue plasminogen activator .@_@tissue plasminogen activator and spontaneous choroidal hemorrhage are not related .
PURPOSE : To determine the cause of spontaneous choroidal hemorrhage in a 67-year - old man after a myocardial infarction and administration of tissue plasminogen activator .@_@tissue plasminogen activator and tissue plasminogen activator are not related .
Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis .@_@Accelerated nodulosis and methotrexate are Adverse-Effect relation .
Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis .@_@Accelerated nodulosis and Accelerated nodulosis are not related .
Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis .@_@methotrexate and Accelerated nodulosis are not related .
Accelerated nodulosis during methotrexate therapy for juvenile rheumatoid arthritis .@_@methotrexate and methotrexate are not related .
Although they had only a few nodules at diagnosis , the nodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients .@_@nodules and methotrexate are Adverse-Effect relation .
Although they had only a few nodules at diagnosis , the nodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients .@_@nodules and nodules are not related .
Although they had only a few nodules at diagnosis , the nodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients .@_@methotrexate and nodules are not related .
Although they had only a few nodules at diagnosis , the nodules increased in number and size 3 to 4 months after the start of methotrexate therapy in both patients .@_@methotrexate and methotrexate are not related .
Physicians treating patients with methotrexate for juvenile rheumatoid arthritis must be aware of this extraarticular side effect .@_@extraarticular side effect and methotrexate are Adverse-Effect relation .
Physicians treating patients with methotrexate for juvenile rheumatoid arthritis must be aware of this extraarticular side effect .@_@extraarticular side effect and extraarticular side effect are not related .
Physicians treating patients with methotrexate for juvenile rheumatoid arthritis must be aware of this extraarticular side effect .@_@methotrexate and extraarticular side effect are not related .
Physicians treating patients with methotrexate for juvenile rheumatoid arthritis must be aware of this extraarticular side effect .@_@methotrexate and methotrexate are not related .
The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other .@_@nodules and methotrexate are Adverse-Effect relation .
The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other .@_@nodules and nodules are not related .
The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other .@_@methotrexate and nodules are not related .
The nodules regressed after withdrawal of methotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other .@_@methotrexate and methotrexate are not related .
We describe two patients with rheumatoid factor - positive , polyarticular - onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy .@_@accelerated nodulosis and methotrexate are Adverse-Effect relation .
We describe two patients with rheumatoid factor - positive , polyarticular - onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy .@_@accelerated nodulosis and accelerated nodulosis are not related .
We describe two patients with rheumatoid factor - positive , polyarticular - onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy .@_@methotrexate and accelerated nodulosis are not related .
We describe two patients with rheumatoid factor - positive , polyarticular - onset juvenile rheumatoid arthritis in whom accelerated nodulosis developed during methotrexate therapy .@_@methotrexate and methotrexate are not related .
A macrophage activation syndrome , possibly related to methotrexate toxicity , developed in a boy with systemic juvenile rheumatoid arthritis .@_@methotrexate toxicity and methotrexate are Adverse-Effect relation .
A macrophage activation syndrome , possibly related to methotrexate toxicity , developed in a boy with systemic juvenile rheumatoid arthritis .@_@macrophage activation syndrome and methotrexate are Adverse-Effect relation .
A macrophage activation syndrome , possibly related to methotrexate toxicity , developed in a boy with systemic juvenile rheumatoid arthritis .@_@macrophage activation syndrome and macrophage activation syndrome are not related .
A macrophage activation syndrome , possibly related to methotrexate toxicity , developed in a boy with systemic juvenile rheumatoid arthritis .@_@macrophage activation syndrome and methotrexate toxicity are not related .
A macrophage activation syndrome , possibly related to methotrexate toxicity , developed in a boy with systemic juvenile rheumatoid arthritis .@_@methotrexate and macrophage activation syndrome are not related .
A macrophage activation syndrome , possibly related to methotrexate toxicity , developed in a boy with systemic juvenile rheumatoid arthritis .@_@methotrexate and methotrexate are not related .
A macrophage activation syndrome , possibly related to methotrexate toxicity , developed in a boy with systemic juvenile rheumatoid arthritis .@_@methotrexate and methotrexate toxicity are not related .
A macrophage activation syndrome , possibly related to methotrexate toxicity , developed in a boy with systemic juvenile rheumatoid arthritis .@_@methotrexate toxicity and macrophage activation syndrome are not related .
A macrophage activation syndrome , possibly related to methotrexate toxicity , developed in a boy with systemic juvenile rheumatoid arthritis .@_@methotrexate toxicity and methotrexate toxicity are not related .
Jaundice induced by streptokinase .@_@Jaundice and streptokinase are Adverse-Effect relation .
Jaundice induced by streptokinase .@_@Jaundice and Jaundice are not related .
Jaundice induced by streptokinase .@_@streptokinase and Jaundice are not related .
Jaundice induced by streptokinase .@_@streptokinase and streptokinase are not related .
Only a few reports of overt jaundice are associated with streptokinase .@_@jaundice and streptokinase are Adverse-Effect relation .
Only a few reports of overt jaundice are associated with streptokinase .@_@jaundice and jaundice are not related .
Only a few reports of overt jaundice are associated with streptokinase .@_@streptokinase and jaundice are not related .
Only a few reports of overt jaundice are associated with streptokinase .@_@streptokinase and streptokinase are not related .
Although both patients recovered from the colitis after the administration of vancomycin , the first case demonstrated a relapse of the colitis after receiving a subsequent course of the same chemotherapy with cisplatin .@_@colitis and cisplatin are Adverse-Effect relation .
Although both patients recovered from the colitis after the administration of vancomycin , the first case demonstrated a relapse of the colitis after receiving a subsequent course of the same chemotherapy with cisplatin .@_@colitis and colitis are not related .
Although both patients recovered from the colitis after the administration of vancomycin , the first case demonstrated a relapse of the colitis after receiving a subsequent course of the same chemotherapy with cisplatin .@_@cisplatin and colitis are not related .
Although both patients recovered from the colitis after the administration of vancomycin , the first case demonstrated a relapse of the colitis after receiving a subsequent course of the same chemotherapy with cisplatin .@_@cisplatin and cisplatin are not related .
Based on our findings , it is thus concluded that cisplatin may cause C. difficile colitis .@_@C. difficile colitis and cisplatin are Adverse-Effect relation .
Based on our findings , it is thus concluded that cisplatin may cause C. difficile colitis .@_@C. difficile colitis and C. difficile colitis are not related .
Based on our findings , it is thus concluded that cisplatin may cause C. difficile colitis .@_@cisplatin and C. difficile colitis are not related .
Based on our findings , it is thus concluded that cisplatin may cause C. difficile colitis .@_@cisplatin and cisplatin are not related .
Both patients were then treated with a carboplatin alternative to cisplatin in the following courses , which resulted in neither a relapse of the colitis nor a recurrence of the malignancies up to this time .@_@colitis and cisplatin are Adverse-Effect relation .
Both patients were then treated with a carboplatin alternative to cisplatin in the following courses , which resulted in neither a relapse of the colitis nor a recurrence of the malignancies up to this time .@_@colitis and colitis are not related .
Both patients were then treated with a carboplatin alternative to cisplatin in the following courses , which resulted in neither a relapse of the colitis nor a recurrence of the malignancies up to this time .@_@cisplatin and colitis are not related .
Both patients were then treated with a carboplatin alternative to cisplatin in the following courses , which resulted in neither a relapse of the colitis nor a recurrence of the malignancies up to this time .@_@cisplatin and cisplatin are not related .
Clostridium difficile colitis associated with cisplatin - based chemotherapy in ovarian cancer patients .@_@Clostridium difficile colitis and cisplatin are Adverse-Effect relation .
Clostridium difficile colitis associated with cisplatin - based chemotherapy in ovarian cancer patients .@_@Clostridium difficile colitis and Clostridium difficile colitis are not related .
Clostridium difficile colitis associated with cisplatin - based chemotherapy in ovarian cancer patients .@_@cisplatin and Clostridium difficile colitis are not related .
Clostridium difficile colitis associated with cisplatin - based chemotherapy in ovarian cancer patients .@_@cisplatin and cisplatin are not related .
Severe C. difficile colitis occurred in 2 patients ( 6.1 % ) after receiving cisplatin - based combination chemotherapy for ovarian malignancies .@_@C. difficile colitis and cisplatin are Adverse-Effect relation .
Severe C. difficile colitis occurred in 2 patients ( 6.1 % ) after receiving cisplatin - based combination chemotherapy for ovarian malignancies .@_@C. difficile colitis and C. difficile colitis are not related .
Severe C. difficile colitis occurred in 2 patients ( 6.1 % ) after receiving cisplatin - based combination chemotherapy for ovarian malignancies .@_@cisplatin and C. difficile colitis are not related .
Severe C. difficile colitis occurred in 2 patients ( 6.1 % ) after receiving cisplatin - based combination chemotherapy for ovarian malignancies .@_@cisplatin and cisplatin are not related .
The purpose of this study was to examine the incidence and cause of Clostridium difficile colitis occurring after cisplatin - based combination chemotherapy in ovarian cancer patients .@_@Clostridium difficile colitis and cisplatin are Adverse-Effect relation .
The purpose of this study was to examine the incidence and cause of Clostridium difficile colitis occurring after cisplatin - based combination chemotherapy in ovarian cancer patients .@_@Clostridium difficile colitis and Clostridium difficile colitis are not related .
The purpose of this study was to examine the incidence and cause of Clostridium difficile colitis occurring after cisplatin - based combination chemotherapy in ovarian cancer patients .@_@cisplatin and Clostridium difficile colitis are not related .
The purpose of this study was to examine the incidence and cause of Clostridium difficile colitis occurring after cisplatin - based combination chemotherapy in ovarian cancer patients .@_@cisplatin and cisplatin are not related .
A patient with severe cholestatic jaundice induced by captopril is presented .@_@severe cholestatic jaundice and captopril are Adverse-Effect relation .
A patient with severe cholestatic jaundice induced by captopril is presented .@_@severe cholestatic jaundice and severe cholestatic jaundice are not related .
A patient with severe cholestatic jaundice induced by captopril is presented .@_@captopril and severe cholestatic jaundice are not related .
A patient with severe cholestatic jaundice induced by captopril is presented .@_@captopril and captopril are not related .
Captopril - associated " pseudocholangitis ' .@_@pseudocholangitis and Captopril are Adverse-Effect relation .
Captopril - associated " pseudocholangitis ' .@_@pseudocholangitis and pseudocholangitis are not related .
Captopril - associated " pseudocholangitis ' .@_@Captopril and pseudocholangitis are not related .
Captopril - associated " pseudocholangitis ' .@_@Captopril and Captopril are not related .
Captopril is known to be associated with dermatologic , hematologic , and pulmonary adverse effects .@_@dermatologic , hematologic , and pulmonary adverse effects and Captopril are Adverse-Effect relation .
Captopril is known to be associated with dermatologic , hematologic , and pulmonary adverse effects .@_@dermatologic , hematologic , and pulmonary adverse effects and dermatologic , hematologic , and pulmonary adverse effects are not related .
Captopril is known to be associated with dermatologic , hematologic , and pulmonary adverse effects .@_@Captopril and dermatologic , hematologic , and pulmonary adverse effects are not related .
Captopril is known to be associated with dermatologic , hematologic , and pulmonary adverse effects .@_@Captopril and Captopril are not related .
Patients treated with captopril who develop " atypical cholangitis " should be suspected of having captopril - associated liver damage .@_@atypical cholangitis and captopril are Adverse-Effect relation .
Patients treated with captopril who develop " atypical cholangitis " should be suspected of having captopril - associated liver damage .@_@liver damage and captopril are Adverse-Effect relation .
Patients treated with captopril who develop " atypical cholangitis " should be suspected of having captopril - associated liver damage .@_@atypical cholangitis and atypical cholangitis are not related .
Patients treated with captopril who develop " atypical cholangitis " should be suspected of having captopril - associated liver damage .@_@atypical cholangitis and liver damage are not related .
Patients treated with captopril who develop " atypical cholangitis " should be suspected of having captopril - associated liver damage .@_@captopril and atypical cholangitis are not related .
Patients treated with captopril who develop " atypical cholangitis " should be suspected of having captopril - associated liver damage .@_@captopril and captopril are not related .
Patients treated with captopril who develop " atypical cholangitis " should be suspected of having captopril - associated liver damage .@_@captopril and liver damage are not related .
Patients treated with captopril who develop " atypical cholangitis " should be suspected of having captopril - associated liver damage .@_@liver damage and atypical cholangitis are not related .
Patients treated with captopril who develop " atypical cholangitis " should be suspected of having captopril - associated liver damage .@_@liver damage and liver damage are not related .
Development of nephrotic syndrome in a patient with acute myeloblastic leukemia after treatment with macrophage - colony - stimulating factor .@_@nephrotic syndrome and macrophage - colony - stimulating factor are Adverse-Effect relation .
Development of nephrotic syndrome in a patient with acute myeloblastic leukemia after treatment with macrophage - colony - stimulating factor .@_@nephrotic syndrome and nephrotic syndrome are not related .
Development of nephrotic syndrome in a patient with acute myeloblastic leukemia after treatment with macrophage - colony - stimulating factor .@_@macrophage - colony - stimulating factor and nephrotic syndrome are not related .
Development of nephrotic syndrome in a patient with acute myeloblastic leukemia after treatment with macrophage - colony - stimulating factor .@_@macrophage - colony - stimulating factor and macrophage - colony - stimulating factor are not related .
It should be emphasized that the recurrence of nephrotic syndrome was observed after the following chemotherapy , including M - CSF , whereas the bone marrow still remained completely remitted .@_@nephrotic syndrome and M - CSF are Adverse-Effect relation .
It should be emphasized that the recurrence of nephrotic syndrome was observed after the following chemotherapy , including M - CSF , whereas the bone marrow still remained completely remitted .@_@nephrotic syndrome and nephrotic syndrome are not related .
It should be emphasized that the recurrence of nephrotic syndrome was observed after the following chemotherapy , including M - CSF , whereas the bone marrow still remained completely remitted .@_@M - CSF and nephrotic syndrome are not related .
It should be emphasized that the recurrence of nephrotic syndrome was observed after the following chemotherapy , including M - CSF , whereas the bone marrow still remained completely remitted .@_@M - CSF and M - CSF are not related .
The possibility can be raised that M - CSF accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus , leading to the development of nephrotic syndrome .@_@nephrotic syndrome and M - CSF are Adverse-Effect relation .
The possibility can be raised that M - CSF accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus , leading to the development of nephrotic syndrome .@_@renal disease and M - CSF are Adverse-Effect relation .
The possibility can be raised that M - CSF accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus , leading to the development of nephrotic syndrome .@_@nephrotic syndrome and nephrotic syndrome are not related .
The possibility can be raised that M - CSF accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus , leading to the development of nephrotic syndrome .@_@nephrotic syndrome and renal disease are not related .
The possibility can be raised that M - CSF accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus , leading to the development of nephrotic syndrome .@_@M - CSF and nephrotic syndrome are not related .
The possibility can be raised that M - CSF accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus , leading to the development of nephrotic syndrome .@_@M - CSF and M - CSF are not related .
The possibility can be raised that M - CSF accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus , leading to the development of nephrotic syndrome .@_@M - CSF and renal disease are not related .
The possibility can be raised that M - CSF accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus , leading to the development of nephrotic syndrome .@_@renal disease and nephrotic syndrome are not related .
The possibility can be raised that M - CSF accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus , leading to the development of nephrotic syndrome .@_@renal disease and renal disease are not related .
These evolutional changes in both proteinuria and glomerular histology suggest a close linkage between the M - CSF treatment and macrophage - related glomerular injury .@_@macrophage - related glomerular injury and M - CSF are Adverse-Effect relation .
These evolutional changes in both proteinuria and glomerular histology suggest a close linkage between the M - CSF treatment and macrophage - related glomerular injury .@_@macrophage - related glomerular injury and macrophage - related glomerular injury are not related .
These evolutional changes in both proteinuria and glomerular histology suggest a close linkage between the M - CSF treatment and macrophage - related glomerular injury .@_@M - CSF and macrophage - related glomerular injury are not related .
These evolutional changes in both proteinuria and glomerular histology suggest a close linkage between the M - CSF treatment and macrophage - related glomerular injury .@_@M - CSF and M - CSF are not related .
We describe a patient with acute myeloblastic leukemia ( AML ) who developed nephrotic syndrome after receiving several courses of chemotherapy , including macrophage - colony - stimulating factor ( M - CSF ) .@_@nephrotic syndrome and M - CSF are Adverse-Effect relation .
We describe a patient with acute myeloblastic leukemia ( AML ) who developed nephrotic syndrome after receiving several courses of chemotherapy , including macrophage - colony - stimulating factor ( M - CSF ) .@_@nephrotic syndrome and macrophage - colony - stimulating factor are Adverse-Effect relation .
We describe a patient with acute myeloblastic leukemia ( AML ) who developed nephrotic syndrome after receiving several courses of chemotherapy , including macrophage - colony - stimulating factor ( M - CSF ) .@_@nephrotic syndrome and nephrotic syndrome are not related .
We describe a patient with acute myeloblastic leukemia ( AML ) who developed nephrotic syndrome after receiving several courses of chemotherapy , including macrophage - colony - stimulating factor ( M - CSF ) .@_@macrophage - colony - stimulating factor and nephrotic syndrome are not related .
We describe a patient with acute myeloblastic leukemia ( AML ) who developed nephrotic syndrome after receiving several courses of chemotherapy , including macrophage - colony - stimulating factor ( M - CSF ) .@_@macrophage - colony - stimulating factor and macrophage - colony - stimulating factor are not related .
We describe a patient with acute myeloblastic leukemia ( AML ) who developed nephrotic syndrome after receiving several courses of chemotherapy , including macrophage - colony - stimulating factor ( M - CSF ) .@_@macrophage - colony - stimulating factor and M - CSF are not related .
We describe a patient with acute myeloblastic leukemia ( AML ) who developed nephrotic syndrome after receiving several courses of chemotherapy , including macrophage - colony - stimulating factor ( M - CSF ) .@_@M - CSF and nephrotic syndrome are not related .
We describe a patient with acute myeloblastic leukemia ( AML ) who developed nephrotic syndrome after receiving several courses of chemotherapy , including macrophage - colony - stimulating factor ( M - CSF ) .@_@M - CSF and macrophage - colony - stimulating factor are not related .
We describe a patient with acute myeloblastic leukemia ( AML ) who developed nephrotic syndrome after receiving several courses of chemotherapy , including macrophage - colony - stimulating factor ( M - CSF ) .@_@M - CSF and M - CSF are not related .
On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone , edema developed in both labia .@_@edema and terbutaline are Adverse-Effect relation .
On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone , edema developed in both labia .@_@edema and magnesium sulfate are Adverse-Effect relation .
On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone , edema developed in both labia .@_@edema and nifedipine are Adverse-Effect relation .
On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone , edema developed in both labia .@_@edema and betamethasone are Adverse-Effect relation .
On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone , edema developed in both labia .@_@edema and edema are not related .
On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone , edema developed in both labia .@_@betamethasone and edema are not related .
On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone , edema developed in both labia .@_@betamethasone and betamethasone are not related .
On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone , edema developed in both labia .@_@betamethasone and magnesium sulfate are not related .
On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone , edema developed in both labia .@_@betamethasone and nifedipine are not related .
On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone , edema developed in both labia .@_@betamethasone and terbutaline are not related .
On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone , edema developed in both labia .@_@magnesium sulfate and edema are not related .
On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone , edema developed in both labia .@_@magnesium sulfate and betamethasone are not related .
On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone , edema developed in both labia .@_@magnesium sulfate and magnesium sulfate are not related .
On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone , edema developed in both labia .@_@magnesium sulfate and nifedipine are not related .
On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone , edema developed in both labia .@_@magnesium sulfate and terbutaline are not related .
On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone , edema developed in both labia .@_@nifedipine and edema are not related .
On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone , edema developed in both labia .@_@nifedipine and betamethasone are not related .
On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone , edema developed in both labia .@_@nifedipine and magnesium sulfate are not related .
On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone , edema developed in both labia .@_@nifedipine and nifedipine are not related .
On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone , edema developed in both labia .@_@nifedipine and terbutaline are not related .
On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone , edema developed in both labia .@_@terbutaline and edema are not related .
On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone , edema developed in both labia .@_@terbutaline and betamethasone are not related .
On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone , edema developed in both labia .@_@terbutaline and magnesium sulfate are not related .
On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone , edema developed in both labia .@_@terbutaline and nifedipine are not related .
On the fifth day of tocolysis with magnesium sulfate , nifedipine , terbutaline and betamethasone , edema developed in both labia .@_@terbutaline and terbutaline are not related .
Milk - alkali syndrome induced by 1,25(OH)2D in a patient with hypoparathyroidism .@_@Milk - alkali syndrome and 1,25(OH)2D are Adverse-Effect relation .
Milk - alkali syndrome induced by 1,25(OH)2D in a patient with hypoparathyroidism .@_@Milk - alkali syndrome and Milk - alkali syndrome are not related .
Milk - alkali syndrome induced by 1,25(OH)2D in a patient with hypoparathyroidism .@_@1,25(OH)2D and Milk - alkali syndrome are not related .
Milk - alkali syndrome induced by 1,25(OH)2D in a patient with hypoparathyroidism .@_@1,25(OH)2D and 1,25(OH)2D are not related .
This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk - alkali syndrome .@_@milk - alkali syndrome and calcium carbonate are Adverse-Effect relation .
This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk - alkali syndrome .@_@milk - alkali syndrome and calcitriol are Adverse-Effect relation .
This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk - alkali syndrome .@_@milk - alkali syndrome and milk - alkali syndrome are not related .
This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk - alkali syndrome .@_@calcitriol and milk - alkali syndrome are not related .
This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk - alkali syndrome .@_@calcitriol and calcitriol are not related .
This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk - alkali syndrome .@_@calcitriol and calcium carbonate are not related .
This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk - alkali syndrome .@_@calcium carbonate and milk - alkali syndrome are not related .
This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk - alkali syndrome .@_@calcium carbonate and calcitriol are not related .
This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk - alkali syndrome .@_@calcium carbonate and calcium carbonate are not related .
After receiving 3 doses of ifosfamide / mesna , she was found to be unresponsive .@_@unresponsive and ifosfamide are Adverse-Effect relation .
After receiving 3 doses of ifosfamide / mesna , she was found to be unresponsive .@_@unresponsive and mesna are Adverse-Effect relation .
After receiving 3 doses of ifosfamide / mesna , she was found to be unresponsive .@_@unresponsive and unresponsive are not related .
After receiving 3 doses of ifosfamide / mesna , she was found to be unresponsive .@_@ifosfamide and unresponsive are not related .
After receiving 3 doses of ifosfamide / mesna , she was found to be unresponsive .@_@ifosfamide and ifosfamide are not related .
After receiving 3 doses of ifosfamide / mesna , she was found to be unresponsive .@_@ifosfamide and mesna are not related .
After receiving 3 doses of ifosfamide / mesna , she was found to be unresponsive .@_@mesna and unresponsive are not related .
After receiving 3 doses of ifosfamide / mesna , she was found to be unresponsive .@_@mesna and ifosfamide are not related .
After receiving 3 doses of ifosfamide / mesna , she was found to be unresponsive .@_@mesna and mesna are not related .
CONCLUSIONS : There was a temporal relationship between the onset of nonconvulsive status epilepticus and initiation of ifosfamide infusion .@_@nonconvulsive status epilepticus and ifosfamide are Adverse-Effect relation .
CONCLUSIONS : There was a temporal relationship between the onset of nonconvulsive status epilepticus and initiation of ifosfamide infusion .@_@nonconvulsive status epilepticus and nonconvulsive status epilepticus are not related .
CONCLUSIONS : There was a temporal relationship between the onset of nonconvulsive status epilepticus and initiation of ifosfamide infusion .@_@ifosfamide and nonconvulsive status epilepticus are not related .
CONCLUSIONS : There was a temporal relationship between the onset of nonconvulsive status epilepticus and initiation of ifosfamide infusion .@_@ifosfamide and ifosfamide are not related .
DISCUSSION : Central nervous system ( CNS ) toxicity has been described with ifosfamide , with most cases reported in the pediatric population .@_@Central nervous system ( CNS ) toxicity and ifosfamide are Adverse-Effect relation .
DISCUSSION : Central nervous system ( CNS ) toxicity has been described with ifosfamide , with most cases reported in the pediatric population .@_@Central nervous system ( CNS ) toxicity and Central nervous system ( CNS ) toxicity are not related .
DISCUSSION : Central nervous system ( CNS ) toxicity has been described with ifosfamide , with most cases reported in the pediatric population .@_@ifosfamide and Central nervous system ( CNS ) toxicity are not related .
DISCUSSION : Central nervous system ( CNS ) toxicity has been described with ifosfamide , with most cases reported in the pediatric population .@_@ifosfamide and ifosfamide are not related .
Ifosfamide - induced nonconvulsive status epilepticus .@_@nonconvulsive status epilepticus and Ifosfamide are Adverse-Effect relation .
Ifosfamide - induced nonconvulsive status epilepticus .@_@nonconvulsive status epilepticus and nonconvulsive status epilepticus are not related .
Ifosfamide - induced nonconvulsive status epilepticus .@_@Ifosfamide and nonconvulsive status epilepticus are not related .
Ifosfamide - induced nonconvulsive status epilepticus .@_@Ifosfamide and Ifosfamide are not related .
OBJECTIVE : To describe a patient with ifosfamide - induced nonconvulsive status epilepticus .@_@nonconvulsive status epilepticus and ifosfamide are Adverse-Effect relation .
OBJECTIVE : To describe a patient with ifosfamide - induced nonconvulsive status epilepticus .@_@nonconvulsive status epilepticus and nonconvulsive status epilepticus are not related .
OBJECTIVE : To describe a patient with ifosfamide - induced nonconvulsive status epilepticus .@_@ifosfamide and nonconvulsive status epilepticus are not related .
OBJECTIVE : To describe a patient with ifosfamide - induced nonconvulsive status epilepticus .@_@ifosfamide and ifosfamide are not related .
This represents the first report of nonconvulsive status epilepticus induced by ifosfamide .@_@nonconvulsive status epilepticus and ifosfamide are Adverse-Effect relation .
This represents the first report of nonconvulsive status epilepticus induced by ifosfamide .@_@nonconvulsive status epilepticus and nonconvulsive status epilepticus are not related .
This represents the first report of nonconvulsive status epilepticus induced by ifosfamide .@_@ifosfamide and nonconvulsive status epilepticus are not related .
This represents the first report of nonconvulsive status epilepticus induced by ifosfamide .@_@ifosfamide and ifosfamide are not related .
Albendazole - induced pseudomembranous colitis .@_@pseudomembranous colitis and Albendazole are Adverse-Effect relation .
Albendazole - induced pseudomembranous colitis .@_@pseudomembranous colitis and pseudomembranous colitis are not related .
Albendazole - induced pseudomembranous colitis .@_@Albendazole and pseudomembranous colitis are not related .
Albendazole - induced pseudomembranous colitis .@_@Albendazole and Albendazole are not related .
Although a few case reports link metronidazole with the development of pseudomembranous colitis , albendazole has not been associated with the development of this condition .@_@pseudomembranous colitis and metronidazole are Adverse-Effect relation .
Although a few case reports link metronidazole with the development of pseudomembranous colitis , albendazole has not been associated with the development of this condition .@_@pseudomembranous colitis and pseudomembranous colitis are not related .
Although a few case reports link metronidazole with the development of pseudomembranous colitis , albendazole has not been associated with the development of this condition .@_@metronidazole and pseudomembranous colitis are not related .
Although a few case reports link metronidazole with the development of pseudomembranous colitis , albendazole has not been associated with the development of this condition .@_@metronidazole and metronidazole are not related .
While undergoing treatment with albendazole , he developed worsening diarrhea with abdominal pain and fever .@_@abdominal pain and albendazole are Adverse-Effect relation .
While undergoing treatment with albendazole , he developed worsening diarrhea with abdominal pain and fever .@_@worsening diarrhea and albendazole are Adverse-Effect relation .
While undergoing treatment with albendazole , he developed worsening diarrhea with abdominal pain and fever .@_@fever and albendazole are Adverse-Effect relation .
While undergoing treatment with albendazole , he developed worsening diarrhea with abdominal pain and fever .@_@abdominal pain and abdominal pain are not related .
While undergoing treatment with albendazole , he developed worsening diarrhea with abdominal pain and fever .@_@abdominal pain and fever are not related .
While undergoing treatment with albendazole , he developed worsening diarrhea with abdominal pain and fever .@_@abdominal pain and worsening diarrhea are not related .
While undergoing treatment with albendazole , he developed worsening diarrhea with abdominal pain and fever .@_@albendazole and abdominal pain are not related .
While undergoing treatment with albendazole , he developed worsening diarrhea with abdominal pain and fever .@_@albendazole and albendazole are not related .
While undergoing treatment with albendazole , he developed worsening diarrhea with abdominal pain and fever .@_@albendazole and fever are not related .
While undergoing treatment with albendazole , he developed worsening diarrhea with abdominal pain and fever .@_@albendazole and worsening diarrhea are not related .
While undergoing treatment with albendazole , he developed worsening diarrhea with abdominal pain and fever .@_@fever and abdominal pain are not related .
While undergoing treatment with albendazole , he developed worsening diarrhea with abdominal pain and fever .@_@fever and fever are not related .
While undergoing treatment with albendazole , he developed worsening diarrhea with abdominal pain and fever .@_@fever and worsening diarrhea are not related .
While undergoing treatment with albendazole , he developed worsening diarrhea with abdominal pain and fever .@_@worsening diarrhea and abdominal pain are not related .
While undergoing treatment with albendazole , he developed worsening diarrhea with abdominal pain and fever .@_@worsening diarrhea and fever are not related .
While undergoing treatment with albendazole , he developed worsening diarrhea with abdominal pain and fever .@_@worsening diarrhea and worsening diarrhea are not related .
Aluminum intoxication , along with other factors , was considered to be the cause of TC development .@_@Aluminum intoxication and Aluminum are Adverse-Effect relation .
Aluminum intoxication , along with other factors , was considered to be the cause of TC development .@_@TC and Aluminum are Adverse-Effect relation .
Aluminum intoxication , along with other factors , was considered to be the cause of TC development .@_@Aluminum intoxication and Aluminum intoxication are not related .
Aluminum intoxication , along with other factors , was considered to be the cause of TC development .@_@Aluminum intoxication and TC are not related .
Aluminum intoxication , along with other factors , was considered to be the cause of TC development .@_@Aluminum and Aluminum intoxication are not related .
Aluminum intoxication , along with other factors , was considered to be the cause of TC development .@_@Aluminum and Aluminum are not related .
Aluminum intoxication , along with other factors , was considered to be the cause of TC development .@_@Aluminum and TC are not related .
Aluminum intoxication , along with other factors , was considered to be the cause of TC development .@_@TC and Aluminum intoxication are not related .
Aluminum intoxication , along with other factors , was considered to be the cause of TC development .@_@TC and TC are not related .
Oculomotor disturbances associated with 5-fluorouracil chemotherapy .@_@Oculomotor disturbances and 5-fluorouracil are Adverse-Effect relation .
Oculomotor disturbances associated with 5-fluorouracil chemotherapy .@_@Oculomotor disturbances and Oculomotor disturbances are not related .
Oculomotor disturbances associated with 5-fluorouracil chemotherapy .@_@5-fluorouracil and Oculomotor disturbances are not related .
Oculomotor disturbances associated with 5-fluorouracil chemotherapy .@_@5-fluorouracil and 5-fluorouracil are not related .
The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem .@_@neurotoxicity and 5-FU are Adverse-Effect relation .
The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem .@_@ocular motor disturbances and 5-FU are Adverse-Effect relation .
The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem .@_@neurotoxicity and neurotoxicity are not related .
The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem .@_@neurotoxicity and ocular motor disturbances are not related .
The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem .@_@5-FU and neurotoxicity are not related .
The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem .@_@5-FU and 5-FU are not related .
The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem .@_@5-FU and ocular motor disturbances are not related .
The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem .@_@ocular motor disturbances and neurotoxicity are not related .
The ocular motor disturbances are probably an expression of regional 5-FU neurotoxicity primarily affecting the brain stem .@_@ocular motor disturbances and ocular motor disturbances are not related .
Two patients treated with 5-fluorouracil ( 5-FU ) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity .@_@cerebellar dysfunction and 5-fluorouracil are Adverse-Effect relation .
Two patients treated with 5-fluorouracil ( 5-FU ) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity .@_@neurotoxicity and 5-FU are Adverse-Effect relation .
Two patients treated with 5-fluorouracil ( 5-FU ) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity .@_@neurotoxicity and 5-fluorouracil are Adverse-Effect relation .
Two patients treated with 5-fluorouracil ( 5-FU ) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity .@_@cerebellar dysfunction and 5-FU are Adverse-Effect relation .
Two patients treated with 5-fluorouracil ( 5-FU ) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity .@_@cerebellar dysfunction and cerebellar dysfunction are not related .
Two patients treated with 5-fluorouracil ( 5-FU ) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity .@_@cerebellar dysfunction and neurotoxicity are not related .
Two patients treated with 5-fluorouracil ( 5-FU ) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity .@_@5-fluorouracil and cerebellar dysfunction are not related .
Two patients treated with 5-fluorouracil ( 5-FU ) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity .@_@5-fluorouracil and 5-fluorouracil are not related .
Two patients treated with 5-fluorouracil ( 5-FU ) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity .@_@5-fluorouracil and 5-FU are not related .
Two patients treated with 5-fluorouracil ( 5-FU ) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity .@_@5-fluorouracil and neurotoxicity are not related .
Two patients treated with 5-fluorouracil ( 5-FU ) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity .@_@5-FU and cerebellar dysfunction are not related .
Two patients treated with 5-fluorouracil ( 5-FU ) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity .@_@5-FU and 5-fluorouracil are not related .
Two patients treated with 5-fluorouracil ( 5-FU ) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity .@_@5-FU and 5-FU are not related .
Two patients treated with 5-fluorouracil ( 5-FU ) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity .@_@5-FU and neurotoxicity are not related .
Two patients treated with 5-fluorouracil ( 5-FU ) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity .@_@neurotoxicity and cerebellar dysfunction are not related .
Two patients treated with 5-fluorouracil ( 5-FU ) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity .@_@neurotoxicity and neurotoxicity are not related .
Assessment of cortisol response was by insulin - induced hypoglycaemia in three cases , by short tetracosactrin test in two , and by low - dose tetracosactrin and 24-hour urinary cortisol / creatinine ratio in one .@_@hypoglycaemia and insulin are Adverse-Effect relation .
Assessment of cortisol response was by insulin - induced hypoglycaemia in three cases , by short tetracosactrin test in two , and by low - dose tetracosactrin and 24-hour urinary cortisol / creatinine ratio in one .@_@hypoglycaemia and hypoglycaemia are not related .
Assessment of cortisol response was by insulin - induced hypoglycaemia in three cases , by short tetracosactrin test in two , and by low - dose tetracosactrin and 24-hour urinary cortisol / creatinine ratio in one .@_@insulin and hypoglycaemia are not related .
Assessment of cortisol response was by insulin - induced hypoglycaemia in three cases , by short tetracosactrin test in two , and by low - dose tetracosactrin and 24-hour urinary cortisol / creatinine ratio in one .@_@insulin and insulin are not related .
FINDINGS : Six children with growth retardation noted after treatment with high - dose fluticasone propionate were found to have adrenal suppression .@_@adrenal suppression and fluticasone propionate are Adverse-Effect relation .
FINDINGS : Six children with growth retardation noted after treatment with high - dose fluticasone propionate were found to have adrenal suppression .@_@growth retardation and fluticasone propionate are Adverse-Effect relation .
FINDINGS : Six children with growth retardation noted after treatment with high - dose fluticasone propionate were found to have adrenal suppression .@_@adrenal suppression and adrenal suppression are not related .
FINDINGS : Six children with growth retardation noted after treatment with high - dose fluticasone propionate were found to have adrenal suppression .@_@adrenal suppression and growth retardation are not related .
FINDINGS : Six children with growth retardation noted after treatment with high - dose fluticasone propionate were found to have adrenal suppression .@_@fluticasone propionate and adrenal suppression are not related .
FINDINGS : Six children with growth retardation noted after treatment with high - dose fluticasone propionate were found to have adrenal suppression .@_@fluticasone propionate and fluticasone propionate are not related .
FINDINGS : Six children with growth retardation noted after treatment with high - dose fluticasone propionate were found to have adrenal suppression .@_@fluticasone propionate and growth retardation are not related .
FINDINGS : Six children with growth retardation noted after treatment with high - dose fluticasone propionate were found to have adrenal suppression .@_@growth retardation and adrenal suppression are not related .
FINDINGS : Six children with growth retardation noted after treatment with high - dose fluticasone propionate were found to have adrenal suppression .@_@growth retardation and growth retardation are not related .
Growth and adrenal suppression in asthmatic children treated with high - dose fluticasone propionate .@_@Growth and adrenal suppression and fluticasone propionate are Adverse-Effect relation .
Growth and adrenal suppression in asthmatic children treated with high - dose fluticasone propionate .@_@Growth and adrenal suppression and Growth and adrenal suppression are not related .
Growth and adrenal suppression in asthmatic children treated with high - dose fluticasone propionate .@_@fluticasone propionate and Growth and adrenal suppression are not related .
Growth and adrenal suppression in asthmatic children treated with high - dose fluticasone propionate .@_@fluticasone propionate and fluticasone propionate are not related .
INTERPRETATION : When high doses of fluticasone propionate are used , growth may be retarded and adrenal suppression may occur .@_@adrenal suppression and fluticasone propionate are Adverse-Effect relation .
INTERPRETATION : When high doses of fluticasone propionate are used , growth may be retarded and adrenal suppression may occur .@_@growth may be retarded and fluticasone propionate are Adverse-Effect relation .
INTERPRETATION : When high doses of fluticasone propionate are used , growth may be retarded and adrenal suppression may occur .@_@adrenal suppression and adrenal suppression are not related .
INTERPRETATION : When high doses of fluticasone propionate are used , growth may be retarded and adrenal suppression may occur .@_@adrenal suppression and growth may be retarded are not related .
INTERPRETATION : When high doses of fluticasone propionate are used , growth may be retarded and adrenal suppression may occur .@_@fluticasone propionate and adrenal suppression are not related .
INTERPRETATION : When high doses of fluticasone propionate are used , growth may be retarded and adrenal suppression may occur .@_@fluticasone propionate and fluticasone propionate are not related .
INTERPRETATION : When high doses of fluticasone propionate are used , growth may be retarded and adrenal suppression may occur .@_@fluticasone propionate and growth may be retarded are not related .
INTERPRETATION : When high doses of fluticasone propionate are used , growth may be retarded and adrenal suppression may occur .@_@growth may be retarded and adrenal suppression are not related .
INTERPRETATION : When high doses of fluticasone propionate are used , growth may be retarded and adrenal suppression may occur .@_@growth may be retarded and growth may be retarded are not related .
METHODS : Growth retardation was observed in six severely asthmatic children after introduction of high - dose fluticasone propionate treatment ( dry powder ) .@_@Growth retardation and fluticasone propionate are Adverse-Effect relation .
METHODS : Growth retardation was observed in six severely asthmatic children after introduction of high - dose fluticasone propionate treatment ( dry powder ) .@_@Growth retardation and Growth retardation are not related .
METHODS : Growth retardation was observed in six severely asthmatic children after introduction of high - dose fluticasone propionate treatment ( dry powder ) .@_@fluticasone propionate and Growth retardation are not related .
METHODS : Growth retardation was observed in six severely asthmatic children after introduction of high - dose fluticasone propionate treatment ( dry powder ) .@_@fluticasone propionate and fluticasone propionate are not related .
Metipranolol associated granulomatous anterior uveitis : not so uncommon as thought .@_@granulomatous anterior uveitis and Metipranolol are Adverse-Effect relation .
Metipranolol associated granulomatous anterior uveitis : not so uncommon as thought .@_@granulomatous anterior uveitis and granulomatous anterior uveitis are not related .
Metipranolol associated granulomatous anterior uveitis : not so uncommon as thought .@_@Metipranolol and granulomatous anterior uveitis are not related .
Metipranolol associated granulomatous anterior uveitis : not so uncommon as thought .@_@Metipranolol and Metipranolol are not related .
Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6 % eye drops .@_@bilateral granulomatous anterior uveitis and metripranolol are Adverse-Effect relation .
Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6 % eye drops .@_@bilateral granulomatous anterior uveitis and bilateral granulomatous anterior uveitis are not related .
Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6 % eye drops .@_@metripranolol and bilateral granulomatous anterior uveitis are not related .
Two case reports of bilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with metripranolol 0.6 % eye drops .@_@metripranolol and metripranolol are not related .
A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia , all of whom experienced seizures or altered mental status .@_@seizures and desmopressin are Adverse-Effect relation .
A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia , all of whom experienced seizures or altered mental status .@_@hyponatremia and desmopressin are Adverse-Effect relation .
A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia , all of whom experienced seizures or altered mental status .@_@altered mental status and desmopressin are Adverse-Effect relation .
A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia , all of whom experienced seizures or altered mental status .@_@altered mental status and altered mental status are not related .
A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia , all of whom experienced seizures or altered mental status .@_@altered mental status and hyponatremia are not related .
A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia , all of whom experienced seizures or altered mental status .@_@altered mental status and seizures are not related .
A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia , all of whom experienced seizures or altered mental status .@_@desmopressin and altered mental status are not related .
A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia , all of whom experienced seizures or altered mental status .@_@desmopressin and desmopressin are not related .
A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia , all of whom experienced seizures or altered mental status .@_@desmopressin and hyponatremia are not related .
A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia , all of whom experienced seizures or altered mental status .@_@desmopressin and seizures are not related .
A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia , all of whom experienced seizures or altered mental status .@_@hyponatremia and altered mental status are not related .
A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia , all of whom experienced seizures or altered mental status .@_@hyponatremia and hyponatremia are not related .
A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia , all of whom experienced seizures or altered mental status .@_@hyponatremia and seizures are not related .
A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia , all of whom experienced seizures or altered mental status .@_@seizures and altered mental status are not related .
A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia , all of whom experienced seizures or altered mental status .@_@seizures and hyponatremia are not related .
A review of the literature found 11 children and 2 adults in whom intranasal desmopressin was associated with hyponatremia , all of whom experienced seizures or altered mental status .@_@seizures and seizures are not related .
Intranasal desmopressin - induced hyponatremia .@_@hyponatremia and desmopressin are Adverse-Effect relation .
Intranasal desmopressin - induced hyponatremia .@_@hyponatremia and hyponatremia are not related .
Intranasal desmopressin - induced hyponatremia .@_@desmopressin and hyponatremia are not related .
Intranasal desmopressin - induced hyponatremia .@_@desmopressin and desmopressin are not related .
When vague symptoms develop during desmopressin therapy , hyponatremia must be considered as part of the differential diagnosis .@_@vague symptoms and desmopressin are Adverse-Effect relation .
When vague symptoms develop during desmopressin therapy , hyponatremia must be considered as part of the differential diagnosis .@_@hyponatremia and desmopressin are Adverse-Effect relation .
When vague symptoms develop during desmopressin therapy , hyponatremia must be considered as part of the differential diagnosis .@_@hyponatremia and hyponatremia are not related .
When vague symptoms develop during desmopressin therapy , hyponatremia must be considered as part of the differential diagnosis .@_@hyponatremia and vague symptoms are not related .
When vague symptoms develop during desmopressin therapy , hyponatremia must be considered as part of the differential diagnosis .@_@desmopressin and hyponatremia are not related .
When vague symptoms develop during desmopressin therapy , hyponatremia must be considered as part of the differential diagnosis .@_@desmopressin and desmopressin are not related .
When vague symptoms develop during desmopressin therapy , hyponatremia must be considered as part of the differential diagnosis .@_@desmopressin and vague symptoms are not related .
When vague symptoms develop during desmopressin therapy , hyponatremia must be considered as part of the differential diagnosis .@_@vague symptoms and hyponatremia are not related .
When vague symptoms develop during desmopressin therapy , hyponatremia must be considered as part of the differential diagnosis .@_@vague symptoms and vague symptoms are not related .
Within 24 hours of fluid restriction and cessation of desmopressin , her symptoms and hyponatremia resolved .@_@hyponatremia and desmopressin are Adverse-Effect relation .
Within 24 hours of fluid restriction and cessation of desmopressin , her symptoms and hyponatremia resolved .@_@hyponatremia and hyponatremia are not related .
Within 24 hours of fluid restriction and cessation of desmopressin , her symptoms and hyponatremia resolved .@_@desmopressin and hyponatremia are not related .
Within 24 hours of fluid restriction and cessation of desmopressin , her symptoms and hyponatremia resolved .@_@desmopressin and desmopressin are not related .
Without other causes for the hyponatremia , she was diagnosed with the syndrome of inappropriate antidiuretic hormone , presumably caused by desmopressin .@_@hyponatremia and desmopressin are Adverse-Effect relation .
Without other causes for the hyponatremia , she was diagnosed with the syndrome of inappropriate antidiuretic hormone , presumably caused by desmopressin .@_@syndrome of inappropriate antidiuretic hormone and desmopressin are Adverse-Effect relation .
Without other causes for the hyponatremia , she was diagnosed with the syndrome of inappropriate antidiuretic hormone , presumably caused by desmopressin .@_@hyponatremia and hyponatremia are not related .
Without other causes for the hyponatremia , she was diagnosed with the syndrome of inappropriate antidiuretic hormone , presumably caused by desmopressin .@_@hyponatremia and syndrome of inappropriate antidiuretic hormone are not related .
Without other causes for the hyponatremia , she was diagnosed with the syndrome of inappropriate antidiuretic hormone , presumably caused by desmopressin .@_@desmopressin and hyponatremia are not related .
Without other causes for the hyponatremia , she was diagnosed with the syndrome of inappropriate antidiuretic hormone , presumably caused by desmopressin .@_@desmopressin and desmopressin are not related .
Without other causes for the hyponatremia , she was diagnosed with the syndrome of inappropriate antidiuretic hormone , presumably caused by desmopressin .@_@desmopressin and syndrome of inappropriate antidiuretic hormone are not related .
Without other causes for the hyponatremia , she was diagnosed with the syndrome of inappropriate antidiuretic hormone , presumably caused by desmopressin .@_@syndrome of inappropriate antidiuretic hormone and hyponatremia are not related .
Without other causes for the hyponatremia , she was diagnosed with the syndrome of inappropriate antidiuretic hormone , presumably caused by desmopressin .@_@syndrome of inappropriate antidiuretic hormone and syndrome of inappropriate antidiuretic hormone are not related .
Uveitis during treatment of disseminated Mycobacterium avium - intracellulare complex infection with the combination of rifabutin , clarithromycin and ethambutol .@_@Uveitis and clarithromycin are Adverse-Effect relation .
Uveitis during treatment of disseminated Mycobacterium avium - intracellulare complex infection with the combination of rifabutin , clarithromycin and ethambutol .@_@Uveitis and ethambutol are Adverse-Effect relation .
Uveitis during treatment of disseminated Mycobacterium avium - intracellulare complex infection with the combination of rifabutin , clarithromycin and ethambutol .@_@Uveitis and rifabutin are Adverse-Effect relation .
Uveitis during treatment of disseminated Mycobacterium avium - intracellulare complex infection with the combination of rifabutin , clarithromycin and ethambutol .@_@Uveitis and Uveitis are not related .
Uveitis during treatment of disseminated Mycobacterium avium - intracellulare complex infection with the combination of rifabutin , clarithromycin and ethambutol .@_@clarithromycin and Uveitis are not related .
Uveitis during treatment of disseminated Mycobacterium avium - intracellulare complex infection with the combination of rifabutin , clarithromycin and ethambutol .@_@clarithromycin and clarithromycin are not related .
Uveitis during treatment of disseminated Mycobacterium avium - intracellulare complex infection with the combination of rifabutin , clarithromycin and ethambutol .@_@clarithromycin and ethambutol are not related .
Uveitis during treatment of disseminated Mycobacterium avium - intracellulare complex infection with the combination of rifabutin , clarithromycin and ethambutol .@_@clarithromycin and rifabutin are not related .
Uveitis during treatment of disseminated Mycobacterium avium - intracellulare complex infection with the combination of rifabutin , clarithromycin and ethambutol .@_@ethambutol and Uveitis are not related .
Uveitis during treatment of disseminated Mycobacterium avium - intracellulare complex infection with the combination of rifabutin , clarithromycin and ethambutol .@_@ethambutol and clarithromycin are not related .
Uveitis during treatment of disseminated Mycobacterium avium - intracellulare complex infection with the combination of rifabutin , clarithromycin and ethambutol .@_@ethambutol and ethambutol are not related .
Uveitis during treatment of disseminated Mycobacterium avium - intracellulare complex infection with the combination of rifabutin , clarithromycin and ethambutol .@_@ethambutol and rifabutin are not related .
Uveitis during treatment of disseminated Mycobacterium avium - intracellulare complex infection with the combination of rifabutin , clarithromycin and ethambutol .@_@rifabutin and Uveitis are not related .
Uveitis during treatment of disseminated Mycobacterium avium - intracellulare complex infection with the combination of rifabutin , clarithromycin and ethambutol .@_@rifabutin and clarithromycin are not related .
Uveitis during treatment of disseminated Mycobacterium avium - intracellulare complex infection with the combination of rifabutin , clarithromycin and ethambutol .@_@rifabutin and ethambutol are not related .
Uveitis during treatment of disseminated Mycobacterium avium - intracellulare complex infection with the combination of rifabutin , clarithromycin and ethambutol .@_@rifabutin and rifabutin are not related .
Does acyclovir increase serum lithium levels ?@_@increase serum lithium levels and acyclovir are Adverse-Effect relation .
Does acyclovir increase serum lithium levels ?@_@increase serum lithium levels and increase serum lithium levels are not related .
Does acyclovir increase serum lithium levels ?@_@acyclovir and increase serum lithium levels are not related .
Does acyclovir increase serum lithium levels ?@_@acyclovir and acyclovir are not related .
Six days after starting acyclovir she exhibited signs of lithium toxicity .@_@lithium toxicity and acyclovir are Adverse-Effect relation .
Six days after starting acyclovir she exhibited signs of lithium toxicity .@_@lithium toxicity and lithium are Adverse-Effect relation .
Six days after starting acyclovir she exhibited signs of lithium toxicity .@_@lithium toxicity and lithium toxicity are not related .
Six days after starting acyclovir she exhibited signs of lithium toxicity .@_@acyclovir and lithium toxicity are not related .
Six days after starting acyclovir she exhibited signs of lithium toxicity .@_@acyclovir and acyclovir are not related .
Six days after starting acyclovir she exhibited signs of lithium toxicity .@_@acyclovir and lithium are not related .
Six days after starting acyclovir she exhibited signs of lithium toxicity .@_@lithium and lithium toxicity are not related .
Six days after starting acyclovir she exhibited signs of lithium toxicity .@_@lithium and acyclovir are not related .
Six days after starting acyclovir she exhibited signs of lithium toxicity .@_@lithium and lithium are not related .
This case suggests that acyclovir when given intravenously in doses of 10 mg / kg may result in increased serum lithium concentrations .@_@increased serum lithium and lithium are Adverse-Effect relation .
This case suggests that acyclovir when given intravenously in doses of 10 mg / kg may result in increased serum lithium concentrations .@_@increased serum lithium and acyclovir are Adverse-Effect relation .
This case suggests that acyclovir when given intravenously in doses of 10 mg / kg may result in increased serum lithium concentrations .@_@increased serum lithium and increased serum lithium are not related .
This case suggests that acyclovir when given intravenously in doses of 10 mg / kg may result in increased serum lithium concentrations .@_@acyclovir and increased serum lithium are not related .
This case suggests that acyclovir when given intravenously in doses of 10 mg / kg may result in increased serum lithium concentrations .@_@acyclovir and acyclovir are not related .
This case suggests that acyclovir when given intravenously in doses of 10 mg / kg may result in increased serum lithium concentrations .@_@acyclovir and lithium are not related .
This case suggests that acyclovir when given intravenously in doses of 10 mg / kg may result in increased serum lithium concentrations .@_@lithium and increased serum lithium are not related .
This case suggests that acyclovir when given intravenously in doses of 10 mg / kg may result in increased serum lithium concentrations .@_@lithium and acyclovir are not related .
This case suggests that acyclovir when given intravenously in doses of 10 mg / kg may result in increased serum lithium concentrations .@_@lithium and lithium are not related .
Until additional data are available , if intravenous acyclovir is administered concurrently with lithium , we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day .@_@lithium toxicity and lithium are Adverse-Effect relation .
Until additional data are available , if intravenous acyclovir is administered concurrently with lithium , we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day .@_@lithium toxicity and acyclovir are Adverse-Effect relation .
Until additional data are available , if intravenous acyclovir is administered concurrently with lithium , we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day .@_@lithium toxicity and lithium toxicity are not related .
Until additional data are available , if intravenous acyclovir is administered concurrently with lithium , we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day .@_@acyclovir and lithium toxicity are not related .
Until additional data are available , if intravenous acyclovir is administered concurrently with lithium , we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day .@_@acyclovir and acyclovir are not related .
Until additional data are available , if intravenous acyclovir is administered concurrently with lithium , we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day .@_@acyclovir and lithium are not related .
Until additional data are available , if intravenous acyclovir is administered concurrently with lithium , we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day .@_@lithium and lithium toxicity are not related .
Until additional data are available , if intravenous acyclovir is administered concurrently with lithium , we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day .@_@lithium and acyclovir are not related .
Until additional data are available , if intravenous acyclovir is administered concurrently with lithium , we recommend closely monitoring patients for signs of lithium toxicity and measuring serum lithium levels every second or third day .@_@lithium and lithium are not related .
When measured , the serum lithium level had increased 4-fold during acyclovir therapy .@_@serum lithium level had increased and lithium are Adverse-Effect relation .
When measured , the serum lithium level had increased 4-fold during acyclovir therapy .@_@serum lithium level had increased and acyclovir are Adverse-Effect relation .
When measured , the serum lithium level had increased 4-fold during acyclovir therapy .@_@serum lithium level had increased and serum lithium level had increased are not related .
When measured , the serum lithium level had increased 4-fold during acyclovir therapy .@_@acyclovir and serum lithium level had increased are not related .
When measured , the serum lithium level had increased 4-fold during acyclovir therapy .@_@acyclovir and acyclovir are not related .
When measured , the serum lithium level had increased 4-fold during acyclovir therapy .@_@acyclovir and lithium are not related .
When measured , the serum lithium level had increased 4-fold during acyclovir therapy .@_@lithium and serum lithium level had increased are not related .
When measured , the serum lithium level had increased 4-fold during acyclovir therapy .@_@lithium and acyclovir are not related .
When measured , the serum lithium level had increased 4-fold during acyclovir therapy .@_@lithium and lithium are not related .
Dapsone syndrome in cutaneous lupus erythematosus .@_@Dapsone syndrome and Dapsone are Adverse-Effect relation .
Dapsone syndrome in cutaneous lupus erythematosus .@_@Dapsone syndrome and Dapsone syndrome are not related .
Dapsone syndrome in cutaneous lupus erythematosus .@_@Dapsone and Dapsone syndrome are not related .
Dapsone syndrome in cutaneous lupus erythematosus .@_@Dapsone and Dapsone are not related .
Physicians should be aware of the potentially lethal side effects of dapsone .@_@lethal and dapsone are Adverse-Effect relation .
Physicians should be aware of the potentially lethal side effects of dapsone .@_@lethal and lethal are not related .
Physicians should be aware of the potentially lethal side effects of dapsone .@_@dapsone and lethal are not related .
Physicians should be aware of the potentially lethal side effects of dapsone .@_@dapsone and dapsone are not related .
We describe 2 patients with cutaneous lupus erythematosus who developed severe dapsone reaction after low dose therapy , with a fatal outcome in one .@_@dapsone reaction and dapsone are Adverse-Effect relation .
We describe 2 patients with cutaneous lupus erythematosus who developed severe dapsone reaction after low dose therapy , with a fatal outcome in one .@_@fatal and dapsone are Adverse-Effect relation .
We describe 2 patients with cutaneous lupus erythematosus who developed severe dapsone reaction after low dose therapy , with a fatal outcome in one .@_@dapsone reaction and dapsone reaction are not related .
We describe 2 patients with cutaneous lupus erythematosus who developed severe dapsone reaction after low dose therapy , with a fatal outcome in one .@_@dapsone reaction and fatal are not related .
We describe 2 patients with cutaneous lupus erythematosus who developed severe dapsone reaction after low dose therapy , with a fatal outcome in one .@_@dapsone and dapsone reaction are not related .
We describe 2 patients with cutaneous lupus erythematosus who developed severe dapsone reaction after low dose therapy , with a fatal outcome in one .@_@dapsone and dapsone are not related .
We describe 2 patients with cutaneous lupus erythematosus who developed severe dapsone reaction after low dose therapy , with a fatal outcome in one .@_@dapsone and fatal are not related .
We describe 2 patients with cutaneous lupus erythematosus who developed severe dapsone reaction after low dose therapy , with a fatal outcome in one .@_@fatal and dapsone reaction are not related .
We describe 2 patients with cutaneous lupus erythematosus who developed severe dapsone reaction after low dose therapy , with a fatal outcome in one .@_@fatal and fatal are not related .
A case is presented which illustrates a probably fatal interaction between minoxidil and a coagulation disorder .@_@fatal interaction and minoxidil are Adverse-Effect relation .
A case is presented which illustrates a probably fatal interaction between minoxidil and a coagulation disorder .@_@fatal interaction and fatal interaction are not related .
A case is presented which illustrates a probably fatal interaction between minoxidil and a coagulation disorder .@_@minoxidil and fatal interaction are not related .
A case is presented which illustrates a probably fatal interaction between minoxidil and a coagulation disorder .@_@minoxidil and minoxidil are not related .
Nephrogenic diabetes insipidus ( NDI ) is a well - documented complication of lithium use .@_@Nephrogenic diabetes insipidus and lithium are Adverse-Effect relation .
Nephrogenic diabetes insipidus ( NDI ) is a well - documented complication of lithium use .@_@NDI and lithium are Adverse-Effect relation .
Nephrogenic diabetes insipidus ( NDI ) is a well - documented complication of lithium use .@_@NDI and NDI are not related .
Nephrogenic diabetes insipidus ( NDI ) is a well - documented complication of lithium use .@_@NDI and Nephrogenic diabetes insipidus are not related .
Nephrogenic diabetes insipidus ( NDI ) is a well - documented complication of lithium use .@_@lithium and NDI are not related .
Nephrogenic diabetes insipidus ( NDI ) is a well - documented complication of lithium use .@_@lithium and lithium are not related .
Nephrogenic diabetes insipidus ( NDI ) is a well - documented complication of lithium use .@_@lithium and Nephrogenic diabetes insipidus are not related .
Nephrogenic diabetes insipidus ( NDI ) is a well - documented complication of lithium use .@_@Nephrogenic diabetes insipidus and NDI are not related .
Nephrogenic diabetes insipidus ( NDI ) is a well - documented complication of lithium use .@_@Nephrogenic diabetes insipidus and Nephrogenic diabetes insipidus are not related .
Potential mechanisms regarding the pathophysiology of lithium - associated CDI are discussed .@_@CDI and lithium are Adverse-Effect relation .
Potential mechanisms regarding the pathophysiology of lithium - associated CDI are discussed .@_@CDI and CDI are not related .
Potential mechanisms regarding the pathophysiology of lithium - associated CDI are discussed .@_@lithium and CDI are not related .
Potential mechanisms regarding the pathophysiology of lithium - associated CDI are discussed .@_@lithium and lithium are not related .
The association of central diabetes insipidus ( CDI ) with lithium use is rare .@_@CDI and lithium are Adverse-Effect relation .
The association of central diabetes insipidus ( CDI ) with lithium use is rare .@_@central diabetes insipidus and lithium are Adverse-Effect relation .
The association of central diabetes insipidus ( CDI ) with lithium use is rare .@_@CDI and CDI are not related .
The association of central diabetes insipidus ( CDI ) with lithium use is rare .@_@CDI and central diabetes insipidus are not related .
The association of central diabetes insipidus ( CDI ) with lithium use is rare .@_@lithium and CDI are not related .
The association of central diabetes insipidus ( CDI ) with lithium use is rare .@_@lithium and lithium are not related .
The association of central diabetes insipidus ( CDI ) with lithium use is rare .@_@lithium and central diabetes insipidus are not related .
The association of central diabetes insipidus ( CDI ) with lithium use is rare .@_@central diabetes insipidus and CDI are not related .
The association of central diabetes insipidus ( CDI ) with lithium use is rare .@_@central diabetes insipidus and central diabetes insipidus are not related .
This case emphasizes the importance of the evaluation of lithium - associated polyuria with a direct measurement of plasma vasopressin , interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management .@_@polyuria and lithium are Adverse-Effect relation .
This case emphasizes the importance of the evaluation of lithium - associated polyuria with a direct measurement of plasma vasopressin , interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management .@_@polyuria and polyuria are not related .
This case emphasizes the importance of the evaluation of lithium - associated polyuria with a direct measurement of plasma vasopressin , interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management .@_@lithium and polyuria are not related .
This case emphasizes the importance of the evaluation of lithium - associated polyuria with a direct measurement of plasma vasopressin , interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management .@_@lithium and lithium are not related .
To the best of our knowledge , this is the first case of lithium - associated CDI and NDI presenting concurrently .@_@NDI and lithium are Adverse-Effect relation .
To the best of our knowledge , this is the first case of lithium - associated CDI and NDI presenting concurrently .@_@CDI and lithium are Adverse-Effect relation .
To the best of our knowledge , this is the first case of lithium - associated CDI and NDI presenting concurrently .@_@CDI and CDI are not related .
To the best of our knowledge , this is the first case of lithium - associated CDI and NDI presenting concurrently .@_@CDI and NDI are not related .
To the best of our knowledge , this is the first case of lithium - associated CDI and NDI presenting concurrently .@_@lithium and CDI are not related .
To the best of our knowledge , this is the first case of lithium - associated CDI and NDI presenting concurrently .@_@lithium and lithium are not related .
To the best of our knowledge , this is the first case of lithium - associated CDI and NDI presenting concurrently .@_@lithium and NDI are not related .
To the best of our knowledge , this is the first case of lithium - associated CDI and NDI presenting concurrently .@_@NDI and CDI are not related .
To the best of our knowledge , this is the first case of lithium - associated CDI and NDI presenting concurrently .@_@NDI and NDI are not related .
Transient central diabetes insipidus in the setting of underlying chronic nephrogenic diabetes insipidus associated with lithium use .@_@Transient central diabetes insipidus and lithium are Adverse-Effect relation .
Transient central diabetes insipidus in the setting of underlying chronic nephrogenic diabetes insipidus associated with lithium use .@_@Transient central diabetes insipidus and Transient central diabetes insipidus are not related .
Transient central diabetes insipidus in the setting of underlying chronic nephrogenic diabetes insipidus associated with lithium use .@_@lithium and Transient central diabetes insipidus are not related .
Transient central diabetes insipidus in the setting of underlying chronic nephrogenic diabetes insipidus associated with lithium use .@_@lithium and lithium are not related .
We report a patient receiving chronic lithium therapy who presented with a transient CDI occurring in the setting of underlying chronic NDI .@_@CDI and lithium are Adverse-Effect relation .
We report a patient receiving chronic lithium therapy who presented with a transient CDI occurring in the setting of underlying chronic NDI .@_@CDI and CDI are not related .
We report a patient receiving chronic lithium therapy who presented with a transient CDI occurring in the setting of underlying chronic NDI .@_@lithium and CDI are not related .
We report a patient receiving chronic lithium therapy who presented with a transient CDI occurring in the setting of underlying chronic NDI .@_@lithium and lithium are not related .
CASE : We report a case of a woman with severe human insulin - induced lipoatrophy who has been treated exclusively with recombinant DNA human insulin since the onset of IDDM .@_@lipoatrophy and recombinant DNA human insulin are Adverse-Effect relation .
CASE : We report a case of a woman with severe human insulin - induced lipoatrophy who has been treated exclusively with recombinant DNA human insulin since the onset of IDDM .@_@lipoatrophy and human insulin are Adverse-Effect relation .
CASE : We report a case of a woman with severe human insulin - induced lipoatrophy who has been treated exclusively with recombinant DNA human insulin since the onset of IDDM .@_@lipoatrophy and lipoatrophy are not related .
CASE : We report a case of a woman with severe human insulin - induced lipoatrophy who has been treated exclusively with recombinant DNA human insulin since the onset of IDDM .@_@human insulin and lipoatrophy are not related .
CASE : We report a case of a woman with severe human insulin - induced lipoatrophy who has been treated exclusively with recombinant DNA human insulin since the onset of IDDM .@_@human insulin and human insulin are not related .
CASE : We report a case of a woman with severe human insulin - induced lipoatrophy who has been treated exclusively with recombinant DNA human insulin since the onset of IDDM .@_@human insulin and recombinant DNA human insulin are not related .
CASE : We report a case of a woman with severe human insulin - induced lipoatrophy who has been treated exclusively with recombinant DNA human insulin since the onset of IDDM .@_@recombinant DNA human insulin and lipoatrophy are not related .
CASE : We report a case of a woman with severe human insulin - induced lipoatrophy who has been treated exclusively with recombinant DNA human insulin since the onset of IDDM .@_@recombinant DNA human insulin and human insulin are not related .
CASE : We report a case of a woman with severe human insulin - induced lipoatrophy who has been treated exclusively with recombinant DNA human insulin since the onset of IDDM .@_@recombinant DNA human insulin and recombinant DNA human insulin are not related .
CONCLUSIONS : Jet - injection devices might constitute a helpful method to treat those patients affected by severe human insulin - induced lipoatrophy .@_@lipoatrophy and human insulin are Adverse-Effect relation .
CONCLUSIONS : Jet - injection devices might constitute a helpful method to treat those patients affected by severe human insulin - induced lipoatrophy .@_@lipoatrophy and lipoatrophy are not related .
CONCLUSIONS : Jet - injection devices might constitute a helpful method to treat those patients affected by severe human insulin - induced lipoatrophy .@_@human insulin and lipoatrophy are not related .
CONCLUSIONS : Jet - injection devices might constitute a helpful method to treat those patients affected by severe human insulin - induced lipoatrophy .@_@human insulin and human insulin are not related .
Human insulin - induced lipoatrophy .@_@lipoatrophy and Human insulin are Adverse-Effect relation .
Human insulin - induced lipoatrophy .@_@lipoatrophy and lipoatrophy are not related .
Human insulin - induced lipoatrophy .@_@Human insulin and lipoatrophy are not related .
Human insulin - induced lipoatrophy .@_@Human insulin and Human insulin are not related .
OBJECTIVE : To evaluate the efficacy of the administration of insulin by a jet - injector device in stopping and reversing severe human insulin - induced lipoatrophy .@_@lipoatrophy and human insulin are Adverse-Effect relation .
OBJECTIVE : To evaluate the efficacy of the administration of insulin by a jet - injector device in stopping and reversing severe human insulin - induced lipoatrophy .@_@lipoatrophy and lipoatrophy are not related .
OBJECTIVE : To evaluate the efficacy of the administration of insulin by a jet - injector device in stopping and reversing severe human insulin - induced lipoatrophy .@_@human insulin and lipoatrophy are not related .
OBJECTIVE : To evaluate the efficacy of the administration of insulin by a jet - injector device in stopping and reversing severe human insulin - induced lipoatrophy .@_@human insulin and human insulin are not related .
Improved awareness of and further investigation into the neurotoxic effects of ofloxacin may enhance its safe use .@_@neurotoxic effects and ofloxacin are Adverse-Effect relation .
Improved awareness of and further investigation into the neurotoxic effects of ofloxacin may enhance its safe use .@_@neurotoxic effects and neurotoxic effects are not related .
Improved awareness of and further investigation into the neurotoxic effects of ofloxacin may enhance its safe use .@_@ofloxacin and neurotoxic effects are not related .
Improved awareness of and further investigation into the neurotoxic effects of ofloxacin may enhance its safe use .@_@ofloxacin and ofloxacin are not related .
Seizures associated with ofloxacin therapy .@_@Seizures and ofloxacin are Adverse-Effect relation .
Seizures associated with ofloxacin therapy .@_@Seizures and Seizures are not related .
Seizures associated with ofloxacin therapy .@_@ofloxacin and Seizures are not related .
Seizures associated with ofloxacin therapy .@_@ofloxacin and ofloxacin are not related .
The renal insufficiency of three patients and the timing of the seizures implicate accumulation of ofloxacin as a contributing factor .@_@seizures and ofloxacin are Adverse-Effect relation .
The renal insufficiency of three patients and the timing of the seizures implicate accumulation of ofloxacin as a contributing factor .@_@renal insufficiency and ofloxacin are Adverse-Effect relation .
The renal insufficiency of three patients and the timing of the seizures implicate accumulation of ofloxacin as a contributing factor .@_@renal insufficiency and renal insufficiency are not related .
The renal insufficiency of three patients and the timing of the seizures implicate accumulation of ofloxacin as a contributing factor .@_@renal insufficiency and seizures are not related .
The renal insufficiency of three patients and the timing of the seizures implicate accumulation of ofloxacin as a contributing factor .@_@ofloxacin and renal insufficiency are not related .
The renal insufficiency of three patients and the timing of the seizures implicate accumulation of ofloxacin as a contributing factor .@_@ofloxacin and ofloxacin are not related .
The renal insufficiency of three patients and the timing of the seizures implicate accumulation of ofloxacin as a contributing factor .@_@ofloxacin and seizures are not related .
The renal insufficiency of three patients and the timing of the seizures implicate accumulation of ofloxacin as a contributing factor .@_@seizures and renal insufficiency are not related .
The renal insufficiency of three patients and the timing of the seizures implicate accumulation of ofloxacin as a contributing factor .@_@seizures and seizures are not related .
We describe four patients who had seizures while receiving ofloxacin ; no other causes were evident .@_@seizures and ofloxacin are Adverse-Effect relation .
We describe four patients who had seizures while receiving ofloxacin ; no other causes were evident .@_@seizures and seizures are not related .
We describe four patients who had seizures while receiving ofloxacin ; no other causes were evident .@_@ofloxacin and seizures are not related .
We describe four patients who had seizures while receiving ofloxacin ; no other causes were evident .@_@ofloxacin and ofloxacin are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@erythroderma and phenytoin are Adverse-Effect relation .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@phenytoin hypersensitivity syndrome and phenytoin are Adverse-Effect relation .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@abnormal liver function tests and phenytoin are Adverse-Effect relation .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@fever and phenytoin are Adverse-Effect relation .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@tibial and facial oedema and phenytoin are Adverse-Effect relation .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@pinhead - sized facial pustules and phenytoin are Adverse-Effect relation .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@abnormal liver function tests and abnormal liver function tests are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@abnormal liver function tests and erythroderma are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@abnormal liver function tests and fever are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@abnormal liver function tests and phenytoin hypersensitivity syndrome are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@abnormal liver function tests and pinhead - sized facial pustules are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@abnormal liver function tests and tibial and facial oedema are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@phenytoin and abnormal liver function tests are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@phenytoin and phenytoin are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@phenytoin and erythroderma are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@phenytoin and fever are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@phenytoin and phenytoin hypersensitivity syndrome are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@phenytoin and pinhead - sized facial pustules are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@phenytoin and tibial and facial oedema are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@erythroderma and abnormal liver function tests are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@erythroderma and erythroderma are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@erythroderma and fever are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@erythroderma and phenytoin hypersensitivity syndrome are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@erythroderma and pinhead - sized facial pustules are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@erythroderma and tibial and facial oedema are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@fever and abnormal liver function tests are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@fever and erythroderma are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@fever and fever are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@fever and phenytoin hypersensitivity syndrome are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@fever and pinhead - sized facial pustules are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@fever and tibial and facial oedema are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@phenytoin hypersensitivity syndrome and abnormal liver function tests are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@phenytoin hypersensitivity syndrome and erythroderma are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@phenytoin hypersensitivity syndrome and fever are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@phenytoin hypersensitivity syndrome and phenytoin hypersensitivity syndrome are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@phenytoin hypersensitivity syndrome and pinhead - sized facial pustules are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@phenytoin hypersensitivity syndrome and tibial and facial oedema are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@pinhead - sized facial pustules and abnormal liver function tests are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@pinhead - sized facial pustules and erythroderma are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@pinhead - sized facial pustules and fever are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@pinhead - sized facial pustules and phenytoin hypersensitivity syndrome are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@pinhead - sized facial pustules and pinhead - sized facial pustules are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@pinhead - sized facial pustules and tibial and facial oedema are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@tibial and facial oedema and abnormal liver function tests are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@tibial and facial oedema and erythroderma are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@tibial and facial oedema and fever are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@tibial and facial oedema and phenytoin hypersensitivity syndrome are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@tibial and facial oedema and pinhead - sized facial pustules are not related .
A patient is described with the characteristic features of phenytoin hypersensitivity syndrome ( PHS ) including fever , erythroderma , tibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests .@_@tibial and facial oedema and tibial and facial oedema are not related .
Systemic corticosteroids in the phenytoin hypersensitivity syndrome .@_@phenytoin hypersensitivity syndrome and phenytoin are Adverse-Effect relation .
Systemic corticosteroids in the phenytoin hypersensitivity syndrome .@_@phenytoin hypersensitivity syndrome and phenytoin hypersensitivity syndrome are not related .
Systemic corticosteroids in the phenytoin hypersensitivity syndrome .@_@phenytoin and phenytoin hypersensitivity syndrome are not related .
Systemic corticosteroids in the phenytoin hypersensitivity syndrome .@_@phenytoin and phenytoin are not related .
A patient is described who developed a poorly differentiated sarcoma after cyclophosphamide was used to treat his rheumatoid arthritis .@_@sarcoma and cyclophosphamide are Adverse-Effect relation .
A patient is described who developed a poorly differentiated sarcoma after cyclophosphamide was used to treat his rheumatoid arthritis .@_@sarcoma and sarcoma are not related .
A patient is described who developed a poorly differentiated sarcoma after cyclophosphamide was used to treat his rheumatoid arthritis .@_@cyclophosphamide and sarcoma are not related .
A patient is described who developed a poorly differentiated sarcoma after cyclophosphamide was used to treat his rheumatoid arthritis .@_@cyclophosphamide and cyclophosphamide are not related .
Sarcoma complicating therapy with cyclophosphamide .@_@Sarcoma and cyclophosphamide are Adverse-Effect relation .
Sarcoma complicating therapy with cyclophosphamide .@_@Sarcoma and Sarcoma are not related .
Sarcoma complicating therapy with cyclophosphamide .@_@cyclophosphamide and Sarcoma are not related .
Sarcoma complicating therapy with cyclophosphamide .@_@cyclophosphamide and cyclophosphamide are not related .
A chronic reaction associated with long - term treatment with nitrofurantoin has also been reported and causes irreversible pulmonary fibrosis .@_@pulmonary fibrosis and nitrofurantoin are Adverse-Effect relation .
A chronic reaction associated with long - term treatment with nitrofurantoin has also been reported and causes irreversible pulmonary fibrosis .@_@pulmonary fibrosis and pulmonary fibrosis are not related .
A chronic reaction associated with long - term treatment with nitrofurantoin has also been reported and causes irreversible pulmonary fibrosis .@_@nitrofurantoin and pulmonary fibrosis are not related .
A chronic reaction associated with long - term treatment with nitrofurantoin has also been reported and causes irreversible pulmonary fibrosis .@_@nitrofurantoin and nitrofurantoin are not related .
Acute pulmonary reactions to nitrofurantoin are an uncommon side effect of therapy and can cause minor or life - threatening pulmonary dysfunction .@_@Acute pulmonary reactions and nitrofurantoin are Adverse-Effect relation .
Acute pulmonary reactions to nitrofurantoin are an uncommon side effect of therapy and can cause minor or life - threatening pulmonary dysfunction .@_@pulmonary dysfunction and nitrofurantoin are Adverse-Effect relation .
Acute pulmonary reactions to nitrofurantoin are an uncommon side effect of therapy and can cause minor or life - threatening pulmonary dysfunction .@_@Acute pulmonary reactions and Acute pulmonary reactions are not related .
Acute pulmonary reactions to nitrofurantoin are an uncommon side effect of therapy and can cause minor or life - threatening pulmonary dysfunction .@_@Acute pulmonary reactions and pulmonary dysfunction are not related .
Acute pulmonary reactions to nitrofurantoin are an uncommon side effect of therapy and can cause minor or life - threatening pulmonary dysfunction .@_@nitrofurantoin and Acute pulmonary reactions are not related .
Acute pulmonary reactions to nitrofurantoin are an uncommon side effect of therapy and can cause minor or life - threatening pulmonary dysfunction .@_@nitrofurantoin and nitrofurantoin are not related .
Acute pulmonary reactions to nitrofurantoin are an uncommon side effect of therapy and can cause minor or life - threatening pulmonary dysfunction .@_@nitrofurantoin and pulmonary dysfunction are not related .
Acute pulmonary reactions to nitrofurantoin are an uncommon side effect of therapy and can cause minor or life - threatening pulmonary dysfunction .@_@pulmonary dysfunction and Acute pulmonary reactions are not related .
Acute pulmonary reactions to nitrofurantoin are an uncommon side effect of therapy and can cause minor or life - threatening pulmonary dysfunction .@_@pulmonary dysfunction and pulmonary dysfunction are not related .
Despite the known pulmonary side effects of nitrofurantoin , there is no report of this toxicity occurring in pregnant patients .@_@pulmonary side effects and nitrofurantoin are Adverse-Effect relation .
Despite the known pulmonary side effects of nitrofurantoin , there is no report of this toxicity occurring in pregnant patients .@_@pulmonary side effects and pulmonary side effects are not related .
Despite the known pulmonary side effects of nitrofurantoin , there is no report of this toxicity occurring in pregnant patients .@_@nitrofurantoin and pulmonary side effects are not related .
Despite the known pulmonary side effects of nitrofurantoin , there is no report of this toxicity occurring in pregnant patients .@_@nitrofurantoin and nitrofurantoin are not related .
Nitrofurantoin - induced pulmonary toxicity during pregnancy : a report of a case and review of the literature .@_@pulmonary toxicity and Nitrofurantoin are Adverse-Effect relation .
Nitrofurantoin - induced pulmonary toxicity during pregnancy : a report of a case and review of the literature .@_@pulmonary toxicity and pulmonary toxicity are not related .
Nitrofurantoin - induced pulmonary toxicity during pregnancy : a report of a case and review of the literature .@_@Nitrofurantoin and pulmonary toxicity are not related .
Nitrofurantoin - induced pulmonary toxicity during pregnancy : a report of a case and review of the literature .@_@Nitrofurantoin and Nitrofurantoin are not related .
We present a case of respiratory failure occurring in a woman at 16 weeks ' gestation who was being treated with nitrofurantoin for a urinary tract infection .@_@respiratory failure and nitrofurantoin are Adverse-Effect relation .
We present a case of respiratory failure occurring in a woman at 16 weeks ' gestation who was being treated with nitrofurantoin for a urinary tract infection .@_@respiratory failure and respiratory failure are not related .
We present a case of respiratory failure occurring in a woman at 16 weeks ' gestation who was being treated with nitrofurantoin for a urinary tract infection .@_@nitrofurantoin and respiratory failure are not related .
We present a case of respiratory failure occurring in a woman at 16 weeks ' gestation who was being treated with nitrofurantoin for a urinary tract infection .@_@nitrofurantoin and nitrofurantoin are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@severe hypoalbuminemia without proteinuria and dapsone are Adverse-Effect relation .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@peripheral neuropathy and dapsone are Adverse-Effect relation .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@toxic hepatitis and dapsone are Adverse-Effect relation .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@nephrotic syndrome and dapsone are Adverse-Effect relation .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@cutaneous eruptions and dapsone are Adverse-Effect relation .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@leukopenia and dapsone are Adverse-Effect relation .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@psychosis and dapsone are Adverse-Effect relation .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@renal papillary necrosis and dapsone are Adverse-Effect relation .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@minor neurological and gastrointestinal complaints and dapsone are Adverse-Effect relation .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@an infectious mononucleosis - like syndrome and dapsone are Adverse-Effect relation .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@cholestatic jaundice and dapsone are Adverse-Effect relation .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@agranulocytosis and dapsone are Adverse-Effect relation .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@agranulocytosis and agranulocytosis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@agranulocytosis and an infectious mononucleosis - like syndrome are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@agranulocytosis and cholestatic jaundice are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@agranulocytosis and cutaneous eruptions are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@agranulocytosis and leukopenia are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@agranulocytosis and minor neurological and gastrointestinal complaints are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@agranulocytosis and nephrotic syndrome are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@agranulocytosis and peripheral neuropathy are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@agranulocytosis and psychosis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@agranulocytosis and renal papillary necrosis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@agranulocytosis and severe hypoalbuminemia without proteinuria are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@agranulocytosis and toxic hepatitis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@dapsone and agranulocytosis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@dapsone and dapsone are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@dapsone and an infectious mononucleosis - like syndrome are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@dapsone and cholestatic jaundice are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@dapsone and cutaneous eruptions are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@dapsone and leukopenia are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@dapsone and minor neurological and gastrointestinal complaints are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@dapsone and nephrotic syndrome are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@dapsone and peripheral neuropathy are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@dapsone and psychosis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@dapsone and renal papillary necrosis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@dapsone and severe hypoalbuminemia without proteinuria are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@dapsone and toxic hepatitis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@an infectious mononucleosis - like syndrome and agranulocytosis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@an infectious mononucleosis - like syndrome and an infectious mononucleosis - like syndrome are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@an infectious mononucleosis - like syndrome and cholestatic jaundice are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@an infectious mononucleosis - like syndrome and cutaneous eruptions are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@an infectious mononucleosis - like syndrome and leukopenia are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@an infectious mononucleosis - like syndrome and minor neurological and gastrointestinal complaints are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@an infectious mononucleosis - like syndrome and nephrotic syndrome are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@an infectious mononucleosis - like syndrome and peripheral neuropathy are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@an infectious mononucleosis - like syndrome and psychosis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@an infectious mononucleosis - like syndrome and renal papillary necrosis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@an infectious mononucleosis - like syndrome and severe hypoalbuminemia without proteinuria are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@an infectious mononucleosis - like syndrome and toxic hepatitis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@cholestatic jaundice and agranulocytosis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@cholestatic jaundice and an infectious mononucleosis - like syndrome are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@cholestatic jaundice and cholestatic jaundice are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@cholestatic jaundice and cutaneous eruptions are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@cholestatic jaundice and leukopenia are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@cholestatic jaundice and minor neurological and gastrointestinal complaints are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@cholestatic jaundice and nephrotic syndrome are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@cholestatic jaundice and peripheral neuropathy are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@cholestatic jaundice and psychosis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@cholestatic jaundice and renal papillary necrosis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@cholestatic jaundice and severe hypoalbuminemia without proteinuria are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@cholestatic jaundice and toxic hepatitis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@cutaneous eruptions and agranulocytosis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@cutaneous eruptions and an infectious mononucleosis - like syndrome are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@cutaneous eruptions and cholestatic jaundice are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@cutaneous eruptions and cutaneous eruptions are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@cutaneous eruptions and leukopenia are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@cutaneous eruptions and minor neurological and gastrointestinal complaints are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@cutaneous eruptions and nephrotic syndrome are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@cutaneous eruptions and peripheral neuropathy are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@cutaneous eruptions and psychosis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@cutaneous eruptions and renal papillary necrosis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@cutaneous eruptions and severe hypoalbuminemia without proteinuria are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@cutaneous eruptions and toxic hepatitis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@leukopenia and agranulocytosis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@leukopenia and an infectious mononucleosis - like syndrome are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@leukopenia and cholestatic jaundice are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@leukopenia and cutaneous eruptions are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@leukopenia and leukopenia are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@leukopenia and minor neurological and gastrointestinal complaints are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@leukopenia and nephrotic syndrome are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@leukopenia and peripheral neuropathy are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@leukopenia and psychosis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@leukopenia and renal papillary necrosis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@leukopenia and severe hypoalbuminemia without proteinuria are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@leukopenia and toxic hepatitis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@minor neurological and gastrointestinal complaints and agranulocytosis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@minor neurological and gastrointestinal complaints and an infectious mononucleosis - like syndrome are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@minor neurological and gastrointestinal complaints and cholestatic jaundice are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@minor neurological and gastrointestinal complaints and cutaneous eruptions are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@minor neurological and gastrointestinal complaints and leukopenia are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@minor neurological and gastrointestinal complaints and minor neurological and gastrointestinal complaints are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@minor neurological and gastrointestinal complaints and nephrotic syndrome are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@minor neurological and gastrointestinal complaints and peripheral neuropathy are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@minor neurological and gastrointestinal complaints and psychosis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@minor neurological and gastrointestinal complaints and renal papillary necrosis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@minor neurological and gastrointestinal complaints and severe hypoalbuminemia without proteinuria are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@minor neurological and gastrointestinal complaints and toxic hepatitis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@nephrotic syndrome and agranulocytosis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@nephrotic syndrome and an infectious mononucleosis - like syndrome are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@nephrotic syndrome and cholestatic jaundice are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@nephrotic syndrome and cutaneous eruptions are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@nephrotic syndrome and leukopenia are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@nephrotic syndrome and minor neurological and gastrointestinal complaints are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@nephrotic syndrome and nephrotic syndrome are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@nephrotic syndrome and peripheral neuropathy are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@nephrotic syndrome and psychosis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@nephrotic syndrome and renal papillary necrosis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@nephrotic syndrome and severe hypoalbuminemia without proteinuria are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@nephrotic syndrome and toxic hepatitis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@peripheral neuropathy and agranulocytosis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@peripheral neuropathy and an infectious mononucleosis - like syndrome are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@peripheral neuropathy and cholestatic jaundice are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@peripheral neuropathy and cutaneous eruptions are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@peripheral neuropathy and leukopenia are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@peripheral neuropathy and minor neurological and gastrointestinal complaints are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@peripheral neuropathy and nephrotic syndrome are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@peripheral neuropathy and peripheral neuropathy are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@peripheral neuropathy and psychosis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@peripheral neuropathy and renal papillary necrosis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@peripheral neuropathy and severe hypoalbuminemia without proteinuria are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@peripheral neuropathy and toxic hepatitis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@psychosis and agranulocytosis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@psychosis and an infectious mononucleosis - like syndrome are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@psychosis and cholestatic jaundice are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@psychosis and cutaneous eruptions are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@psychosis and leukopenia are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@psychosis and minor neurological and gastrointestinal complaints are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@psychosis and nephrotic syndrome are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@psychosis and peripheral neuropathy are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@psychosis and psychosis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@psychosis and renal papillary necrosis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@psychosis and severe hypoalbuminemia without proteinuria are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@psychosis and toxic hepatitis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@renal papillary necrosis and agranulocytosis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@renal papillary necrosis and an infectious mononucleosis - like syndrome are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@renal papillary necrosis and cholestatic jaundice are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@renal papillary necrosis and cutaneous eruptions are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@renal papillary necrosis and leukopenia are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@renal papillary necrosis and minor neurological and gastrointestinal complaints are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@renal papillary necrosis and nephrotic syndrome are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@renal papillary necrosis and peripheral neuropathy are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@renal papillary necrosis and psychosis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@renal papillary necrosis and renal papillary necrosis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@renal papillary necrosis and severe hypoalbuminemia without proteinuria are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@renal papillary necrosis and toxic hepatitis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@severe hypoalbuminemia without proteinuria and agranulocytosis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@severe hypoalbuminemia without proteinuria and an infectious mononucleosis - like syndrome are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@severe hypoalbuminemia without proteinuria and cholestatic jaundice are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@severe hypoalbuminemia without proteinuria and cutaneous eruptions are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@severe hypoalbuminemia without proteinuria and leukopenia are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@severe hypoalbuminemia without proteinuria and minor neurological and gastrointestinal complaints are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@severe hypoalbuminemia without proteinuria and nephrotic syndrome are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@severe hypoalbuminemia without proteinuria and peripheral neuropathy are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@severe hypoalbuminemia without proteinuria and psychosis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@severe hypoalbuminemia without proteinuria and renal papillary necrosis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@severe hypoalbuminemia without proteinuria and severe hypoalbuminemia without proteinuria are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@severe hypoalbuminemia without proteinuria and toxic hepatitis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@toxic hepatitis and agranulocytosis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@toxic hepatitis and an infectious mononucleosis - like syndrome are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@toxic hepatitis and cholestatic jaundice are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@toxic hepatitis and cutaneous eruptions are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@toxic hepatitis and leukopenia are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@toxic hepatitis and minor neurological and gastrointestinal complaints are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@toxic hepatitis and nephrotic syndrome are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@toxic hepatitis and peripheral neuropathy are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@toxic hepatitis and psychosis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@toxic hepatitis and renal papillary necrosis are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@toxic hepatitis and severe hypoalbuminemia without proteinuria are not related .
Less common adverse events to dapsone include the idiosyncratic reactions of leukopenia and agranulocytosis , cutaneous eruptions , peripheral neuropathy , psychosis , toxic hepatitis , cholestatic jaundice , nephrotic syndrome , renal papillary necrosis , severe hypoalbuminemia without proteinuria , an infectious mononucleosis - like syndrome , and minor neurological and gastrointestinal complaints .@_@toxic hepatitis and toxic hepatitis are not related .
Methemoglobinemia is another common finding among patients receiving dapsone therapy , but rarely does it result in prominent symptoms other than transient pallor .@_@Methemoglobinemia and dapsone are Adverse-Effect relation .
Methemoglobinemia is another common finding among patients receiving dapsone therapy , but rarely does it result in prominent symptoms other than transient pallor .@_@Methemoglobinemia and Methemoglobinemia are not related .
Methemoglobinemia is another common finding among patients receiving dapsone therapy , but rarely does it result in prominent symptoms other than transient pallor .@_@dapsone and Methemoglobinemia are not related .
Methemoglobinemia is another common finding among patients receiving dapsone therapy , but rarely does it result in prominent symptoms other than transient pallor .@_@dapsone and dapsone are not related .
Acetazolamide - accelerated anticonvulsant osteomalacia .@_@osteomalacia and Acetazolamide are Adverse-Effect relation .
Acetazolamide - accelerated anticonvulsant osteomalacia .@_@osteomalacia and osteomalacia are not related .
Acetazolamide - accelerated anticonvulsant osteomalacia .@_@Acetazolamide and osteomalacia are not related .
Acetazolamide - accelerated anticonvulsant osteomalacia .@_@Acetazolamide and Acetazolamide are not related .
Acetazolamide may have accelerated the development of osteomalacia by several mechanisms , including increased renal calcium excretion .@_@osteomalacia and Acetazolamide are Adverse-Effect relation .
Acetazolamide may have accelerated the development of osteomalacia by several mechanisms , including increased renal calcium excretion .@_@osteomalacia and osteomalacia are not related .
Acetazolamide may have accelerated the development of osteomalacia by several mechanisms , including increased renal calcium excretion .@_@Acetazolamide and osteomalacia are not related .
Acetazolamide may have accelerated the development of osteomalacia by several mechanisms , including increased renal calcium excretion .@_@Acetazolamide and Acetazolamide are not related .
Severe osteomalacia was present in two epileptic patients who were under long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide .@_@Severe osteomalacia and acetazolamide are Adverse-Effect relation .
Severe osteomalacia was present in two epileptic patients who were under long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide .@_@Severe osteomalacia and phenytoin are Adverse-Effect relation .
Severe osteomalacia was present in two epileptic patients who were under long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide .@_@Severe osteomalacia and phenobarbital are Adverse-Effect relation .
Severe osteomalacia was present in two epileptic patients who were under long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide .@_@Severe osteomalacia and Severe osteomalacia are not related .
Severe osteomalacia was present in two epileptic patients who were under long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide .@_@acetazolamide and Severe osteomalacia are not related .
Severe osteomalacia was present in two epileptic patients who were under long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide .@_@acetazolamide and acetazolamide are not related .
Severe osteomalacia was present in two epileptic patients who were under long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide .@_@acetazolamide and phenobarbital are not related .
Severe osteomalacia was present in two epileptic patients who were under long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide .@_@acetazolamide and phenytoin are not related .
Severe osteomalacia was present in two epileptic patients who were under long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide .@_@phenobarbital and Severe osteomalacia are not related .
Severe osteomalacia was present in two epileptic patients who were under long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide .@_@phenobarbital and acetazolamide are not related .
Severe osteomalacia was present in two epileptic patients who were under long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide .@_@phenobarbital and phenobarbital are not related .
Severe osteomalacia was present in two epileptic patients who were under long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide .@_@phenobarbital and phenytoin are not related .
Severe osteomalacia was present in two epileptic patients who were under long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide .@_@phenytoin and Severe osteomalacia are not related .
Severe osteomalacia was present in two epileptic patients who were under long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide .@_@phenytoin and acetazolamide are not related .
Severe osteomalacia was present in two epileptic patients who were under long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide .@_@phenytoin and phenobarbital are not related .
Severe osteomalacia was present in two epileptic patients who were under long - term treatment with congeners of phenytoin , phenobarbital , and acetazolamide .@_@phenytoin and phenytoin are not related .
The delayed encephalopathy developed 9 and 22 months respectively after the first dose of intrathecal methotrexate .@_@encephalopathy and methotrexate are Adverse-Effect relation .
The delayed encephalopathy developed 9 and 22 months respectively after the first dose of intrathecal methotrexate .@_@encephalopathy and encephalopathy are not related .
The delayed encephalopathy developed 9 and 22 months respectively after the first dose of intrathecal methotrexate .@_@methotrexate and encephalopathy are not related .
The delayed encephalopathy developed 9 and 22 months respectively after the first dose of intrathecal methotrexate .@_@methotrexate and methotrexate are not related .
We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and hydrocephalus related to central nervous system prophylaxis by , in the first case intrathecally administered methotrexate and , in the second by intrathecally administered methotrexate and cranial irradiation .@_@hydrocephalus and methotrexate are Adverse-Effect relation .
We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and hydrocephalus related to central nervous system prophylaxis by , in the first case intrathecally administered methotrexate and , in the second by intrathecally administered methotrexate and cranial irradiation .@_@leukoencephalopathy and methotrexate are Adverse-Effect relation .
We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and hydrocephalus related to central nervous system prophylaxis by , in the first case intrathecally administered methotrexate and , in the second by intrathecally administered methotrexate and cranial irradiation .@_@hydrocephalus and hydrocephalus are not related .
We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and hydrocephalus related to central nervous system prophylaxis by , in the first case intrathecally administered methotrexate and , in the second by intrathecally administered methotrexate and cranial irradiation .@_@hydrocephalus and leukoencephalopathy are not related .
We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and hydrocephalus related to central nervous system prophylaxis by , in the first case intrathecally administered methotrexate and , in the second by intrathecally administered methotrexate and cranial irradiation .@_@methotrexate and hydrocephalus are not related .
We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and hydrocephalus related to central nervous system prophylaxis by , in the first case intrathecally administered methotrexate and , in the second by intrathecally administered methotrexate and cranial irradiation .@_@methotrexate and methotrexate are not related .
We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and hydrocephalus related to central nervous system prophylaxis by , in the first case intrathecally administered methotrexate and , in the second by intrathecally administered methotrexate and cranial irradiation .@_@methotrexate and leukoencephalopathy are not related .
We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and hydrocephalus related to central nervous system prophylaxis by , in the first case intrathecally administered methotrexate and , in the second by intrathecally administered methotrexate and cranial irradiation .@_@leukoencephalopathy and hydrocephalus are not related .
We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and hydrocephalus related to central nervous system prophylaxis by , in the first case intrathecally administered methotrexate and , in the second by intrathecally administered methotrexate and cranial irradiation .@_@leukoencephalopathy and leukoencephalopathy are not related .
A retrospective study was conducted of 40 loperamide poisoning cases recorded at the Centre National d'Informations Toxicologiques Veterinaires .@_@loperamide poisoning and loperamide are Adverse-Effect relation .
A retrospective study was conducted of 40 loperamide poisoning cases recorded at the Centre National d'Informations Toxicologiques Veterinaires .@_@loperamide poisoning and loperamide poisoning are not related .
A retrospective study was conducted of 40 loperamide poisoning cases recorded at the Centre National d'Informations Toxicologiques Veterinaires .@_@loperamide and loperamide poisoning are not related .
A retrospective study was conducted of 40 loperamide poisoning cases recorded at the Centre National d'Informations Toxicologiques Veterinaires .@_@loperamide and loperamide are not related .
Loperamide poisoning in the dog .@_@Loperamide poisoning and Loperamide are Adverse-Effect relation .
Loperamide poisoning in the dog .@_@Loperamide poisoning and Loperamide poisoning are not related .
Loperamide poisoning in the dog .@_@Loperamide and Loperamide poisoning are not related .
Loperamide poisoning in the dog .@_@Loperamide and Loperamide are not related .
a 67-year - old man with bipolar disorder developed a Creutzfeldt - Jakob like syndrome during lithium carbonate treatment .@_@Creutzfeldt - Jakob like syndrome and lithium carbonate are Adverse-Effect relation .
a 67-year - old man with bipolar disorder developed a Creutzfeldt - Jakob like syndrome during lithium carbonate treatment .@_@Creutzfeldt - Jakob like syndrome and Creutzfeldt - Jakob like syndrome are not related .
a 67-year - old man with bipolar disorder developed a Creutzfeldt - Jakob like syndrome during lithium carbonate treatment .@_@lithium carbonate and Creutzfeldt - Jakob like syndrome are not related .
a 67-year - old man with bipolar disorder developed a Creutzfeldt - Jakob like syndrome during lithium carbonate treatment .@_@lithium carbonate and lithium carbonate are not related .
Lithium - induced Creutzfeldt - Jakob syndrome .@_@Creutzfeldt - Jakob syndrome and Lithium are Adverse-Effect relation .
Lithium - induced Creutzfeldt - Jakob syndrome .@_@Creutzfeldt - Jakob syndrome and Creutzfeldt - Jakob syndrome are not related .
Lithium - induced Creutzfeldt - Jakob syndrome .@_@Lithium and Creutzfeldt - Jakob syndrome are not related .
Lithium - induced Creutzfeldt - Jakob syndrome .@_@Lithium and Lithium are not related .
Lithium neurotoxicity should be considered in Creutzfeldt - Jakob disease differential diagnosis , serial electroencephalograms being the most valuable .@_@Lithium neurotoxicity and Lithium are Adverse-Effect relation .
Lithium neurotoxicity should be considered in Creutzfeldt - Jakob disease differential diagnosis , serial electroencephalograms being the most valuable .@_@Creutzfeldt - Jakob disease and Lithium are Adverse-Effect relation .
Lithium neurotoxicity should be considered in Creutzfeldt - Jakob disease differential diagnosis , serial electroencephalograms being the most valuable .@_@Creutzfeldt - Jakob disease and Creutzfeldt - Jakob disease are not related .
Lithium neurotoxicity should be considered in Creutzfeldt - Jakob disease differential diagnosis , serial electroencephalograms being the most valuable .@_@Creutzfeldt - Jakob disease and Lithium neurotoxicity are not related .
Lithium neurotoxicity should be considered in Creutzfeldt - Jakob disease differential diagnosis , serial electroencephalograms being the most valuable .@_@Lithium and Creutzfeldt - Jakob disease are not related .
Lithium neurotoxicity should be considered in Creutzfeldt - Jakob disease differential diagnosis , serial electroencephalograms being the most valuable .@_@Lithium and Lithium are not related .
Lithium neurotoxicity should be considered in Creutzfeldt - Jakob disease differential diagnosis , serial electroencephalograms being the most valuable .@_@Lithium and Lithium neurotoxicity are not related .
Lithium neurotoxicity should be considered in Creutzfeldt - Jakob disease differential diagnosis , serial electroencephalograms being the most valuable .@_@Lithium neurotoxicity and Creutzfeldt - Jakob disease are not related .
Lithium neurotoxicity should be considered in Creutzfeldt - Jakob disease differential diagnosis , serial electroencephalograms being the most valuable .@_@Lithium neurotoxicity and Lithium neurotoxicity are not related .
Several cases of lithium - induced Creutzfeldt - Jakob syndrome have been reported to date ; all of them were elderly patients and a half had " therapeutic " lithium serum levels .@_@Creutzfeldt - Jakob syndrome and lithium are Adverse-Effect relation .
Several cases of lithium - induced Creutzfeldt - Jakob syndrome have been reported to date ; all of them were elderly patients and a half had " therapeutic " lithium serum levels .@_@Creutzfeldt - Jakob syndrome and Creutzfeldt - Jakob syndrome are not related .
Several cases of lithium - induced Creutzfeldt - Jakob syndrome have been reported to date ; all of them were elderly patients and a half had " therapeutic " lithium serum levels .@_@lithium and Creutzfeldt - Jakob syndrome are not related .
Several cases of lithium - induced Creutzfeldt - Jakob syndrome have been reported to date ; all of them were elderly patients and a half had " therapeutic " lithium serum levels .@_@lithium and lithium are not related .
A noninvasive method in the differential diagnosis of vecuronium - induced and magnesium - induced protracted neuromuscular block in a severely preeclamptic patient .@_@protracted neuromuscular block and magnesium are Adverse-Effect relation .
A noninvasive method in the differential diagnosis of vecuronium - induced and magnesium - induced protracted neuromuscular block in a severely preeclamptic patient .@_@protracted neuromuscular block and vecuronium are Adverse-Effect relation .
A noninvasive method in the differential diagnosis of vecuronium - induced and magnesium - induced protracted neuromuscular block in a severely preeclamptic patient .@_@protracted neuromuscular block and protracted neuromuscular block are not related .
A noninvasive method in the differential diagnosis of vecuronium - induced and magnesium - induced protracted neuromuscular block in a severely preeclamptic patient .@_@magnesium and protracted neuromuscular block are not related .
A noninvasive method in the differential diagnosis of vecuronium - induced and magnesium - induced protracted neuromuscular block in a severely preeclamptic patient .@_@magnesium and magnesium are not related .
A noninvasive method in the differential diagnosis of vecuronium - induced and magnesium - induced protracted neuromuscular block in a severely preeclamptic patient .@_@magnesium and vecuronium are not related .
A noninvasive method in the differential diagnosis of vecuronium - induced and magnesium - induced protracted neuromuscular block in a severely preeclamptic patient .@_@vecuronium and protracted neuromuscular block are not related .
A noninvasive method in the differential diagnosis of vecuronium - induced and magnesium - induced protracted neuromuscular block in a severely preeclamptic patient .@_@vecuronium and magnesium are not related .
A noninvasive method in the differential diagnosis of vecuronium - induced and magnesium - induced protracted neuromuscular block in a severely preeclamptic patient .@_@vecuronium and vecuronium are not related .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@vascular retinopathy and interferon are Adverse-Effect relation .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@anterior ischemic optic neuropathy and interferon alfa are Adverse-Effect relation .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@anterior ischemic optic neuropathy and anterior ischemic optic neuropathy are not related .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@anterior ischemic optic neuropathy and vascular retinopathy are not related .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@anterior ischemic optic neuropathy and interferon are not related .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@interferon alfa and anterior ischemic optic neuropathy are not related .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@interferon alfa and interferon alfa are not related .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@interferon alfa and vascular retinopathy are not related .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@interferon alfa and interferon are not related .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@vascular retinopathy and anterior ischemic optic neuropathy are not related .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@vascular retinopathy and interferon alfa are not related .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@vascular retinopathy and vascular retinopathy are not related .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@interferon and anterior ischemic optic neuropathy are not related .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@interferon and interferon alfa are not related .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@interferon and vascular retinopathy are not related .
The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy .@_@interferon and interferon are not related .
The authors describe a case of neuroleptic malignant syndrome that occurred in a patient on amitriptyline and lithium carbonate .@_@neuroleptic malignant syndrome and amitriptyline are Adverse-Effect relation .
The authors describe a case of neuroleptic malignant syndrome that occurred in a patient on amitriptyline and lithium carbonate .@_@neuroleptic malignant syndrome and lithium carbonate are Adverse-Effect relation .
The authors describe a case of neuroleptic malignant syndrome that occurred in a patient on amitriptyline and lithium carbonate .@_@neuroleptic malignant syndrome and neuroleptic malignant syndrome are not related .
The authors describe a case of neuroleptic malignant syndrome that occurred in a patient on amitriptyline and lithium carbonate .@_@amitriptyline and neuroleptic malignant syndrome are not related .
The authors describe a case of neuroleptic malignant syndrome that occurred in a patient on amitriptyline and lithium carbonate .@_@amitriptyline and amitriptyline are not related .
The authors describe a case of neuroleptic malignant syndrome that occurred in a patient on amitriptyline and lithium carbonate .@_@amitriptyline and lithium carbonate are not related .
The authors describe a case of neuroleptic malignant syndrome that occurred in a patient on amitriptyline and lithium carbonate .@_@lithium carbonate and neuroleptic malignant syndrome are not related .
The authors describe a case of neuroleptic malignant syndrome that occurred in a patient on amitriptyline and lithium carbonate .@_@lithium carbonate and amitriptyline are not related .
The authors describe a case of neuroleptic malignant syndrome that occurred in a patient on amitriptyline and lithium carbonate .@_@lithium carbonate and lithium carbonate are not related .
CASE SUMMARIES : Two patients with stable hypothyroidism experienced symptoms of hypothyroidism with increased serum thyroid - stimulating hormone ( TSH ) concentrations after switching from 1 levothyroxine product to another .@_@increased serum thyroid - stimulating hormone and levothyroxine are Adverse-Effect relation .
CASE SUMMARIES : Two patients with stable hypothyroidism experienced symptoms of hypothyroidism with increased serum thyroid - stimulating hormone ( TSH ) concentrations after switching from 1 levothyroxine product to another .@_@increased serum thyroid - stimulating hormone and increased serum thyroid - stimulating hormone are not related .
CASE SUMMARIES : Two patients with stable hypothyroidism experienced symptoms of hypothyroidism with increased serum thyroid - stimulating hormone ( TSH ) concentrations after switching from 1 levothyroxine product to another .@_@levothyroxine and increased serum thyroid - stimulating hormone are not related .
CASE SUMMARIES : Two patients with stable hypothyroidism experienced symptoms of hypothyroidism with increased serum thyroid - stimulating hormone ( TSH ) concentrations after switching from 1 levothyroxine product to another .@_@levothyroxine and levothyroxine are not related .
Evidence is shown in this report that adenosine was associated with dangerous worsening of arrhythmia in patients with atrial flutter .@_@arrhythmia and adenosine are Adverse-Effect relation .
Evidence is shown in this report that adenosine was associated with dangerous worsening of arrhythmia in patients with atrial flutter .@_@arrhythmia and arrhythmia are not related .
Evidence is shown in this report that adenosine was associated with dangerous worsening of arrhythmia in patients with atrial flutter .@_@adenosine and arrhythmia are not related .
Evidence is shown in this report that adenosine was associated with dangerous worsening of arrhythmia in patients with atrial flutter .@_@adenosine and adenosine are not related .
Life - threatening alterations in heart rate after the use of adenosine in atrial flutter .@_@alterations in heart rate and adenosine are Adverse-Effect relation .
Life - threatening alterations in heart rate after the use of adenosine in atrial flutter .@_@alterations in heart rate and alterations in heart rate are not related .
Life - threatening alterations in heart rate after the use of adenosine in atrial flutter .@_@adenosine and alterations in heart rate are not related .
Life - threatening alterations in heart rate after the use of adenosine in atrial flutter .@_@adenosine and adenosine are not related .
Comparable adverse effects , such as disorientation and temporary amnesia , have been reported in patients in the analogous agent , propranolol .@_@disorientation and propranolol are Adverse-Effect relation .
Comparable adverse effects , such as disorientation and temporary amnesia , have been reported in patients in the analogous agent , propranolol .@_@temporary amnesia and propranolol are Adverse-Effect relation .
Comparable adverse effects , such as disorientation and temporary amnesia , have been reported in patients in the analogous agent , propranolol .@_@disorientation and disorientation are not related .
Comparable adverse effects , such as disorientation and temporary amnesia , have been reported in patients in the analogous agent , propranolol .@_@disorientation and temporary amnesia are not related .
Comparable adverse effects , such as disorientation and temporary amnesia , have been reported in patients in the analogous agent , propranolol .@_@propranolol and disorientation are not related .
Comparable adverse effects , such as disorientation and temporary amnesia , have been reported in patients in the analogous agent , propranolol .@_@propranolol and propranolol are not related .
Comparable adverse effects , such as disorientation and temporary amnesia , have been reported in patients in the analogous agent , propranolol .@_@propranolol and temporary amnesia are not related .
Comparable adverse effects , such as disorientation and temporary amnesia , have been reported in patients in the analogous agent , propranolol .@_@temporary amnesia and disorientation are not related .
Comparable adverse effects , such as disorientation and temporary amnesia , have been reported in patients in the analogous agent , propranolol .@_@temporary amnesia and temporary amnesia are not related .
OBJECTIVE : To describe a probable case of transient global amnesia caused by propafenone .@_@transient global amnesia and propafenone are Adverse-Effect relation .
OBJECTIVE : To describe a probable case of transient global amnesia caused by propafenone .@_@transient global amnesia and transient global amnesia are not related .
OBJECTIVE : To describe a probable case of transient global amnesia caused by propafenone .@_@propafenone and transient global amnesia are not related .
OBJECTIVE : To describe a probable case of transient global amnesia caused by propafenone .@_@propafenone and propafenone are not related .
Probable propafenone - induced transient global amnesia .@_@transient global amnesia and propafenone are Adverse-Effect relation .
Probable propafenone - induced transient global amnesia .@_@transient global amnesia and transient global amnesia are not related .
Probable propafenone - induced transient global amnesia .@_@propafenone and transient global amnesia are not related .
Probable propafenone - induced transient global amnesia .@_@propafenone and propafenone are not related .
A case of acute subdural haematoma originating spontaneously from an angiomatous meningioma in a patient receiving prophylactic aspirin therapy is presented .@_@acute subdural haematoma and aspirin are Adverse-Effect relation .
A case of acute subdural haematoma originating spontaneously from an angiomatous meningioma in a patient receiving prophylactic aspirin therapy is presented .@_@acute subdural haematoma and acute subdural haematoma are not related .
A case of acute subdural haematoma originating spontaneously from an angiomatous meningioma in a patient receiving prophylactic aspirin therapy is presented .@_@aspirin and acute subdural haematoma are not related .
A case of acute subdural haematoma originating spontaneously from an angiomatous meningioma in a patient receiving prophylactic aspirin therapy is presented .@_@aspirin and aspirin are not related .
Intracranial haemorrhage from a meningioma in a patient receiving aspirin prophylaxis : a case report .@_@Intracranial haemorrhage and aspirin are Adverse-Effect relation .
Intracranial haemorrhage from a meningioma in a patient receiving aspirin prophylaxis : a case report .@_@Intracranial haemorrhage and Intracranial haemorrhage are not related .
Intracranial haemorrhage from a meningioma in a patient receiving aspirin prophylaxis : a case report .@_@aspirin and Intracranial haemorrhage are not related .
Intracranial haemorrhage from a meningioma in a patient receiving aspirin prophylaxis : a case report .@_@aspirin and aspirin are not related .
Beneficial effect of low - dose mianserin on fluvoxamine - induced akathisia in an obsessive - compulsive patient .@_@akathisia and fluvoxamine are Adverse-Effect relation .
Beneficial effect of low - dose mianserin on fluvoxamine - induced akathisia in an obsessive - compulsive patient .@_@akathisia and akathisia are not related .
Beneficial effect of low - dose mianserin on fluvoxamine - induced akathisia in an obsessive - compulsive patient .@_@fluvoxamine and akathisia are not related .
Beneficial effect of low - dose mianserin on fluvoxamine - induced akathisia in an obsessive - compulsive patient .@_@fluvoxamine and fluvoxamine are not related .
Extrapyramidal side effects induced by some selective serotonin reuptake inhibitors ( SSRIs ) , i.e. fluoxetine and sertraline , have been previously reported in patients with depression and obsessive - compulsive disorder ( OCD ) .@_@Extrapyramidal side effects and fluoxetine are Adverse-Effect relation .
Extrapyramidal side effects induced by some selective serotonin reuptake inhibitors ( SSRIs ) , i.e. fluoxetine and sertraline , have been previously reported in patients with depression and obsessive - compulsive disorder ( OCD ) .@_@Extrapyramidal side effects and sertraline are Adverse-Effect relation .
Extrapyramidal side effects induced by some selective serotonin reuptake inhibitors ( SSRIs ) , i.e. fluoxetine and sertraline , have been previously reported in patients with depression and obsessive - compulsive disorder ( OCD ) .@_@Extrapyramidal side effects and Extrapyramidal side effects are not related .
Extrapyramidal side effects induced by some selective serotonin reuptake inhibitors ( SSRIs ) , i.e. fluoxetine and sertraline , have been previously reported in patients with depression and obsessive - compulsive disorder ( OCD ) .@_@fluoxetine and Extrapyramidal side effects are not related .
Extrapyramidal side effects induced by some selective serotonin reuptake inhibitors ( SSRIs ) , i.e. fluoxetine and sertraline , have been previously reported in patients with depression and obsessive - compulsive disorder ( OCD ) .@_@fluoxetine and fluoxetine are not related .
Extrapyramidal side effects induced by some selective serotonin reuptake inhibitors ( SSRIs ) , i.e. fluoxetine and sertraline , have been previously reported in patients with depression and obsessive - compulsive disorder ( OCD ) .@_@fluoxetine and sertraline are not related .
Extrapyramidal side effects induced by some selective serotonin reuptake inhibitors ( SSRIs ) , i.e. fluoxetine and sertraline , have been previously reported in patients with depression and obsessive - compulsive disorder ( OCD ) .@_@sertraline and Extrapyramidal side effects are not related .
Extrapyramidal side effects induced by some selective serotonin reuptake inhibitors ( SSRIs ) , i.e. fluoxetine and sertraline , have been previously reported in patients with depression and obsessive - compulsive disorder ( OCD ) .@_@sertraline and fluoxetine are not related .
Extrapyramidal side effects induced by some selective serotonin reuptake inhibitors ( SSRIs ) , i.e. fluoxetine and sertraline , have been previously reported in patients with depression and obsessive - compulsive disorder ( OCD ) .@_@sertraline and sertraline are not related .
However , the occurrence and management of akathisia induced by fluvoxamine have not been described .@_@akathisia and fluvoxamine are Adverse-Effect relation .
However , the occurrence and management of akathisia induced by fluvoxamine have not been described .@_@akathisia and akathisia are not related .
However , the occurrence and management of akathisia induced by fluvoxamine have not been described .@_@fluvoxamine and akathisia are not related .
However , the occurrence and management of akathisia induced by fluvoxamine have not been described .@_@fluvoxamine and fluvoxamine are not related .
In the presented case fluvoxamine - induced akathisia in an OCD patient was partially resistant to the anticholinergic agent biperiden , and was successfully treated with the 5-HT2A/5-HT2C antagonist mianserin .@_@akathisia and fluvoxamine are Adverse-Effect relation .
In the presented case fluvoxamine - induced akathisia in an OCD patient was partially resistant to the anticholinergic agent biperiden , and was successfully treated with the 5-HT2A/5-HT2C antagonist mianserin .@_@akathisia and akathisia are not related .
In the presented case fluvoxamine - induced akathisia in an OCD patient was partially resistant to the anticholinergic agent biperiden , and was successfully treated with the 5-HT2A/5-HT2C antagonist mianserin .@_@fluvoxamine and akathisia are not related .
In the presented case fluvoxamine - induced akathisia in an OCD patient was partially resistant to the anticholinergic agent biperiden , and was successfully treated with the 5-HT2A/5-HT2C antagonist mianserin .@_@fluvoxamine and fluvoxamine are not related .
A 42 year old man , treated for testicular carcinoma with combination chemotherapy that included bleomycin , developed life threatening interstitial pneumonitis .@_@interstitial pneumonitis and bleomycin are Adverse-Effect relation .
A 42 year old man , treated for testicular carcinoma with combination chemotherapy that included bleomycin , developed life threatening interstitial pneumonitis .@_@interstitial pneumonitis and interstitial pneumonitis are not related .
A 42 year old man , treated for testicular carcinoma with combination chemotherapy that included bleomycin , developed life threatening interstitial pneumonitis .@_@bleomycin and interstitial pneumonitis are not related .
A 42 year old man , treated for testicular carcinoma with combination chemotherapy that included bleomycin , developed life threatening interstitial pneumonitis .@_@bleomycin and bleomycin are not related .
Severe bleomycin lung toxicity : reversal with high dose corticosteroids .@_@lung toxicity and bleomycin are Adverse-Effect relation .
Severe bleomycin lung toxicity : reversal with high dose corticosteroids .@_@lung toxicity and lung toxicity are not related .
Severe bleomycin lung toxicity : reversal with high dose corticosteroids .@_@bleomycin and lung toxicity are not related .
Severe bleomycin lung toxicity : reversal with high dose corticosteroids .@_@bleomycin and bleomycin are not related .
This report suggests that bleomycin lung toxicity may be reversible if treated aggressively .@_@lung toxicity and bleomycin are Adverse-Effect relation .
This report suggests that bleomycin lung toxicity may be reversible if treated aggressively .@_@lung toxicity and lung toxicity are not related .
This report suggests that bleomycin lung toxicity may be reversible if treated aggressively .@_@bleomycin and lung toxicity are not related .
This report suggests that bleomycin lung toxicity may be reversible if treated aggressively .@_@bleomycin and bleomycin are not related .
Reversal of gold - induced neutropenia with granulocyte colony - stimulating factor ( G - CSF ) .@_@neutropenia and gold are Adverse-Effect relation .
Reversal of gold - induced neutropenia with granulocyte colony - stimulating factor ( G - CSF ) .@_@neutropenia and neutropenia are not related .
Reversal of gold - induced neutropenia with granulocyte colony - stimulating factor ( G - CSF ) .@_@gold and neutropenia are not related .
Reversal of gold - induced neutropenia with granulocyte colony - stimulating factor ( G - CSF ) .@_@gold and gold are not related .
We have successfully overcome severe neutropenia in an RA patient treated with gold salts , using granulocyte colony - stimulating factor ( G - CSF ) , reducing the duration of neutropenia and risk of infection .@_@severe neutropenia and gold are Adverse-Effect relation .
We have successfully overcome severe neutropenia in an RA patient treated with gold salts , using granulocyte colony - stimulating factor ( G - CSF ) , reducing the duration of neutropenia and risk of infection .@_@severe neutropenia and severe neutropenia are not related .
We have successfully overcome severe neutropenia in an RA patient treated with gold salts , using granulocyte colony - stimulating factor ( G - CSF ) , reducing the duration of neutropenia and risk of infection .@_@gold and severe neutropenia are not related .
We have successfully overcome severe neutropenia in an RA patient treated with gold salts , using granulocyte colony - stimulating factor ( G - CSF ) , reducing the duration of neutropenia and risk of infection .@_@gold and gold are not related .
Arrhythmias and cardiac arrest have been reported during amphotericin B administration but no effective technique has been described to prevent them .@_@Arrhythmias and amphotericin B are Adverse-Effect relation .
Arrhythmias and cardiac arrest have been reported during amphotericin B administration but no effective technique has been described to prevent them .@_@cardiac arrest and amphotericin B are Adverse-Effect relation .
Arrhythmias and cardiac arrest have been reported during amphotericin B administration but no effective technique has been described to prevent them .@_@Arrhythmias and Arrhythmias are not related .
Arrhythmias and cardiac arrest have been reported during amphotericin B administration but no effective technique has been described to prevent them .@_@Arrhythmias and cardiac arrest are not related .
Arrhythmias and cardiac arrest have been reported during amphotericin B administration but no effective technique has been described to prevent them .@_@amphotericin B and Arrhythmias are not related .
Arrhythmias and cardiac arrest have been reported during amphotericin B administration but no effective technique has been described to prevent them .@_@amphotericin B and amphotericin B are not related .
Arrhythmias and cardiac arrest have been reported during amphotericin B administration but no effective technique has been described to prevent them .@_@amphotericin B and cardiac arrest are not related .
Arrhythmias and cardiac arrest have been reported during amphotericin B administration but no effective technique has been described to prevent them .@_@cardiac arrest and Arrhythmias are not related .
Arrhythmias and cardiac arrest have been reported during amphotericin B administration but no effective technique has been described to prevent them .@_@cardiac arrest and cardiac arrest are not related .
Correction of serum electrolyte imbalance prevents cardiac arrhythmia during amphotericin B administration .@_@cardiac arrhythmia and amphotericin B are Adverse-Effect relation .
Correction of serum electrolyte imbalance prevents cardiac arrhythmia during amphotericin B administration .@_@cardiac arrhythmia and cardiac arrhythmia are not related .
Correction of serum electrolyte imbalance prevents cardiac arrhythmia during amphotericin B administration .@_@amphotericin B and cardiac arrhythmia are not related .
Correction of serum electrolyte imbalance prevents cardiac arrhythmia during amphotericin B administration .@_@amphotericin B and amphotericin B are not related .
I saw two patients with kala - azar resistant to sodium stibogluconate who developed cardiac arrest after amphotericin infusion ( in spite of tolerating a test dose ) .@_@cardiac arrest and amphotericin are Adverse-Effect relation .
I saw two patients with kala - azar resistant to sodium stibogluconate who developed cardiac arrest after amphotericin infusion ( in spite of tolerating a test dose ) .@_@cardiac arrest and cardiac arrest are not related .
I saw two patients with kala - azar resistant to sodium stibogluconate who developed cardiac arrest after amphotericin infusion ( in spite of tolerating a test dose ) .@_@amphotericin and cardiac arrest are not related .
I saw two patients with kala - azar resistant to sodium stibogluconate who developed cardiac arrest after amphotericin infusion ( in spite of tolerating a test dose ) .@_@amphotericin and amphotericin are not related .
We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts .@_@angry outbursts and lithium are Adverse-Effect relation .
We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts .@_@irritability and lithium are Adverse-Effect relation .
We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts .@_@angry outbursts and angry outbursts are not related .
We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts .@_@angry outbursts and irritability are not related .
We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts .@_@lithium and angry outbursts are not related .
We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts .@_@lithium and lithium are not related .
We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts .@_@lithium and irritability are not related .
We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts .@_@irritability and angry outbursts are not related .
We describe two cases that illustrate the use of lithium in the treatment of veterans with PTSD who complained of serious problems with irritability or angry outbursts .@_@irritability and irritability are not related .
Graves ' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C .@_@transient thyrotoxicosis and interferon are Adverse-Effect relation .
Graves ' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C .@_@Graves ' hyperthyroidism and interferon are Adverse-Effect relation .
Graves ' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C .@_@Graves ' hyperthyroidism and Graves ' hyperthyroidism are not related .
Graves ' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C .@_@Graves ' hyperthyroidism and transient thyrotoxicosis are not related .
Graves ' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C .@_@interferon and Graves ' hyperthyroidism are not related .
Graves ' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C .@_@interferon and interferon are not related .
Graves ' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C .@_@interferon and transient thyrotoxicosis are not related .
Graves ' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C .@_@transient thyrotoxicosis and Graves ' hyperthyroidism are not related .
Graves ' hyperthyroidism following transient thyrotoxicosis during interferon therapy for chronic hepatitis type C .@_@transient thyrotoxicosis and transient thyrotoxicosis are not related .
This case showed sequential manifestation from transient thyrotoxicosis to the appearance of TSH - receptor autoantibodies , and then the occurrence of Graves ' hyperthyroidism during IFN therapy .@_@Graves ' hyperthyroidism and IFN are Adverse-Effect relation .
This case showed sequential manifestation from transient thyrotoxicosis to the appearance of TSH - receptor autoantibodies , and then the occurrence of Graves ' hyperthyroidism during IFN therapy .@_@Graves ' hyperthyroidism and Graves ' hyperthyroidism are not related .
This case showed sequential manifestation from transient thyrotoxicosis to the appearance of TSH - receptor autoantibodies , and then the occurrence of Graves ' hyperthyroidism during IFN therapy .@_@IFN and Graves ' hyperthyroidism are not related .
